<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003188.pub4" GROUP_ID="HAEMATOL" ID="195499090212142666" MERGED_FROM="" MODIFIED="2017-12-18 15:52:21 +0000" MODIFIED_BY="Nicole Skoetz" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="16.0"><COVER_SHEET MODIFIED="2017-12-18 15:52:12 +0000" MODIFIED_BY="Nicole Skoetz"><TITLE MODIFIED="2016-02-19 19:16:01 +0100" MODIFIED_BY="[Empty name]">Bisphosphonates in multiple myeloma: an updated network meta-analysis</TITLE><CONTACT MODIFIED="2017-12-18 15:52:12 +0000" MODIFIED_BY="Nicole Skoetz"><PERSON ID="6B3EA40482E26AA200DE9984CCAA276E" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ambuj</FIRST_NAME><LAST_NAME>Kumar</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>akumar1@health.usf.edu</EMAIL_1><EMAIL_2>drambujkr@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Center for Evidence Based Medicine and Health Outcomes Research</DEPARTMENT><ORGANISATION>University of South Florida</ORGANISATION><CITY>Tampa</CITY><REGION>Florida</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>813-396-9194</PHONE_1><FAX_1>813-905-8909</FAX_1></ADDRESS></PERSON></CONTACT><CREATORS MODIFIED="2017-12-18 15:52:12 +0000" MODIFIED_BY="Nicole Skoetz"><PERSON ID="44145014117833128947091001144555" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Rahul</FIRST_NAME><LAST_NAME>Mhaskar</LAST_NAME><EMAIL_1>rmhaskar@health.usf.edu</EMAIL_1><ADDRESS><DEPARTMENT>Center for Evidence Based Medicine and Health Outcomes Research</DEPARTMENT><ORGANISATION>University of South Florida</ORGANISATION><CITY>Tampa</CITY><REGION>Florida</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON><PERSON ID="6B3EA40482E26AA200DE9984CCAA276E" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ambuj</FIRST_NAME><LAST_NAME>Kumar</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>akumar1@health.usf.edu</EMAIL_1><EMAIL_2>drambujkr@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Center for Evidence Based Medicine and Health Outcomes Research</DEPARTMENT><ORGANISATION>University of South Florida</ORGANISATION><CITY>Tampa</CITY><REGION>Florida</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>813-396-9194</PHONE_1><FAX_1>813-905-8909</FAX_1></ADDRESS></PERSON><PERSON ID="34752199349318258431091006115630" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Branko</FIRST_NAME><LAST_NAME>Miladinovic</LAST_NAME><EMAIL_1>dr.branko.miladinovic@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Center for Evidence-based Medicine</DEPARTMENT><ORGANISATION>University of South Florida</ORGANISATION><CITY>Tampa</CITY><REGION>Florida</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON><PERSON ID="30139973236749609469101201140340" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Benjamin</FIRST_NAME><LAST_NAME>Djulbegovic</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Distinguished Professor</POSITION><EMAIL_1>bdjulbeg@health.usf.edu</EMAIL_1><EMAIL_2>benjamin.djulbegovic@moffitt.org</EMAIL_2><URL>www.hsc.usf.edu/</URL><ADDRESS><DEPARTMENT>USF Program for Comparative Effectiveness Research &amp; Dpt of Hematology, Moffitt Cancer Ctr</DEPARTMENT><ORGANISATION>University of South Florida &amp; Mofftt Cancer Center</ORGANISATION><CITY>Tampa</CITY><REGION>Florida</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON></CREATORS><DATES MODIFIED="2017-08-31 17:16:52 +0200" MODIFIED_BY="[Empty name]"><UP_TO_DATE><DATE DAY="17" MONTH="7" YEAR="2017"/></UP_TO_DATE><LAST_SEARCH><DATE DAY="17" MONTH="7" YEAR="2017"/></LAST_SEARCH><NEXT_STAGE><DATE DAY="2" MONTH="4" YEAR="2018"/></NEXT_STAGE><PROTOCOL_PUBLISHED ISSUE="2" YEAR="2001"/><REVIEW_PUBLISHED ISSUE="4" YEAR="2001"/><LAST_CITATION_ISSUE ISSUE="12" YEAR="2017"/></DATES><WHATS_NEW MODIFIED="2017-11-16 19:29:49 +0100" MODIFIED_BY="[Empty name]"><WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-11-16 18:52:02 +0100" MODIFIED_BY="[Empty name]"><DATE DAY="31" MONTH="7" YEAR="2017"/><DESCRIPTION><P>Update of previous version. Four new studies added. Conclusions remain unchanged.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-11-16 18:52:02 +0100" MODIFIED_BY="[Empty name]"><DATE DAY="31" MONTH="7" YEAR="2017"/><DESCRIPTION><P>Update of previous systematic review published in 2012</P></DESCRIPTION></WHATS_NEW_ENTRY></WHATS_NEW><HISTORY MODIFIED="2017-08-31 17:15:39 +0200" MODIFIED_BY="[Empty name]"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-08-31 17:15:39 +0200" MODIFIED_BY="[Empty name]"><DATE DAY="19" MONTH="6" YEAR="2012"/><DESCRIPTION><P>Affiliation JR corrected</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2012-06-19 13:53:55 +0200" MODIFIED_BY="[Empty name]"><DATE DAY="6" MONTH="2" YEAR="2012"/><DESCRIPTION><P>Revised conclusions</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2011-10-21 22:33:06 +0200" MODIFIED_BY="[Empty name]"><DATE DAY="20" MONTH="10" YEAR="2011"/><DESCRIPTION><P>Amendments done</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-06-19 13:53:57 +0200" MODIFIED_BY="[Empty name]"><DATE DAY="15" MONTH="10" YEAR="2011"/><DESCRIPTION><P>New search</P></DESCRIPTION></WHATS_NEW_ENTRY></HISTORY><SOURCES_OF_SUPPORT MODIFIED="2012-03-20 15:57:30 +0100" MODIFIED_BY="[Empty name]"><INTERNAL_SOURCES MODIFIED="2012-03-20 15:57:30 +0100" MODIFIED_BY="[Empty name]"><SOURCE MODIFIED="2012-03-20 15:57:30 +0100" MODIFIED_BY="[Empty name]"><NAME>Center for Evidence-based Medicine,The University of South Florida</NAME><COUNTRY CODE="US">USA</COUNTRY><DESCRIPTION/></SOURCE><SOURCE MODIFIED="2012-03-20 15:57:09 +0100" MODIFIED_BY="Rahul S Mhaskar"><NAME>Department of Internal Medicine, University of Bonn</NAME><COUNTRY CODE="DE">Germany</COUNTRY><DESCRIPTION/></SOURCE></INTERNAL_SOURCES><EXTERNAL_SOURCES MODIFIED="2009-12-15 16:28:20 +0100" MODIFIED_BY="[Empty name]"><SOURCE MODIFIED="2009-12-15 16:28:20 +0100" MODIFIED_BY="[Empty name]"><NAME>Leukämie-Initiative Bonn e.v.</NAME><COUNTRY CODE="DE">Germany</COUNTRY><DESCRIPTION/></SOURCE><SOURCE><NAME>Cochrane Haematological Malignancies Group (CHMG)</NAME><COUNTRY CODE="DE">Germany</COUNTRY><DESCRIPTION/></SOURCE></EXTERNAL_SOURCES></SOURCES_OF_SUPPORT><MESH_TERMS VERIFIED="NO"/><KEYWORDS/></COVER_SHEET><MAIN_TEXT MODIFIED="2017-11-16 19:40:32 +0100" MODIFIED_BY="[Empty name]"><SUMMARY MODIFIED="2017-11-16 18:52:02 +0100" MODIFIED_BY="[Empty name]"><TITLE MODIFIED="2010-02-12 17:05:20 +0100" MODIFIED_BY="[Empty name]">Bisphosphonates in multiple myeloma</TITLE><SUMMARY_BODY MODIFIED="2017-11-16 18:52:02 +0100" MODIFIED_BY="[Empty name]"><P><B>Review question: </B>What is the effect of bisphosphonates if added to the existing treatments for multiple myeloma?</P><P><B>Background: </B>Multiple myeloma (also known as myeloma or plasma cell myeloma) is a B-cell malignancy or, more precisely, plasma cell neoplasm. This cancer grows inside or outside of bones. The bone damage, or osteolytic lesions, may lead to fractures of the long bones or compression fractures in the spine. The mechanism of bone destruction appears to be related to increased bone resorption by cells called osteoclasts. Bisphosphonates are drugs that can inhibit bone resorption by reducing the number and activity of osteoclasts.</P><P><B>Search date:</B> The evidence is current to July 2017.</P><P><B>Study characteristics: </B>This is an updated review of 24 trials enrolling 7293 participants. Twenty randomized controlled trials compared bisphosphonates with either placebo or no treatment and four randomized controlled trials involved another bisphosphonate as a comparator.</P><P><B>Key results: </B>Use of bisphosphonates in participants with multiple myeloma did not improve overall survival or disease progression-free survival. Use of bisphosphonates in participants with multiple myeloma reduces overall fractures, fractures of the vertebra but not the non-vertebral fractures. Bisphosphonates also alleviates pain without many side effects except a significant increase in reduced blood flow to bones of the jaw resulting in decay of the bone also called osteonecrosis. Overall, for every 1000 participants treated with bisphosphonates, about one patient will suffer from the osteonecrosis of the jaw. Zoledronate was found to be better than etidronate and placebo, but not superior to pamidronate or clodronate for improving overall survival and other outcomes such as fractures in general or specifically fractures of vertebra. There was no evidence of superiority of any specific aminobisphosphonate (zoledronate, pamidronate or ibandronate) or non-aminobisphosphonate (etidronate or clodronate) for any outcome.</P><P><B>Quality of evidence: </B>The overall quality of evidence ranged from moderate to very low indicating the need for more research on this issue and specifically randomized controlled trials comparing different bisphosphonates directly instead of no treatment or placebo.</P></SUMMARY_BODY></SUMMARY><ABSTRACT MODIFIED="2017-11-16 19:30:15 +0100" MODIFIED_BY="[Empty name]"><ABS_BACKGROUND MODIFIED="2017-11-16 18:52:02 +0100" MODIFIED_BY="[Empty name]"><P>Bisphosphonates are specific inhibitors of osteoclastic activity and are used in the treatment of patients with multiple myeloma (MM). While bisphosphonates are shown to be effective in reducing vertebral fractures and pain, their role in improving overall survival (OS) remains unclear. This is an update of a Cochrane review first published in 2002 and previously updated in 2010 and 2012.</P></ABS_BACKGROUND><ABS_OBJECTIVES MODIFIED="2017-11-16 18:52:02 +0100" MODIFIED_BY="[Empty name]"><P>To assess the evidence related to benefits and harms associated with use of various types of bisphosphonates (aminobisphosphonates versus non-aminobisphosphonates) in the management of patients with MM. Our primary objective was to determine whether adding bisphosphonates to standard therapy in MM improves OS and progression-free survival (PFS), and decreases skeletal-related morbidity. Our secondary objectives were to determine the effects of bisphosphonates on pain, quality of life, incidence of hypercalcemia, incidence of bisphosphonate-related gastrointestinal toxicities, osteonecrosis of jaw (ONJ) and hypocalcemia.</P></ABS_OBJECTIVES><ABS_SEARCH_STRATEGY MODIFIED="2017-11-16 18:52:02 +0100" MODIFIED_BY="[Empty name]"><P>We searched MEDLINE, Embase (September 2011 to July 2017) and the CENTRAL (2017, Issue 7) to identify all randomized controlled trial (RCT) in MM up to July 2017 using a combination of text and MeSH terms.</P></ABS_SEARCH_STRATEGY><ABS_SELECTION_CRITERIA MODIFIED="2017-11-16 18:52:02 +0100" MODIFIED_BY="[Empty name]"><P>Any randomized controlled trial (RCT) comparing bisphosphonates versus placebo/no treatment/bisphosphonates and observational studies or case reports examining bisphosphonate-related ONJ in patients with MM were eligible for inclusion.</P></ABS_SELECTION_CRITERIA><ABS_DATA_COLLECTION MODIFIED="2017-11-16 18:52:02 +0100" MODIFIED_BY="[Empty name]"><P>Two review authors extracted the data. Data were pooled and reported as hazard ratio (HR) or risk ratio (RR) using a random-effects model. We used meta-regression to explore statistical heterogeneity. Network meta-analysis using Bayesian approach was conducted.</P></ABS_DATA_COLLECTION><ABS_RESULTS MODIFIED="2017-11-16 19:30:15 +0100" MODIFIED_BY="[Empty name]"><P>In this update, we included four new studies (601 participants), resulting in a total of 24 included studies.</P><P>Twenty RCTs compared bisphosphonates with either placebo or no treatment and four RCTs involved another bisphosphonate as a comparator. The 24 included RCTs enrolled 7293 participants. Pooled results showed that there was moderate-quality evidence of a reduction in mortality with on OS from 41% to 31%, but the confidence interval is consistent with a larger reduction and small increase in mortality compared with placebo or no treatment (HR 0.90, 95% CI 0.76 to 1.07; 14 studies; 2706 participants). There was substantial heterogeneity among the included RCTs (I<SUP>2 </SUP>= 65%) for OS. To explain this heterogeneity we performed a meta-regression assessing the relationship between bisphosphonate potency and improvement in OS, which found an OS benefit with zoledronate but limited evidence of an effect on PFS. This provided a further rationale for performing a network meta-analyses of the various types of bisphosphonates that were not compared head-to-head in RCTs. Results from network meta-analyses showed evidence of a benefit for OS with zoledronate compared with etidronate (HR 0.56, 95% CI 0.29 to 0.87) and placebo (HR 0.67, 95% CI 0.46 to 0.91). However, there was no evidence for a difference between zoledronate and other bisphosphonates.</P><P>The effect of bisphosphonates on disease progression (PFS) is uncertain. Based on the HR of 0.75 (95% CI 0.57 to 1.00; seven studies; 908 participants), 47% participants would experience disease progression without treatment compared with between 30% and 47% with bisphosphonates (low-quality evidence). There is probably a similar risk of non-vertebral fractures between treatment groups (RR 1.03, 95% CI 0.68 to 1.56; six studies; 1389 participants; moderate-quality evidence). Pooled analysis demonstrated evidence for a difference favoring bisphosphonates compared with placebo or no treatment on prevention of pathological vertebral fractures (RR 0.74, 95% CI 0.62 to 0.89; seven studies; 1116 participants; moderate-quality evidence) and skeletal-related events (SREs) (RR 0.74, 95% CI 0.63 to 0.88; 10 studies; 2141 participants; moderate-quality evidence). The evidence for less pain with bisphosphonates was of very low quality (RR 0.75, 95% CI 0.60 to 0.95; eight studies; 1281 participants).</P><P>Bisphosphonates may increase ONJ compared with placebo but the confidence interval is very wide (RR 4.61, 95% CI 0.99 to 21.35; P = 0.05; six studies; 1284 participants; low-quality evidence). The results from the network meta-analysis did not show any evidence for a difference in the incidence of ONJ (eight RCTs, 3746 participants) between bisphosphonates. Data from nine observational studies (1400 participants) reported an incidence of 5% to 51% with combination of pamidronate and zoledronate, 3% to 11% with zoledronate alone, and 0% to 18% with pamidronate alone.</P><P>The pooled results showed no evidence for a difference in increase in frequency of gastrointestinal symptoms with the use of bisphosphonates compared with placebo or no treatment (RR 1.23, 95% CI 0.95 to 1.59; seven studies; 1829 participants; low-quality evidence).The pooled results showed no evidence for a difference in increase in frequency of hypocalcemia with the use of bisphosphonates compared with placebo or no treatment (RR 2.19, 95% CI 0.49 to 9.74; three studies; 1090 participants; low-quality evidence). The results from network meta-analysis did not show any evidence for differences in the incidence of hypocalcemia, renal dysfunction and gastrointestinal toxicity between the bisphosphonates used.</P></ABS_RESULTS><ABS_CONCLUSIONS MODIFIED="2017-11-16 18:52:02 +0100" MODIFIED_BY="[Empty name]"><P>Use of bisphosphonates in participants with MM reduces pathological vertebral fractures, SREs and pain. Bisphosphonates were associated with an increased risk of developing ONJ. For every 1000 participants treated with bisphosphonates, about one patient will suffer from the ONJ. We found no evidence of superiority of any specific aminobisphosphonate (zoledronate, pamidronate or ibandronate) or non-aminobisphosphonate (etidronate or clodronate) for any outcome. However, zoledronate was found to be better than placebo and first-generation bisposphonate (etidronate) in pooled direct and indirect analyses for improving OS and other outcomes such as vertebral fractures. Direct head-to-head trials of the second-generation bisphosphonates are needed to settle the issue if zoledronate is truly the most efficacious bisphosphonate currently used in practice.</P></ABS_CONCLUSIONS></ABSTRACT><BODY MODIFIED="2017-11-16 19:40:32 +0100" MODIFIED_BY="[Empty name]"><BACKGROUND MODIFIED="2017-11-16 19:30:58 +0100" MODIFIED_BY="[Empty name]"><CONDITION MODIFIED="2017-11-16 19:30:30 +0100" MODIFIED_BY="[Empty name]"><P>Multiple myeloma (MM) is characterized by neoplastic proliferation of plasma cells, mainly contained within the bone marrow. It is a debilitating malignancy that is a part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance to plasma cell leukemia (<LINK REF="REF-Anderson-2015" TYPE="REFERENCE">Anderson 2015</LINK>; <LINK REF="REF-Tricot-2000" TYPE="REFERENCE">Tricot 2000</LINK>). MM can present outside the bone marrow as a solitary plasmacytoma or extramedullary plasmacytoma. MM is more prevalent after the age of 40 years. A diagnosis of symptomatic myeloma requires the presence of monoclonal protein (M-protein) in serum, urine, or both; bone marrow clonal plasma cells (&gt; 10%) or plasmacytoma; and related organ or tissue impairment) (<LINK REF="REF-Anderson-2015" TYPE="REFERENCE">Anderson 2015</LINK>; <LINK REF="REF-Greipp-2005" TYPE="REFERENCE">Greipp 2005</LINK>). Ninety-seven per cent of people with MM have M-protein present in serum, urine, or both. A diagnosis of asymptomatic myeloma (also known as smoldering myeloma) requires the presence of M-protein in serum of 30 g/L or more and bone marrow clonal plasma cells of 10%, and no related organ or tissue impairment or symptoms (<LINK REF="REF-Anderson-2015" TYPE="REFERENCE">Anderson 2015</LINK>). A mnemonic for end-organ damage, which is the hallmark of MM, is CRAB, for hyper<U><B>c</B></U>alcemia, <U><B>r</B></U>enal insufficiency,<B> <U>a</U></B>nemia and lytic <U><B>b</B></U>one lesions. The most common symptoms of MM are those related to anemia, renal dysfunction, infections and bone lesions. In the majority of patients, slow and steady progressive bone damage (osteolytic lesions) caused by myeloma may lead to fractures of the long bones or compression fractures in the spine. Bone pain is often a symptom of this disease, especially in the form of severe back pain.</P></CONDITION><INTERVENTION MODIFIED="2017-11-16 19:30:58 +0100" MODIFIED_BY="[Empty name]"><P>Bisphosphonates are used in the management of MM as supportive therapy to inhibit progression of osteoclastic activity and affect skeletal-related morbidity and mortality secondary to this process. Several randomized trials (<LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK>) have been conducted investigating the use of bisphosphonates in MM. Etidronate was the first bisphosphonate tested in a clinical setting, but with no apparent benefit (<A HREF="http://www.mrw.interscience.wiley.com.ezproxy.hsc.usf.edu/cochrane/clsysrev/articles/CD003188/bibliography.html#CD003188-bbs2-0001">Belch 1991</A>). Pamidronate, a second-generation bisphosphonate, demonstrated a significant clinical effect on the rate of skeletal-related events (SREs) and pain control in a double-blind, placebo-included randomized controlled trial (RCT) (<A HREF="http://www.mrw.interscience.wiley.com.ezproxy.hsc.usf.edu/cochrane/clsysrev/articles/CD003188/bibliography.html#CD003188-bbs2-0002">Berenson 1998</A>). This study also suggested a trend toward an increase in survival with pamidronate in a subgroup of participants. Similarly, RCTs comparing zoledronate with no therapy showed a survival benefit with zoledronate (<LINK REF="STD-Aviles-2007" TYPE="STUDY">Aviles 2007</LINK>; <LINK REF="STD-Aviles-2013" TYPE="STUDY">Aviles 2013</LINK>), and more recently an RCT comparing zoledronate with clodronate showed survival benefit with zoledronate as well (<LINK REF="STD-Morgan-2010" TYPE="STUDY">Morgan 2010</LINK>), indicating the need for the updating of previous reviews (<LINK REF="REF-Mhaskar-2010" TYPE="REFERENCE">Mhaskar 2010</LINK>; <LINK REF="REF-Mhaskar-2012" TYPE="REFERENCE">Mhaskar 2012</LINK>). In another RCT, the proportion of participants who experienced a progression of lytic lesions was smaller in the clodronate-treated group than in the placebo group (<A HREF="http://www.mrw.interscience.wiley.com.ezproxy.hsc.usf.edu/cochrane/clsysrev/articles/CD003188/bibliography.html#CD003188-bbs2-0009">Lahtinen 1992</A>). However, no significant effect on survival was seen. In a German open-label study, there was a trend toward reduction in the number of new bone lesions in the clodronate-treated group (<A HREF="http://www.mrw.interscience.wiley.com.ezproxy.hsc.usf.edu/cochrane/clsysrev/articles/CD003188/bibliography.html#CD003188-bbs2-0007">Heim 1995</A>). Again, no significant effect on survival was seen. Moreover, our previous systematic reviews published in 2010 and 2012 (<LINK REF="REF-Mhaskar-2010" TYPE="REFERENCE">Mhaskar 2010</LINK>; <LINK REF="REF-Mhaskar-2012" TYPE="REFERENCE">Mhaskar 2012</LINK>) found that adding bisphosphonates to the treatment of myeloma reduces pathological vertebral fractures and pain but&#8212;from the published evidence available then&#8212;not mortality.</P><P>All bisphosphonates are poorly absorbed after oral administration, but effective plasma levels can be achieved with clodronate. Aminobisphosphonates such as pamidronate have caused gastrointestinal (GI) ulceration when given orally (<LINK REF="REF-Lufkin-1994" TYPE="REFERENCE">Lufkin 1994</LINK>). The other adverse effects associated with the use of bisphosphonates typically consist of renal functional impairment, myalgias and hypocalcemia. Osteonecrosis of the jaw (ONJ) has been described as a serious new complication associated with bisphosphonates (<LINK REF="REF-Bagan-2006" TYPE="REFERENCE">Bagan 2006</LINK>; <LINK REF="REF-Durie-2005" TYPE="REFERENCE">Durie 2005</LINK>; <LINK REF="REF-Ruggiero-2004" TYPE="REFERENCE">Ruggiero 2004</LINK>). Bisphosphonate-associated ONJ has been described in various malignancies, including MM, breast cancer and prostate cancer, and can be a debilitating problem associated with significant morbidity.</P></INTERVENTION><THEORY MODIFIED="2017-11-16 18:52:03 +0100" MODIFIED_BY="[Empty name]"><P>Bisphosphonates are specific inhibitors of osteoclastic activity (<LINK REF="REF-Berenson-1998b" TYPE="REFERENCE">Berenson 1998b</LINK>). In addition, some studies in vitro suggest an additional antitumor effect of bisphosphonates (<LINK REF="REF-Aparicio-1998" TYPE="REFERENCE">Aparicio 1998</LINK>; <LINK REF="REF-Shipman-1997" TYPE="REFERENCE">Shipman 1997</LINK>). Therefore, there exists a pharmacological rationale for the use of these agents in MM. Bisphosphonates are a heterogeneous group of molecules that resemble pyrophosphates that are used in technical chemistry for calcium binding. The bisphosphonate core structure is formed by two phosphonate groups attached to a single carbon atom (the so called P-C-P structure). In contrast to pyrophosphates, bisphosphonates are stable in biological environments. There are many types of bisphosphonates. Alendronate, risedronate, ibandronate, pamidronate and zoledronate, termed aminobisphosphonates (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>), are bisphosphonates containing nitrogen in one of the side chains. These nitrogen-containing bisphosphonates inhibit the mevalonate pathway (the main target being farnesyl diphosphate synthase). Clodronate, etidronate and tiludronate, termed non-aminobisphosphonates (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>), do not contain nitrogen and are incorporated into hydrolytically stable analogs of adenosine triphosphate. Both events cause impairment of osteoclast cell function and, ultimately, lead to osteoclast apoptosis (<LINK REF="REF-Brown-2004" TYPE="REFERENCE">Brown 2004</LINK>). The pathogenesis of osteoclast bone resorption may also be understood to be the result of abnormal cytokine signaling between malignant plasma cells, osteoclasts and osteoblasts. Increased levels of RANK ligand produced by myeloma cells and marrow stromal cells, coupled with suppression of soluble osteoprotegerin, favors osteoclast bone resorption (<LINK REF="REF-Cassidy-2006" TYPE="REFERENCE">Cassidy 2006</LINK>). Other cytokines such as interleukin-6 further support an excess of osteoclast activity (<LINK REF="REF-Cassidy-2006" TYPE="REFERENCE">Cassidy 2006</LINK>). In summary, bisphosphonates are broadly classified into two categories (amino- and non-aminobisphosphonates) based on their chemical structure and molecular mechanism of action. Aminobisphosphonates are considered to be more potent than non-aminobisphosphonates. Based on in vitro data, zoledronate is considered the most potent and etidronate the least potent among bisphosphonates (<LINK REF="REF-Drake-2008" TYPE="REFERENCE">Drake 2008</LINK>; <LINK REF="REF-Dunford-2001" TYPE="REFERENCE">Dunford 2001</LINK>) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P></THEORY><IMPORTANCE MODIFIED="2017-11-16 18:52:03 +0100" MODIFIED_BY="[Empty name]"><P>This is an update of our previous systematic review addressing the uncertainty regarding the role of bisphosphonates in the management of MM (<LINK REF="REF-Mhaskar-2012" TYPE="REFERENCE">Mhaskar 2012</LINK>). While we found no direct effect of bisphosphonates on overall survival (OS) compared with placebo or no treatment, there was statistically significant heterogeneity for the outcome of OS among the included RCTs (<LINK REF="REF-Mhaskar-2012" TYPE="REFERENCE">Mhaskar 2012</LINK>). However, since our last review, a new study claiming OS benefit (<LINK REF="STD-Aviles-2013" TYPE="STUDY">Aviles 2013</LINK>) and additional data from a study (<LINK REF="STD-Morgan-2010" TYPE="STUDY">Morgan 2010</LINK>) that was included in our 2012 systematic review have been published. This created the impetus to update our previous review to assess the evidence related to benefits and harms associated with the use of various types of bisphosphonates (aminobisphosphonates versus non-aminobisphosphonates) in the management of patients with MM.</P></IMPORTANCE></BACKGROUND><OBJECTIVES MODIFIED="2017-11-16 18:52:03 +0100" MODIFIED_BY="[Empty name]"><P>Our primary objective was to determine whether adding bisphosphonates to standard therapy in MM decreases skeletal-related morbidity (pathological fractures) and improves overall survival (OS) and progression-free survival (PFS).</P><P>Our secondary objectives were to determine the effects of bisphosphonates on pain, quality of life, incidence of hypercalcemia, incidence of bisphosphonate-related GI toxicities, ONJ and hypocalcemia.</P></OBJECTIVES><METHODS MODIFIED="2017-11-16 19:32:18 +0100" MODIFIED_BY="[Empty name]"><SELECTION_CRITERIA MODIFIED="2017-11-16 18:52:03 +0100" MODIFIED_BY="[Empty name]"><CRIT_STUDIES MODIFIED="2017-11-16 18:52:03 +0100" MODIFIED_BY="[Empty name]"><P>We included randomized controlled trials (RCTs) in which interventions consisted of bisphosphonates versus placebo or no treatment or other bisphosphonates in patients with MM.</P><P>We excluded studies that used other agents to affect skeletal-related morbidity or mortality (e.g. fluoride), duplicate reports and those studies that reported subgroup analyses from larger RCTs. In the case of duplicate reports, we extracted data from the articles published at later dates. We also excluded studies that included participants with an underlying disease other than MM and studies that reported insufficient data, as well as studies with fewer than 10 participants.</P><P>We also included observational studies and case reports regarding bisphosphonate-related osteonecrosis of the jaw (ONJ).</P></CRIT_STUDIES><CRIT_PARTICIPANTS MODIFIED="2017-04-10 21:32:16 +0200" MODIFIED_BY="[Empty name]"><P>Participants with the diagnosis of MM as defined by the researchers in each study. We found no uniform criteria for the diagnosis (<LINK REF="REF-Alexanian-1994" TYPE="REFERENCE">Alexanian 1994</LINK>; <LINK REF="REF-Anderson-2015" TYPE="REFERENCE">Anderson 2015</LINK>) among the studies selected for this systematic review. However, all studies required biopsy-proven myeloma as the diagnostic criterion and bone involvement that met criteria for administration of bisphosphonates according to the studies' investigators.</P></CRIT_PARTICIPANTS><CRIT_INTERVENTIONS MODIFIED="2017-11-16 18:52:03 +0100" MODIFIED_BY="[Empty name]"><UL><LI>Experimental group: treatment included any bisphosphonate</LI><LI>Control group: no therapy, placebo or other bisphosphonates</LI></UL></CRIT_INTERVENTIONS><CRIT_OUTCOMES MODIFIED="2017-11-16 18:52:03 +0100" MODIFIED_BY="[Empty name]"><P>We extracted data on the following outcomes.</P><CRIT_OUTCOMES_PRIMARY MODIFIED="2017-11-16 18:52:03 +0100" MODIFIED_BY="[Empty name]"><UL><LI>Overall survival (OS) (measured as mortality)</LI><LI>Progression-free survival (PFS)</LI><LI>Skeletal-related events (SRE): number of participants experiencing pathological fractures (vertebral and non-vertebral), total skeletal-related events (SREs) (as defined by individual authors; these included vertebral fractures, non-vertebral fractures and osteolytic lesions)</LI></UL></CRIT_OUTCOMES_PRIMARY><CRIT_OUTCOMES_SECONDARY MODIFIED="2017-11-16 18:52:03 +0100" MODIFIED_BY="[Empty name]"><UL><LI>Number of participants with pain relief (as defined by individual authors)</LI><LI>Incidence of hypercalcemia (defined as &#8805; 2.65 mmol/L)</LI><LI>Adverse events (grade III/IV)</LI><LI>Quality of life (as defined by individual authors)</LI></UL></CRIT_OUTCOMES_SECONDARY></CRIT_OUTCOMES></SELECTION_CRITERIA><SEARCH_METHODS MODIFIED="2017-11-16 19:31:52 +0100" MODIFIED_BY="[Empty name]"><P>This is an update of the review published in 2012 (<LINK REF="REF-Mhaskar-2012" TYPE="REFERENCE">Mhaskar 2012</LINK>). We searched the electronic databases from September 01 2011 onwards up to 17 July 2017.</P><ELECTRONIC_SEARCHES MODIFIED="2017-11-16 18:52:03 +0100" MODIFIED_BY="[Empty name]"><P>We identified all RCTs in MM in the following databases:</P><UL><LI>MEDLINE (2011/09/01 to July 2017) (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>);</LI><LI>Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library 2017, Issue 7) (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>);      </LI><LI>ClinicalTrials.gov (search date: July 2017) (see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>);</LI><LI>Embase (2011/09/01 to July 2017) (see <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</LI></UL><P>We also identified observational studies and case reports regarding bisphosphonate-related ONJ in the following database:</P><UL><LI>MEDLINE (2011/09/01 to July 2017) (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</LI></UL></ELECTRONIC_SEARCHES><OTHER_SEARCHES MODIFIED="2017-11-16 18:52:03 +0100" MODIFIED_BY="[Empty name]"><P>We searched the American Society of Hematology (date of search 5 February 2016) EudraCT, ISRCTN (date of search 24 May, 2016) and WHO registry (date of search 21 September, 2017).</P><P>Contacting authors: Where a study contained unclear information, we contacted the authors to ensure accuracy. This occurred in one instance, but the email listed on the publication was not a valid email address. Hence we were not able to contact the author (<LINK REF="STD-Aviles-2013" TYPE="STUDY">Aviles 2013</LINK>).</P></OTHER_SEARCHES></SEARCH_METHODS><DATA_COLLECTION MODIFIED="2017-11-16 19:32:18 +0100" MODIFIED_BY="[Empty name]"><STUDY_SELECTION MODIFIED="2017-11-16 18:52:03 +0100" MODIFIED_BY="[Empty name]"><P>Review authors RM and AK independently scanned the retrieved titles and abstracts of all studies for their eligibility for inclusion in this systematic review. If a decision on inclusion was not made on the basis of the review of the title and abstract, we obtained the full text of the article to assess eligibility. Disagreements in the selection of studies were resolved by consensus (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>). At every stage of searching and screening, the overall numbers of studies identified, excluded and included with reasons, were documented according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines (<LINK REF="REF-Liberati-2009" TYPE="REFERENCE">Liberati 2009</LINK>). We used this information to create a flow diagram (Figure 2).</P></STUDY_SELECTION><DATA_EXTRACTION MODIFIED="2017-11-16 18:52:03 +0100" MODIFIED_BY="[Empty name]"><P>For this update two review authors (RM and AK) extracted all data and resolved disagreements by consensus. After the extraction, a third review author (BM) rechecked all data. The outcomes extracted are listed above. Data regarding the methods of trial conduct and design were also extracted. Specifically, we extracted data regarding methods of allocation concealment, method of randomization, adequacy of blinding procedures (who was blinded: participants, investigators, data analysts, etc), description of withdrawals and dropouts, and method of data analysis (intention-to-treat (ITT)/per protocol). To determine whether the analysis was performed according to the ITT principle, data were extracted and matched on the numbers of participants randomized and analyzed. If the numbers of participants randomized and analyzed were the same, we considered the analysis as ITT.</P><P>We also extracted details regarding drug, dose, average length of treatment, length of follow-up, number of randomized participants, number of participants excluded from the analysis, OS and PFS, presence of pain, level of calcium and adverse events. Unfortunately, we were not able to extract all data from all papers (see <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>; ).<BR/></P></DATA_EXTRACTION><QUALITY_ASSESSMENT MODIFIED="2017-11-16 18:52:03 +0100" MODIFIED_BY="[Empty name]"><P>Two review authors (RM and AK) independently assessed all eligible studies for their risk of bias (assessment of methodological quality) using methods suggested in Chapter 8 of the <I>Cochrane</I> <I>Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>). We used the extracted data to assess the methodological quality (risk of bias and random error) of each trial. The review authors judged each quality domain based on the following three-point scale.</P><UL><LI>'Yes' (low risk of bias: plausible bias unlikely to seriously alter the results if all criteria were met)</LI><LI>'No' (high risk of bias: plausible bias that seriously weakens confidence in the results if one or more criteria were not met)</LI><LI>'Unclear' (uncertain risk of bias: plausible bias that raises some doubt about the results if one or more criteria were assessed as unclear)</LI></UL><P>The risk of bias domain included the following: selection bias, performance bias, detection bias and other bias.</P><P>The quality items related to risk of random error included details about the power of the study (beta error), predetermination of alpha error and a priori estimation of sample size.</P></QUALITY_ASSESSMENT><EFFECT_MEASURES MODIFIED="2017-11-16 18:52:03 +0100" MODIFIED_BY="[Empty name]"><UL><LI>For time-to-event outcome: data were summarized as hazard ratio (HR) and 95% confidence intervals (CIs).</LI><LI>For dichotomous outcome: data were measured as risk ratio (RR) with 95% CIs.</LI><LI>For continuous outcome: data were summarized as mean difference and standard deviation.</LI></UL></EFFECT_MEASURES><UNIT_OF_ANALYSIS MODIFIED="2017-11-16 18:52:03 +0100" MODIFIED_BY="[Empty name]"><P>The unit of analysis was a study from which we extracted the aggregate data as follows: for dichotomous variables, the number of participants in the intervention arm and the number of participants in the control arm. For continuous outcomes, we extracted the mean, standard deviation, and the number of participants in the intervention and control arm. For time-to-event outcomes, we extracted log HR and the standard error of log HR.</P></UNIT_OF_ANALYSIS><MISSING_DATA MODIFIED="2016-02-16 21:16:53 +0100" MODIFIED_BY="[Empty name]"><P>We did not conduct analyses for the missing data.</P></MISSING_DATA><HETEROGENEITY_ASSESSMENT MODIFIED="2017-11-16 18:52:03 +0100" MODIFIED_BY="[Empty name]"><P>We calculated the Chi<SUP>2</SUP> and I<SUP>2</SUP> statistics to test for heterogeneity. We assessed the degree of heterogeneity among trials and between subgroups using the I² statistic. We used the following guide to interpret the I² statistic: I² = 0% to 40%(heterogeneity that might not be important), I² = 30% to 60% (moderate heterogeneity), I² = 50% to 90% (substantial heterogeneity), I² = 75% to 100% (considerable heterogeneity) (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>).</P></HETEROGENEITY_ASSESSMENT><BIAS_ASSESSMENT MODIFIED="2017-11-16 18:52:03 +0100" MODIFIED_BY="[Empty name]"><P>We investigated the possibility of publication bias using the funnel plot method of Begg and Mazumdar (<LINK REF="REF-Begg-1994" TYPE="REFERENCE">Begg 1994</LINK>) and Egger and colleagues (<LINK REF="REF-Egger-2001" TYPE="REFERENCE">Egger 2001</LINK>) as outlined in chapter 10 of the <I>Cochrane</I> <I>Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011d" TYPE="REFERENCE">Higgins 2011d</LINK>).</P></BIAS_ASSESSMENT><DATA_SYNTHESIS MODIFIED="2017-11-16 19:32:18 +0100" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="4">Direct comparison of treatment effects (bisphosphonates versus placebo or no treatment)</HEADING><P>We summarized dichotomous data using RR and pooled these data using a random-effects model in Review Manager 5.3 (RevMan) (<LINK REF="REF-RevMan-5.3" TYPE="REFERENCE">RevMan 5.3</LINK>). In cases of time-to-event data, for each included RCT, we calculated the observed minus expected events and variance from the reported mortality estimates to calculate HR. In cases where the authors did not report the mortality estimates, we extracted data from papers using methods described by Tierney and colleagues (<LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>). We pooled the time-to-event data using the random-effects model (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>) in Revman 5.3 (<LINK REF="REF-RevMan-5.3" TYPE="REFERENCE">RevMan 5.3</LINK>) to calculate overall HRs. We also calculated the number of participants who needed to be treated to avoid one adverse outcome and number of participants who were treated to cause an additional harm (<LINK REF="REF-Laupacis-1988" TYPE="REFERENCE">Laupacis 1988</LINK>) to express treatment benefits and harms, respectively, in the context of the estimated absolute risks in the control arms. All data are reported with 95% CIs.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Indirect comparison of treatment effects</HEADING><P>For this update, we used the Bayesian method outlined by Lu and colleagues (<LINK REF="REF-Lu-2004" TYPE="REFERENCE">Lu 2004</LINK>) to perform the indirect meta-analyses.</P><P>We used the Bayesian methods under random-effects multiple treatment comparisons (MTC) for indirect comparisons (<LINK REF="REF-Lu-2004" TYPE="REFERENCE">Lu 2004</LINK>; <LINK REF="REF-Higgins-1996" TYPE="REFERENCE">Higgins 1996</LINK>). The random-effects model assumes homogeneous between-studies variance. We derived posterior estimates for Bayesian methods using Gibbs sampling via Markov chain Monte Carlo simulation in WinBUGS (version 1.4). All means were given a vague prior distribution (normal distribution with mean 0 and sufficiently large variance). We report the HR or RR estimates and credibility intervals based on Bayesian methods (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). In the presence of loops, the consistency of the network was assessed using methods described by Dias and colleagues (<LINK REF="REF-Dias-2010" TYPE="REFERENCE">Dias 2010</LINK>). We followed guidelines suggested by Salanti and colleagues (<LINK REF="REF-Salanti-2011" TYPE="REFERENCE">Salanti 2011</LINK>) for graphical presentations and numerical summaries of the multiple treatment meta-analysis. For each comparison, we also derived ranking probability based on SUCRA (Surface Under the Cumulative Ranking Curve) (<LINK REF="REF-Chaimani-2013" TYPE="REFERENCE">Chaimani 2013</LINK>). A formal assessment of transitivity was not done. The assumption of transitivity was difficult to assess due to the lack of closed loops in the networks for different outcomes. However, since the distribution of treatment effects in direct comparison was in agreement with the results of the network meta-analysis, we had no reason to believe the transitivity principle was violated (<LINK REF="REF-Salanti-2014" TYPE="REFERENCE">Salanti 2014</LINK>). Additionally, small studies received less weight in our network meta-analysis.</P><P>We performed and reported the work according to PRISMA guidelines (<LINK REF="REF-Cornell-2015" TYPE="REFERENCE">Cornell 2015</LINK>; <LINK REF="REF-Liberati-2009" TYPE="REFERENCE">Liberati 2009</LINK>). We created a 'Summary of findings' table using the GRADE software for direct comparisons (<LINK REF="REF-Balshem-2011" TYPE="REFERENCE">Balshem 2011</LINK>; <LINK REF="REF-GRADEpro-2008" TYPE="REFERENCE">GRADEpro 2008</LINK>; <LINK REF="REF-Guyatt-2011" TYPE="REFERENCE">Guyatt 2011</LINK>; <LINK REF="REF-Guyatt-2011a" TYPE="REFERENCE">Guyatt 2011a</LINK>; <LINK REF="REF-Guyatt-2011b" TYPE="REFERENCE">Guyatt 2011b</LINK>; <LINK REF="REF-Guyatt-2011c" TYPE="REFERENCE">Guyatt 2011c</LINK>; <LINK REF="REF-Guyatt-2011d" TYPE="REFERENCE">Guyatt 2011d</LINK>; <LINK REF="REF-Guyatt-2011e" TYPE="REFERENCE">Guyatt 2011e</LINK>) and network meta-analysis (<LINK REF="REF-Puhan-2014" TYPE="REFERENCE">Puhan 2014</LINK>) separately.</P></SUBSECTION></DATA_SYNTHESIS><SUBGROUP_ANALYSIS MODIFIED="2017-11-16 18:52:03 +0100" MODIFIED_BY="[Empty name]"><P>Apart from sensitivity analyses, we conducted subgroup analyses based on duration of treatment. We assessed the differences between the subgroups using the test of heterogeneity between subgroups in RevMan 5.3 (<LINK REF="REF-RevMan-5.3" TYPE="REFERENCE">RevMan 5.3</LINK>). In the presence of relevant heterogeneity, we used meta-regression to estimate the extent to which covariates explain the treatment effects (<LINK REF="REF-Thompson-2002" TYPE="REFERENCE">Thompson 2002</LINK>). Meta-regression was performed with the Knapp-Hartung modification, which is more sensitive to false-positive rates than the normal approximation estimates (<LINK REF="REF-Higgins-2004" TYPE="REFERENCE">Higgins 2004</LINK>) using STATA statistical analysis software (<LINK REF="REF-STATA-V10.1" TYPE="REFERENCE">STATA V10.1</LINK>). Meta-regression was performed using only one covariate of bisphosphonate potency and has been reported (not adjusted for any other variables). We used potency as a covariate and expressed the association as a slope of (1-Hazard Ratio) per 1000 unit increase in potency.</P></SUBGROUP_ANALYSIS><SENSITIVITY_ANALYSIS MODIFIED="2012-03-20 15:33:57 +0100" MODIFIED_BY="Rahul S Mhaskar"><P>We conducted sensitivity analyses according to methodological quality dimensions to assess the existence of a potential bias in our results (<LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>). In particular, we focused on those dimensions that have been empirically linked to bias and random error on all outcomes.</P></SENSITIVITY_ANALYSIS></DATA_COLLECTION></METHODS><RESULTS MODIFIED="2017-11-16 19:40:32 +0100" MODIFIED_BY="[Empty name]"><STUDY_DESCRIPTION MODIFIED="2017-11-16 18:52:04 +0100" MODIFIED_BY="[Empty name]"><SEARCH_RESULTS MODIFIED="2017-11-16 18:52:04 +0100" MODIFIED_BY="[Empty name]"><P>For this update, we searched the electronic databases from 1 September 2011 onwards until 17 July, 2017. The initial search identified 994 citations. We excluded 769 studies and reviewed the full text of 15 studies. Our initial search for observational studies reporting osteonecrosis of the jaw (ONJ) identified 39 citations. We excluded 35 citations and included four case reports/case series reporting ONJ (<LINK REF="REF-Gabbert-2015" TYPE="REFERENCE">Gabbert 2015</LINK>; <LINK REF="REF-Gander-2014" TYPE="REFERENCE">Gander 2014</LINK>; <LINK REF="REF-Watters-2013" TYPE="REFERENCE">Watters 2013</LINK>; <LINK REF="REF-Wickham-2013" TYPE="REFERENCE">Wickham 2013</LINK>).</P><P>Of these, seven studies were found to be ineligible due to following reasons: two were non-randomized studies (<LINK REF="STD-Chiang-2013" TYPE="STUDY">Chiang 2013</LINK>; <LINK REF="STD-Teoh-2012" TYPE="STUDY">Teoh 2012</LINK>), one was a cost-effectiveness study (<LINK REF="STD-Delea-2012" TYPE="STUDY">Delea 2012</LINK>), three studies addressed the role of denosumab (<LINK REF="STD-Henry-2014" TYPE="STUDY">Henry 2014</LINK>; <LINK REF="STD-Lipton-2012" TYPE="STUDY">Lipton 2012</LINK>; <LINK REF="STD-Vadhan_x002d_Raj-2012" TYPE="STUDY">Vadhan-Raj 2012</LINK>), and in one study participants in both arms received the same dose of zoledronate with a hypothesis that treatment with thalidomide and zoledronate would prolong the time to progression to MM over alone (<LINK REF="STD-Witzig-2013" TYPE="STUDY">Witzig 2013</LINK>). We identified four publications related to the study by Morgan and colleagues (<LINK REF="STD-Morgan-2010" TYPE="STUDY">Morgan 2010</LINK>), which was included in the previous version. We included additional data from these four publications in this update and we added the citations of these publications under <LINK REF="STD-Morgan-2010" TYPE="STUDY">Morgan 2010</LINK>. In summary, we identified and included three new RCTs (<LINK REF="STD-Aviles-2013" TYPE="STUDY">Aviles 2013</LINK>; <LINK REF="STD-Sezer-2010" TYPE="STUDY">Sezer 2010</LINK>; <LINK REF="STD-Zhang-2012" TYPE="STUDY">Zhang 2012</LINK>) in this review (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). The study by Zhang and colleagues was published in English and Chinese. We reviewed both publications. However, none of the publications included outcomes that are relevant for our systematic review. One additional study was identified through personal communication with the Cochrane Hematological Malignancies group (<LINK REF="STD-Garcia_x002d_Sanz-2015" TYPE="STUDY">Garcia-Sanz 2015</LINK>) and was not retrieved through the formal search.</P><P>We also found one ongoing open-label multi-center international RCT comparing zoledronic acid for four years versus stopping treatment with zoledronic acid after two years (<LINK REF="STD-Lund-2014" TYPE="STUDY">Lund 2014</LINK>).</P></SEARCH_RESULTS><INCLUDED_STUDIES_DESCR MODIFIED="2017-11-16 18:52:04 +0100" MODIFIED_BY="[Empty name]"><P>In this update, we included four new studies (<LINK REF="STD-Aviles-2013" TYPE="STUDY">Aviles 2013</LINK>; <LINK REF="STD-Garcia_x002d_Sanz-2015" TYPE="STUDY">Garcia-Sanz 2015</LINK>; <LINK REF="STD-Sezer-2010" TYPE="STUDY">Sezer 2010</LINK>; <LINK REF="STD-Zhang-2012" TYPE="STUDY">Zhang 2012</LINK>) that were not part of the previous published version (<LINK REF="REF-Mhaskar-2012" TYPE="REFERENCE">Mhaskar 2012</LINK>), resulting in 20 RCTs comparing bisphosphonates with either placebo or no treatment and four RCTs with a different bisphosphonate as a comparator.</P><P>Two trials reported the effects of etidronate compared with placebo or no treatment (<LINK REF="STD-Belch-1991" TYPE="STUDY">Belch 1991</LINK>; <LINK REF="STD-Daragon-1993" TYPE="STUDY">Daragon 1993</LINK>); seven trials reported the effects of pamidronate compared with placebo or no treatment (<LINK REF="STD-Attal-2006" TYPE="STUDY">Attal 2006</LINK>; <LINK REF="STD-Berenson-1998a" TYPE="STUDY">Berenson 1998a</LINK>; <LINK REF="STD-Brincker-1998" TYPE="STUDY">Brincker 1998</LINK>; <LINK REF="STD-Kraj-2000" TYPE="STUDY">Kraj 2000</LINK>; <LINK REF="STD-Leng-2002" TYPE="STUDY">Leng 2002</LINK>; <LINK REF="STD-Musto-2003" TYPE="STUDY">Musto 2003</LINK>; <LINK REF="STD-Terpos-2000" TYPE="STUDY">Terpos 2000</LINK>); five trials reported the effects of clodronate compared with placebo or no treatment (<LINK REF="STD-Delmas-1982" TYPE="STUDY">Delmas 1982</LINK>; <LINK REF="STD-Heim-1995" TYPE="STUDY">Heim 1995</LINK>; <LINK REF="STD-Lahtinen-1992" TYPE="STUDY">Lahtinen 1992</LINK>; <LINK REF="STD-McCloskey-2001" TYPE="STUDY">McCloskey 2001</LINK>; <LINK REF="STD-Zhang-2012" TYPE="STUDY">Zhang 2012</LINK>) and one trial described the effects of ibandronate compared with placebo (<LINK REF="STD-Menssen-2002" TYPE="STUDY">Menssen 2002</LINK>). Five trials compared the effects of zoledronate versus no therapy in myeloma (<LINK REF="STD-Aviles-2007" TYPE="STUDY">Aviles 2007</LINK>; <LINK REF="STD-Aviles-2013" TYPE="STUDY">Aviles 2013</LINK>; <LINK REF="STD-Garcia_x002d_Sanz-2015" TYPE="STUDY">Garcia-Sanz 2015</LINK>; <LINK REF="STD-Musto-2008" TYPE="STUDY">Musto 2008</LINK>; <LINK REF="STD-Sezer-2010" TYPE="STUDY">Sezer 2010</LINK>).</P><P>We also included the following RCTs comparing pamidronate versus ibandronate (<LINK REF="STD-Terpos-2003" TYPE="STUDY">Terpos 2003</LINK>), zoledronate versus pamidronate (<LINK REF="STD-Morgan-2010" TYPE="STUDY">Morgan 2010</LINK>), 30 mg of pamidronate versus 90 mg of pamidronate (<LINK REF="STD-Gimsing-2010" TYPE="STUDY">Gimsing 2010</LINK>) and zoledronate versus pamidronate (<LINK REF="STD-Rosen-2003" TYPE="STUDY">Rosen 2003</LINK>). In this update, we included four additional publications related to the study by Morgan and colleagues (<LINK REF="STD-Morgan-2010" TYPE="STUDY">Morgan 2010</LINK>).</P><P>In total we included 24 RCTs in this systematic review (see details in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P></INCLUDED_STUDIES_DESCR><EXCLUDED_STUDIES_DESCR MODIFIED="2017-11-16 18:52:04 +0100" MODIFIED_BY="[Empty name]"><P>The search conducted for our previous review excluded 16 trials (see details in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). One trial studied antitumor and bone metabolism effects and reported no outcomes of interest (<LINK REF="STD-Martin-2002" TYPE="STUDY">Martin 2002</LINK>). One was a duplicate report (<LINK REF="STD-Kraj-2000a" TYPE="STUDY">Kraj 2000a</LINK>); seven trials were not randomized (<LINK REF="STD-Ali-2001" TYPE="STUDY">Ali 2001</LINK>; <LINK REF="STD-Barlogie-2008" TYPE="STUDY">Barlogie 2008</LINK>; <LINK REF="STD-Bergner-2007" TYPE="STUDY">Bergner 2007</LINK>; <LINK REF="STD-Morris-2001" TYPE="STUDY">Morris 2001</LINK>; <LINK REF="STD-Spencer-2008" TYPE="STUDY">Spencer 2008</LINK>; <LINK REF="STD-Tassinari-2007" TYPE="STUDY">Tassinari 2007</LINK>; <LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK>). One trial with nine enrolled participants was too small to be included (<LINK REF="STD-Kraj-2002" TYPE="STUDY">Kraj 2002</LINK>). Three studies had used combination therapy (<LINK REF="STD-Caparrotti-2003" TYPE="STUDY">Caparrotti 2003</LINK>; <LINK REF="STD-Ciepluch-2002" TYPE="STUDY">Ciepluch 2002</LINK>; <LINK REF="STD-Tosi-2006a" TYPE="STUDY">Tosi 2006a</LINK>). We also excluded two phase II RCTs that tested denosumab (<LINK REF="STD-Fizazi-2009" TYPE="STUDY">Fizazi 2009</LINK>; <LINK REF="STD-Vij-2009" TYPE="STUDY">Vij 2009</LINK>) and one prognostic study (<LINK REF="STD-Terpos-2010" TYPE="STUDY">Terpos 2010</LINK>).</P><P>For this update, we excluded a further seven studies; two non-randomized studies (<LINK REF="STD-Chiang-2013" TYPE="STUDY">Chiang 2013</LINK>; <LINK REF="STD-Teoh-2012" TYPE="STUDY">Teoh 2012</LINK>), one cost-effectiveness study (<LINK REF="STD-Delea-2012" TYPE="STUDY">Delea 2012</LINK>), three studies addressing the role of denosumab (<LINK REF="STD-Henry-2014" TYPE="STUDY">Henry 2014</LINK>; <LINK REF="STD-Lipton-2012" TYPE="STUDY">Lipton 2012</LINK>; <LINK REF="STD-Vadhan_x002d_Raj-2012" TYPE="STUDY">Vadhan-Raj 2012</LINK>), and one study in which patients in both the arms received the same dose of zoledronate with a hypothesis that treatment with thalidomide and zoledronate would prolong the time to progression to MM over zoledronate alone (<LINK REF="STD-Witzig-2013" TYPE="STUDY">Witzig 2013</LINK>).</P><P>In total, in this update we excluded 23 studies (see details in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P></EXCLUDED_STUDIES_DESCR></STUDY_DESCRIPTION><STUDY_QUALITY MODIFIED="2017-11-16 18:52:04 +0100" MODIFIED_BY="[Empty name]"><P>We have presented the results of the 'Risk of bias' assessment in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. The study by Sezer and colleagues was published as meeting abstract (<LINK REF="STD-Sezer-2010" TYPE="STUDY">Sezer 2010</LINK>) and lacked the details needed for us to assess the methodological quality of this study. Hence we have extracted data from www.clinicaltrials.gov related to this study (<LINK REF="STD-Sezer-2010" TYPE="STUDY">Sezer 2010</LINK>).</P><ALLOCATION MODIFIED="2017-11-16 18:52:04 +0100" MODIFIED_BY="[Empty name]"><P>Twenty-nine per cent (7/24) of trials reported the method of generating the randomization sequence and are deemed as having a low risk of selection bias. Sixteen studies had a high risk of selection bias and one study had an unclear risk of selection bias.</P><P>Thirty-seven percent (9/24) of trials had adequate allocation concealment and are deemed as having a low risk of selection bias. Fourteen studies had a high risk of selection bias and one study had an unclear risk of selection bias.</P></ALLOCATION><BLINDING MODIFIED="2017-11-16 18:52:04 +0100" MODIFIED_BY="[Empty name]"><P>Thirty-seven per cent (9/24) of studies were reported as double-blinded and were deemed to have a low risk of performance bias. However, of these nine studies only four reported blinding procedures and details on specific personnel who were blinded to the intervention assignment and therefore to have a low risk of detection bias.Twelve per cent (3/24) of studies were open-label (<LINK REF="STD-Aviles-2013" TYPE="STUDY">Aviles 2013</LINK>; <LINK REF="STD-Garcia_x002d_Sanz-2015" TYPE="STUDY">Garcia-Sanz 2015</LINK>; <LINK REF="STD-Morgan-2010" TYPE="STUDY">Morgan 2010</LINK>).</P></BLINDING><EXCLUSIONS MODIFIED="2017-11-16 18:52:04 +0100" MODIFIED_BY="[Empty name]"><P>Withdrawals and dropouts (attrition bias) were described in 62% (15/24) of trials and deemed to have a low risk of attrition bias. Nine studies were deemed to have a high risk of attrition bias. Sixty-two per cent (15/24) of trials analyzed the data according to the ITT principle and were considered to have a low risk of attrition bias.</P></EXCLUSIONS><SELECTIVE_REPORTING MODIFIED="2017-11-16 18:52:04 +0100" MODIFIED_BY="[Empty name]"><P>We assessed the included studies for completeness of reporting for both benefits as well as treatment-related harms. All included studies reported the benefits and harms of the interventions in the way specified in the methods section of the trial publications. It is important to note that we did not have access to trial protocols, and hence could not assess the trial publications for selective reporting of outcomes. Overall, the risk of reporting bias was low in the included studies.</P></SELECTIVE_REPORTING><OTHER_BIAS_SOURCES MODIFIED="2017-11-16 18:52:04 +0100" MODIFIED_BY="[Empty name]"><P>The expected difference in the primary outcomes was prespecified in 37% (9/24) of RCTs. Type I and type II errors were reported in 33% (8/24) of RCTs. A priori sample size calculations were reported in 33% (8/24) of RCTs. (see <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> and <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> for details). We have categorized the elements extracted to calculate the risk of random error (pre-specification of alpha and beta errors and sample size calculation) as "other bias" in the 'risk of bias' table (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). The funnel plots for the primary outcome of overall mortality did not suggest publication bias.</P></OTHER_BIAS_SOURCES></STUDY_QUALITY><INTERVENTION_EFFECTS MODIFIED="2017-11-16 19:40:32 +0100" MODIFIED_BY="[Empty name]"><P>Altogether 24 RCTs enrolled 3680 participants in the bisphosphonates treatment group and 3621 in the control group. The study by Zhang et al did not report data on any of the outcomes of interest for this SR (<LINK REF="STD-Zhang-2012" TYPE="STUDY">Zhang 2012</LINK>). Data on overall survival (OS)/mortality were reported in 67% (16/24) of RCTs, and 37% (9/24) of RCTs reported PFS estimates. Data on vertebral fractures were reported in 353 (8/24) of RCTs, and 29% (7/24) of RCTs reported non-vertebral fracture data. Data on SREs were reported in 58% (14/24) of RCTs. Data on pain amelioration were reported in 37% (9/24) of RCTs. Data on hypercalcemia were reported in 50% (12/24) of RCTs. Data on GI toxicities were reported in 29% (7/24) of RCTs, and data on renal dysfunction were reported in only 12% (3/24) of RCTs. Data on hypocalcemia were reported in 12% (3/24) of RCTs. Calcium data were extractable in the continuous format from only two RCTs. However, effects of bisphosphonates on calcium were reported in the dichotomous (number of participants with hypocalcemia or hypercalcemia) format in most of the studies. Hence, we performed an meta-analysis using the dichotomous data. Data on the quality of life were not reported at all.</P><SUBSECTION><HEADING LEVEL="3">Results of direct comparison of treatment effects (bisphosphonates versus placebo or no treatment)</HEADING><SUBSECTION><HEADING LEVEL="4">Efficacy of bisphosphonates (benefits)</HEADING><P>(see also: <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>) </P><SUBSECTION><HEADING LEVEL="5">1) Effect on overall survival (OS)</HEADING><P>Data were extractable from 14 RCTs. These studies enrolled 2706 participants. The pooled results showed no evidence for a difference in improvement of OS with the use of bisphosphonates compared with placebo or no treatment. The pooled hazard ratio (HR) for the outcome of OS was 0.90 (95% confidence interval (CI) 0.76 to 1.07; P = 0.24) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). There was substantial heterogeneity among included trials (I<SUP>2 </SUP>= 65%; P = 0.0004) (see 'Assessment of bias: sensitivity analysis' section below for explanation of heterogeneity). The overall quality of evidence for OS was moderate (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">2) Effect on progression-free survival (PFS)</HEADING><P>Data were extractable from seven RCTs. These studies enrolled 908 participants. Use of bisphosphonates showed no evidence for a difference in improvement in PFS compared with placebo or no treatment. The pooled HR for PFS was 0.75 (95% CI 0.57 to 1.00; P = 0.05) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). There was no heterogeneity among trials reporting PFS estimates (I<SUP>2 </SUP>= 41%; P = 0.12). The overall quality of evidence for PFS was low (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">3) Effect on the number of participants with vertebral fractures</HEADING><P>Data were extractable from seven RCTs. These studies enrolled 1116 participants. The pooled results showed evidence for a difference in improvement in reducing vertebral fractures with use of bisphosphonates compared with placebo or no treatment. The pooled RR for the outcome of vertebral fractures was 0.74 (95% CI 0.62 to 0.89; P = 0.001) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). There was no heterogeneity among included RCTs (I<SUP>2 </SUP>= 7%; P = 0.38). The overall quality of evidence for vertebral fractures was moderate (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">4) Effect on the number of participants with non-vertebral fractures</HEADING><P>Data were extractable from six RCTs. These studies enrolled 1389 participants. The pooled results showed no evidence for a difference in reducing non-vertebral fractures with use of bisphosphonates compared with placebo or no treatment. The pooled RR for the outcome of vertebral fractures was 1.03 (95% CI 0.68 to 1.56; P = 0.90) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). We noted moderate heterogeneity among the included trials (I<SUP>2 </SUP>= 54%; P = 0.07). The overall quality of evidence for non-vertebral ractures was moderate (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">5) Effect on the total skeletal-related events (SREs)</HEADING><P>Data were extractable from 10 RCTs. These studies enrolled 2141 participants. The pooled results showed evidence for a difference in reducing SREs with use of bisphosphonates compared with placebo or no treatment. The pooled RR for the outcome of SREs was 0.74 (95% CI 0.63 to 0.88; P = 0.0005) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). We noted moderate heterogeneity among included RCTs (I<SUP>2 </SUP>= 48%; P = 0.04). The overall quality of evidence for SREs was moderate (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">6) Effect on pain</HEADING><P>Data were extractable from eight RCTs. These studies enrolled 1281 participants. The pooled results showed evidence for a difference in amelioration of pain with use of bisphosphonates compared with placebo or no treatment. The pooled RR for the outcome of pain was 0.75 (95% CI 0.60 to 0.95; P = 0.01) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). There was substantial heterogeneity among included RCTs (I<SUP>2 </SUP>= 63%; P = 0.008) (see 'Assessment of bias: sensitivity analysis' section below for explanation of heterogeneity). The overall quality of evidence for pain was very low (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">7) Effect on the incidence of hypercalcemia (&#8805; 2.65 mmol/L)</HEADING><P>Data were extractable from 10 RCTs. These studies enrolled 2174 participants. The pooled results showed no evidence for a difference in reducing hypercalcemia with use of bisphosphonates compared with placebo or no treatment. The pooled RR for the outcome of hypercalcemia was 0.78 (95% CI 0.56 to 1.09; P = 0.14) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).There was no heterogeneity among included RCTs (I<SUP>2 </SUP>= 21%; P = 0.25).</P><P><B>Treatment-related harms</B></P><P>The bisphosphonate-related harms that were extractable among eligible studies were gastrointestinal (GI) symptoms, hypocalcemia, renal dysfunction and ONJ. No bisphosphonate-related mortality was reported in any of the studies eligible for the analysis.</P><P><B>1) Osteonecrosis of the jaw (ONJ)</B></P><P>Data were extractable from six RCTs. These studies enrolled 1284 participants. The pooled results showed evidence for a difference in frequency of ONJ with use of bisphosphonates compared with placebo or no treatment. The pooled RR for the outcome of ONJ was 4.61 (95% CI 0.99 to 21.35; P = 0.05) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). There was no statistically significant heterogeneity among included RCTs (I<SUP>2 </SUP>= 0%; P = 0.95). The overall quality of evidence for ONJ was low (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P><P>Two RCTs with bisphosphonate as the comparator also reported estimates of ONJ. In the RCT by Morgan et al (<LINK REF="STD-Morgan-2010" TYPE="STUDY">Morgan 2010</LINK>), zoledronate was associated with higher rates of ONJ (35/983 (4%)) than was clodronate (3/979 (&lt; 1%)). In the RCT by Gimsing et al, ONJ was reported in 2 of 252 participants receiving 30 mg of pamidronate compared with 8 of 250 participants receiving 90 mg of pamidronate (<LINK REF="STD-Gimsing-2010" TYPE="STUDY">Gimsing 2010</LINK>). Even though only 5 RCTs reported ONJ, a growing number of ONJ case reports and observational studies evaluating ONJ have been published in recent years (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>; <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>; <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>). We analyzed 9 observational trials that evaluated 1400 participants regarding ONJ. The highest frequencies of ONJ were seen in studies that used a combination of pamidronate and zoledronate (range 5% to 51%). Zoledronate was associated with ONJ in 3% to 11% of cases. Pamidronate related frequencies of ONJ ranged from 0% to 18%. Overall, for every 1,000 participants treated with bisphosphonates, about one patient will suffer from the ONJ.</P><P><B>2) Gastrointestinal symptoms</B></P><P>Data were extractable from seven RCTs. These studies enrolled 1829 participants. The pooled results showed no evidence for a difference in frequency of GI symptoms with use of bisphosphonates compared with placebo or no treatment. The pooled RR for the outcome of GI symptoms was 1.23 (95% CI 0.95 to 1.59; P = 0.12) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). There was no significant statistical heterogeneity among included RCTs (I<SUP>2 </SUP>= 0%; P = 0.95).</P><P>One RCT with bisphosphonate as the comparator also reported estimates of GI symptoms (<LINK REF="STD-Morgan-2010" TYPE="STUDY">Morgan 2010</LINK>). In the RCT by Morgan and colleagues, 24 of 981 participants enrolled in the zoledronate arm had GI symptoms, and 30 of 979 participants receiving clodronate had GI symptoms (<LINK REF="STD-Morgan-2010" TYPE="STUDY">Morgan 2010</LINK>).</P><P>The most common adverse events with oral bisphosphonates are upper GI toxicities, such as gastritis (<LINK REF="REF-Van-Holten_x002d_Verzantvoort-1993" TYPE="REFERENCE">Van Holten-Verzantvoort 1993</LINK>) and diarrhea (<LINK REF="REF-Atula-2003" TYPE="REFERENCE">Atula 2003</LINK>). The intravenous infusions can be associated with injection site reaction and acute systematic inflammatory reactions (<LINK REF="REF-Tanvetyanon-2006" TYPE="REFERENCE">Tanvetyanon 2006</LINK>). Different authors have used various methods to assess GI symptoms. Our first choice was to use the overall number of participants with GI symptoms. When this number was not available, we used the most common symptoms; in the majority of cases, it was abdominal pain. However, in some studies, nausea or vomiting was a more prevalent symptom. For our analysis, we pooled all GI symptoms together.</P><P><B>3) Hypocalcemia</B></P><P>Data were extractable from three RCTs. These studies enrolled 1090 participants. The pooled results showed no evidence for a difference in frequency of hypocalcemia with use of bisphosphonates compared with placebo or no treatment. The pooled RR for the outcome of hypocalcemia was 2.19 (95% CI 0.49 to 9.74; P = 0.30) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). There was no statistically significant heterogeneity among included RCTs (I<SUP>2 </SUP>= 0%; P = 0.88).</P><P>One RCT with bisphosphonate as the comparator also reported estimates of hypocalcemia (<LINK REF="STD-Terpos-2003" TYPE="STUDY">Terpos 2003</LINK>). In the RCT by Terpos and colleagues, none of the 23 participants enrolled in the pamidronate arm had hypocalcemia, while two of 19 participants receiving ibandronate did (<LINK REF="STD-Terpos-2003" TYPE="STUDY">Terpos 2003</LINK>). All bisphosphonates can cause hypocalcemia, regardless of the method of administration, although this only occurs infrequently as a clinically symptomatic problem. Effects of bisphosphonates on calcium were reported in the dichotomous (number of participants with hypocalcemia) rather than in the continuous format in most of the studies, leading to loss of available information.                                    </P><P><B>4) Renal dysfunction</B></P><P>Data were extractable from two RCTs (<LINK REF="STD-Daragon-1993" TYPE="STUDY">Daragon 1993</LINK>; <LINK REF="STD-Lahtinen-1992" TYPE="STUDY">Lahtinen 1992</LINK>) in the form of serum creatinine estimates. These studies enrolled 414 participants. The pooled results showed no evidence for a difference in the frequency of elevated serum creatinine with the use of bisphosphonates compared with placebo or no treatment. The pooled mean difference for the outcome of renal dysfunction was &#8722;0.36 (95% CI &#8722;9.75 to 9.03; P = 0.94) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). There was no significant statistical heterogeneity among included RCTs (I<SUP>2 </SUP>= 18%; P = 0.27).</P><P>One RCT (<LINK REF="STD-Garcia_x002d_Sanz-2015" TYPE="STUDY">Garcia-Sanz 2015</LINK>), reported estimates of renal dysfunction where two of 51 participants enrolled in the zoledronate arm and two of 49 participants in the control arm reported renal dysfunction. One RCT with bisphosphonate as the comparator also reported estimates of renal failure (<LINK REF="STD-Morgan-2010" TYPE="STUDY">Morgan 2010</LINK>); 57 of 983 participants enrolled in the zoledronate arm had renal failure, while 60 of 979 participants receiving clodronate had renal failure (<LINK REF="STD-Morgan-2010" TYPE="STUDY">Morgan 2010</LINK>).</P><P>Renal dysfunction is a particularly problematic adverse event that can also occur after infusion of intravenous bisphosphonates. The US Food and Drug Administration reported that 72 participants had renal failure following zoledronate therapy (<LINK REF="REF-Chang-2003" TYPE="REFERENCE">Chang 2003</LINK>). As a result, the product labels for pamidronate and zoledronate were amended to include additional nephrotoxicity warnings. However, the true incidence of this adverse event remains unknown.</P><P><B>Quality of life: </B>None of the included studies reported quality of life.</P><P><B>Assessment of bias: sensitivity analysis </B></P><P>Sensitivity analyses were performed to assess the robustness of our findings and explore possible reasons for heterogeneity.</P><P><B>Sensitivity analysis according to methodological quality of reporting </B></P><P>All trials were evaluated according to methodological quality dimensions to assess the existence of potential inaccuracies in our results (<LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>). In particular, we focused on dimensions that have been empirically linked to bias and random error. We preformed sensitivity analyses according to adequacy of allocation concealment (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>), blinding, ITT analysis, description of withdrawals and dropouts, and pre specification of type I and II errors for all outcomes (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). The results did not change for any outcome except in case of pain. We found that RCTs with double-blinding showed no significant benefit of bisphosphonates over placebo for amelioration of pain (RR 0.83, 95% CI 0.69 to 1.00), while non-blinded RCTs favored bisphosphonates over placebo for pain relief (RR 0.28, 95% CI 0.12 to 0.67; test of interaction: P = 0.005). Similarly, RCTs with ITT analysis showed no significant benefit of bisphosphonates over placebo for amelioration of pain (RR 0.93, 95% CI 0.75 to 1.14), while RCTs with per protocol analysis favored bisphosphonates over placebo for pain relief (RR 0.54, 95% CI 0.33 to 0.89) (test of interaction: P = 0.04).</P><P>Examples based on the outcome of vertebral fractures and corresponding figures are provided to give a visual impression of results of the sensitivity analyses (<LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>). Only two out of seven studies that reported the rate of vertebral fractures had adequate allocation concealment but sensitivity analysis performed according to this criterion indicated no change in the results. Three of seven trials reporting vertebral fractures were performed according to ITT analysis, and these trials showed a smaller treatment effect, which may be due to the exclusion of the largest trial from the analysis (<LINK REF="STD-Berenson-1998a" TYPE="STUDY">Berenson 1998a</LINK>). Five of seven studies reporting vertebral fractures were double-blind, but the results were unchanged in this subgroup analysis. Only one of seven studies reporting vertebral fractures described the randomization method, but the results were also unchanged in this subgroup analysis. Furthermore, only two of seven studies reporting vertebral fractures clearly noted the withdrawals and dropouts, but the results remained unchanged in this subgroup analysis. Only <LINK REF="STD-Lahtinen-1992" TYPE="STUDY">Lahtinen 1992</LINK> prespecified the type I and II errors out of seven studies reporting vertebral fractures, but the results were unchanged in this subgroup analysis. </P><P><B>Sensitivity analysis according to bisphosphonate potency</B></P><P>The potential cause of heterogeneity was explored by meta-regression. We investigated whether potency of bisphosphonates contributed to the decrease in mortality according to bisphosphonate potency as a covariate (on the log scale) (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). The Knapp-Hartung meta-regression showed that HR decreases by 7% per 1000 unit increase in bisphosphonate potency (HR 0.94, 95% CI 0.90 to 0.98) given on the log scale. The bisphosphonate potency explained 91.34% of between-study variance (the between-study variance dropped from 0.035 to 0.009). Meta-regression results indicated that the beneficial effect of bisphosphonates on survival in participants with MM may be a function of drug potency, with zoledronate being the most potent bisphosphonate (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P><P>We also conducted meta-regression for PFS. However, meta-regression results indicated that the effect of a bisphosphonate on restricting disease progression in participants with MM did not differ by bisphosphonate potency (HR 0.94, 95%CI 0.77 to 1.14).</P><P><B>Sensitivity analysis according to treatment duration</B></P><P>We conducted additional sensitivity analyses based on duration of treatment (indefinite versus 0 to 24 months). The results were unchanged for all outcomes except for non-vertebral fractures. The only RCT (<LINK REF="STD-McCloskey-2001" TYPE="STUDY">McCloskey 2001</LINK>) with an indefinite duration of treatment with clodronate showed a statistically significant benefit in favor of clodronate (RR 0.53, 95% CI 0.29 to 0.97), while four RCTs with 0 to 24 months of treatment duration showed no benefit for reduction of non-vertebral fractures (RR 1.25, 95% CI 0.94 to 1.66) (test of interaction: P = 0.01).</P><P><B>Sensitivity analysis according to route of administration for gastrointestinal toxicity outcome</B></P><P>We conducted additional sensitivity analyses based on route of administration (oral versus intravenous) for GI toxicity outcome (<LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>). The results were unchanged for this outcome (test of interaction: P = 0.97).</P></SUBSECTION></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Results of network meta-analysis of treatment effects</HEADING><P>Indirect comparisons or network meta-analysis was conducted for all the outcomes. Data for only the key outcomes are shown here.</P><SUBSECTION><HEADING LEVEL="4">Efficacy of bisphosphonates (benefits)</HEADING><P><B>1) Effect on overall survival (OS)</B></P><P>Overall survival/mortality data were available from 16 RCTs involving 5260 participants. A total of 21 indirect comparisons were possible (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). The network meta-analysis by MTC method (16 RCTs, 5260 participants) showed the superiority of zoledronate over placebo (HR 0.67, 95% CI 0.46 to 0.91) and etidronate (HR 0.56, 95% CI 0.29 to 0.87) (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). The results of the MTC method are in agreement with the direct comparison of zoledronate versus placebo in two RCTs (<LINK REF="STD-Aviles-2007" TYPE="STUDY">Aviles 2007</LINK>; <LINK REF="STD-Aviles-2013" TYPE="STUDY">Aviles 2013</LINK>).</P><P><B>2) Effect on progression-free survival (PFS)</B></P><P>Data on PFS were available from nine RCTs involving 3472 participants. A total of 10 indirect comparisons were possible (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). The network meta-analysis by MTC method (Nine RCTs, 3472 participants) did not show the superiority of any particular bisphosphonate regimen over others (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). MTC analysis did not show a benefit with zoledronate over clodronate ( nine RCTs, 3472 participants; HR 1.10, 95% CI 0.46 to 1.95) (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P><P><B>3) Effect on the number of participants with vertebral fractures</B></P><P>Data on participants with vertebral fractures were available from eight RCTs involving 3076 participants. A total of six indirect comparisons were possible (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). The head-to-head (direct) comparison of zoledronate with clodronate in the RCT <LINK REF="STD-Morgan-2010" TYPE="STUDY">Morgan 2010</LINK> showed a statistically significant benefit with zoledronate over clodronate (one RCT, 1960 participants; RR 0.62, 95% CI 0.44 to 0.87). The MTC method did not show a benefit with zoledronate over clodronate (eight RCTs, 3076 participants; HR 0.59, 95% CI 0.22 to 1.17) (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). The results of MTC analysis showed that zoledronate was superior (eight RCTs, 3076 participants; RR 0.42, 95% CI 0.12 to 0.94) to placebo (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). For all other comparisons the network meta-analysis by MTC method (eight RCTs, 3076 participants) did not show the superiority of any particular bisphosphonate regimen over others (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P><P><B>4) Effect on the total skeletal-related events</B></P><P>Data on participants with SREs were available from 13 RCTs involving 5727 participants. A total of 21 indirect comparisons were possible (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). Indirect comparison by MTC showed the superiority of zoledronate over placebo (RR 0.57, 95% CI 0.37 to 0.76), zoledronate over ibandronate (RR 0.56, 95% CI 0.26 to 0.98) and pamidronate 90 mg over placebo (RR 0.71, 95% CI 0.49 to 0.96). For all other comparisons the network meta-analysis by MTC method (13 RCTs, 5727 participants) did not show the superiority of any particular bisphosphonate regimen over others (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P><P><B>5) Effect on pain   </B>                                                                                                                                    </P><P>Data on the effect of bisphosphonates on pain control were available from eight RCTs involving 1281 participants. A total of six indirect comparisons were possible. The network meta-analysis by MTC method (eight RCTs, 1281 participants) did not show superiority of any particular bisphosphonate regimen over others (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). MTC analysis did not show a benefit with clodronate over ibandronate (eight RCTs, 1281 participants; RR 4.13, 95% CI 0.57 to 16.99) (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P><P><B>6) Effect on hypercalcemia   </B>                                                                                                                                    </P><P>Data on the effect of bisphosphonates on hypercalcemia were available from 11 RCTs involving 4146 participants. Indirect comparisons by the MTC method (11 RCTs, 4146 participants) did not show superiority of any particular bisphosphonate regimen over others (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P><P><B>Treatment-related harms</B></P><P>We also conducted network meta-analysis by the MTC method for the outcomes of hypocalcemia, renal dysfunction, GI toxicity and ONJ. Results of network meta-analysis by the MTC method were consistent with the results from direct comparisons. Network meta-analysis by the MTC method did not show any differences in the incidence of hypocalcemia, renal dysfunction, and GI toxicity among the bisphosphonates used.</P><P>Effect on osteonecrosis of the jaw (ONJ)</P><P>Data on the effect of bisphosphonates on ONJ were available from eight RCTs involving 3746 participants. Indirect comparisons by the MTC method show an increased risk of ONJ with zoledronate over clodronate (RR 0.13, 95% CI 0.02 to 0.44). For all other comparisons network meta-analysis by the MTC method did not show any differences in the incidence of ONJ (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P><P>Since our network has only one triangle loop, its consistency was assessed using a simple method described by Bucher and colleagues (<LINK REF="REF-Bucher-1997" TYPE="REFERENCE">Bucher 1997</LINK>). The estimates of consistency indicate that the network was consistent for OS (95% CI &#8722;0.86 to 0.07) and PFS (95% CI &#8722;0.38 to 0.33). We also ranked each treatment according to the probability that it is best for the outcomes of OS, PFS, SREs, hypercalcemia, GI toxicity and ONJ (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). We also calculated the surface under the cumulative ranking (SUCRA) line for each treatment, which is equal to 1 when the treatment is certain to be the best and 0 when it is certain to be the worst (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). As both rankogram SUCRA show, zoledronate consistently ranked as the best treatment, followed by pamidronate and clodronate. Since the choice of prior for between-studies variance can lead to drastic variation in results (<LINK REF="REF-Lambert-2005" TYPE="REFERENCE">Lambert 2005</LINK>), especially in a small number of studies, we had already performed an extensive sensitivity analysis in our previous systematic reviews (<LINK REF="REF-Mhaskar-2010" TYPE="REFERENCE">Mhaskar 2010</LINK>; <LINK REF="REF-Mhaskar-2012" TYPE="REFERENCE">Mhaskar 2012</LINK>), in which we assessed a total of five priors (gamma, uniform, Pareto, logistic and half-normal) based on their application in the literature (<LINK REF="REF-Scurrah-2000" TYPE="REFERENCE">Scurrah 2000</LINK>; <LINK REF="REF-Thompson-1997" TYPE="REFERENCE">Thompson 1997</LINK>). Gamma and logistic priors exhibited poor convergence. Generally, as the number of studies decreased, the selection of prior dominated the estimates. We noted that the credibility intervals became wider for the less informative priors.</P></SUBSECTION></SUBSECTION></INTERVENTION_EFFECTS></RESULTS><DISCUSSION MODIFIED="2017-11-16 19:39:07 +0100" MODIFIED_BY="[Empty name]"><SUMMARY_OF_RESULTS MODIFIED="2017-11-16 18:52:04 +0100" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="3">Key benefits with use of bisphosphonates:</HEADING><P>The potential beneficial effect of bisphosphonates on survival is the most intriguing question, as anti-tumor effects against myeloma cells were seen both in vitro (<LINK REF="REF-Aparicio-1998" TYPE="REFERENCE">Aparicio 1998</LINK>; <LINK REF="REF-Shipman-1997" TYPE="REFERENCE">Shipman 1997</LINK>) and in vivo (<LINK REF="REF-Dhodapkar-1998" TYPE="REFERENCE">Dhodapkar 1998</LINK>). The direct comparisons in this meta-analysis demonstrate no evidence for a difference related to survival with bisphosphonate compared to placebo. However, evidence for a difference in overall survival (OS) with bisphosphonates compared with placebo/other bisphosphonate was seen in three RCTs (<LINK REF="STD-Aviles-2007" TYPE="STUDY">Aviles 2007</LINK>; <LINK REF="STD-Aviles-2013" TYPE="STUDY">Aviles 2013</LINK>; <LINK REF="STD-Morgan-2010" TYPE="STUDY">Morgan 2010</LINK>). The two studies by Aviles and colleagues comparing zoledronate with placebo showed evidence for a difference with zoledronate in improving OS compared with placebo (<LINK REF="STD-Aviles-2007" TYPE="STUDY">Aviles 2007</LINK>; <LINK REF="STD-Aviles-2013" TYPE="STUDY">Aviles 2013</LINK>). The study by Morgan and colleagues showed a clinically significant anti-MM effect of zoledronic acid compared with clodronate on OS (<LINK REF="STD-Morgan-2010" TYPE="STUDY">Morgan 2010</LINK>). However, the results from our network meta-analysis of 15 randomized controlled trials (RCTs) and 4866 participants showed no evidence for a difference with zoledronate over any other amino-bisphosphonates or clodronate for OS. Similarly, direct comparisons and network meta-analysis did not show superiority of any specific bisphosphonate over placebo or no treatment and other bisphosphonates in improving progression-free survival (PFS).</P><P>The results of this meta-analysis show a reduction in total skeletal-related events (SREs) and vertebral fractures, a significant advantage for the participants treated with bisphosphonates. Our results show evidence for a difference with bisphosphonates compared with placebo for the prevention of pathological fractures, most likely due to the effect on preventing pathological vertebral collapses. Interestingly, there was no evidence for a difference with bisphosphonates compared with placebo on reduction of non-vertebral fractures. Bisphosphonates inhibit osteoclastic bone resorption and thereby increase the degree of bone mineralization. Animal models focusing on trabecular bones have also shown that the mechanical properties of the bone (torsion stiffness and elasticity) are improved with the use of bisphosphonates. A comparative study of trabecular and cortical bones in beagle dogs demonstrated that the effect of pamidronate to improve torsion stiffness and elasticity is restricted to trabecular bones, whereas no change was seen in cortical bones (<LINK REF="REF-Acito-1994" TYPE="REFERENCE">Acito 1994</LINK>). Similar observations have been made in postmenopausal women treated with pamidronate (<LINK REF="REF-Fromm-1991" TYPE="REFERENCE">Fromm 1991</LINK>). These studies support our findings that the vertebral fractures are clearly reduced and there was no significant effect on non-vertebral fractures. However, it must be taken into consideration that several studies did not report these events in sufficient detail.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Key harms with use of bisphosphonates:</HEADING><P>There was evidence for a difference with bisphosphonates related to increased risk for osteonecrosis of the jaw (ONJ) in participants using bisphosphonates compared with placebo or no treatment, which was not seen in the previous meta-analysis (<LINK REF="REF-Mhaskar-2012" TYPE="REFERENCE">Mhaskar 2012</LINK>). RCTs showed that, on average, for every 1000 participants treated with bisphosphonates, about one patient will suffer from the ONJ. Only eight RCTs reported ONJ, and the network meta-analysis showed that no specific bisphosphonate was associated with an increased incidence of ONJ compared with other bisphosphonates. However, this in part could be a reflection of rare events and thus RCTs with more power are needed for more precise estimates. We also identified 61 observational studies (including case reports) reporting 676 cases of ONJ. The observational studies estimated ONJ to be 0% to 51%, which is in a stark contrast with the estimates obtained from RCTs. The reason for this discrepancy is probably due to the combined effect of inherent limitations associated with observational studies and different eligibility criteria in RCTs versus non-RCTs. No other significant adverse effects associated with the administration of bisphosphonates were identified in the included RCTs.</P></SUBSECTION></SUMMARY_OF_RESULTS><APPLICABILITY_OF_FINDINGS MODIFIED="2017-11-16 18:52:04 +0100" MODIFIED_BY="[Empty name]"><P>Physicians&#8217; choices regarding type of bisphosphonates for the management of people with multiple myeloma should ideally be based on evidence from comparative trials. There are only four head-to-head comparative studies of bisphosphonates (<LINK REF="STD-Gimsing-2010" TYPE="STUDY">Gimsing 2010</LINK>; <LINK REF="STD-Morgan-2010" TYPE="STUDY">Morgan 2010</LINK>; <LINK REF="STD-Rosen-2003" TYPE="STUDY">Rosen 2003</LINK>; <LINK REF="STD-Terpos-2003" TYPE="STUDY">Terpos 2003</LINK>). Unfortunately, the data from <LINK REF="STD-Rosen-2003" TYPE="STUDY">Rosen 2003</LINK> were not extractable for participants with MM for outcomes other than SREs, and Terpos and colleagues (<LINK REF="STD-Terpos-2003" TYPE="STUDY">Terpos 2003</LINK>) report data addressing only two outcomes (hypercalcemia and hypocalcemia) of interest for this systematic review. <LINK REF="STD-Terpos-2003" TYPE="STUDY">Terpos 2003</LINK> concluded that a monthly dose of 90 mg of pamidronate is more effective than 4 mg of ibandronate in reducing osteoclast activity, bone resorption and possibly tumour burden in MM. The RCT by Morgan and colleagues compared the effects of zoledronate versus clodronate in participants with MM. The results of this head-to-head comparison showed that treatment with zoledronate was associated with a significant reduction in the proportion of participants with SREs (27% versus 35% with clodronate) and vertebral fractures (5% versus 9% with clodronate), and slightly increased median PFS by two months. But most remarkably, the median OS was significantly improved by 5.5 months with zoledronate compared with clodronate (<LINK REF="STD-Morgan-2010" TYPE="STUDY">Morgan 2010</LINK>; <LINK REF="REF-Rajkumar-2010" TYPE="REFERENCE">Rajkumar 2010</LINK>). Our meta-regression analysis showed a significant trend (P = 0.007) based on the bisphosphonate potency (7% reduction in mortality for each 1000 unit increase in bisphosphonate potency), with zoledronate being the most potent bisphosphonate (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). This would imply that zoledronate indeed is the most effective bisphosphonate. However, no such effect was seen in a meta-regression for PFS raising the issue of the mechanism of improving survival, if PFS is not affected, it does not appear to be plausible to improve OS. In addition, our network meta-analyses of 15 RCTs and 5160 participants indicated that zoledronate was not superior to any other bisphosphonate for any outcomes except etidronate. Nevertheless, we should note that in the context of MTC uncertainty analysis, zoledronate ranked as the best treatment, followed by clodronate and pamidronate. However, we noted no difference when pamidronate was compared with clodronate or zoledronate for all outcomes. These findings underscore the need for comparative evaluation of the newer potent amino-bisphosphonates, especially zoledronate versus pamidronate, in an RCT to enable appropriate healthcare decision making. Also, future studies should investigate bisphosphonate treatments as a palliative treatment by measuring its influence on quality-of-life outcomes.</P></APPLICABILITY_OF_FINDINGS><QUALITY_OF_EVIDENCE MODIFIED="2017-11-16 18:52:04 +0100" MODIFIED_BY="[Empty name]"><P>We assessed the potential risk of bias of the included trials according to the previously described quality domains; these are represented in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. The majority of included trials suffered from a high risk of selection bias. The majority of the included studies reported analyses according to the principle of intention to-treat (ITT). The majority of included trials had a high risk of performance and detection bias. Twelve per cent (3/24) of studies were open-label (<LINK REF="STD-Aviles-2013" TYPE="STUDY">Aviles 2013</LINK>; <LINK REF="STD-Garcia_x002d_Sanz-2015" TYPE="STUDY">Garcia-Sanz 2015</LINK>; <LINK REF="STD-Morgan-2010" TYPE="STUDY">Morgan 2010</LINK>).</P><P>Overall, the quality of evidence according to the GRADE criteria was moderate to low. The study by Zhang and colleagues was published in both English and Mandarin language. We have reviewed and have included both of these publications in this systematic review (<LINK REF="STD-Zhang-2012" TYPE="STUDY">Zhang 2012</LINK>). Nonetheless, we noticed that the publication in the Mandarin language referred to this study as a randomized study but the English language publication does not explicitly mention any details regarding randomization. However, it is important to note that, this study did not report any of the outcomes of interest for this systematic review. We also noticed a discrepancy between the <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A> record and the publication of the study by Aviles and colleagues (<LINK REF="STD-Aviles-2013" TYPE="STUDY">Aviles 2013</LINK>). Specifically, on the <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A> this study has been labeled as an observational case-control type of study and the publication refers to this study as a randomized control trial.</P><P>One criterion for high-quality reporting is that the data should be reported in a form that allow them to be extracted and used in a quantitative research synthesis (i.e. meta-analysis). In most of the studies included in this systematic review, treatment-related morbidities were not reported as events per patient and thus could not be used in the meta-analysis. That is, treatment-related morbidities were reported using statements that did not allow us to distinguish between specific adverse events occurring in multiple participants or multiple events occurring in a single patient.</P></QUALITY_OF_EVIDENCE><POTENTIAL_BIASES MODIFIED="2017-11-16 19:38:23 +0100" MODIFIED_BY="[Empty name]"><P>We did not find any methodological issues in the preparation of the review that could put it at risk for bias. We identified one ongoing study comparing zoledronic acid with no treatment. No findings were available as the trial is still recruiting participants (<LINK REF="STD-Lund-2014" TYPE="STUDY">Lund 2014</LINK>). <LINK REF="STD-Sezer-2010" TYPE="STUDY">Sezer 2010</LINK> was published as a meeting abstract only. We were able to obtain some data form <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A> record for this study. Nonetheless, for reasons unknown to us, this study was not published as a full manuscript, and hence we were not able to access the complete data and findings from this study. Indeed, we were not able to extract data on all outcomes from all the studies (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Furthermore, one RCT (<LINK REF="STD-Garcia_x002d_Sanz-2015" TYPE="STUDY">Garcia-Sanz 2015</LINK>) did not come up in the formal search and was identified by the Cochrane Hematological Malignancies Group which, we suspect, was due to inadequate cataloguing. The funnel plot for assessment of publication bias showed asymmetry only for the outcome of pain, indicating the possibility of outcome reporting bias or publication bias (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>). However, the findings are also consistent with heterogeneity in interventions or the tendency for the smaller studies to show larger treatment effects (<LINK REF="REF-Sterne-2001" TYPE="REFERENCE">Sterne 2001</LINK>). Similarly, the observed between-trial heterogeneity makes interpretation of funnel plots difficult and increases the false-positive rate of the tests. Given the comprehensiveness of our search efforts and the fact that most of the trials testing bisphosphonates were small and underpowered, the small-study effect is the most likely explanation for the asymmetry seen in the funnel plots (<LINK REF="REF-Sterne-2001" TYPE="REFERENCE">Sterne 2001</LINK>).</P></POTENTIAL_BIASES><AGREEMENT MODIFIED="2017-11-16 19:39:07 +0100" MODIFIED_BY="[Empty name]"><P>A Cochrane systematic review examined relief of pain secondary to bone metastases by using bisphosphonates in 30 identified RCTs (<LINK REF="REF-Wong-2002" TYPE="REFERENCE">Wong 2002</LINK>). The review concluded that the evidence is insufficient to recommend bisphosphonates for immediate pain-relief effect. This finding contradicts our results, as well as those of earlier reviews examining the role of bisphosphonates in myeloma patients (<LINK REF="REF-Mhaskar-2010" TYPE="REFERENCE">Mhaskar 2010</LINK>; <LINK REF="REF-Mhaskar-2012" TYPE="REFERENCE">Mhaskar 2012</LINK>), indicating a likely beneficial effect of bisphosphonates on pain reduction. The discrepancy between the results of our systematic review and the systematic review by Wong and colleagues lies in the decision about which studies should be included and methods of pain reporting as extensively discussed in our previous reviews (<LINK REF="REF-Mhaskar-2010" TYPE="REFERENCE">Mhaskar 2010</LINK>; <LINK REF="REF-Mhaskar-2012" TYPE="REFERENCE">Mhaskar 2012</LINK>). Although there was a beneficial effect of bisphosphonates on the number of patients with myeloma reporting bone pain in this review, these data must be treated with caution because of the lack of uniformity in data reporting and the presence of statistically significant heterogeneity. The variation in the methods of reporting pain and the quality of included RCTs contributed to the statistically significant heterogeneity observed in pain estimates.</P></AGREEMENT></DISCUSSION><CONCLUSIONS MODIFIED="2017-11-16 18:52:04 +0100" MODIFIED_BY="[Empty name]"><IMPLICATIONS_PRACTICE MODIFIED="2017-11-16 18:52:04 +0100" MODIFIED_BY="[Empty name]"><P>Adding bisphosphonates to the treatment of multiple myeloma (MM) reduces vertebral fractures and probably pain. We found no evidence for a difference for overall survival (OS) and progression-free survival (PFS) with bisphosphonates compared with placebo. The benefits of bisphosphonates should be considered, keeping in mind the risk of developing osteonecrosis of the jaw (ONJ). Zoledronate appears to be superior to etidronate (non-aminobisphosphonate) and placebo for the outcome of OS. However, whether zoledronate is superior to pamidronate and other aminobisphosphonates remains to be determined.</P></IMPLICATIONS_PRACTICE><IMPLICATIONS_RESEARCH MODIFIED="2017-11-16 18:52:04 +0100" MODIFIED_BY="[Empty name]"><P>Our findings underscore the urgent need for a randomized controlled trial (RCT) with a head-to-head comparison of zoledronate and pamidronate for their efficacy and safety in patients with MM. In addition, future studies should investigate bisphosphonate treatments as a palliative treatment by measuring its influence on quality-of-life outcomes. There is also a need for studies addressing cost-effectiveness and adverse events, especially ONJ, of bisphosphonate therapy.</P></IMPLICATIONS_RESEARCH></CONCLUSIONS></BODY><ACKNOWLEDGEMENTS MODIFIED="2017-11-16 19:39:47 +0100" MODIFIED_BY="[Empty name]"><P>We want to thank Dr Terpos and Dr McCloskey for verification of extracted data from their papers, as well as Dr Ruiz-Erenchun, Hoffmann-La Roche Ltd, Basel, Switzerland, who provided additional data from the ibandronate trial. Dr Poglód provided additional information on the trials of his group. We also want to thank the Cochrane peer-reviewers and editors for critical reading of our review and helpful feedback. We thank Dr Thomas A. Trikalinos for his suggestions regarding meta-regression. We also thank the Cochrane Hematological Malignancies Group for their assistance in identifying the RCT by Garcia-Sanz and colleagues.</P></ACKNOWLEDGEMENTS><CONFLICT_OF_INTEREST MODIFIED="2017-11-16 19:39:20 +0100" MODIFIED_BY="[Empty name]"><P>RM: None known. </P><P>AK: None known.</P><P>BM: None known.</P><P>BD: None known.</P></CONFLICT_OF_INTEREST><CONTRIBUTIONS MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]"><P>For this update:</P><P>RM handsearched journals and references, extracted and analyzed data, wrote the initial and final drafts and participated in all phases of the project.</P><P>BD oversaw and co-ordinated the group activity, maintained contact with Cochrane, provided vital content and methodological inputs, and edited the review.</P><P>AK extracted data, contacted a researcher regarding unpublished data, and maintained contact with Cochrane.</P><P>BM conducted the indirect comparisons using Bayesian methods.</P><P>BD, RM and AK discussed methodological problems.</P><P>All co-authors interpreted data, provided constructive critiques and agreed on the final version of the paper.</P></CONTRIBUTIONS><PRO_REV_DIFF MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]"><P>Compared with the last version of this systematic review, we employed only the Bayesian method for the network meta-analysis. That is, we have not used the frequentist method for performing adjusted indirect comparisons as described by Bucher, Glenny and Caldwell and colleagues. According to the revised guidelines for network meta analysis; we used the Bayesian methods under random-effects multiple treatment comparisons (MTC) for indirect comparisons/network meta analysis (<LINK REF="REF-Higgins-1996" TYPE="REFERENCE">Higgins 1996</LINK>; <LINK REF="REF-Lu-2004" TYPE="REFERENCE">Lu 2004</LINK>). Also, as per the peer reviewer's suggestions; we conducted additional sensitivity analyses based on the route of administration (oral versus intravenous) for gastrointestinal toxicity outcome (<LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>), which was not part of the protocol.</P><P>We also identified observational studies and case reports regarding bisphosphonate-related ONJ in the MEDLINE database</P></PRO_REV_DIFF><PUBLIC_NOTES/></MAIN_TEXT><STUDIES_AND_REFERENCES MODIFIED="2017-12-18 15:52:21 +0000" MODIFIED_BY="Nicole Skoetz">
<STUDIES MODIFIED="2017-11-16 19:44:16 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2017-11-16 19:44:16 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Attal-2006" MODIFIED="2016-06-29 15:46:43 +0200" MODIFIED_BY="[Empty name]" NAME="Attal 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-08-17 16:26:53 +0200" MODIFIED_BY="Rahul S Mhaskar" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, et al</AU>
<TI>Maintenance therapy with thalidomide improves survival in patients with multiple myeloma</TI>
<SO>Blood</SO>
<YR>2006</YR>
<VL>108</VL>
<NO>10</NO>
<PG>3289-94</PG>
<IDENTIFIERS MODIFIED="2009-06-26 23:08:11 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891790"/><IDENTIFIER TYPE="PUBMED" VALUE="16873668"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-06-29 15:46:43 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891789"/><IDENTIFIER MODIFIED="2016-06-29 15:46:43 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1182/blood-2006-05-022962"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aviles-2007" MODIFIED="2016-06-29 15:49:04 +0200" MODIFIED_BY="[Empty name]" NAME="Aviles 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-22 17:32:18 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aviles A, Nambo MJ, Neri N, Castaneda C, Cleto S, Huerta-Guzman J</AU>
<TI>Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma</TI>
<SO>Medical Oncology (Northwood, London, England)</SO>
<YR>2007</YR>
<VL>24</VL>
<NO>2</NO>
<PG>227-30</PG>
<IDENTIFIERS MODIFIED="2009-06-22 16:42:05 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891792"/><IDENTIFIER TYPE="PUBMED" VALUE="17848748"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-06-29 15:49:04 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891791"/><IDENTIFIER MODIFIED="2016-06-29 15:49:04 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1007/BF02698044"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aviles-2013" MODIFIED="2016-06-28 22:50:25 +0200" MODIFIED_BY="[Empty name]" NAME="Aviles 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-02-19 20:45:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Aviles A, Neri N, Huerta-Guzman J, Nambo MJ</AU>
<TI>Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation</TI>
<SO>Current oncology (Toronto, Ont.)</SO>
<YR>2013</YR>
<VL>20</VL>
<NO>1</NO>
<PG>e13-20</PG>
<IDENTIFIERS MODIFIED="2016-02-19 20:45:19 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891794"/><IDENTIFIER TYPE="DOI" VALUE="10.3747/co.20.1055"/><IDENTIFIER TYPE="OTHER" VALUE="CN-00912202"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-06-28 22:50:25 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-06-28 22:49:59 +0200" MODIFIED_BY="[Empty name]" OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891793"/><IDENTIFIER MODIFIED="2016-06-28 22:50:25 +0200" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01234129"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belch-1991" MODIFIED="2017-10-30 12:47:19 +0100" MODIFIED_BY="Heather Maxwell" NAME="Belch 1991" YEAR="1991">
<REFERENCE MODIFIED="2017-10-30 12:47:19 +0100" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;Main end point was non survival data. From four end point we show one which we thought was most important.It was Vertebral deformity measured by a vertebral index (mean increase in vertebral index over time ) Patients on EHDP showed less deterioration in their vertebral index.(not sta. sig.)We showed and survival data.The overall survival curves show a late divergence of borderline statistical significance.The survival data was reported also.&lt;/p&gt;" NOTES_MODIFIED="2017-10-30 12:47:19 +0100" NOTES_MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belch AR, Bergsagel DE, Wilson K</AU>
<TI>Effect of daily etidronate on the osteolysis of multiple myeloma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1991</YR>
<VL>9</VL>
<PG>1397-402</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891796"/><IDENTIFIER TYPE="MEDLINE" VALUE="14"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891795"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berenson-1998a" MODIFIED="2016-06-28 23:09:21 +0200" MODIFIED_BY="[Empty name]" NAME="Berenson 1998a" YEAR="1998">
<REFERENCE MODIFIED="2011-08-17 16:27:17 +0200" MODIFIED_BY="Rahul S Mhaskar" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al</AU>
<TI>Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>334</VL>
<PG>488-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891798"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Update of Berenson 1996&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Berenson JR, Lichtenstein A, Porter L</AU>
<TI>Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<PG>593-602</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891799"/><IDENTIFIER TYPE="MEDLINE" VALUE="115"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-06-28 23:09:21 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891797"/><IDENTIFIER MODIFIED="2016-06-28 23:09:21 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1056/NEJM199602223340802"/><IDENTIFIER MODIFIED="2016-06-28 23:09:07 +0200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="PMID: 8559201"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brincker-1998" MODIFIED="2016-06-29 15:54:20 +0200" MODIFIED_BY="[Empty name]" NAME="Brincker 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-01-26 08:56:45 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abildgaard N, Rungby J, Glerup H, Brixen K, Kassem M, Brincker H, et al</AU>
<TI>Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma</TI>
<SO>European Journal of Hematology</SO>
<YR>1998</YR>
<VL>61</VL>
<PG>128-34</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891801"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-17 16:27:32 +0200" MODIFIED_BY="Rahul S Mhaskar" NOTES="&lt;p&gt;The primary aim of the study was to demonstrate if Pamidronate compared to placebo could reduce the occurrence of skeletal related events.&lt;/p&gt;" NOTES_MODIFIED="2011-08-17 16:27:32 +0200" NOTES_MODIFIED_BY="Rahul S Mhaskar" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brincker JW, Abildgaard N</AU>
<TI>Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial</TI>
<SO>British Journal of Haematology</SO>
<YR>1998</YR>
<VL>101</VL>
<PG>280-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891802"/><IDENTIFIER TYPE="MEDLINE" VALUE="110"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-06-29 15:54:20 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891800"/><IDENTIFIER MODIFIED="2016-06-29 15:54:20 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1111/j.1600-0609.1998.tb01073.x"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daragon-1993" MODIFIED="2017-10-30 12:48:22 +0100" MODIFIED_BY="Heather Maxwell" NAME="Daragon 1993" YEAR="1993">
<REFERENCE MODIFIED="2017-10-30 12:48:22 +0100" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;Etidronate seems to be a useful adjuvant treatment to reduce bone resorption in patients with MM.&lt;/p&gt;" NOTES_MODIFIED="2017-10-30 12:48:22 +0100" NOTES_MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daragon A, Humez C, Michot CXLL</AU>
<TI>Treatment of multiple myeloma with etidronate results of a multicentre double-blind study</TI>
<SO>European Journal of Medicine</SO>
<YR>1993</YR>
<VL>2</VL>
<PG>449-52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891804"/><IDENTIFIER TYPE="MEDLINE" VALUE="36"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-06-29 15:58:31 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891803"/><IDENTIFIER MODIFIED="2016-06-29 15:56:41 +0200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="PMID:8258043"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delmas-1982" MODIFIED="2017-10-30 12:48:35 +0100" MODIFIED_BY="Heather Maxwell" NAME="Delmas 1982" YEAR="1982">
<REFERENCE MODIFIED="2017-10-30 12:48:35 +0100" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;Non survival data -number of patients without pain .There was a striking decrease in pain in all patients,(from 4.43 to 0.86  p&amp;lt;.025) of CL2MDP therapy.In the same period of time ,the mean pain index increased from 3.17 to 5.83. In the group receiving the placebo.&lt;/p&gt;" NOTES_MODIFIED="2017-10-30 12:48:35 +0100" NOTES_MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delmas PD, Charhon S, Chapuy MC, Vignon E, Briancon D, Edouard C, et al</AU>
<TI>Long-term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma</TI>
<SO>Metabolic Bone Disease and Related Research</SO>
<YR>1982</YR>
<VL>4</VL>
<PG>163-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891806"/><IDENTIFIER TYPE="MEDLINE" VALUE="133"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-06-29 15:58:45 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891805"/><IDENTIFIER MODIFIED="2016-06-29 15:57:44 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/0221-8747(82)90013-3"/><IDENTIFIER MODIFIED="2016-06-29 15:58:45 +0200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="PMID:6218370"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia_x002d_Sanz-2015" MODIFIED="2016-06-28 23:05:49 +0200" MODIFIED_BY="[Empty name]" NAME="Garcia-Sanz 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-03-14 21:43:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Sanz R, Oriol A, Moreno MJ, de la Rubia J, Payer AR, Hernandez MT, et al</AU>
<TI>Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial</TI>
<SO>Haematologica</SO>
<YR>2015</YR>
<VL>100</VL>
<NO>9</NO>
<PG>1207-13</PG>
<IDENTIFIERS MODIFIED="2016-03-14 21:43:51 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4242466"/><IDENTIFIER TYPE="PUBMED" VALUE="26069291"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-06-28 23:05:49 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4242465"/><IDENTIFIER MODIFIED="2016-06-28 23:05:48 +0200" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01087008"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gimsing-2010" MODIFIED="2017-11-16 19:11:06 +0100" MODIFIED_BY="[Empty name]" NAME="Gimsing 2010" YEAR="2010">
<REFERENCE MODIFIED="2017-11-16 19:11:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, et al</AU>
<TI>Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial</TI>
<SO>Lancet Oncology</SO>
<YR>2010</YR>
<VL>11</VL>
<NO>10</NO>
<PG>973-82</PG>
<IDENTIFIERS MODIFIED="2011-03-07 22:06:19 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891808"/><IDENTIFIER TYPE="PUBMED" VALUE="20863761"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-06-28 22:54:45 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891807"/><IDENTIFIER MODIFIED="2016-06-28 22:54:45 +0200" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00376883"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Heim-1995" MODIFIED="2017-11-16 19:35:36 +0100" MODIFIED_BY="[Empty name]" NAME="Heim 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-11-14 20:36:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Clemens MR, Fessele K, Heim ME</AU>
<TI>Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications</TI>
<SO>Annals of Hematology</SO>
<YR>1993</YR>
<VL>66</VL>
<PG>141-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891810"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-11-14 20:36:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heim ME, Clemens MR, Queißer W, Pecherstorfer M, Boewer C, Herold M, et al</AU>
<TI>Prospective randomized trial of dichloromethilene bisphosphonate (clodronate) in patients with multiple myeloma</TI>
<SO>Onkologie</SO>
<YR>1995</YR>
<VL>18</VL>
<PG>439-48</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891811"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891809"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kraj-2000" MODIFIED="2017-11-09 19:03:42 +0100" MODIFIED_BY="[Empty name]" NAME="Kraj 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-12-08 19:44:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kraj M, Póglod R, Pawlikowski J, Maj S, Nasiloska B</AU>
<TI>Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1: The results of the 12 months of pamidronate therapy</TI>
<SO>Acta Poloniae Pharmaceutica</SO>
<YR>2000</YR>
<VL>57 (suppl 1)</VL>
<PG>113-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7340162"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kraj M, Poglód R, Pawlikowsky J, Maj S</AU>
<TI>The effect of long-term pamidronate treatment on skeletal morbidity in advanced multiple myeloma</TI>
<SO>Acta Haematologica Polonica</SO>
<YR>2000</YR>
<VL>31</VL>
<PG>379-89</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7340163"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7340161"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lahtinen-1992" MODIFIED="2017-10-30 12:54:42 +0100" MODIFIED_BY="Heather Maxwell" NAME="Lahtinen 1992" YEAR="1992">
<REFERENCE MODIFIED="2017-10-30 12:54:42 +0100" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;End point was non-survival data .Percentage of patients feeling no pain increased more in the clodronate group&lt;/p&gt;" NOTES_MODIFIED="2017-10-30 12:54:42 +0100" NOTES_MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lahtinen R, Laakso M, Palva I</AU>
<TI>Randomized, placebo-controlled multicentre trial of clodronate in multiple myeloma</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>340</VL>
<PG>1049-52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891816"/><IDENTIFIER TYPE="MEDLINE" VALUE="61"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891815"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leng-2002" MODIFIED="2017-11-16 19:12:45 +0100" MODIFIED_BY="[Empty name]" NAME="Leng 2002" YEAR="2002">
<REFERENCE MODIFIED="2017-11-16 19:12:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leng Y, Chen SL, Shi HZ</AU>
<TI>Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma</TI>
<SO>Hang tian yi xue yu yi xue gong cheng [Space Medicine &amp; Medical Engineering]</SO>
<YR>2002</YR>
<VL>15</VL>
<NO>5</NO>
<PG>377-8</PG>
<IDENTIFIERS MODIFIED="2009-06-26 23:14:32 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891818"/><IDENTIFIER TYPE="PUBMED" VALUE="12449148"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891817"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-McCloskey-2001" MODIFIED="2016-06-28 23:10:24 +0200" MODIFIED_BY="[Empty name]" NAME="McCloskey 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Update of  McCloskey 1998&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McCloskey EV, Dunn JA, Kanis JA, MacLennan ICM, Drayson MT</AU>
<TI>Long-term follow-up of a prospective, double-blind, placebo-controlled randomised trial of clodronate in multiple myeloma</TI>
<SO>British Journal of Haematology</SO>
<YR>2001</YR>
<VL>113</VL>
<PG>1035-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891820"/><IDENTIFIER TYPE="MEDLINE" VALUE="113"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-12 17:45:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA</AU>
<TI>A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults</TI>
<SO>British Journal of Haematology</SO>
<YR>1998</YR>
<VL>100</VL>
<PG>317-25</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891821"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-06-28 23:10:24 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891819"/><IDENTIFIER MODIFIED="2016-06-28 23:10:24 +0200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="PMID: 11442499"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Menssen-2002" MODIFIED="2017-11-16 19:44:11 +0100" MODIFIED_BY="[Empty name]" NAME="Menssen 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-26 08:53:11 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fontana A, Herrmann Z, Menssen HD, Sakalova A, Boewer C, Facon T, et al</AU>
<TI>Effects of intravenous ibandronate therapy on skeletal related events (SRE) and survival in patients with advanced multiple myeloma</TI>
<SO>Blood</SO>
<YR>1998</YR>
<VL>92</VL>
<NO>Suppl 1</NO>
<PG>106a</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891823"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-12 17:46:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Menssen HD, Sakalová A, Fontana A, Herrmann Z, Boewer C, Facon T, et al</AU>
<TI>Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival and bone resorption in patients with advanced multiple myeloma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2002</YR>
<VL>20 (9)</VL>
<PG>2353-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891824"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-06-28 23:11:11 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891822"/><IDENTIFIER MODIFIED="2016-06-28 23:11:09 +0200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="PMID: 11981007"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morgan-2010" MODIFIED="2017-11-16 19:44:16 +0100" MODIFIED_BY="[Empty name]" NAME="Morgan 2010" YEAR="2010">
<REFERENCE MODIFIED="2017-11-16 19:10:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jackson GH, Morgan GJ, Davies FE, Wu P, Gregory WM, Bell SE, et al</AU>
<TI>Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results</TI>
<SO>British Journal of Haematology</SO>
<YR>2014</YR>
<VL>166</VL>
<NO>1</NO>
<PG>109-17</PG>
<IDENTIFIERS MODIFIED="2016-02-19 20:51:39 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891826"/><IDENTIFIER TYPE="PUBMED" VALUE="24673708"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-19 20:51:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Larocca A, Child JA, Cook G, Jackson GH, Russell N, Szubert A, et al</AU>
<TI>The impact of response on bone-directed therapy in patients with multiple myeloma</TI>
<SO>Blood</SO>
<YR>2013</YR>
<VL>122</VL>
<NO>17</NO>
<PG>2974-7</PG>
<IDENTIFIERS MODIFIED="2016-02-19 20:51:39 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891827"/><IDENTIFIER TYPE="PUBMED" VALUE="23974194"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-16 19:10:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Cook G, et al</AU>
<TI>Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment</TI>
<SO>Clinical Cancer Research : an official journal of the American Association for Cancer Research</SO>
<YR>2013</YR>
<VL>19</VL>
<NO>21</NO>
<PG>6030-8</PG>
<IDENTIFIERS MODIFIED="2016-02-19 20:51:39 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891828"/><IDENTIFIER TYPE="PUBMED" VALUE="23995858"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-10-30 13:03:51 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, et al</AU>
<TI>First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>376</VL>
<NO>9757</NO>
<PG>1989-99</PG>
<IDENTIFIERS MODIFIED="2011-01-10 16:00:10 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891829"/><IDENTIFIER TYPE="PUBMED" VALUE="21131037"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-16 19:10:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Morgan GJ, Jackson GH, Davies F, Wu P, Gregory W, Bell SE, et al</AU>
<TI>Efficacy and side-effect profile of long-term bisphosphonate therapy in patients (pts) with multiple myeloma (MM): MRC myeloma IX study results</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2012</YR>
<VL>30</VL>
<NO>15 SUPPL. 1</NO>
<IDENTIFIERS MODIFIED="2016-02-19 20:50:19 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891830"/><IDENTIFIER TYPE="OTHER" VALUE="CN-01028214"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-06-28 23:02:15 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-06-28 22:43:29 +0200" MODIFIED_BY="[Empty name]" OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891825"/><IDENTIFIER MODIFIED="2016-06-28 23:02:14 +0200" MODIFIED_BY="[Empty name]" TYPE="ISRCTN" VALUE="68454111"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Musto-2003" MODIFIED="2016-06-29 17:01:32 +0200" MODIFIED_BY="[Empty name]" NAME="Musto 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-03-12 17:46:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>D'arena G, Gobbi PG, Broglia C, Sacchi S, Quarta G, Baldini L, et al</AU>
<TI>Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study</TI>
<SO>Leukemia &amp; Lymphoma</SO>
<YR>2011</YR>
<VL>1</VL>
<PG>1-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891832"/><IDENTIFIER TYPE="PUBMED" VALUE="21299465"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-12 17:46:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Musto P, Falcone A, Sanpaolo G, Bodenizza C, Cascavilla N, Melillo L, et al</AU>
<TI>Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial</TI>
<SO>Leukemia &amp; Lymphoma</SO>
<YR>2003</YR>
<VL>44</VL>
<NO>9</NO>
<PG>1545-8</PG>
<IDENTIFIERS MODIFIED="2009-06-26 23:09:31 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891833"/><IDENTIFIER TYPE="PUBMED" VALUE="14565658"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-06-29 17:01:32 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891831"/><IDENTIFIER MODIFIED="2016-06-29 17:01:31 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.3109/10428190309178778"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Musto-2008" MODIFIED="2016-06-29 17:02:09 +0200" MODIFIED_BY="[Empty name]" NAME="Musto 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-06-26 23:10:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V, et al</AU>
<TI>A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma</TI>
<SO>Cancer</SO>
<YR>2008</YR>
<VL>113</VL>
<NO>7</NO>
<PG>1588-95</PG>
<IDENTIFIERS MODIFIED="2009-06-26 23:09:31 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891835"/><IDENTIFIER TYPE="PUBMED" VALUE="18683218"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-06-29 17:02:09 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891834"/><IDENTIFIER MODIFIED="2016-06-29 17:02:09 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/cncr.23783."/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosen-2003" MODIFIED="2016-06-28 23:04:45 +0200" MODIFIED_BY="[Empty name]" NAME="Rosen 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-08-17 16:28:08 +0200" MODIFIED_BY="Rahul S Mhaskar" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, et al</AU>
<TI>Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: a double-blind, randomized dose-response study</TI>
<SO>Cancer</SO>
<YR>2001</YR>
<VL>91</VL>
<NO>7</NO>
<PG>1191-200</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891837"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-08 17:13:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al</AU>
<TI>Long term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma</TI>
<SO>Cancer</SO>
<YR>2003</YR>
<VL>98</VL>
<NO>8</NO>
<PG>1735-44</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891838"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-08 17:12:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al</AU>
<TI>Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial</TI>
<SO>Cancer</SO>
<YR>2001</YR>
<VL>7</VL>
<NO>5</NO>
<PG>377-87</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891839"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-03-08 17:12:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, et al</AU>
<TI>Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion</TI>
<SO>Cancer</SO>
<YR>2004</YR>
<VL>100</VL>
<PG>36-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891840"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-06-28 23:04:45 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891836"/><IDENTIFIER MODIFIED="2016-06-28 23:04:45 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/cncr.11701"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sezer-2010" MODIFIED="2017-11-16 19:10:16 +0100" MODIFIED_BY="[Empty name]" NAME="Sezer 2010" YEAR="2010">
<REFERENCE MODIFIED="2017-11-16 19:10:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sezer O, Jakob C, Aldaoud A, Schmidt K, Schwarzer A, Maintz C, et al</AU>
<TI>Zoledronic acid therapy versus control in patients with multiple myeloma in stage I (Durie &amp; Salmon): results of a phase III study of the DSMM and OSHO</TI>
<SO>15th Congress of the European Hematology Association Abstr 0361</SO>
<YR>Jun 10&#8211;13, 2010</YR>
<CY>Barcelona, Spain</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891842"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891841"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Terpos-2000" MODIFIED="2016-06-29 17:03:15 +0200" MODIFIED_BY="[Empty name]" NAME="Terpos 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-12-08 19:47:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Terpos E, Palermos J, Tsionos K, Anargyrou K, Viniou N, Papassavas P, et al</AU>
<TI>Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma</TI>
<SO>European Journal of Haematology</SO>
<YR>2000</YR>
<VL>65</VL>
<PG>331-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891844"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-06-29 17:03:15 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891843"/><IDENTIFIER MODIFIED="2016-06-29 17:03:15 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1034/j.1600-0609.2000.065005331.x"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Terpos-2003" MODIFIED="2016-06-29 17:04:15 +0200" MODIFIED_BY="[Empty name]" NAME="Terpos 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-03-12 17:47:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Terpos E, Viniou N, de la Fuente J, Meletis J, Voskaridou E, Karkantaris C, et al</AU>
<TI>Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6and b2-microglobulin in multiple myeloma</TI>
<SO>European Journal of Haematology</SO>
<YR>2003</YR>
<VL>70</VL>
<PG>34-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891846"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-06-29 17:04:15 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891845"/><IDENTIFIER MODIFIED="2016-06-29 17:04:15 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1034/j.1600-0609.2003.02823.x"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2012" MODIFIED="2017-11-16 19:35:54 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-02-19 20:53:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang X, Chang C, Zhao Y, Wu L, Zhang Z, Li X</AU>
<TI>The effect of the combination of bisphosphonates and conventional chemotherapy on bone metabolic markers in multiple myeloma patients</TI>
<SO>Hematology (Amsterdam, Netherlands)</SO>
<YR>2012</YR>
<VL>17</VL>
<NO>5</NO>
<PG>255-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891848"/><IDENTIFIER TYPE="PUBMED" VALUE="22971530"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-11-16 19:12:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang X, Chang CK, Zhang Z, Zhao YS, Xiao C, Li X</AU>
<TI>[Influence of bisphosphonate combined with chemotherapy on bone mineral density of patients with multiple myeloma]</TI>
<SO>Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui [Journal of experimental hematology / Chinese Association of Pathophysiology]</SO>
<YR>2012</YR>
<VL>20</VL>
<NO>5</NO>
<PG>1135-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891849"/><IDENTIFIER TYPE="PUBMED" VALUE="23114134"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-06-28 23:12:14 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891847"/><IDENTIFIER MODIFIED="2016-06-28 23:12:14 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1179/1607845412Y.0000000021."/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-11-16 19:36:21 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ali-2001" MODIFIED="2010-01-26 09:06:53 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Ali 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-26 09:06:53 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ali SM, Esteva FJ, Hortobagyi G, Harvey H, Seaman J, Knight R, et al</AU>
<TI>Safety and efficacy of bisphosphonates beyond 24 months in cancer patients</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>14</NO>
<PG>3434-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891851"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891850"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barlogie-2008" MODIFIED="2010-01-26 09:08:12 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Barlogie 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-01-26 09:08:12 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barlogie B, van Rhee F, Shaughnessy JD Jr, Epstein J, Yaccoby S, Pineda-Roman M, et al</AU>
<TI>Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease</TI>
<SO>Blood</SO>
<YR>2008</YR>
<VL>112</VL>
<NO>8</NO>
<PG>3122-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891853"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891852"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergner-2007" MODIFIED="2010-01-26 09:09:23 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Bergner 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-01-26 09:09:23 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergner R, Henrich DM, Hoffmann M, Honecker A, Mikus G, Nauth B, et al</AU>
<TI>Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>2007</YR>
<VL>47</VL>
<NO>8</NO>
<PG>942-50</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891855"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891854"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caparrotti-2003" MODIFIED="2017-11-16 19:09:47 +0100" MODIFIED_BY="[Empty name]" NAME="Caparrotti 2003" YEAR="2003">
<REFERENCE MODIFIED="2017-11-16 19:09:47 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;span modified=&quot;2009-11-22 17:40:00 +0100&quot; class=&quot;inserted&quot; modified_by=&quot;Nicole Skoetz&quot;&gt;according to style guide: please give the full name of the journal&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2017-11-16 19:09:47 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caparrotti G, Catalano L, Feo C, Vallone R, Pagnini D, Rotoli B</AU>
<TI>Perspective study on pamidronate in stage I multiple myeloma</TI>
<SO>Hematology Journal</SO>
<YR>2003</YR>
<VL>4</VL>
<NO>6</NO>
<PG>459-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891857"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891856"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chiang-2013" MODIFIED="2017-11-16 19:09:38 +0100" MODIFIED_BY="[Empty name]" NAME="Chiang 2013" YEAR="2013">
<REFERENCE MODIFIED="2017-11-16 19:09:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chiang PH, Wang HC, Lai YL, Chen SC, Yen-Hwa W, Kok CK, et al</AU>
<TI>Zoledronic acid treatment for cancerous bone metastases: a phase IV study in Taiwan</TI>
<SO>Journal of Cancer Research and Therapeutics</SO>
<YR>2013</YR>
<VL>9</VL>
<NO>4</NO>
<PG>653-9</PG>
<IDENTIFIERS MODIFIED="2016-02-19 21:23:48 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891859"/><IDENTIFIER TYPE="PUBMED" VALUE="24518712"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891858"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ciepluch-2002" MODIFIED="2010-01-26 09:10:55 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Ciepluch 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-26 09:10:55 +0100" MODIFIED_BY="Nicole Skoetz" NOTES="&lt;p&gt;&lt;span modified=&quot;2009-11-22 17:41:00 +0100&quot; class=&quot;inserted&quot; modified_by=&quot;Nicole Skoetz&quot;&gt;full name of the journal&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-01-26 09:10:55 +0100" NOTES_MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ciepluch H, Baran W, Hellmann A</AU>
<TI>Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma</TI>
<SO>Medical Science Monitor</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>4</NO>
<PG>PI31-PI36</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891861"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891860"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delea-2012" MODIFIED="2017-11-16 19:09:26 +0100" MODIFIED_BY="[Empty name]" NAME="Delea 2012" YEAR="2012">
<REFERENCE MODIFIED="2017-11-16 19:09:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delea TE, Rotter J, Taylor M, Chandiwana D, Bains M, El Ouagari K, et al</AU>
<TI>Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective</TI>
<SO>Journal of Medical Economics</SO>
<YR>2012</YR>
<VL>15</VL>
<NO>3</NO>
<PG>454-64</PG>
<IDENTIFIERS MODIFIED="2016-02-19 21:21:00 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891863"/><IDENTIFIER TYPE="PUBMED" VALUE="22316275"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891862"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fizazi-2009" MODIFIED="2012-03-12 17:49:01 +0100" MODIFIED_BY="Rahul S Mhaskar" NAME="Fizazi 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-03-12 17:49:01 +0100" MODIFIED_BY="Rahul S Mhaskar" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, et al</AU>
<TI>Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>10</NO>
<PG>1564-71</PG>
<IDENTIFIERS MODIFIED="2011-06-10 21:43:48 +0200" MODIFIED_BY="Rahul S Mhaskar"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891865"/><IDENTIFIER TYPE="PUBMED" VALUE="19237632"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891864"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henry-2014" MODIFIED="2017-11-16 19:09:17 +0100" MODIFIED_BY="[Empty name]" NAME="Henry 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-11-16 19:09:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henry D, Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, et al</AU>
<TI>Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors</TI>
<SO>Supportive Care in Cancer : official journal of the Multinational Association of Supportive Care in Cancer</SO>
<YR>2014</YR>
<VL>22</VL>
<NO>3</NO>
<PG>679-87</PG>
<IDENTIFIERS MODIFIED="2016-02-19 21:10:52 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891867"/><IDENTIFIER TYPE="PUBMED" VALUE="24162260"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891866"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kraj-2000a" MODIFIED="2017-11-09 19:04:34 +0100" MODIFIED_BY="[Empty name]" NAME="Kraj 2000a" YEAR="2000">
<REFERENCE MODIFIED="2012-03-12 17:49:23 +0100" MODIFIED_BY="Anne Federer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kraj M, Póglod R, Pawlikowski J, Maj S, Nasilowska B</AU>
<TI>Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy</TI>
<SO>Acta Poloniae Pharmaceutica</SO>
<YR>2000</YR>
<VL>57</VL>
<NO>suppl 1</NO>
<PG>113-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7340165"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7340164"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kraj-2002" MODIFIED="2010-01-26 09:11:18 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Kraj 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-26 09:11:18 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kraj M, Poglod R, Maj S, Pawlikowski J, Sokolowska U, Szczepanik J</AU>
<TI>Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience)</TI>
<SO>Acta Poloniae Pharmaceutica</SO>
<YR>2002</YR>
<VL>59</VL>
<NO>6</NO>
<PG>478-82</PG>
<IDENTIFIERS MODIFIED="2009-06-26 23:20:03 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891871"/><IDENTIFIER TYPE="PUBMED" VALUE="12669777"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891870"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lipton-2012" MODIFIED="2017-11-16 19:09:05 +0100" MODIFIED_BY="[Empty name]" NAME="Lipton 2012" YEAR="2012">
<REFERENCE MODIFIED="2017-11-16 19:09:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al</AU>
<TI>Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials</TI>
<SO>European Journal of Cancer (Oxford, England : 1990)</SO>
<YR>2012</YR>
<VL>48</VL>
<NO>16</NO>
<PG>3082-92</PG>
<IDENTIFIERS MODIFIED="2016-02-19 21:17:25 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891873"/><IDENTIFIER TYPE="PUBMED" VALUE="22975218"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891872"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-2002" MODIFIED="2010-01-26 09:01:32 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Martin 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-26 09:01:32 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martín A, García-Sanz R, Hernández J, Bladé J, Suquía B, Fernández-Calvo J, et al</AU>
<TI>Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect</TI>
<SO>British Journal of Haematology</SO>
<YR>2002</YR>
<VL>118</VL>
<NO>1</NO>
<PG>239-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891875"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891874"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morris-2001" MODIFIED="2010-01-26 09:11:33 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Morris 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-26 09:11:33 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morris TC, Ranaghan L, Morrison J</AU>
<TI>Phase II trial of clarithromycin and pamidronate therapy in myeloma</TI>
<SO>Medical Oncology</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>1</NO>
<PG>79-84</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891877"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891876"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spencer-2008" MODIFIED="2010-01-26 09:17:26 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Spencer 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-01-26 09:17:26 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spencer A, Roberts A, Kennedy N, Ravera C, Cremers S, Bilic S, et al</AU>
<TI>Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study</TI>
<SO>BMC Clinical Pharmacology</SO>
<YR>2008</YR>
<VL>8</VL>
<PG>2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891879"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891878"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tassinari-2007" MODIFIED="2010-01-26 09:18:53 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Tassinari 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-01-26 09:18:53 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tassinari D, Poggi B, Nicoletti S, Fantini M, Tamburini E, Possenti C, et al</AU>
<TI>Zoledronic acid treatment at home: safety data from an observational prospective trial</TI>
<SO>Journal of Palliative Medicine</SO>
<YR>2007</YR>
<VL>10</VL>
<NO>2</NO>
<PG>352-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891881"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891880"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teoh-2012" MODIFIED="2017-11-16 19:08:50 +0100" MODIFIED_BY="[Empty name]" NAME="Teoh 2012" YEAR="2012">
<REFERENCE MODIFIED="2017-11-16 19:08:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teoh G, Chen Y, Kim K, Srivastava A, Pai VR, Yoon SS, et al</AU>
<TI>Lower dose dexamethasone/thalidomide and zoledronic acid every 3 weeks in previously untreated multiple myeloma</TI>
<SO>Clinical Lymphoma, Myeloma &amp; Leukemia</SO>
<YR>2012</YR>
<VL>12</VL>
<NO>2</NO>
<PG>118-26</PG>
<IDENTIFIERS MODIFIED="2016-02-19 21:13:35 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891883"/><IDENTIFIER TYPE="PUBMED" VALUE="22206804"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891882"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Terpos-2010" MODIFIED="2012-03-12 17:50:03 +0100" MODIFIED_BY="Rahul S Mhaskar" NAME="Terpos 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-03-12 17:50:03 +0100" MODIFIED_BY="Rahul S Mhaskar" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Terpos E, Berenson J, Cook RJ, Lipton A, Coleman RE</AU>
<TI>Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease</TI>
<SO>Leukemia</SO>
<YR>2010</YR>
<VL>24</VL>
<NO>5</NO>
<PG>1043-9</PG>
<IDENTIFIERS MODIFIED="2011-06-10 21:43:48 +0200" MODIFIED_BY="Rahul S Mhaskar"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891885"/><IDENTIFIER TYPE="PUBMED" VALUE="20376081"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891884"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tosi-2006a" MODIFIED="2010-01-26 09:19:59 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Tosi 2006a" YEAR="2006">
<REFERENCE MODIFIED="2010-01-26 09:19:59 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tosi P, Zamagni E, Cellini C, Parente R, Cangini D, Tacchetti P, et al</AU>
<TI>First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma</TI>
<SO>European Journal of Haematology</SO>
<YR>2006</YR>
<VL>76</VL>
<NO>5</NO>
<PG>399-404</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891887"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891886"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vadhan_x002d_Raj-2012" MODIFIED="2017-11-16 19:08:29 +0100" MODIFIED_BY="[Empty name]" NAME="Vadhan-Raj 2012" YEAR="2012">
<REFERENCE MODIFIED="2017-11-16 19:08:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vadhan-Raj S, von Moos R, Fallowfield LJ, Patrick DL, Goldwasser F, Cleeland CS, et al</AU>
<TI>Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid</TI>
<SO>Annals of Oncology : official journal of the European Society for Medical Oncology / ESMO</SO>
<YR>2012</YR>
<VL>23</VL>
<NO>12</NO>
<PG>3045-51</PG>
<IDENTIFIERS MODIFIED="2016-02-19 21:15:45 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891889"/><IDENTIFIER TYPE="PUBMED" VALUE="22851406"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891888"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vij-2009" MODIFIED="2012-03-12 17:50:19 +0100" MODIFIED_BY="Rahul S Mhaskar" NAME="Vij 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-03-12 17:50:19 +0100" MODIFIED_BY="Rahul S Mhaskar" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vij R, Horvath N, Spencer A, Taylor K, Vadhan-Raj S, Vescio R, et al</AU>
<TI>An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma</TI>
<SO>American Journal of Hematology</SO>
<YR>2009</YR>
<VL>84</VL>
<NO>10</NO>
<PG>650-6</PG>
<IDENTIFIERS MODIFIED="2011-06-10 21:43:48 +0200" MODIFIED_BY="Rahul S Mhaskar"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891891"/><IDENTIFIER TYPE="PUBMED" VALUE="19714603"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891890"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vogel-2004" MODIFIED="2010-01-26 09:21:00 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Vogel 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-26 09:21:00 +0100" MODIFIED_BY="Nicole Skoetz" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vogel CL, Yanagihara RH, Wood AJ, Schnell FM, Henderson C, Kaplan BH, et al</AU>
<TI>Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy</TI>
<SO>Oncologist</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>6</NO>
<PG>687-95</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891893"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891892"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Witzig-2013" MODIFIED="2017-11-16 19:36:21 +0100" MODIFIED_BY="[Empty name]" NAME="Witzig 2013" YEAR="2013">
<REFERENCE MODIFIED="2017-10-30 13:25:34 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Witzig TE, Laumann KM, Lacy MQ, Hayman SR, Dispenzieri A, Kumar S, et al</AU>
<TI>A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma</TI>
<SO>Leukemia</SO>
<YR>2013</YR>
<VL>27</VL>
<NO>1</NO>
<PG>220-5</PG>
<IDENTIFIERS MODIFIED="2016-02-19 21:06:43 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891895"/><IDENTIFIER TYPE="PUBMED" VALUE="22902362"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-19 21:07:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Witzig TE, Mandrekar S, Detweiler-Short K, Q Lacy M, Laumann K, Dispenzieri A, et al</AU>
<TI>A phase III randomized trial of thalidomide (THAL) plus zoledronic acid (ZLD) versus zoledronic acid alone in patients with early stage multiple myeloma (MC0289)</TI>
<SO>Blood</SO>
<YR>2010</YR>
<VL>116</VL>
<NO>21</NO>
<IDENTIFIERS MODIFIED="2016-02-19 21:07:45 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2891896"/><IDENTIFIER TYPE="OTHER" VALUE="CN-01032934"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-06-28 23:00:03 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2891894"/><IDENTIFIER MODIFIED="2016-06-28 23:00:03 +0200" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00432458"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2017-11-16 19:07:52 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Lund-2014" MODIFIED="2017-11-16 19:07:52 +0100" MODIFIED_BY="[Empty name]" NAME="Lund 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-11-16 19:07:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Thomas Lund</AU>
<TI>Magnolia study prolonged protection from bone disease in multiple myeloma. An open label phase 3 multicenter international randomised trial</TI>
<SO>https://clinicaltrials.gov/ct2/show/NCT02286830</SO>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7340167"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7340166"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-11-16 19:11:43 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2017-11-16 19:11:43 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Acito-1994" MODIFIED="2009-12-08 19:49:16 +0100" MODIFIED_BY="[Empty name]" NAME="Acito 1994" TYPE="JOURNAL_ARTICLE">
<AU>Acito AJ, Kasra M, Lee JM, Grynpas MD</AU>
<TI>Effect of intermittent administration of pamidronate on the mechanical proprieties of canine cortical and trabecular bone</TI>
<SO>Journal of Orthopedic Research</SO>
<YR>1994</YR>
<VL>12</VL>
<PG>742-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alexanian-1994" MODIFIED="2010-01-26 09:22:41 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Alexanian 1994" TYPE="JOURNAL_ARTICLE">
<AU>Alexanian R, Dimopulos M</AU>
<TI>The treatment of multiple myeloma</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>484-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anderson-2015" MODIFIED="2016-02-29 23:17:24 +0100" MODIFIED_BY="[Empty name]" NAME="Anderson 2015" TYPE="JOURNAL_ARTICLE">
<AU>Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, et al</AU>
<TI>Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology</TI>
<SO>Journal of the National Comprehensive Cancer Network : JNCCN</SO>
<YR>2015</YR>
<VL>13</VL>
<NO>11</NO>
<PG>1398-435</PG>
<IDENTIFIERS MODIFIED="2016-02-29 23:17:09 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="26553768"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Aparicio-1998" MODIFIED="2010-01-26 09:22:52 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Aparicio 1998" TYPE="JOURNAL_ARTICLE">
<AU>Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A</AU>
<TI>In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates</TI>
<SO>Leukemia</SO>
<YR>1998</YR>
<VL>12</VL>
<PG>220-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Atula-2003" MODIFIED="2010-01-26 09:23:56 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Atula 2003" TYPE="JOURNAL_ARTICLE">
<AU>Atula S, Powles T, Paterson A, McCloskey E, Nevalainen J, Kanis J</AU>
<TI>Extended safety profile of oral clodronate after long term use in primary breast cancer patients</TI>
<SO>Drug Safety</SO>
<YR>2003</YR>
<VL>26</VL>
<PG>661-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Badros-2006" MODIFIED="2010-01-26 09:25:22 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Badros 2006" TYPE="JOURNAL_ARTICLE">
<AU>Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al</AU>
<TI>Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>6</NO>
<PG>945-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bagan-2006" MODIFIED="2010-01-26 09:27:28 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Bagan 2006" TYPE="JOURNAL_ARTICLE">
<AU>Bagan JV, Jimenez Y, Murillo J, Hernandez S, Poveda R, Sanchis JM, et al</AU>
<TI>Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases [Letter]</TI>
<SO>Oral Oncology</SO>
<YR>2006</YR>
<VL>42</VL>
<PG>327-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Balshem-2011" MODIFIED="2016-02-22 17:17:53 +0100" MODIFIED_BY="[Empty name]" NAME="Balshem 2011" TYPE="JOURNAL_ARTICLE">
<AU>Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al</AU>
<TI>GRADE guidelines 3: Rating the quality of evidence - introduction</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>401-6</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21208779"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Battley-2006" MODIFIED="2017-11-16 19:07:31 +0100" MODIFIED_BY="[Empty name]" NAME="Battley 2006" TYPE="JOURNAL_ARTICLE">
<AU>Battley J, Jayathissa S, Seneviratne E</AU>
<TI>Jaw osteonecrosis associated with bisphosphonates</TI>
<SO>New Zealand Medical Journal</SO>
<YR>2006</YR>
<VL>119</VL>
<NO>1246</NO>
<PG>U2341</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1994" MODIFIED="2009-07-07 17:49:50 +0200" MODIFIED_BY="[Empty name]" NAME="Begg 1994" TYPE="JOURNAL_ARTICLE">
<AU>Begg CB, Mazumdar M</AU>
<TI>Operating characteristics of a rank correlation test for publication bias</TI>
<SO>Biometrics</SO>
<YR>1994</YR>
<VL>50</VL>
<NO>4</NO>
<PG>1088-101</PG>
<IDENTIFIERS MODIFIED="2009-07-07 17:49:41 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="7786990"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Berenson-1998b" NAME="Berenson 1998b" TYPE="JOURNAL_ARTICLE">
<AU>Berenson JR</AU>
<TI>The efficacy of pamidronate disodium in the treatment of osteolytic lesions and bone pain in multiple myeloma</TI>
<SO>Reviews in Contemporary Pharmacotherapy</SO>
<YR>1998</YR>
<VL>9</VL>
<PG>195-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berenson-2011" MODIFIED="2012-03-12 17:51:53 +0100" MODIFIED_BY="[Empty name]" NAME="Berenson 2011" TYPE="JOURNAL_ARTICLE">
<AU>Berenson JR, Yellin O, Crowley J, Makary A, Gravenor DS, Yang HH, et al</AU>
<TI>Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid</TI>
<SO>American Journal of Hematology</SO>
<YR>2011</YR>
<VL>86</VL>
<NO>1</NO>
<PG>25-30</PG>
<IDENTIFIERS MODIFIED="2011-03-04 17:35:25 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21120861"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Braun-2006" MODIFIED="2010-01-26 09:27:49 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Braun 2006" TYPE="JOURNAL_ARTICLE">
<AU>Braun E, Iacono VJ</AU>
<TI>Bisphosphonates: case report of non surgical periodontal therapy and osteochemonecrosis</TI>
<SO>International Journal of Periodontics and Restorative Dentistry</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>4</NO>
<PG>315-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Broglia-2006" MODIFIED="2011-08-17 16:28:57 +0200" MODIFIED_BY="Rahul S Mhaskar" NAME="Broglia 2006" TYPE="JOURNAL_ARTICLE">
<AU>Broglia C, Merlati G, Valentino F, Benatti C, Gobbi P, Ascari E, et al</AU>
<TI>Avascular jaw osteonecrosis associated with bisphosphonate therapy</TI>
<SO>Recenti Progressi in Medicina (Roma)</SO>
<YR>2006</YR>
<VL>97</VL>
<NO>3</NO>
<PG>140-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2004" MODIFIED="2010-01-26 09:29:10 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Brown 2004" TYPE="JOURNAL_ARTICLE">
<AU>Brown JE, Neville-Webbe H, Coleman RE</AU>
<TI>The role of bisphosphonates in breast and prostate cancers</TI>
<SO>Endocrine Related Cancer</SO>
<YR>2004</YR>
<VL>11</VL>
<PG>207-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bucher-1997" MODIFIED="2010-01-26 09:29:26 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Bucher 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bucher HC, Guyatt GH, Griffith LE, Walter SD</AU>
<TI>The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1997</YR>
<VL>50</VL>
<NO>6</NO>
<PG>683-91</PG>
<IDENTIFIERS MODIFIED="2009-07-07 17:49:41 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="9250266"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bujanda-2007" MODIFIED="2010-01-26 09:29:41 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Bujanda 2007" TYPE="JOURNAL_ARTICLE">
<AU>Bujanda AD, Sarmiento BU, Suarez CMA, Morales AJ</AU>
<TI>Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis</TI>
<SO>Annals of Oncology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>3</NO>
<PG>556-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Calvo_x002d_Villas-2006" MODIFIED="2010-01-26 09:30:44 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Calvo-Villas 2006" TYPE="JOURNAL_ARTICLE">
<AU>Calvo-Villas JM, Tapia Torres M, Govantes Rodríguez J, Carreter de Granda E, Sicilia Guillén F</AU>
<TI>Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid</TI>
<SO>Medicina Clinicia (Barcelona)</SO>
<YR>2006</YR>
<VL>127</VL>
<NO>15</NO>
<PG>576-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Capalbo-2006" MODIFIED="2010-01-26 09:32:04 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Capalbo 2006" TYPE="JOURNAL_ARTICLE">
<AU>Capalbo S, Delia M, Diomede D, Dargenio M, Chiefa A, Favia G, et al</AU>
<TI>Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients</TI>
<SO>International Journal of Hematology</SO>
<YR>2006</YR>
<VL>83</VL>
<NO>5</NO>
<PG>439-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carneiro-2006" MODIFIED="2010-01-26 09:32:16 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Carneiro 2006" TYPE="JOURNAL_ARTICLE">
<AU>Carneiro E, Vibhute P, Montazem A, Som PM</AU>
<TI>Bisphosphonate-associated mandibular osteonecrosis</TI>
<SO>American Journal of Neuroradiology</SO>
<YR>2006</YR>
<VL>27</VL>
<NO>5</NO>
<PG>1096-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carter-2005" MODIFIED="2010-01-26 09:32:27 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Carter 2005" TYPE="JOURNAL_ARTICLE">
<AU>Carter G, Goss AN, Doecke C</AU>
<TI>Bisphosphonates and avascular necrosis of the jaw: a possible association</TI>
<SO>Medical Journal of Australia (Sydney)</SO>
<YR>2005</YR>
<VL>182</VL>
<PG>413-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cassidy-2006" MODIFIED="2012-03-12 17:55:14 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Cassidy 2006" TYPE="BOOK">
<AU>Cassidy J, Bisset D, Spence RAJ, Payne M, editors</AU>
<SO>Oxford Handbook of Oncology</SO>
<YR>2006</YR>
<PG>504-5</PG>
<PB>Oxford University Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cetiner-2009" MODIFIED="2012-03-12 17:55:30 +0100" MODIFIED_BY="[Empty name]" NAME="Cetiner 2009" TYPE="JOURNAL_ARTICLE">
<AU>Cetiner S, Sucak GT, Kahraman SA, Aki SZ, Kocakahyaoglu B, Gultekin SE, et al</AU>
<TI>Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid</TI>
<SO>Journal of Bone and Mineral Metabolism</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>4</NO>
<PG>435-43</PG>
<IDENTIFIERS MODIFIED="2011-03-04 16:08:06 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="19240969"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chaimani-2013" MODIFIED="2017-11-16 19:07:09 +0100" MODIFIED_BY="[Empty name]" NAME="Chaimani 2013" TYPE="JOURNAL_ARTICLE">
<AU>Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G</AU>
<TI>Graphical tools for network meta-analysis in STATA</TI>
<SO>PLOS One</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>10</NO>
<PG>e76654</PG>
<IDENTIFIERS MODIFIED="2016-12-01 21:09:58 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="24098547"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chang-2003" MODIFIED="2010-01-26 09:32:49 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Chang 2003" TYPE="JOURNAL_ARTICLE">
<AU>Chang JT, Green L, Beitz J</AU>
<TI>Renal failure with the use of zoledronic acid</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<PG>1676-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2007" MODIFIED="2012-03-12 17:55:58 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Clarke 2007" TYPE="JOURNAL_ARTICLE">
<AU>Clarke BM, Boyette J, Vural E, Suen JY, Anaissie EJ, Stack BC Jr</AU>
<TI>Bisphosphonates and jaw osteonecrosis: the UAMS experience</TI>
<SO>Otolaryngology--Head and Neck Surgery</SO>
<YR>2007</YR>
<VL>136</VL>
<NO>3</NO>
<PG>396-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cornell-2015" MODIFIED="2017-11-16 19:07:00 +0100" MODIFIED_BY="[Empty name]" NAME="Cornell 2015" TYPE="OTHER">
<AU>Cornell JE</AU>
<TI>The PRISMA extension for network meta-analysis: bringing clarity and guidance to the reporting of systematic reviews incorporating network meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2015</YR>
<VL>162</VL>
<NO>11</NO>
<PG>797-8</PG>
<IDENTIFIERS MODIFIED="2016-02-26 15:24:24 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="26030637"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Corso-2007" MODIFIED="2010-02-12 17:45:47 +0100" MODIFIED_BY="[Empty name]" NAME="Corso 2007" TYPE="JOURNAL_ARTICLE">
<AU>Corso A, Varettoni M, Zappasodi P, Klersy C, Mangiacavalli S, Pica G, et al</AU>
<TI>A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma</TI>
<SO>Leukemia</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>7</NO>
<PG>1545-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curi-2007" MODIFIED="2012-03-12 17:56:14 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Curi 2007" TYPE="JOURNAL_ARTICLE">
<AU>Curi MM, Cossolin GS, Koga DH, Araújo SR, Feher O, dos Santos MO, et al</AU>
<TI>Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: report of 3 cases</TI>
<SO>Journal of Oral Maxillofacial Surgery</SO>
<YR>2007</YR>
<VL>65</VL>
<NO>2</NO>
<PG>349-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dannemann-2007" MODIFIED="2010-01-26 10:58:20 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Dannemann 2007" TYPE="JOURNAL_ARTICLE">
<AU>Dannemann C, Graetz KW, Riener MO, Zwahlen RA</AU>
<TI>Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder</TI>
<SO>Bone</SO>
<YR>2007</YR>
<VL>40</VL>
<NO>4</NO>
<PG>828-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2016-06-28 20:08:58 +0200" MODIFIED_BY="[Empty name]" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2012-03-12 17:56:27 +0100" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS MODIFIED="2009-07-07 17:49:41 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="3802833"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dhodapkar-1998" MODIFIED="2010-01-26 10:59:09 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Dhodapkar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Dhodapkar MV, Singh J, Mehta J, Fassas A, Desikan KR, Perlman M, et al</AU>
<TI>Anti-myeloma activity of pamidronate in vivo</TI>
<SO>British Journal of Haematology</SO>
<YR>1998</YR>
<VL>103</VL>
<PG>530-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dias-2010" MODIFIED="2012-03-12 17:56:39 +0100" MODIFIED_BY="[Empty name]" NAME="Dias 2010" TYPE="JOURNAL_ARTICLE">
<AU>Dias S, Welton NJ, Caldwell DM, Ades AE</AU>
<TI>Checking consistency in mixed treatment comparison meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2010</YR>
<VL>29</VL>
<NO>7-8</NO>
<PG>932-44</PG>
<IDENTIFIERS MODIFIED="2011-02-25 15:28:33 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="20213715"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Diego-2007" MODIFIED="2012-03-12 17:56:59 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Diego 2007" TYPE="JOURNAL_ARTICLE">
<AU>Diego R, D'Orto O, Pagani D, Agazzi A, Marzano U, Derada Troletti G, et al</AU>
<TI>Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics</SO>
<YR>2007</YR>
<VL>103</VL>
<NO>3</NO>
<PG>e1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dimitrakopoulos--2006" MODIFIED="2010-01-26 11:01:31 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Dimitrakopoulos  2006" TYPE="JOURNAL_ARTICLE">
<AU>Dimitrakopoulos I, Magopoulos C, Karakasis D</AU>
<TI>Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases</TI>
<SO>International Journal of Oral and Maxillofacillary Surgery</SO>
<YR>2006</YR>
<VL>35</VL>
<NO>7</NO>
<PG>588-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dimopoulos-2006" MODIFIED="2010-01-26 11:03:34 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Dimopoulos 2006" TYPE="JOURNAL_ARTICLE">
<AU>Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, et al</AU>
<TI>Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid</TI>
<SO>Haematologica</SO>
<YR>2006</YR>
<VL>91</VL>
<PG>968-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Drake-2008" MODIFIED="2012-03-12 17:58:36 +0100" MODIFIED_BY="Rahul S Mhaskar" NAME="Drake 2008" TYPE="JOURNAL_ARTICLE">
<AU>Drake MT, Clarke BL, Khosla S</AU>
<TI>Bisphosphonates: mechanism of action and role in clinical practice</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>2008</YR>
<VL>83</VL>
<NO>9</NO>
<PG>1032-45</PG>
<IDENTIFIERS MODIFIED="2011-06-10 16:53:32 +0200" MODIFIED_BY="Rahul S Mhaskar"><IDENTIFIER TYPE="PUBMED" VALUE="18775204"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dunford-2001" MODIFIED="2017-11-16 19:06:44 +0100" MODIFIED_BY="[Empty name]" NAME="Dunford 2001" TYPE="JOURNAL_ARTICLE">
<AU>Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, et al</AU>
<TI>Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates</TI>
<SO>Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>2001</YR>
<VL>296</VL>
<NO>2</NO>
<PG>235-42</PG>
<IDENTIFIERS MODIFIED="2011-06-10 16:53:32 +0200" MODIFIED_BY="Rahul S Mhaskar"><IDENTIFIER TYPE="PUBMED" VALUE="11160603"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Durie-2005" MODIFIED="2017-11-16 19:06:28 +0100" MODIFIED_BY="[Empty name]" NAME="Durie 2005" TYPE="OTHER">
<AU>Durie BG, Katz M, Crowley J</AU>
<TI>Osteonecrosis of the jaw and bisphosphonates</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<NO>1</NO>
<PG>99-102.</PG>
<IDENTIFIERS MODIFIED="2009-08-04 22:39:24 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="16000365"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-2001" MODIFIED="2017-10-31 16:38:32 +0100" MODIFIED_BY="Heather Maxwell" NAME="Egger 2001" TYPE="BOOK">
<AU>Egger M, Davey Smith G, Altman DG</AU>
<SO>Systematic Reviews in Health Care: Meta-analysis in Context. 2nd edition</SO>
<YR>2001</YR>
<PB>BMJ</PB>
<CY>London</CY>
<IDENTIFIERS MODIFIED="2009-07-07 17:39:30 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Elad-2006" MODIFIED="2010-01-26 11:06:50 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Elad 2006" TYPE="JOURNAL_ARTICLE">
<AU>Elad S, Yarom N, Hamed W, Ayalon S, Yahalom R, Regev E</AU>
<TI>Osteomylelitis and necrosis of the jaw in patients treated with bisphosphonates: a comparative study focused on multiple myeloma</TI>
<SO>Clinical and Laboratory Haematology</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>6</NO>
<PG>393-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ficarra-2005" MODIFIED="2010-01-26 11:08:25 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Ficarra 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P, et al</AU>
<TI>Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment</TI>
<SO>Journal of Clinical Periodontology</SO>
<YR>2005</YR>
<VL>32</VL>
<PG>1123-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fortuna-2012" MODIFIED="2017-11-16 19:05:39 +0100" MODIFIED_BY="[Empty name]" NAME="Fortuna 2012" TYPE="JOURNAL_ARTICLE">
<AU>Fortuna G, Ruoppo E, Pollio A, Aria M, Adamo D, Leuci S, et al</AU>
<TI>Multiple myeloma vs. breast cancer patients with bisphosphonates-related osteonecrosis of the jaws: a comparative analysis of response to treatment and predictors of outcome</TI>
<SO>Journal of Oral Pathology &amp; Medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology</SO>
<YR>2012</YR>
<VL>41</VL>
<NO>3</NO>
<PG>222-8</PG>
<IDENTIFIERS MODIFIED="2016-02-24 18:04:21 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="22092390"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fromm-1991" MODIFIED="2010-01-26 11:08:43 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Fromm 1991" TYPE="JOURNAL_ARTICLE">
<AU>Fromm GA, Vega E, Plantalech L, Galich AM, Mautalen CA</AU>
<TI>Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis</TI>
<SO>Osteoporosis International</SO>
<YR>1991</YR>
<VL>1</VL>
<PG>126-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gabbert-2015" MODIFIED="2017-11-16 19:05:28 +0100" MODIFIED_BY="[Empty name]" NAME="Gabbert 2015" TYPE="JOURNAL_ARTICLE">
<AU>Gabbert TI, Hoffmeister B, Felsenberg D</AU>
<TI>Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients</TI>
<SO>Journal of Cancer Research and Clinical Oncology</SO>
<YR>2015</YR>
<VL>141</VL>
<NO>4</NO>
<PG>749-58</PG>
<IDENTIFIERS MODIFIED="2016-02-24 18:04:51 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="25319961"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gander-2014" MODIFIED="2017-11-16 19:05:18 +0100" MODIFIED_BY="[Empty name]" NAME="Gander 2014" TYPE="JOURNAL_ARTICLE">
<AU>Gander T, Obwegeser JA, Zemann W, Gratz KW, Jacobsen C</AU>
<TI>Malignancy mimicking bisphosphonate-associated osteonecrosis of the jaw: a case series and literature review</TI>
<SO>Oral Surgery, Oral Medicine, oral pathology and Oral Radiology</SO>
<YR>2014</YR>
<VL>117</VL>
<NO>1</NO>
<PG>32-6</PG>
<IDENTIFIERS MODIFIED="2016-02-24 18:06:54 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="24332325"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Garcia_x002d_Garay-2006" MODIFIED="2017-11-16 19:05:04 +0100" MODIFIED_BY="[Empty name]" NAME="Garcia-Garay 2006" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Garay C, Gonzalez-Garcia C, Juliana Majado M, Santos T, Borrego D</AU>
<TI>Osteonecrosis of the jaw in multiple myeloma patients: experience of two hospitals</TI>
<SO>Blood</SO>
<YR>2006</YR>
<VL>108</VL>
<NO>11</NO>
<PG>Abstract 5086</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-2008" MODIFIED="2016-02-22 17:17:53 +0100" MODIFIED_BY="[Empty name]" NAME="GRADEpro 2008" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro</TI>
<YR>2008</YR>
<EN>3.2 for Windows</EN>
<PB>Jan Brozek, Andrew Oxman, Holger Schünemann</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greipp-2005" MODIFIED="2017-11-16 19:04:56 +0100" MODIFIED_BY="[Empty name]" NAME="Greipp 2005" TYPE="JOURNAL_ARTICLE">
<AU>Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al</AU>
<TI>International staging system for multiple myeloma</TI>
<SO>Journal of Clinical oOncology : official journal of the American Society of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>15</NO>
<PG>3412-20</PG>
<IDENTIFIERS MODIFIED="2016-02-29 23:17:09 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="15809451"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011" MODIFIED="2016-02-22 17:17:53 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Oxman AD, Akl E, Kunz R, Vist G, Brozek J, et al</AU>
<TI>GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>383-94</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21195583"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011a" MODIFIED="2016-02-22 17:17:53 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 7. Rating the quality of evidence - inconsistency</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1294-302</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21803546"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011b" MODIFIED="2016-02-22 17:17:53 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 8. Rating the quality of evidence - indirectness</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1303-10</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21802903"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011c" MODIFIED="2016-02-22 17:17:53 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011c" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al</AU>
<TI>GRADE guidelines: 6. Rating the quality of evidence - imprecision</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1283-93</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21839614"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011d" MODIFIED="2016-02-22 17:17:53 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011d" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al</AU>
<TI>GRADE guidelines: 5. Rating the quality of evidence - publication bias</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1277-82</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21802904"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011e" MODIFIED="2016-02-22 17:17:53 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011e" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines: 4. Rating the quality of evidence - risk of bias</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>407-15</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="21247734"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hansen-2006" MODIFIED="2012-03-12 18:01:56 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Hansen 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hansen T, Kunkel M, Weber A, Kirkpatrick CJ</AU>
<TI>Osteonecrosis of the jaws in patients treated with bisphosphonates: histomorphologic analysis in comparison with infected osteoradionecrosis</TI>
<SO>Journal of Oral Pathology &amp; Medicine</SO>
<YR>2006</YR>
<VL>35</VL>
<NO>3</NO>
<PG>155-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hay-2006" MODIFIED="2017-11-16 19:04:39 +0100" MODIFIED_BY="[Empty name]" NAME="Hay 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hay KD, Bishop PA</AU>
<TI>Association of osteonecrosis of the jaws and bisphosphonate pharmacotherapy: dental implications</TI>
<SO>New Zealand Dental Journal</SO>
<YR>2006</YR>
<VL>102</VL>
<NO>1</NO>
<PG>4-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herbozo-2007" MODIFIED="2010-01-26 11:17:03 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Herbozo 2007" TYPE="JOURNAL_ARTICLE">
<AU>Herbozo PJ, Briones DL, Ferres AJ, Torrealba RL</AU>
<TI>Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws</TI>
<SO>Journal of Oral and Maxillofacial Surgery</SO>
<YR>2007</YR>
<VL>65</VL>
<NO>8</NO>
<PG>1650-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-1996" MODIFIED="2010-01-26 11:20:48 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Higgins 1996" TYPE="OTHER">
<AU>Higgins JP, Whitehead A</AU>
<TI>Borrowing strength from external trials in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>1996</YR>
<VL>15</VL>
<NO>24</NO>
<PG>2733-49</PG>
<IDENTIFIERS MODIFIED="2009-12-14 15:18:37 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="DOI" VALUE="10.1002/(SICI)1097-0258(19961230)15:24&lt;2733::AID-SIM562&gt;3.0.CO;2-0"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2004" MODIFIED="2012-03-12 18:02:26 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2004" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG</AU>
<TI>Controlling the risk of spurious findings from meta-regression</TI>
<SO>Statistics in Medicine</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>11</NO>
<PG>1663-82</PG>
<IDENTIFIERS MODIFIED="2011-02-25 15:37:35 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="15160401"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2016-06-28 20:20:31 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ (editors)</AU>
<TI>Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2017-11-16 19:04:23 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors) on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011d" MODIFIED="2017-11-16 19:04:11 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011d" TYPE="OTHER">
<AU>Jonathan AC Sterne, Matthias Egger and David Moher (editors) on behalf of the Cochrane Bias Methods Group</AU>
<TI>Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hoff-2006" MODIFIED="2010-01-26 11:18:17 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Hoff 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al</AU>
<TI>Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<PG>8528a</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Junquera-2009" MODIFIED="2012-03-12 18:02:40 +0100" MODIFIED_BY="[Empty name]" NAME="Junquera 2009" TYPE="JOURNAL_ARTICLE">
<AU>Junquera L, Gallego L, Cuesta P, Pelaz A, de Vicente JC</AU>
<TI>Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases</TI>
<SO>American Journal of Otolaryngology</SO>
<YR>2009</YR>
<VL>30</VL>
<NO>6</NO>
<PG>390-5</PG>
<IDENTIFIERS MODIFIED="2011-03-04 15:58:31 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="19880027"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2001" MODIFIED="2010-02-12 18:07:23 +0100" MODIFIED_BY="[Empty name]" NAME="Jüni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Altman DG, Egger M</AU>
<TI>Assessing the quality of controlled clinical trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kademani-2006" MODIFIED="2012-03-12 18:02:50 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Kademani 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kademani D, Koka S, Lacy MQ, Rajkumar SV</AU>
<TI>Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>2006</YR>
<VL>81</VL>
<NO>8</NO>
<PG>1100-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kamoh-2012" MODIFIED="2017-11-16 19:03:57 +0100" MODIFIED_BY="[Empty name]" NAME="Kamoh 2012" TYPE="JOURNAL_ARTICLE">
<AU>Kamoh AK, Ogle O</AU>
<TI>Bisphosphonate-related osteonecrosis of the jaws--a case report</TI>
<SO>Compendium of Continuing Education in Dentistry (Jamesburg, N.J. : 1995)</SO>
<YR>2012</YR>
<VL>33</VL>
<NO>5</NO>
<PG>e74-7</PG>
<IDENTIFIERS MODIFIED="2016-02-24 16:45:36 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="23268588"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Katz-2005" MODIFIED="2010-01-26 11:21:24 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Katz 2005" TYPE="JOURNAL_ARTICLE">
<AU>Katz H</AU>
<TI>Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: a report of three cases</TI>
<SO>Journal of Endodontics</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>831-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Khamaisi-2006" MODIFIED="2017-11-16 19:03:46 +0100" MODIFIED_BY="[Empty name]" NAME="Khamaisi 2006" TYPE="JOURNAL_ARTICLE">
<AU>Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, et al</AU>
<TI>Possible association between diabetes and bisphosphonate-related jaw osteonecrosis</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>2007</YR>
<VL>92</VL>
<NO>3</NO>
<PG>1172-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kumar-2007" MODIFIED="2010-01-26 11:23:33 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Kumar 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kumar V, Pass B, Guttenberg SA, Ludlow J, Emery RW, Tyndall DA, et al</AU>
<TI>Bisphosphonate-related osteonecrosis of the jaws: a report of three cases demonstrating variability in outcomes and morbidity</TI>
<SO>Journal of the American Dental Association</SO>
<YR>2007</YR>
<VL>138</VL>
<NO>5</NO>
<PG>602-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kut-2004" MODIFIED="2017-11-16 19:03:30 +0100" MODIFIED_BY="[Empty name]" NAME="Kut 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kut V, Mehta J, Tariman J, et al</AU>
<TI>Osteonecrosis of the jaw in myeloma patients receiving pamidronate or zoledronate</TI>
<SO>Blood</SO>
<YR>2004</YR>
<VL>104</VL>
<PG>Abstract 4933</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lambert-2005" MODIFIED="2010-01-26 11:24:18 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Lambert 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR</AU>
<TI>How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS</TI>
<SO>Statistics in Medicine</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>15</NO>
<PG>2401-28</PG>
<IDENTIFIERS MODIFIED="2009-12-09 16:31:39 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="16015676"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Laupacis-1988" MODIFIED="2010-01-26 08:55:33 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Laupacis 1988" TYPE="JOURNAL_ARTICLE">
<AU>Laupacis A, Sackett DL, Roberts RS</AU>
<TI>An assessment of clinically useful measures of the consequences of treatment</TI>
<SO>New England Journal of Medicine</SO>
<YR>1988</YR>
<VL>318</VL>
<PG>1728-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lazarovici-2009" MODIFIED="2012-03-12 18:03:40 +0100" MODIFIED_BY="[Empty name]" NAME="Lazarovici 2009" TYPE="JOURNAL_ARTICLE">
<AU>Lazarovici TS, Yahalom R, Taicher S, Elad S, Hardan I, Yarom N</AU>
<TI>Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients</TI>
<SO>Journal of Oral and Maxillofacial Surgery</SO>
<YR>2009</YR>
<VL>67</VL>
<NO>4</NO>
<PG>850-5</PG>
<IDENTIFIERS MODIFIED="2011-03-04 17:22:19 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="19304045"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lenz-2005" MODIFIED="2010-01-26 11:25:22 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Lenz 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lenz JH, Steiner-Krammer B, Schmidt W, Fietkau R, Mueller PC, Gundlach KK</AU>
<TI>Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?</TI>
<SO>Jornal of Craniomaxillofacillary Surgery</SO>
<YR>2005</YR>
<VL>33</VL>
<PG>395-403</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liberati-2009" MODIFIED="2010-01-26 11:25:43 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Liberati 2009" TYPE="JOURNAL_ARTICLE">
<AU>Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al</AU>
<TI>The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2009</YR>
<VL>62</VL>
<NO>10</NO>
<PG>e1-34</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="19631507"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lu-2004" MODIFIED="2011-08-17 17:20:34 +0200" MODIFIED_BY="Rahul S Mhaskar" NAME="Lu 2004" TYPE="OTHER">
<AU>Lu G, Ades AE</AU>
<TI>Combination of direct and indirect evidence in mixed treatment comparisons</TI>
<SO>Statistics in Medicine</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>20</NO>
<PG>3105-24</PG>
<IDENTIFIERS MODIFIED="2009-12-14 15:18:22 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="DOI" VALUE="10.1002/sim.1875"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lufkin-1994" MODIFIED="2010-01-26 11:27:53 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Lufkin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Lufkin EG, Argueta R, Whitaker MD, Cameron AL, Wong VH, Egan KS, et al</AU>
<TI>Pamidronate: an unrecognized problem in gastrointestinal tolerability</TI>
<SO>Osteoporosis International</SO>
<YR>1994</YR>
<VL>4</VL>
<PG>320-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lugassy-2004" MODIFIED="2012-03-12 18:04:04 +0100" MODIFIED_BY="Rahul S Mhaskar" NAME="Lugassy 2004" TYPE="JOURNAL_ARTICLE">
<AU>Lugassy G, Shaham R, Nemets A, Ben-Dor D, Nahlieli O</AU>
<TI>Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity</TI>
<SO>American Journal of Medicine</SO>
<YR>2004</YR>
<VL>117</VL>
<PG>440-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Magopoulos-2007" MODIFIED="2012-03-12 18:04:11 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Magopoulos 2007" TYPE="JOURNAL_ARTICLE">
<AU>Magopoulos C, Karakinaris G, Telioudis Z, Vahtsevanos K, Dimitrakopoulos I, Antoniadis K, et al</AU>
<TI>Osteonecrosis of the jaws due to bisphosphonate use: a review of 60 cases and treatment proposals</TI>
<SO>American Journal of Otolaryngology</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>3</NO>
<PG>158-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marunick-2005" MODIFIED="2010-01-26 11:29:25 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Marunick 2005" TYPE="JOURNAL_ARTICLE">
<AU>Marunick M, Miller R, Gordon S</AU>
<TI>Adverse oral sequelae to bisphosphonate administration</TI>
<SO>Journal of Michigan Dental Association</SO>
<YR>2005</YR>
<VL>87</VL>
<PG>44-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Melo-2005" MODIFIED="2017-10-30 15:55:18 +0100" MODIFIED_BY="Heather Maxwell" NAME="Melo 2005" TYPE="JOURNAL_ARTICLE">
<AU>Melo MD, Obeid G</AU>
<TI>Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition</TI>
<SO>Journal of the American Dental Association</SO>
<YR>2005</YR>
<VL>136</VL>
<NO>12</NO>
<PG>1675-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Merigo-2006" MODIFIED="2010-01-26 11:36:28 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Merigo 2006" TYPE="JOURNAL_ARTICLE">
<AU>Merigo E, Manfredi M, Meleti M, Guidotti R, Ripasarti A, Zanzucchi E, et al</AU>
<TI>Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases</TI>
<SO>Acta Bio-medica: Atenei Parmensis</SO>
<YR>2006</YR>
<VL>77</VL>
<NO>2</NO>
<PG>109-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Migliorati-2005" MODIFIED="2009-07-12 15:03:20 +0200" MODIFIED_BY="[Empty name]" NAME="Migliorati 2005" TYPE="JOURNAL_ARTICLE">
<AU>Migliorati CA, Schubert MM, Peterson DE, Seneda LM</AU>
<TI>Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy</TI>
<SO>Cancer</SO>
<YR>2005</YR>
<VL>104</VL>
<PG>83-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montazeri-2007" MODIFIED="2009-12-23 20:19:48 +0100" MODIFIED_BY="[Empty name]" NAME="Montazeri 2007" TYPE="JOURNAL_ARTICLE">
<AU>Montazeri AH, Erskine JG, McQuaker IG</AU>
<TI>Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma</TI>
<SO>European Journal of Haematology</SO>
<YR>2007</YR>
<VL>79</VL>
<NO>1</NO>
<PG>69-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mortensen-2007" MODIFIED="2010-01-26 11:37:26 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Mortensen 2007" TYPE="JOURNAL_ARTICLE">
<AU>Mortensen M, Lawson W, Montazem A</AU>
<TI>Osteonecrosis of the jaw associated with bisphosphonate use: Presentation of seven cases and literature review</TI>
<SO>Laryngoscope</SO>
<YR>2007</YR>
<VL>117</VL>
<NO>1</NO>
<PG>30-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murad-2007" MODIFIED="2010-01-26 11:37:11 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Murad 2007" TYPE="JOURNAL_ARTICLE">
<AU>Murad OM, Arora S, Farag AF, Guber HA</AU>
<TI>Bisphosphonates and osteonecrosis of the jaw: a retrospective study</TI>
<SO>Endocrine Practice</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>3</NO>
<PG>232-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pastor_x002d_Zuazaga-2006" MODIFIED="2017-11-16 19:11:43 +0100" MODIFIED_BY="[Empty name]" NAME="Pastor-Zuazaga 2006" TYPE="JOURNAL_ARTICLE">
<AU>Pastor-Zuazaga D, Garatea-Crelgo J, Martino-Gorbea R, Etayo-Pérez A, Sebastián-López C</AU>
<TI>Osteonecrosis of the jaws and bisphosphonates: report of three cases</TI>
<SO>Medicina Oral, Patología Oral y Cirugía Bucal</SO>
<YR>2006</YR>
<VL>11</VL>
<NO>1</NO>
<PG>76-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Phal-2007" MODIFIED="2010-01-26 11:43:58 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Phal 2007" TYPE="JOURNAL_ARTICLE">
<AU>Phal PM, Myall RW, Assael LA, Weissman JL</AU>
<TI>Imaging findings of bisphosphonate-associated osteonecrosis of the jaws</TI>
<SO>American Journal of Neuroradiology</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>6</NO>
<PG>1139-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pires-2005" MODIFIED="2011-08-17 16:30:20 +0200" MODIFIED_BY="Rahul S Mhaskar" NAME="Pires 2005" TYPE="JOURNAL_ARTICLE">
<AU>Pires FR, Miranda A, Cardoso ES, Cardoso AS, Fregnani ER, Pereira CM, et al</AU>
<TI>Oral avascular bone necrosis associated with chemotherapy and bisphosphonate therapy</TI>
<SO>Oral Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<PG>365-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Polizzotto-2006" MODIFIED="2009-12-23 20:22:08 +0100" MODIFIED_BY="[Empty name]" NAME="Polizzotto 2006" TYPE="JOURNAL_ARTICLE">
<AU>Polizzotto MN, Cousins V, Schwarer AP</AU>
<TI>Bisphosphonate-associated osteonecrosis of the auditory canal</TI>
<SO>British Journal of Haematology</SO>
<YR>2006</YR>
<VL>132</VL>
<NO>1</NO>
<PG>114</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pozzi-2007" MODIFIED="2010-01-26 11:46:15 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Pozzi 2007" TYPE="JOURNAL_ARTICLE">
<AU>Pozzi S, Marcheselli R, Sacchi S, Baldini L, Angrilli F, Pennese E, et al</AU>
<TI>Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients</TI>
<SO>Leukemia &amp; Lymphoma</SO>
<YR>2007</YR>
<VL>48</VL>
<NO>1</NO>
<PG>56-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Puhan-2014" MODIFIED="2016-05-27 15:16:18 +0200" MODIFIED_BY="[Empty name]" NAME="Puhan 2014" TYPE="JOURNAL_ARTICLE">
<AU>Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al</AU>
<TI>A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis</TI>
<SO>BMJ (Clinical research ed.)</SO>
<YR>2014</YR>
<VL>349</VL>
<PG>g5630</PG>
<IDENTIFIERS MODIFIED="2016-05-27 15:16:15 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="25252733"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Purcell-2005" MODIFIED="2012-03-12 18:06:30 +0100" MODIFIED_BY="[Empty name]" NAME="Purcell 2005" TYPE="JOURNAL_ARTICLE">
<AU>Purcell PM, Boyd IW</AU>
<TI>Bisphosphonates and osteonecrosis of the jaw</TI>
<SO>Medical Journal of Australia</SO>
<YR>2005</YR>
<VL>182</VL>
<PG>417-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rajkumar-2010" MODIFIED="2011-01-10 19:46:40 +0100" MODIFIED_BY="[Empty name]" NAME="Rajkumar 2010" TYPE="JOURNAL_ARTICLE">
<AU>Rajkumar SV</AU>
<TI>Zoledronic acid in myeloma: MRC Myeloma IX</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>376</VL>
<NO>9757</NO>
<PG>1965-6</PG>
<IDENTIFIERS MODIFIED="2011-01-10 19:46:38 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21131042"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-5.3" MODIFIED="2016-02-22 17:15:49 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 5.3" TYPE="COMPUTER_PROGRAM">
<AU>The Nordic Cochrane Centre</AU>
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ruggiero-2004" MODIFIED="2010-01-26 11:48:57 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Ruggiero 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ruggiero SL, Meherotra B, Rosenberg TJ, Engroff SL</AU>
<TI>Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases</TI>
<SO>Journal of Oral and Maxillofacillary Surgery</SO>
<YR>2004</YR>
<VL>62</VL>
<PG>527-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saad-2012" MODIFIED="2017-11-16 19:02:22 +0100" MODIFIED_BY="[Empty name]" NAME="Saad 2012" TYPE="JOURNAL_ARTICLE">
<AU>Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al</AU>
<TI>Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases</TI>
<SO>Annals of Oncology : official journal of the European Society for Medical Oncology / ESMO</SO>
<YR>2012</YR>
<VL>23</VL>
<NO>5</NO>
<PG>1341-7</PG>
<IDENTIFIERS MODIFIED="2016-02-24 18:22:59 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21986094"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Salanti-2011" MODIFIED="2012-03-12 18:07:29 +0100" MODIFIED_BY="[Empty name]" NAME="Salanti 2011" TYPE="JOURNAL_ARTICLE">
<AU>Salanti G, Ades AE, Ioannidis JP</AU>
<TI>Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>2</NO>
<PG>163-71</PG>
<IDENTIFIERS MODIFIED="2011-02-25 15:38:17 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="20688472"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Salanti-2014" MODIFIED="2017-11-16 19:02:08 +0100" MODIFIED_BY="[Empty name]" NAME="Salanti 2014" TYPE="JOURNAL_ARTICLE">
<AU>Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP</AU>
<TI>Evaluating the quality of evidence from a network meta-analysis</TI>
<SO>PLOS One</SO>
<YR>2014</YR>
<VL>9</VL>
<NO>7</NO>
<PG>e99682</PG>
<IDENTIFIERS MODIFIED="2017-09-21 21:33:37 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="24992266"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Salesi-2006" MODIFIED="2010-01-26 11:50:53 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Salesi 2006" TYPE="JOURNAL_ARTICLE">
<AU>Salesi N, Pistilli R, Marcelli V, Govoni FA, Bozza F, Bossone G, et al</AU>
<TI>Bisphosphonates and oral cavity avascular bone necrosis: a review of twelve cases</TI>
<SO>Anticancer Research</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>4B</NO>
<PG>3111-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saussez-2009" MODIFIED="2017-11-16 19:01:49 +0100" MODIFIED_BY="[Empty name]" NAME="Saussez 2009" TYPE="JOURNAL_ARTICLE">
<AU>Saussez S, Javadian R, Hupin C, Magremanne M, Chantrain G, Loeb I, et al</AU>
<TI>Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series</TI>
<SO>Laryngoscope</SO>
<YR>2009</YR>
<VL>119</VL>
<NO>2</NO>
<PG>323-9</PG>
<IDENTIFIERS MODIFIED="2011-03-04 15:47:33 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="19172621"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2010-02-12 18:19:14 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias, dimension of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scurrah-2000" MODIFIED="2010-01-26 11:51:36 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Scurrah 2000" TYPE="JOURNAL_ARTICLE">
<AU>Scurrah KJ, Palmer LJ, Burton PR</AU>
<TI>Variance components analysis for pedigree-based censored survival data using generalized linear mixed models (GLMMs) and Gibbs sampling in BUGS</TI>
<SO>Genetic Epidemiology</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>2</NO>
<PG>127-48</PG>
<IDENTIFIERS MODIFIED="2009-08-05 20:52:52 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="10962474"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Senel-2007" MODIFIED="2010-01-26 11:52:44 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Senel 2007" TYPE="JOURNAL_ARTICLE">
<AU>Senel FC, Saracoglu Tekin U, Durmus A, Bagis B</AU>
<TI>Severe osteomyelitis of the mandible associated with the use of non-nitrogen-containing bisphosphonate (disodium clodronate): report of a case</TI>
<SO>Journal of Oral and Maxillofacillary Surgery</SO>
<YR>2007</YR>
<VL>65</VL>
<NO>3</NO>
<PG>562-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shipman-1997" MODIFIED="2010-02-12 18:20:32 +0100" MODIFIED_BY="[Empty name]" NAME="Shipman 1997" TYPE="JOURNAL_ARTICLE">
<AU>Shipman CM, Rogers MJ, Apperley JF</AU>
<TI>Bisphosphonates induce apoptosis in human myeloma cells: a novel anti-tumour activity</TI>
<SO>British Journal of Haematology</SO>
<YR>1997</YR>
<VL>98</VL>
<PG>665-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sitters-2005" MODIFIED="2010-01-26 11:53:33 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Sitters 2005" TYPE="JOURNAL_ARTICLE">
<AU>Sitters MA, Caldwell CS</AU>
<TI>Bisphosphonates, dental care and osteonecrosis of the jaws</TI>
<SO>Texas Dental Journal</SO>
<YR>2005</YR>
<VL>122</VL>
<PG>968-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-STATA-V10.1" MODIFIED="2012-03-12 18:09:10 +0100" MODIFIED_BY="Nicole Skoetz" NAME="STATA V10.1" TYPE="COMPUTER_PROGRAM">
<TI>STATA</TI>
<YR>2008</YR>
<EN>10.1</EN>
<PB>StataCorp LP</PB>
<CY>College Station</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2001" MODIFIED="2012-03-12 18:10:35 +0100" MODIFIED_BY="Anne Federer" NAME="Sterne 2001" TYPE="BOOK_SECTION">
<AU>Sterne JAC, Egger M, Smith GD</AU>
<TI>Investigating and dealing with publication and other biases</TI>
<SO>Systematic Reviews in Health Care: Meta-analysis in Context. 2nd edition</SO>
<YR>2001</YR>
<PG>189-208</PG>
<ED>Egger M, Davey Smith S, Altman DG</ED>
<PB>BMJ Books</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tanvetyanon-2006" MODIFIED="2009-12-23 20:25:31 +0100" MODIFIED_BY="[Empty name]" NAME="Tanvetyanon 2006" TYPE="JOURNAL_ARTICLE">
<AU>Tanvetyanon T, Stiff PJ</AU>
<TI>Management of the adverse effects associated with intravenous bisphosphonates</TI>
<SO>Annals of Oncology</SO>
<YR>2006</YR>
<VL>17</VL>
<PG>897-907</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tennis-2012" MODIFIED="2017-11-16 19:01:27 +0100" MODIFIED_BY="[Empty name]" NAME="Tennis 2012" TYPE="JOURNAL_ARTICLE">
<AU>Tennis P, Rothman KJ, Bohn RL, Tan H, Zavras A, Laskarides C, et al</AU>
<TI>Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis</TI>
<SO>Pharmacoepidemiology and Drug Safety</SO>
<YR>2012</YR>
<VL>21</VL>
<NO>8</NO>
<PG>810-7</PG>
<IDENTIFIERS MODIFIED="2016-02-24 18:25:35 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="22711458"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Then-2012" MODIFIED="2016-02-24 18:23:40 +0100" MODIFIED_BY="[Empty name]" NAME="Then 2012" TYPE="JOURNAL_ARTICLE">
<AU>Then C, Horauf N, Otto S, Pautke C, von Tresckow E, Rohnisch T, et al</AU>
<TI>Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation</TI>
<SO>Onkologie</SO>
<YR>2012</YR>
<VL>35</VL>
<NO>11</NO>
<PG>658-64</PG>
<IDENTIFIERS MODIFIED="2016-02-24 18:23:31 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="23147542"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thompson-1997" MODIFIED="2012-03-12 18:11:11 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Thompson 1997" TYPE="JOURNAL_ARTICLE">
<AU>Thompson SG, Smith TC, Sharp SJ</AU>
<TI>Investigating underlying risk as a source of heterogeneity in meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>1997</YR>
<VL>16</VL>
<NO>23</NO>
<PG>2741-58</PG>
<IDENTIFIERS MODIFIED="2010-01-26 11:53:11 +0100" MODIFIED_BY="Nicole Skoetz"/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-2002" MODIFIED="2012-03-12 18:11:21 +0100" MODIFIED_BY="[Empty name]" NAME="Thompson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Thompson SG, Higgins JP</AU>
<TI>How should meta-regression analyses be undertaken and interpreted?</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1559-73</PG>
<IDENTIFIERS MODIFIED="2011-02-25 15:38:52 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="12111920"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thumbigere_x002d_Math-2012" MODIFIED="2017-11-16 18:59:42 +0100" MODIFIED_BY="[Empty name]" NAME="Thumbigere-Math 2012" TYPE="JOURNAL_ARTICLE">
<AU>Thumbigere-Math V, Tu L, Huckabay S, Dudek AZ, Lunos S, Basi DL, et al</AU>
<TI>A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates</TI>
<SO>American Journal of Clinical Oncology</SO>
<YR>2012</YR>
<VL>35</VL>
<NO>4</NO>
<PG>386-92</PG>
<IDENTIFIERS MODIFIED="2016-02-24 18:26:03 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="22561331"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tierney-2007" MODIFIED="2009-08-04 23:08:13 +0200" MODIFIED_BY="[Empty name]" NAME="Tierney 2007" TYPE="JOURNAL_ARTICLE">
<AU>Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR</AU>
<TI>Practical methods for incorporating summary time-to-event data into meta-analysis</TI>
<SO>Trials</SO>
<YR>2007</YR>
<VL>8</VL>
<PG>16</PG>
<IDENTIFIERS MODIFIED="2009-08-04 23:08:11 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="17555582"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tosi-2006b" MODIFIED="2012-03-12 18:20:18 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Tosi 2006b" TYPE="JOURNAL_ARTICLE">
<AU>Tosi P, Zamagni E, Cangini D, Tacchetti P, Di Raimondo F, Catalano L, et al</AU>
<TI>Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone</TI>
<SO>Blood</SO>
<YR>2006</YR>
<VL>108</VL>
<NO>12</NO>
<PG>3951-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Treister-2006" MODIFIED="2009-12-23 20:25:58 +0100" MODIFIED_BY="[Empty name]" NAME="Treister 2006" TYPE="JOURNAL_ARTICLE">
<AU>Treister N, Woo SB</AU>
<TI>Images in clinical medicine. Bisphosphonate-associated osteonecrosis of the jaw</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>355</VL>
<NO>22</NO>
<PG>2348</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tricot-2000" MODIFIED="2012-03-12 18:14:23 +0100" MODIFIED_BY="[Empty name]" NAME="Tricot 2000" TYPE="BOOK_SECTION">
<AU>Tricot G</AU>
<TI>Multiple myeloma and other plasma cell disorders</TI>
<SO>Hematology: Basic Principles and Practice</SO>
<YR>2000</YR>
<EN>3rd</EN>
<ED>Hoffman R, Benz EJ, Shattil SJ, et al</ED>
<PB>Churchill Livingstone</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Holten_x002d_Verzantvoort-1993" MODIFIED="2010-01-26 21:50:43 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Van Holten-Verzantvoort 1993" TYPE="JOURNAL_ARTICLE">
<AU>Van Holten-Verzantvoort AT, Kroon HM, Bijvoet OL, Cleton FJ, Beex LV, Blijham G, et al</AU>
<TI>Palliative pamidronate treatment in patients with bone metastases from breast cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1993</YR>
<VL>11</VL>
<PG>491-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vannucchi-2005" MODIFIED="2009-12-23 20:26:37 +0100" MODIFIED_BY="[Empty name]" NAME="Vannucchi 2005" TYPE="JOURNAL_ARTICLE">
<AU>Vannucchi AM, Ficarra G, Antonioli E, Bosi A</AU>
<TI>Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma</TI>
<SO>British Journal of Haematology</SO>
<YR>2005</YR>
<VL>28</VL>
<PG>738</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vescovi-2012" MODIFIED="2017-11-16 19:00:01 +0100" MODIFIED_BY="[Empty name]" NAME="Vescovi 2012" TYPE="JOURNAL_ARTICLE">
<AU>Vescovi P, Merigo E, Meleti M, Manfredi M, Guidotti R, Nammour S</AU>
<TI>Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients</TI>
<SO>Journal of Oral Pathology &amp; Medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology</SO>
<YR>2012</YR>
<VL>41</VL>
<NO>3</NO>
<PG>214-21</PG>
<IDENTIFIERS MODIFIED="2016-02-24 18:26:27 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21958312"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Walter-2007" MODIFIED="2009-07-12 15:37:12 +0200" MODIFIED_BY="[Empty name]" NAME="Walter 2007" TYPE="JOURNAL_ARTICLE">
<AU>Walter C, Gr&#337;tz KA, Kunkel M, Al-Nawas B</AU>
<TI>Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis</TI>
<SO>Support Care Cancer</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>2</NO>
<PG>197-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Watters-2013" MODIFIED="2017-11-16 19:00:24 +0100" MODIFIED_BY="[Empty name]" NAME="Watters 2013" TYPE="JOURNAL_ARTICLE">
<AU>Watters AL, Hansen HJ, Williams T, Chou JF, Riedel E, Halpern J, et al</AU>
<TI>Intravenous bisphosphonate-related osteonecrosis of the jaw: long-term follow-up of 109 patients</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</SO>
<YR>2013</YR>
<VL>115</VL>
<NO>2</NO>
<PG>192-200</PG>
<IDENTIFIERS MODIFIED="2016-02-24 18:26:48 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="23036797"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wickham-2013" MODIFIED="2017-11-16 19:00:40 +0100" MODIFIED_BY="[Empty name]" NAME="Wickham 2013" TYPE="JOURNAL_ARTICLE">
<AU>Wickham N, Crawford A, Carney AS, Goss AN</AU>
<TI>Bisphosphonate-associated osteonecrosis of the external auditory canal</TI>
<SO>Journal of Laryngology and Otology</SO>
<YR>2013</YR>
<VL>127 Suppl 2</VL>
<PG>S51-3</PG>
<IDENTIFIERS MODIFIED="2016-02-24 18:27:12 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="23673152"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wong-2002" MODIFIED="2017-10-30 16:14:26 +0100" MODIFIED_BY="Heather Maxwell" NAME="Wong 2002" TYPE="COCHRANE_REVIEW">
<AU>Wong RKS, Wiffen PJ</AU>
<TI>Bisphosphonates for the relief of pain secondary to bone metastases</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2017-10-30 16:14:22 +0100" MODIFIED_BY="Heather Maxwell"><IDENTIFIER MODIFIED="2017-10-30 16:14:22 +0100" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD002068"/><IDENTIFIER MODIFIED="2012-02-09 20:45:57 +0100" MODIFIED_BY="Rahul S Mhaskar" TYPE="PUBMED" VALUE="12076438"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wutzl-2006" MODIFIED="2012-03-12 18:18:11 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Wutzl 2006" TYPE="JOURNAL_ARTICLE">
<AU>Wutzl A, Eisenmenger G, Hoffmann M, Czerny C, Moser D, Pietschmann P, et al</AU>
<TI>Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients</TI>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>2006</YR>
<VL>118</VL>
<NO>15-16</NO>
<PG>473-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yeo-2005" MODIFIED="2009-12-23 20:27:03 +0100" MODIFIED_BY="[Empty name]" NAME="Yeo 2005" TYPE="JOURNAL_ARTICLE">
<AU>Yeo AC, Lye KW, Poon CY</AU>
<TI>Bisphosphonate-related osteonecrosis of the jaws</TI>
<SO>Singapore Dental Journal</SO>
<YR>2005</YR>
<VL>27</VL>
<PG>36-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zarychanski-2006" MODIFIED="2010-01-26 21:52:23 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Zarychanski 2006" TYPE="JOURNAL_ARTICLE">
<AU>Zarychanski R, Elphee E, Walton P, Johnston J</AU>
<TI>Osteonecrosis of the jaw associated with pamidronate therapy</TI>
<SO>American Journal of Hematology</SO>
<YR>2006</YR>
<VL>81</VL>
<PG>73-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zervas-2006" MODIFIED="2010-01-26 21:53:11 +0100" MODIFIED_BY="Nicole Skoetz" NAME="Zervas 2006" TYPE="JOURNAL_ARTICLE">
<AU>Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, et al</AU>
<TI>Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients</TI>
<SO>British Journal of Haematology</SO>
<YR>2006</YR>
<VL>134</VL>
<NO>6</NO>
<PG>620-3</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-10-30 12:38:03 +0100" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Djulbegovic-2002" MODIFIED="2017-10-30 12:37:43 +0100" MODIFIED_BY="Heather Maxwell" NAME="Djulbegovic 2002" TYPE="COCHRANE_REVIEW">
<AU>Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, et al</AU>
<TI>Bisphosphonates in multiple myeloma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2017-10-30 12:37:43 +0100" MODIFIED_BY="Heather Maxwell"><IDENTIFIER MODIFIED="2017-10-30 12:37:43 +0100" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD003188"/><IDENTIFIER TYPE="PUBMED" VALUE="12137679"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mhaskar-2010" MODIFIED="2017-10-30 12:33:16 +0100" MODIFIED_BY="Heather Maxwell" NAME="Mhaskar 2010" TYPE="COCHRANE_REVIEW">
<AU>Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, et al</AU>
<TI>Bisphosphonates in multiple myeloma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>3</NO>
<IDENTIFIERS><IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD003188.pub2"/><IDENTIFIER TYPE="PUBMED" VALUE="20238320"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mhaskar-2012" MODIFIED="2017-10-30 12:28:36 +0100" MODIFIED_BY="Heather Maxwell" NAME="Mhaskar 2012" TYPE="COCHRANE_REVIEW">
<AU>Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, et al</AU>
<TI>Bisphosphonates in multiple myeloma: a network meta-analysis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>5</NO>
<EN>Mhaskar R, Redzepovic J, Wheatley K, Clark OAC, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database of Systematic Reviews 2012, Issue 5. Art. No.: CD003188. DOI: 10.1002/14651858.CD003188.pub3</EN>
<IDENTIFIERS MODIFIED="2017-10-30 12:28:36 +0100" MODIFIED_BY="Heather Maxwell"><IDENTIFIER MODIFIED="2017-10-30 12:28:36 +0100" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD003188.pub3"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES><CHARACTERISTICS_OF_STUDIES MODIFIED="2017-12-18 16:43:49 +0100" MODIFIED_BY="[Empty name]"><CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-12-18 16:43:49 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><INCLUDED_CHAR MODIFIED="2017-12-18 16:43:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Attal-2006"><CHAR_METHODS MODIFIED="2017-12-18 16:43:49 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;span modified=&quot;2009-11-22 17:01:00 +0100&quot; class=&quot;inserted&quot; modified_by=&quot;Nicole Skoetz&quot;&gt;not placebo-controlled, but placebo was used?&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2017-12-18 16:43:49 +0100" NOTES_MODIFIED_BY="[Empty name]"><P>Study design: Parallel, not double-blind</P><P>Study length: not reported</P><P>Study conducted during: not reported (study started in 1999)</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2016-12-29 16:46:34 +0100" MODIFIED_BY="[Empty name]"><P>Bisphosphonates: enrolled 196, analyzed 196.<BR/>Bisphosphonates + thalidomide: enrolled 201, analyzed 201.<BR/>Placebo: enrolled 200, analyzed 200.</P><P>Sex (M/F):</P><P>Bisphosphonates: 109/87<BR/>Bisphosphonates + thalidomide: 112/89<BR/>Placebo: 110/90</P><P>Age: mean(SD):</P><P>Bisphosphonates: 59 (8)<BR/>Bisphosphonates + thalidomide: 58 (8)<BR/>Placebo: 59 (8)</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): I-III</P><P>Osteolytic lesion: NR</P><P>Creatinine: NS</P><P>Calcium: NS</P><P>Other criteria: No cytotoxic chemotherapy prior to entry</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-10-31 11:54:20 +0100" MODIFIED_BY="Heather Maxwell"><P>Pamidronate: 90 mg IV, every 4 weeks; Indefinitely.</P><P>Pamidronate and thalidomide: 400 mg orally, dose reduction to a minimum dose of 50 mg was allowed for treatment-related toxicity.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2009-12-08 16:29:38 +0100" MODIFIED_BY="[Empty name]"><P>Total skeletal-related events; total mortality; response rates; ONJ.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2016-12-01 17:36:18 +0100" MODIFIED_BY="[Empty name]"><P>SRE: bone lesion requiring a specific therapy (chemotherapy, irradiation or surgery).</P><P>Funding: Supported by a major grant from the Programme Hospitalier de Recherche Clinique and by the Swiss Group for Clinical Cancer Research (SAKK).</P><P>COI statement included: The authors declare no competing financial interests.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aviles-2007"><CHAR_METHODS MODIFIED="2016-11-14 17:29:02 +0100" MODIFIED_BY="[Empty name]"><P>Study design: Parallel, not double-blind; not placebo-controlled study</P><P>Study length: not reported</P><P>Study conducted during: Mar 1999 - Dec 2001</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2016-12-29 16:46:50 +0100" MODIFIED_BY="[Empty name]"><P>Bisphosphonates: enrolled 46, analyzed 46.<BR/>Control: enrolled 48, analyzed 48.</P><P>Sex (M/F):</P><P>Bisphosphonates: 26/20<BR/>Control: 23/25</P><P>Mean age (range):</P><P>Bisphosphonates: 67.3 (43-75)<BR/>Control: 65.4 (39-75)</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): III</P><P>Osteolytic lesion: At least one</P><P>Creatinine: NS</P><P>Calcium: NS</P><P>Other criteria: No cytotoxic chemotherapy prior to entry</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-10-31 12:42:42 +0100" MODIFIED_BY="Heather Maxwell"><P>Zoledronate: 4 mg IV, every 4 weeks; indefinitely.</P><P>Control: no zoledronate.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]"><P>Total mortality; PFS.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-10-31 12:12:59 +0100" MODIFIED_BY="Heather Maxwell"><P>SRE: appearance of a new lytic lesion (excluding skull), after patient began zoledronate or progression of previous bone lesion according to criteria of Union Internationale Centre le Cancer.</P><P>Funding: Not reported.</P><P>COI statement included: Not reported.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aviles-2013"><CHAR_METHODS MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]"><P>Study design: Parallel, open-label; not placebo-controlled study</P><P>Study length: not reported</P><P>Study conducted during: Jun 2002 &#8211; Dec 2007</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2016-12-29 16:47:02 +0100" MODIFIED_BY="[Empty name]"><P>Bisphosphonates: enrolled 151, analyzed 151.<BR/>Control: No zoledronate: enrolled 157, analyzed 157.</P><P>Sex (M/F):</P><P>Bisphosphonates: 71/80<BR/>Control: 85/72</P><P>Mean age (range):</P><P>Bisphosphonates: 56.4 (29-65)<BR/>Control: 57.8 (33-65)</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): IIB- IIIB</P><P>Osteolytic lesion: NS</P><P>Creatinine: creatinine clearance &gt; 30 mL/min</P><P>Calcium: NS</P><P>Other criteria: Adult patients at least 18 years but less than 65 years of age with untreated symptomatic multiple myeloma and measurable paraprotein in serum and urine, Eastern Cooperative Oncology Group performance status 0&#8211;2, and adequate renal (no end-stage renal failure and creatinine clearance &gt; 30 mL/min), hematologic (platelet count &gt; 50×109/L, neutrophil count &gt; 0.75×109/L), and liver function were eligible</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]"><P>Zoledronate: IV; 4 mg (or dose-adjusted based on creatinine clearance) once every 28 days for 24 months.</P><P>Control: no zoledronate.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2016-11-14 17:39:48 +0100" MODIFIED_BY="[Empty name]"><P>SRE; overall survival *$; progression free survival *$;</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2016-12-01 17:36:53 +0100" MODIFIED_BY="[Empty name]"><P>PFS is defined as time from the start of high-dose induction therapy (or time from the start of next treatment) to time of progression, relapse, or death.</P><P>The primary endpoints were PFS and OS at 10 years, and the secondary endpoints included overall response, rates of complete response and very good partial response, and safety.</P><P>Funding: This study was supported entirely with resources from the Mexican Institute of Social Security. Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals Corporation, but the study was not sponsored by Novartis or by any other pharmaceutical company. ProEd Communications, Inc., provided medical editorial assistance with this manuscript.</P><P>COI statement included: Aside from support from Novartis Pharmaceuticals Corporation for medical editorial assistance, all authors declare that they have no financial conflicts of interest.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Belch-1991"><CHAR_METHODS MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]"><P>Study design: Parallel, double-blind; placebo-controlled study</P><P>Study length: not reported</P><P>Study conducted during: Nov 1983 &#8211; Feb 1987 (enrollment in the high dose arm was stopped in Jun 1984)</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2016-12-29 16:47:14 +0100" MODIFIED_BY="[Empty name]"><P>Bisphosphonates: enrolled 98, analyzed 92.<BR/>Control: enrolled 78, analyzed 74.</P><P>Sex (M/F):</P><P>Bisphosphonates: 60/32<BR/>Control: 44/30</P><P>Mean age (SD/range): not reported</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): I-III</P><P>Osteolytic lesion: NR</P><P>Creatinine: &lt; 3 mg/dL</P><P>Calcium: Normal or elevated</P><P>Other criteria: No cytotoxic chemotherapy prior to entry</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2016-11-14 18:00:38 +0100" MODIFIED_BY="[Empty name]"><P>Etidronate: capsules (20 mg/kg for 28 days every other 28 days: but this arm was discontinued); enrollment took place for: 5 mg/kg until death or discontinuation.<BR/>Placebo: identical appearance.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2012-03-20 14:58:44 +0100" MODIFIED_BY="[Empty name]"><P>Vertebral index; total mortality*; pain;<BR/>calcium.***</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-10-31 12:13:34 +0100" MODIFIED_BY="Heather Maxwell"><P>SRE: bone progression (appearances of new lesions or worsening of existing ones)$; mortality* (from the date of randomization); calcium reported as a dichotomous variable.</P><P>Funding: Supported by Norwich Eaton Pharmaceuticals Inc. and The National Cancer Institute of Canada.</P><P>COI statement included: not reported.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berenson-1998a"><CHAR_METHODS MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]"><P>Study design: Parallel, double-blind; placebo-controlled study</P><P>Study length: not reported</P><P>Study conducted during: Aug 1990 &#8211; Jun 1993</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2016-12-29 16:47:24 +0100" MODIFIED_BY="[Empty name]"><P>Bisphosphonates: enrolled 205, analyzed 198.<BR/>Placebo: enrolled 187, analyzed 179.</P><P>Sex (M/F):</P><P>Bisphosphonates: 108/88<BR/>Control: 109/72</P><P>Mean age (SD):</P><P>Bisphosphonates: 64 (10)<BR/>Control: 63 (10)</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): III only</P><P>Osteolytic lesion: at least one</P><P>Creatinine: &lt; 5 mg/dL</P><P>Calcium: NS</P><P>Other criteria: No bone specific treatment prior to entry</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]"><P>Pamidronate: 90 mg in 500 mL of 5% dextrose in water, every 4 weeks for 24 months.<BR/>Control: identical placebo in 5% dextrose.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]"><P>SRE (total);<BR/>vertebral fractures; non-vertebral fractures;<BR/>total mortality (#);<BR/>calcium***;<BR/>pain;<BR/>adverse events.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-10-31 12:12:36 +0100" MODIFIED_BY="Heather Maxwell" NOTES="&lt;p&gt;&lt;span modified=&quot;2009-11-22 17:07:00 +0100&quot; class=&quot;inserted&quot; modified_by=&quot;Nicole Skoetz&quot;&gt;please write in full&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2017-10-31 12:12:36 +0100" NOTES_MODIFIED_BY="Heather Maxwell"><P>SRE: pathologic fracture or radiation treatment/surgery on bone or spinal cord compression. Pain control assessment: Bone pain reported by authors at 29 months.</P><P>Funding: Supported by a grant from the Pharmaceuticals Division, Ciba&#8211;Geigy Corporation, Summit, N.J.</P><P>COI statement included: not reported.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brincker-1998"><CHAR_METHODS MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]"><P>Study design: Parallel, double-blind; placebo-controlled study</P><P>Study length: not reported</P><P>Study conducted during: Sept 1990 &#8211; Jul 1995</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2016-12-29 16:47:36 +0100" MODIFIED_BY="[Empty name]"><P>Bisphosphonates: enrolled 152, analyzed 152.<BR/>Placebo: enrolled 148, analyzed 148.</P><P>Sex (M/F):</P><P>Bisphosphonates: 83/69<BR/>Control: 109/72</P><P>Mean age (SD):</P><P>Bisphosphonates: 69 (NR)<BR/>Control: 69 (NR)</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): II-III</P><P>Osteolytic lesion: NS</P><P>Creatinine: &lt; 2.8 mg/dL</P><P>Calcium: Normal or elevated</P><P>Other criteria: No cytotoxic chemotherapy prior to entry</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]"><P>Pamidronate: 75 mg capsules orally bid (total 300mg /day); for at least 2 years.<BR/>Control: identical placebo.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2016-11-14 19:09:36 +0100" MODIFIED_BY="[Empty name]"><P>Total mortality*$; SRE;<BR/>pain;<BR/>calcium(&amp;);<BR/>adverse events</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-10-31 12:12:02 +0100" MODIFIED_BY="Heather Maxwell"><P>SRE: bone fracture other than vertebral or surgery or increase in number of osteolytic lesions + vertebral collapse.<BR/>Pain reported as the number of events, not as the number of patients experiencing pain.</P><P>Funding: not reported.</P><P>COI statement included: not reported.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Daragon-1993"><CHAR_METHODS MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]"><P>Study design: Parallel, double-blind; placebo-controlled study</P><P>Study length: not reported</P><P>Study conducted during: Jan 1985 &#8211; Jun 1990</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2016-12-29 16:47:44 +0100" MODIFIED_BY="[Empty name]"><P>Bisphosphonates: enrolled 49, analyzed 39.<BR/>Placebo: enrolled 45, analyzed 39.</P><P>Sex (M/F):</P><P>Bisphosphonates: 22/27<BR/>Control: 22/23</P><P>Mean age (SD):</P><P>Bisphosphonates: 65.6 (9.8)<BR/>Control: 66.9 (9)</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): II-III</P><P>Osteolytic lesion: NS</P><P>Creatinine: &lt; 2.8 mg/dL</P><P>Calcium: Normal or elevated</P><P>Other criteria: No cytotoxic chemotherapy prior to entry</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]"><P>Etidronate: 10 mg/kg orally daily with lunch; for 4 months.<BR/>Control: identical placebo.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]"><P>Total mortality *$ ;SRE (total);<BR/>total fractures;<BR/>vertebral fractures;<BR/>non-vertebral fractures;<BR/>vertebral index;<BR/>total mortality;<BR/>pain;<BR/>calcium;<BR/>adverse events.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-10-31 12:16:23 +0100" MODIFIED_BY="Heather Maxwell"><P>SRE: new extraspinal osteolytic bone lesions or fractures or vertebral index; total mortality: total number of deaths reported in the text.<BR/>Pain recorded as the number of patients taking class 2 and 3 narcoanalgesics at four months.</P><P>Funding: Supported in part by Nativelle, Issy-les-Moulineaux, France and by INSERM ; etudes biochimiques et therpaeuteques du myeloma multiple, by association pour la researche contre le cancer and by Ligue nationale de lute contre le cancer.</P><P>COI statement included: not reported.</P><P>Pain control assessment: Analgesic use at 4 months.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Delmas-1982"><CHAR_METHODS MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]"><P>Study design: Parallel, double-blind; placebo-controlled study</P><P>Study length: not reported</P><P>Study conducted during: not reported</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2016-12-29 16:47:54 +0100" MODIFIED_BY="[Empty name]"><P>Bisphosphonates: enrolled 7, analyzed 7.<BR/>Placebo: enrolled 6, analyzed 6.</P><P>Sex (M/F): not reported</P><P>Mean age (SD): Not reported</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): NS</P><P>Osteolytic lesion: NS</P><P>Creatinine: &lt; 1.8 mg/dL</P><P>Calcium: Normal or elevated</P><P>Other criteria: none</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-10-31 12:16:59 +0100" MODIFIED_BY="Heather Maxwell"><P>Clodronate: 1600 mg/day orally; for 24 months.<BR/>Control: identical placebo.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]"><P>SRE;<BR/>total fractures;<BR/>vertebral fracture;<BR/>non-vertebral fractures;<BR/>total mortality;<BR/>pain;<BR/>calcium;<BR/>adverse events.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-10-31 12:17:49 +0100" MODIFIED_BY="Heather Maxwell"><P>SRE: new osteolytic lesions or fractures or vertebral index ($);<BR/>vertebral fractures for control group not reported;<BR/>total mortality reported for clodronate group only;<BR/>adverse events stated only (data could not be extracted).</P><P>Pain control assessment: Pain index at 12 months.</P><P>Funding: Clodronate: Dichloromthylene diphosphonate (CI<SUB>2</SUB>MDP) was provided by Procter and Gamble Inc, USA.</P><P>COI statement included: not reported.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garcia_x002d_Sanz-2015"><CHAR_METHODS MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]"><P>Study design: Parallel, open-label; not blinded, not placebo-controlled phase IV study</P><P>Study length: not reported</P><P>Study conducted during: Jun 2010 &#8211; Jul 2012</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2016-12-29 16:48:06 +0100" MODIFIED_BY="[Empty name]"><P>Bisphosphonates: enrolled 51, analyzed 51. The original plan was to enroll 96 patients per-group. After enrollment of 75 patients an interim analysis was performed which suggested a beneficial effect with zoledronate.</P><P>No treatment: 49 enrolled, analyzed 49.</P><P>Sex (M/F):</P><P>Bisphosphonates: 30/21<BR/>Control: 23/26</P><P>Mean age (range): 68 (40 &#8211; 87)</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): Asymptomatic patients; stage not specified</P><P>Osteolytic lesion: NS</P><P>Creatinine: NS</P><P>Calcium: NS</P><P>Other criteria: Confirmed biochemical relapse of MM after an initial response, without symptoms derived from the disease</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]"><P>Zoledronic acid: 4 mg in a 15-minute intravenous infusion every 4 weeks, for a total of 12 doses, plus standard supportive care.</P><P>No treatment: supportive care only.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]"><P>Time to new treatment, overall survival, response rate, time to clinical symptoms, skeletal-related events, time to a skeletal-related event, hypercalcemia, osteonecrosis of jaw and renal dysfunction.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-10-31 12:19:52 +0100" MODIFIED_BY="Heather Maxwell"><P>SRE: bone fracture (vertebral and non-vertebral), requirement for bone radiotherapy, requirement for bone surgery, or hypercalcemia.</P><P>Funding: supported by an unrestricted grant from Novartis Farmaceutica S.A., Barcelona, Spain and sponsored by GEM/PETHEMA. Part of the work was also supported by grants PS09/01450 and PI12/02311 from the Spanish &#8220;Institutode Salud Carlos III (ISCIII)&#8221; and Fondo Europeo de DesarrolloRegional (FEDER), the Spanish Ministry of Economy andCompetitiveness and the European Regional Development Fund(ERDF) &#8220;Una manera de hacer Europa&#8221; (Innocampus; CEI-2010-1-0010), the grant RD12/0036/0069 from &#8220;Red Temáticade Investigación Cooperativa en Cáncer (RTICC), and grant GCB-120981SAN from the &#8220;Asociación Española Contra elCáncer (AECC)&#8221;.</P><P>COI statement included: not reported.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gimsing-2010"><CHAR_METHODS MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]"><P>Study design: Parallel, double-blind, comparing 30 mg versus 90 mg pamidronate</P><P>Study length: median follow-up: 3.4 years (range: 1.1 &#8211; 5.7)</P><P>Study conducted during: Jan 2001 &#8211; Aug 2005</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2016-12-29 16:48:19 +0100" MODIFIED_BY="[Empty name]"><P>Pamidornate 30 mg: enrolled 252, analyzed 198.<BR/>Pamidronate 90 mg: enrolled 252, analyzed 179.</P><P>No treatment: 49 enrolled, analyzed 49.</P><P>Sex (M/F):</P><P>Pamidronate 90 mg: 149/101<BR/>Pamidronate 30 mg: 155/97</P><P>Mean age (range): not reported</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): I-III</P><P>Osteolytic lesion: NS</P><P>Creatinine: &lt; 400 µmol/L</P><P>Calcium: NS</P><P>Other criteria: No prior treatment with bisphosphonates</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]"><P>Pamidronate: 90 mg in 500 mL of 5% dextrose in water, every 4 weeks for at least 36 months.<BR/>Control: 30 mg in 500 mL of 5% dextrose in water, every 4 weeks for at least 36 months.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]"><P>SRE (total);<BR/>vertebral fractures; non-vertebral fractures;<BR/>total mortality (#);<BR/>calcium***;<BR/>pain;<BR/>adverse events.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2016-12-01 17:39:46 +0100" MODIFIED_BY="[Empty name]"><P>SRE: pathologic fracture or radiation treatment/surgery on bone or spinal cord compression.</P><P>Funding: Nordic Cancer Union and Novartis Healthcare.</P><P>COI statement included: &#8220;PG has received grant support from Janssen-Cilag, a speaker&#8217;s bureau from Celgene, and fee as chairman of the data monitoring committee for BioInvent. AW has received grant support from Janssen-Cilag, fees for consultancy from Janssen-Cilag and Pharmion, and payment for advisory board participation from Novartis. HH-H has received speakers fees. The Nordic Myeloma Study Group has received grant support from Janssen-Cilag, Celgene, Amgen, and Nordpharma. All other authors declared no conflicts of interest.&#8221;</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-16 18:52:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heim-1995"><CHAR_METHODS MODIFIED="2017-11-16 18:52:07 +0100" MODIFIED_BY="[Empty name]"><P>Study design: Parallel, placebo-controlled study</P><P>Study length: not reported</P><P>Study conducted during: not reported (stay started in 1989)</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2016-12-29 16:48:28 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;please write in full &lt;/p&gt;" NOTES_MODIFIED="2016-12-29 16:48:28 +0100" NOTES_MODIFIED_BY="[Empty name]"><P>Total: 170; 13 withdrawn after treatment. premature termination in additional 75.<BR/>Bisphosphonates: analyzed: 39.<BR/>Placebo: analyzed: 32.</P><P>Sex (M/F): not available for the entire study cohort</P><P>Mean age (range): not reported</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): I-III</P><P>Osteolytic lesion: NR</P><P>Creatinine: &lt; 2.5 mg/dL</P><P>Calcium: NS</P><P>Other criteria: none</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-16 18:52:07 +0100" MODIFIED_BY="[Empty name]"><P>Clodronate: 1600 mg/day orally; for 12 months.<BR/>Control: no treatment.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2010-02-12 17:05:23 +0100" MODIFIED_BY="[Empty name]"><P>SRE;<BR/>pain;<BR/>total fractures;<BR/>calcium;<BR/>adverse events.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-10-31 12:21:43 +0100" MODIFIED_BY="Heather Maxwell"><P>SRE: bone progression ($); effect on pain characterized as the number of patients without pain or no need for therapy.</P><P>Pain control assessment: Analgesic use OR presence of pain at 9 months.</P><P>Funding: not reported.</P><P>COI statement included: not reported.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-16 18:52:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kraj-2000"><CHAR_METHODS MODIFIED="2017-11-16 18:52:07 +0100" MODIFIED_BY="[Empty name]"><P>Study design: Parallel, not double-blind, placebo-controlled study</P><P>Study length: not reported</P><P>Study conducted during: not reported (study started in 1989)</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2016-12-29 16:48:36 +0100" MODIFIED_BY="[Empty name]"><P>Bisphosphonates: analyzed 23;</P><P>Placebo: analyzed 23.</P><P>Sex (M/F):</P><P>Bisphosphonates: 10/13<BR/>Control: 16/7</P><P>Mean age (SD):</P><P>Bisphosphonates: 60 (10)<BR/>Control: 66 (9)</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): II-III</P><P>Osteolytic lesion: NS</P><P>Creatinine: unclear</P><P>Calcium: NS</P><P>Other criteria: none</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-16 18:52:07 +0100" MODIFIED_BY="[Empty name]"><P>Pamidronate 60 mg IV, every 4 weeks; indefinitely.<BR/>control: no treatment.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2010-02-12 17:05:24 +0100" MODIFIED_BY="[Empty name]"><P>Total mortality, vertebral fractures.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2016-12-01 17:40:38 +0100" MODIFIED_BY="[Empty name]"><P>Funding: not reported</P><P>COI statement included: not reported</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-16 18:52:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lahtinen-1992"><CHAR_METHODS MODIFIED="2016-11-30 17:06:35 +0100" MODIFIED_BY="[Empty name]"><P>Study design: Parallel, double-blind; placebo-controlled study</P><P>Study length: not reported</P><P>Study conducted during: 1986 and 1989</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-16 18:52:07 +0100" MODIFIED_BY="[Empty name]"><P>Bisphosphonates (clodronate): enrolled 168, analyzed 168.<BR/>Placebo: enrolled 168, analyzed 168.</P><P>Sex (M/F):</P><P>Bisphosphonates (clodronate): 84/84<BR/>Placebo: 82/86</P><P>Age: mean(SD):</P><P>Bisphosphonates: Not reported<BR/>Placebo: Not reported</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): NR</P><P>Osteolytic lesion: NR</P><P>Creatinine: NS</P><P>Calcium: NS</P><P>Other criteria: No prior use of bisphosphonates and capacity to tolerate systemic chemotherapy</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-16 18:52:07 +0100" MODIFIED_BY="[Empty name]"><P>Clodronate 2400 mg capsules orally daily.<BR/>Identical placebo.<BR/>Duration 24 months.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-16 18:52:07 +0100" MODIFIED_BY="[Empty name]"><P>SRE (total); total mortality; vertebral fractures; non-vertebral fractures; calcium**</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-10-31 12:25:17 +0100" MODIFIED_BY="Heather Maxwell"><P>Total mortality reported as a total number of deaths. Pain control assessment: Pain index at 12 months.</P><P>Funding: Supported by Huhtamaki Oy, Leiras, Turku and the Finnish Cancer Foundation.</P><P>COI statement included: NR.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-16 18:52:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leng-2002"><CHAR_METHODS MODIFIED="2016-11-30 20:49:35 +0100" MODIFIED_BY="[Empty name]"><P>Study design: Parallel, not double-blind; placebo-controlled study</P><P>Study length: NR</P><P>Study conducted during: NR</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-16 18:52:07 +0100" MODIFIED_BY="[Empty name]"><P>Bisphosphonates (pamidronate): enrolled 16, analyzed 16.<BR/>Placebo: enrolled 18, analyzed 18.</P><P>Sex (M/F):</P><P>Bisphosphonates: NR<BR/>Placebo: NR</P><P>Age: mean(SD):</P><P>Bisphosphonates: NR<BR/>Placebo: NR</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): II-II</P><P>Osteolytic lesion: NS</P><P>Creatinine: NS</P><P>Calcium: NS</P><P>Other criteria: Verbal rating scale &gt; II</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-16 18:52:07 +0100" MODIFIED_BY="[Empty name]"><P>Pamidronate 90 mg daily IV.<BR/>Identical placebo.<BR/>Duration indefinite.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2016-11-30 20:49:35 +0100" MODIFIED_BY="[Empty name]"><P>Pain (continuous data).</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-10-31 12:26:57 +0100" MODIFIED_BY="Heather Maxwell"><P>Pain control assessment: Visual analogue scale.</P><P>Funding: NR.</P><P>COI statement included: NR.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-16 18:52:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCloskey-2001"><CHAR_METHODS MODIFIED="2016-11-30 21:01:19 +0100" MODIFIED_BY="[Empty name]"><P>Study design: Parallel, double-blind; placebo-controlled study</P><P>Study length: NR</P><P>Study conducted during: 1986 to 1992</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2016-12-29 16:49:11 +0100" MODIFIED_BY="[Empty name]"><P>Bisphosphonates: enrolled/analyzed 264.<BR/>Placebo: enrolled/analyzed 272.</P><P>Sex (M/F):</P><P>Bisphosphonates: 1.33 ratio<BR/>Placebo: 1.43 ratio</P><P>Age: Median (Inter-quartile range)</P><P>Bisphosphonates: 62 (55-67)<BR/>Placebo: 63 (57-68)</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): II-II</P><P>Osteolytic lesion: at least one</P><P>Creatinine: any</P><P>Calcium: normal or elevated</P><P>Other criteria: No cytotoxic chemotherapy prior to entry</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-16 18:52:07 +0100" MODIFIED_BY="[Empty name]"><P>Clodronate 1600 mg orally daily.<BR/>Identical placebo.<BR/>Duration indefinite or progression.<BR/></P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-16 18:52:07 +0100" MODIFIED_BY="[Empty name]"><P>Total mortality*; SRE; total fractures; vertebral fractures; non-vertebral fracture; pain; calcium.***</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-10-31 12:29:02 +0100" MODIFIED_BY="Heather Maxwell"><P>SRE: event-free survival (pathological fractures or hypercalcemia), calculated from survival curves; outcome on calcium also reported as a dichotomous variable on the number of patients with hypercalcemia; pain calculated as the number of patients with maximal pain over 24 months.</P><P>Pain control assessment: Severe pain at 24 months.</P><P>Funding: Drug provided by Leiras Oy, Finland and MRC grant.</P><P>COI statement included: NR.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-16 18:52:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Menssen-2002"><CHAR_METHODS MODIFIED="2016-11-30 21:09:21 +0100" MODIFIED_BY="[Empty name]"><P>Study design: Parallel, double-blind; placebo-controlled study</P><P>Study length: NR</P><P>Study conducted during: 1994 to 1996</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2016-12-29 16:49:20 +0100" MODIFIED_BY="[Empty name]"><P>Bisphosphonates: enrolled 107, analyzed 99.<BR/>Placebo: enrolled 107, analyzed 99.</P><P>Sex (M/F):</P><P>Bisphosphonates: 53/46<BR/>Placebo: 51/48</P><P>Age: Mean (SD)</P><P>Bisphosphonates: 62.9 (NR)<BR/>Placebo: 63.4 (NR)</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): II-II</P><P>Osteolytic lesion: at least one</P><P>Creatinine: &#8804; 3 mg/dL</P><P>Calcium: normal</P><P>Other criteria: No bone specific treatment prior to entry</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-16 18:52:07 +0100" MODIFIED_BY="[Empty name]"><P>Ibandronate 2 mg IV every month.<BR/>Identical placebo, duration 24 months.<BR/>Duration: 12 to 24 months.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-16 18:52:08 +0100" MODIFIED_BY="[Empty name]"><P>SRE (total)/year;<BR/>mortality;*<BR/>vertebral fractures (!);<BR/>non-vertebral fractures (!);<BR/>hypercalcemia (!);<BR/>pain (!).</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-10-31 12:30:02 +0100" MODIFIED_BY="Heather Maxwell"><P>SRE: pathological fractures or vertebral fractures, hypercalcemia, severe bone pain, and bone radiotherapy or surgery.<BR/>Pain control assessment: Opiate usage.</P><P>Funding: Roche Diagnostics GmbH, Mannheim, Germany.</P><P>COI statement included: NR.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-16 18:52:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morgan-2010"><CHAR_METHODS MODIFIED="2017-11-16 18:52:08 +0100" MODIFIED_BY="[Empty name]"><P>Study design: Parallel, open-label; comparing zoledronate versus clodronate</P><P>Study length: NR</P><P>Study conducted during: 1994 to 1996</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2016-12-29 16:49:35 +0100" MODIFIED_BY="[Empty name]"><P>Zoledronate: analyzed 981.<BR/>Clodronate: analyzed 979</P><P>Sex (M/F):</P><P>Bisphosphonates: 53/46<BR/>Placebo: 51/48</P><P>Age: Mean (SD)</P><P>Bisphosphonates: NR<BR/>Placebo: NR</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): I-III (International Staging System)</P><P>Osteolytic lesion: NS</P><P>Creatinine: &lt;5.65 mg/dL</P><P>Calcium: NS</P><P>Other criteria: No previous or concurrent active malignancies, No acute renal failure (serum creatinine &gt; 500 µmol/L and unresponsive to 72 hours of rehydration</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-16 18:52:08 +0100" MODIFIED_BY="[Empty name]"><P>Zoledronate 4 mg IV every 3-4 weeks.<BR/>Clodronate 1600 mg orally daily.<BR/>Duration: until progression.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2016-11-30 21:21:14 +0100" MODIFIED_BY="[Empty name]"><P>Mortality; SREs; complete response; vertebral fractures, other fractures; hypercalcemia; renal failure; very good partial response; treatment-related toxicities.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2016-12-01 17:45:00 +0100" MODIFIED_BY="[Empty name]"><P>SRE: vertebral fractures, other fractures, spinal cord compression, need for radiation or surgery to bone lesions, and new osteolytic bone lesions were recorded until disease progression. Complete response: negative immunofixation (100% M-protein reduction) very good partial response: at least 90% M-protein reduction with positive immunofixation.</P><P>Funding: UK MRC, unrestricted educational grants from Novartis, Schering Health Care, Chugai, Pharmion, Celgene, and Ortho Biotech for trial coordination and the laboratory studies. Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals.</P><P>COI statement included: "F.E. Davies has honoraria from Speakers Bureau of Celgene and is a consultant/advisory board member of Celgene and Novartis. G. Cook is a consultant/advisory board member of and has honoraria from Speakers Bureau of Celgene. R.G. Owen has honoraria from Speakers Bureau of Celgene and Ortho Biotech, United Kingdom. G.H. Jackson has honoraria from Speakers Bureau of Celgene and is a consultant/advisory board member of Celgene and J&amp;J. No potential conflicts of interest were disclosed by the other authors."</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-16 18:52:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Musto-2003"><CHAR_METHODS MODIFIED="2017-11-16 18:52:08 +0100" MODIFIED_BY="[Empty name]"><P>Study design: Parallel, not double-blind; not placebo-controlled</P><P>Study length: NR</P><P>Study conducted during: 1996 to 2001</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2016-12-29 16:49:44 +0100" MODIFIED_BY="[Empty name]"><P>Bisphosphonates: analyzed 45.<BR/>Control: analyzed 45.</P><P>Sex (M/F):</P><P>Bisphosphonates: 26/19<BR/>Control: 24/21</P><P>Age: Median (range)</P><P>Bisphosphonates: 67 (47-79)<BR/>Placebo: 68 (45-80)</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): I-II</P><P>Osteolytic lesion: Any</P><P>Creatinine: NS</P><P>Calcium: NS</P><P>Other criteria: No cytotoxic chemotherapy prior to entry</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-16 18:52:08 +0100" MODIFIED_BY="[Empty name]"><P>Pamidronate 60 mg IV, every month.<BR/>Control: NS.<BR/>Duration: 1 year or until progression.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-16 18:52:08 +0100" MODIFIED_BY="[Empty name]"><P>Total skeletal-related events; PFS, adverse events.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2016-11-30 21:34:48 +0100" MODIFIED_BY="[Empty name]"><P>SRE: single/multiple osteolytic lesions, pathological fractures and/or hypercalcemia.</P><P>Funding: NR</P><P>COI statement included: No.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-16 18:52:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Musto-2008"><CHAR_METHODS MODIFIED="2017-11-16 18:52:08 +0100" MODIFIED_BY="[Empty name]"><P>Study design: Parallel, not double-blind; not placebo-controlled</P><P>Study length: NR</P><P>Study conducted during: 1996 to 2001</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2016-12-29 16:49:53 +0100" MODIFIED_BY="[Empty name]"><P>Bisphosphonates: enrolled 81, analyzed 81.<BR/>Control: enrolled 82, analyzed 82.</P><P>Sex (M/F):</P><P>Bisphosphonates: 43/38<BR/>Control: 47/35</P><P>Age: Median (range)</P><P>Bisphosphonates: 66 (41-82)<BR/>Control: 67 (42-84)</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): I</P><P>Osteolytic lesion: Any</P><P>Creatinine: &lt; 1.2 mg/dL</P><P>Calcium: &lt; 10 mg/dL</P><P>Other criteria: No cytotoxic chemotherapy prior to entry</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-16 18:52:08 +0100" MODIFIED_BY="[Empty name]"><P>Zoledronate 4 mg IV, every month.<BR/>Control: observation.<BR/>Duration: 1 year or until progression.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2016-11-30 21:40:17 +0100" MODIFIED_BY="[Empty name]"><P>SRE (total); PFS; ONJ.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-10-31 12:32:52 +0100" MODIFIED_BY="Heather Maxwell"><P>SRE: single/multiple osteolytic lesions, pathological fractures and/or hypercalcemia.</P><P>The trial was prematurely stopped due to ONJ case in patient receiving zoledronate.</P><P>Funding: NR.</P><P>COI statement included: No.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-10-31 12:33:58 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Rosen-2003"><CHAR_METHODS MODIFIED="2017-10-31 12:33:11 +0100" MODIFIED_BY="Heather Maxwell"><P>Study design: Parallel, double-blinded; double dummy; stratified; not placebo-controlled</P><P>Study length: 25 months</P><P>Study conducted during: 1998 to 2000</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2016-12-29 16:50:00 +0100" MODIFIED_BY="[Empty name]"><P>Zoledronate: enrolled 564, analyzed 561<BR/>Pamidronate: enrolled 558, analyzed 555</P><P>Sex (M/F):</P><P>Zoledronate: NR<BR/>Pamidronate: NR</P><P>Age: Mean (SD)</P><P>Zoledronate: 58 (NR)<BR/>Pamidronate: 57 (NR)</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): III</P><P>Osteolytic lesion: at least one</P><P>Creatinine: &lt;= 3 mg/dL</P><P>Calcium: &lt;= 12 mg/dL</P><P>Other criteria: Serum bilirubin &#8804; 2.5 mg/dL. No prior treatment with bisphosphonates within 12 months of the screening visit</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-10-31 12:33:58 +0100" MODIFIED_BY="Heather Maxwell"><P>Zoledronate 4 mg IV, every 4 weeks.<BR/>Pamidronate 90 mg IV, every 4 weeks.<BR/>Duration: 24 months.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2011-06-10 20:52:15 +0200" MODIFIED_BY="Rahul S Mhaskar"><P>SREs</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-10-31 12:33:50 +0100" MODIFIED_BY="Heather Maxwell"><P>SREs were defined as pathologic fracture, spinal cord compression, radiation therapy to bone, and surgery to bone.<BR/>Data for MM and breast carcinoma patients were reported in combined manner for all outcomes except SREs.</P><P>Funding: Novartis Pharmaceuticals Corporation.</P><P>COI statement included: "Dr. Seaman, Dr. Chen, and Dr. Reitsma are employed by Novartis Pharmaceuticals and may own stock in the company; Dr. Coleman has received honoraria from Novartis; and Dr. Hussein has received a research grant from Novartis."</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-16 18:52:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sezer-2010"><CHAR_METHODS MODIFIED="2017-11-16 18:52:08 +0100" MODIFIED_BY="[Empty name]"><P>Study design: Parallel; open-label; placebo-controlled</P><P>Study length: 48 months</P><P>Study conducted during: 2000 to 2008</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-16 18:52:08 +0100" MODIFIED_BY="[Empty name]"><P>Bisphosphonates: enrolled72; analyzed 71.<BR/>Control: enrolled71; analyzed 69.</P><P>Sex (M/F):</P><P>Zoledronate: 30/42<BR/>Control: 40/31</P><P>Age: Mean (SD)</P><P>Zoledronate: 58.8 (12.02)<BR/>Control: 62.1 (10.79)</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): Asymptomatic patients stage I</P><P>Osteolytic lesion: at least one</P><P>Creatinine: NS</P><P>Calcium: NS</P><P>Other criteria: Patients with evidence of paraprotein in the serum or urine and bone marrow infiltration with plasma cells which represent more than 10% of the nucleated cells.</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-16 18:52:08 +0100" MODIFIED_BY="[Empty name]"><P>Zoledronate 4 mg IV (or dose-adjusted based on creatinine clearance) monthly.<BR/>Control: observation.<BR/>Duration: until progression or 48 months whichever comes first.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-16 18:52:08 +0100" MODIFIED_BY="[Empty name]"><P>Days of PFS; SREs (defined as: pathologic fracture, initiation of radiotherapy or surgery on bone, spinal cord compression or hypercalcemia); adverse events.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-11-16 18:52:09 +0100" MODIFIED_BY="[Empty name]"><P>PFS was defined as time from date of randomization to death from any cause or one of the following events:</P><UL><LI>progression to stage II or III per Salmon &amp; Durie classification;</LI><LI>skeletal-related events (pathologic fracture, initiation of radiotherapy or surgery on bone, spinal cord compression or hypercalcemia);</LI><LI>unequivocal progression of osteolytic lesions (at least a 20% increase in the largest diameter of one existing osteolytic lesion which is measured in at least one dimension as 20 mm with conventional techniques), determined radiologically.</LI></UL><P>The trial was stopped early due to slow recruitment.</P><P>Funding: Novartis Pharmaceuticals Corporation.</P><P>COI statement included: No.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-16 18:52:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Terpos-2000"><CHAR_METHODS MODIFIED="2017-11-16 18:52:09 +0100" MODIFIED_BY="[Empty name]"><P>Study design: Parallel; not double-blind; not placebo-controlled</P><P>Study length: NR</P><P>Study conducted during: NR</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-16 18:52:09 +0100" MODIFIED_BY="[Empty name]"><P>Bisphosphonates: enrolled/analyzed 32.<BR/>Control: enrolled/analyzed 30.</P><P>Sex (M/F):</P><P>Pamidronate: 18/14<BR/>Control: 14/16</P><P>Age: Median (range)</P><P>Pamidronate: 68 (55-78)<BR/>Control: 66 (46-78)</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): Stage I-III</P><P>Osteolytic lesion: NS</P><P>Creatinine: &lt;5 mg/dL</P><P>Calcium: NS</P><P>Other criteria: No prior treatment with any kind of bisphosphonate within 3 months before enrollment or calcitonine or mithramycin within 2 weeks before enrollment , or treatment with corticosteroids for any reason except part of the patient's chemotherapeutic regimen.</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2016-12-01 17:14:02 +0100" MODIFIED_BY="[Empty name]"><P>Pamidronate: 90 mg IV monthly.<BR/>Control: observation.<BR/>Duration: 14 months</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-16 18:52:09 +0100" MODIFIED_BY="[Empty name]"><P>Total mortality;*<BR/>total fractures;<BR/>vertebral fractures;<BR/>non-vertebral fracture;<BR/>pain; hypercalcemia; abdominal pain.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2016-12-01 17:14:26 +0100" MODIFIED_BY="[Empty name]"><P>Data provided by the authors of the article. Pain control assessment: Opiate usage</P><P>Funding: NR</P><P>COI statement included: No.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-16 18:52:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Terpos-2003"><CHAR_METHODS MODIFIED="2017-10-31 12:41:48 +0100" MODIFIED_BY="Heather Maxwell"><P>Study design: Parallel; Not double-blind; not placebo-controlled</P><P>Study length: NR</P><P>Study conducted during: 1999 to 2001</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-16 18:52:09 +0100" MODIFIED_BY="[Empty name]"><P>Pamidronate: enrolled 23, analyzed 23.<BR/>Ibandronate: enrolled 21, analyzed 20.</P><P>Sex (M/F):</P><P>Pamidronate: 12/11<BR/>Ibandronate: 12/9</P><P>Age: Median (range)</P><P>Pamidronate: 66 (55-78)<BR/>Ibandronate: 65.5 (60-77)</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): Stage II-III</P><P>Osteolytic lesion: at least one</P><P>Creatinine: &gt;4 mg/dL</P><P>Calcium: NS</P><P>Other criteria: No prior treatment with any kind of bisphosphonate within 3 months before enrollment or calcitonine or mithramycin within 2 weeks before enrollment , or treatment with corticosteroids for any reason except part of the patient's chemotherapeutic regimen.</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-10-31 12:37:11 +0100" MODIFIED_BY="Heather Maxwell"><P>Pamidronate: 90 mg IV monthly.<BR/>Ibandronate: 4 mg IV monthly.<BR/>Duration: 4 months.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2016-12-01 17:24:48 +0100" MODIFIED_BY="[Empty name]"><P>Hypocalcemia, hypercalcemia.****</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-10-31 12:37:15 +0100" MODIFIED_BY="Heather Maxwell"><P>Funding: NR.</P><P>COI statement included: No.</P></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2017-11-16 18:52:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2012"><CHAR_METHODS MODIFIED="2017-11-16 18:52:09 +0100" MODIFIED_BY="[Empty name]"><P>Study design: Parallel; not double-blind; not placebo-controlled</P><P>Study length: NR</P><P>Study conducted during: 2004 to 2009</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2016-12-29 16:50:33 +0100" MODIFIED_BY="[Empty name]"><P>Bisphosphonates: enrolled/analyzed 33.<BR/>Control: enrolled/analyzed 20.</P><P>Sex (M/F):</P><P>Clodronate: 23/10<BR/>Control: 13/7</P><P>Age: Mean (SD)</P><P>Clodronatee: 59.9 (8.1)<BR/>Control: 58.5 (8.2)</P><P>Inclusion criteria:</P><P>Stage (Durie 2005): Stage II-III</P><P>Osteolytic lesion: NS</P><P>Creatinine: NS</P><P>Calcium: NS</P><P>Other criteria: NS</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-16 18:52:09 +0100" MODIFIED_BY="[Empty name]"><P>Clodronate: During the intermittent period of chemotherapy, clodronate injection 300 mg (Bonefos®, Bayer Schering Pharma, Leverkusen, Germany) was administered for 5 days in 250 mL glucose injection through slow intravenous drip; after that, Bonefos® capsules were administered orally at 1600 mg every day in the morning.<BR/>Control: chemotherapy.<BR/>Duration: NS.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2016-02-23 01:07:32 +0100" MODIFIED_BY="[Empty name]"><P>Bone metabolic markers</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2017-10-31 12:38:11 +0100" MODIFIED_BY="Heather Maxwell"><P>Other notes: This study did not report any outcome of interest for this systematic review.</P><P>Funding: NR.</P><P>COI statement included: No.</P></CHAR_NOTES></INCLUDED_CHAR><FOOTNOTES><P><B>COI:</B> conflict of interest; <B>ITT:</B> intention-to-treat; <B>IV:</B> intravenous; <B>MM:</B> multiple myeloma; <B>ONJ:</B> osteonecrosis of the jaw; <B>OS:</B> overall survival; <B>PFS:</B>progression-free survival; <B>SD:</B> standard deviation; <B>SRE:</B> skeletal-related events.<BR/><BR/><BR/><BR/></P><P>* mortality data obtained from authors; *$ mortality data derived using the Tierney method<BR/># total number of deaths reported in Berenson 1996<BR/>$ defined by reviewers<BR/>**hypercalcemia defined as &gt; 2.65 mmol/L<BR/>&amp;hypercalcemia defined as &gt; 2.75 mmol/L<BR/>***hypercalcemia defined as &gt; 3.00 mmol/L</P><P>**** hypercalcemia defined as presence of symptoms or serum calcium concentration, corrected for the serum albumin concentration, of at least 12.0 mg/dL or 3.0 mmol/L<BR/>! Data obtained from (author Fontana et al) and data from previous publication (abstract) were used<BR/></P><P>----------<BR/>The most common adverse effect that was reported was related to gastrointestinal symptoms (abdominal pain, diarrhea, pancreatitis). The number of patients with highest number of gastrointestinal symptoms was recorded and combined in the final analysis (since often it was not clear whether the same patients had one or more gastrointestinal symptoms). Effects on other organs (blood, kidney, liver, etc) were sporadically reported, and therefore not systematically extracted. However, the narrative summary was presented in the review.<BR/>__________<BR/>Effect on pain was non uniformly described. Data were extractable from 8 trials. (Study by Brincker et al reported data as the number of pain episodes instead of the number of patients with pain. Paper by Belch et al did not report data in an extractable form.) Study by McCloskey et al reported effect on back pain only, while other studies reported effect on 'pain' without specifying site of pain. The study by Lahtinen et al also reported pain according to its severity. However, we extracted data on the number of patients with pain on bisphosphonates vs. placebo, except in the study by McCloskey et al, where the effect on pain refers to patients without 'marked improvement in back pain'.</P></FOOTNOTES></CHARACTERISTICS_OF_INCLUDED_STUDIES><CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-12-18 16:41:05 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY"><EXCLUDED_CHAR MODIFIED="2012-03-20 15:29:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ali-2001"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-20 15:29:17 +0100" MODIFIED_BY="[Empty name]"><P>Nonrandomized study</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2012-03-20 15:29:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barlogie-2008"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-20 15:29:27 +0100" MODIFIED_BY="[Empty name]"><P>Nonrandomized study</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2012-03-20 15:29:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bergner-2007"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-20 15:29:29 +0100" MODIFIED_BY="[Empty name]"><P>Nonrandomized study</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2012-03-20 15:29:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caparrotti-2003"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-20 15:29:32 +0100" MODIFIED_BY="[Empty name]"><P>Nonrandomized and a combination therapy</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-02-22 17:36:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chiang-2013"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-22 17:36:36 +0100" MODIFIED_BY="[Empty name]"><P>Observational phase IV study</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2012-03-20 15:29:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ciepluch-2002"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-20 15:29:36 +0100" MODIFIED_BY="[Empty name]"><P>Nonrandomized and a combination therapy</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-11-16 18:52:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Delea-2012"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-11-16 18:52:09 +0100" MODIFIED_BY="[Empty name]"><P>Cost-effectiveness study</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2012-03-20 15:04:44 +0100" MODIFIED_BY="Rahul S Mhaskar" STUDY_ID="STD-Fizazi-2009"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-20 15:04:44 +0100" MODIFIED_BY="Rahul S Mhaskar"><P>Phase II denosumab randomized controlled trial</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-02-22 17:42:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Henry-2014"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-22 17:42:19 +0100" MODIFIED_BY="[Empty name]"><P>Denosumab randomized controlled trial</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2017-12-18 16:41:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kraj-2000a"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-12-18 16:41:05 +0100" MODIFIED_BY="[Empty name]"><P>Duplicate publication </P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2012-03-20 15:04:48 +0100" MODIFIED_BY="Rahul S Mhaskar" STUDY_ID="STD-Kraj-2002"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-20 15:04:48 +0100" MODIFIED_BY="Rahul S Mhaskar"><P>Enrolled only 9 patients. Only one pathological fracture was reported among 6 patients enrolled in zoledronate arm and one pathological fracture among 3 patients enrolled in pamidronate arm.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-02-22 17:37:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lipton-2012"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-22 17:37:47 +0100" MODIFIED_BY="[Empty name]"><P>Study addressing data from denosumab randomized controlled trials</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2009-07-06 15:22:47 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martin-2002"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-06 15:22:47 +0200" MODIFIED_BY="[Empty name]"><P>No data of interest</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2012-03-20 16:01:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morris-2001"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-20 16:01:13 +0100" MODIFIED_BY="[Empty name]"><P>Nonrandomized and a combination therapy</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2012-03-20 16:01:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spencer-2008"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-20 16:01:16 +0100" MODIFIED_BY="[Empty name]"><P>Nonrandomized and a combination therapy</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2012-03-20 15:04:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tassinari-2007"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-20 15:04:53 +0100" MODIFIED_BY="[Empty name]"><P>Observational study</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-02-22 17:39:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Teoh-2012"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-22 17:39:05 +0100" MODIFIED_BY="[Empty name]"><P>Nonrandomized study</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2011-06-10 21:44:55 +0200" MODIFIED_BY="Rahul S Mhaskar" STUDY_ID="STD-Terpos-2010"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-10 21:44:55 +0200" MODIFIED_BY="Rahul S Mhaskar"><P>Prognostic study</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2012-03-20 15:04:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tosi-2006a"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-20 15:04:58 +0100" MODIFIED_BY="[Empty name]"><P>Combination therapy</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-02-22 17:40:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vadhan_x002d_Raj-2012"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-22 17:40:17 +0100" MODIFIED_BY="[Empty name]"><P>Denosumab randomized controlled trial</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2012-03-20 14:57:34 +0100" MODIFIED_BY="Rahul S Mhaskar" STUDY_ID="STD-Vij-2009"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-20 14:57:34 +0100" MODIFIED_BY="Rahul S Mhaskar"><P>Phase II denosumab randomized controlled trial</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2012-03-20 16:01:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vogel-2004"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-20 16:01:21 +0100" MODIFIED_BY="[Empty name]"><P>Nonrandomized study</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-02-22 17:40:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Witzig-2013"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-02-22 17:40:50 +0100" MODIFIED_BY="[Empty name]"><P>Patients in both the study arms received the same dose of zoledronate</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><FOOTNOTES/></CHARACTERISTICS_OF_EXCLUDED_STUDIES><CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><FOOTNOTES/></CHARACTERISTICS_OF_AWAITING_STUDIES><CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2017-11-16 18:52:10 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><ONGOING_CHAR MODIFIED="2017-11-16 18:52:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lund-2014"><CHAR_STUDY_NAME MODIFIED="2017-11-16 18:52:09 +0100" MODIFIED_BY="[Empty name]"><P>Prolonged protection from bone disease in multiple myeloma (Magnolia)</P></CHAR_STUDY_NAME><CHAR_METHODS MODIFIED="2017-11-16 18:52:09 +0100" MODIFIED_BY="[Empty name]"><P>An open-label phase 3 multicenter international randomised trial</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2017-11-16 18:52:09 +0100" MODIFIED_BY="[Empty name]"><P>Inclusion Criteria:</P><UL><LI>Symptomatic multiple myeloma regardless of bone disease status</LI><LI>Signed Informed Consent</LI><LI>Age &#8805; 18 years</LI><LI>Remaining life expectancy &#8805; 2 years</LI><LI>Any concurrently anti-myeloma treatment are allowed</LI></UL><P>Exclusion Criteria:</P><UL><LI>Previous treatment with bisphosphonate within the last 6 months</LI><LI>Severely reduced renal function (creatinine clearance &lt; 30 mL/min despite fluid replacement)</LI><LI>Known concurrent malignancy, excluding skin cancer</LI><LI>Known hypersensitivity to zoledronic acid</LI><LI>Pregnant or lactating women</LI><LI>Women of childbearing potential or men engaging in sexual activity with a woman of childbearing potential who refuse to use contraception</LI></UL></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-11-16 18:52:10 +0100" MODIFIED_BY="[Empty name]"><P>Active Comparator: zoledronic acid (treatment with zoledronic acid for 4 years)</P><P>Placebo Comparator: no treatment (treatment with zoledronic acid withheld after two years)</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-11-16 18:52:10 +0100" MODIFIED_BY="[Empty name]"><P>Primary Outcome Measures:</P><UL><LI>Time to first skeletal-related event after randomizations at year two [Time Frame: From year two to year four] [ Designated as safety issue: Yes] After two years of zoledronic acid treatment patients will be randomized to A continue treatment B stop treatment.</LI></UL><P>Secondary Outcome Measures:</P><UL><LI>Value of serum bone marker ratio (bone resorption/bone formation markers) as predictor of skeletal-related events analyzed by time-dependent multiparameter Cox regression analysis. [Time Frame: 4 years] [Designated as safety issue: No]. Development in bone markers prior to progression in osteolytic lesions will be investigated.</LI></UL></CHAR_OUTCOMES><CHAR_STARTING_DATE MODIFIED="2016-06-28 22:10:00 +0200" MODIFIED_BY="[Empty name]"><P>January 2015</P></CHAR_STARTING_DATE><CHAR_CONTACT_INFORMATION MODIFIED="2016-06-28 22:10:58 +0200" MODIFIED_BY="[Empty name]"><P>Name: Thomas Lund, MD Ph.D.</P><P>Phone: +45 21450256; Email: <A HREF="mailto:thomas.lund1%40rsyd.dk?subject=NCT02286830,%20NMSG%2022/14,%20Prolonged%20Protection%20From%20Bone%20Disease%20in%20Multiple%20Myeloma">thomas.lund1@rsyd.dk</A></P></CHAR_CONTACT_INFORMATION><CHAR_NOTES MODIFIED="2016-06-28 22:07:51 +0200" MODIFIED_BY="[Empty name]"/></ONGOING_CHAR><FOOTNOTES/></CHARACTERISTICS_OF_ONGOING_STUDIES></CHARACTERISTICS_OF_STUDIES><QUALITY_ITEMS MODIFIED="2017-11-16 18:52:09 +0100" MODIFIED_BY="[Empty name]"><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-03-17 15:45:49 +0100" MODIFIED_BY="[Empty name]" NO="1"><NAME>Random sequence generation (selection bias)</NAME><DESCRIPTION><P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 19:56:28 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Attal-2006"><DESCRIPTION><P>Methods used for generation of sequence of randomization are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 19:56:49 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aviles-2007"><DESCRIPTION><P>Methods used for generation of sequence of randomization are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-22 20:18:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aviles-2013"><DESCRIPTION><P>Methods used for generation of sequence of randomization are described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 19:58:22 +0200" MODIFIED_BY="Rahul S Mhaskar" RESULT="NO" STUDY_ID="STD-Belch-1991"><DESCRIPTION><P>Methods used for generation of sequence of randomization are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-25 19:45:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berenson-1998a"><DESCRIPTION><P>Methods used for generation of sequence of randomization are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:06:01 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Brincker-1998"><DESCRIPTION><P>Methods used for generation of sequence of randomization are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:06:10 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Daragon-1993"><DESCRIPTION><P>Methods used for generation of sequence of randomization are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:06:16 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Delmas-1982"><DESCRIPTION><P>Methods used for generation of sequence of randomization are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-17 15:45:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Garcia_x002d_Sanz-2015"><DESCRIPTION><P>Methods used for generation of sequence of randomization are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-25 19:45:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gimsing-2010"><DESCRIPTION><P>Methods used for generation of sequence of randomization are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:06:23 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Heim-1995"><DESCRIPTION><P>Methods used for generation of sequence of randomization are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:06:31 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kraj-2000"><DESCRIPTION><P>Methods used for generation of sequence of randomization are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:06:39 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lahtinen-1992"><DESCRIPTION><P>Methods used for generation of sequence of randomization are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:06:44 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Leng-2002"><DESCRIPTION><P>Methods used for generation of sequence of randomization are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:06:50 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McCloskey-2001"><DESCRIPTION><P>Methods used for generation of sequence of randomization are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:07:03 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Menssen-2002"><DESCRIPTION><P>Methods used for generation of sequence of randomization are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-25 19:46:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morgan-2010"><DESCRIPTION><P>Methods used for generation of sequence of randomization are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:07:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Musto-2003"><DESCRIPTION><P>Methods used for generation of sequence of randomization are described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:07:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Musto-2008"><DESCRIPTION><P>Methods used for generation of sequence of randomization are described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:07:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rosen-2003"><DESCRIPTION><P>Methods used for generation of sequence of randomization are described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-22 20:20:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sezer-2010"><DESCRIPTION><P>Methods used for generation of sequence of randomization are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:08:08 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Terpos-2000"><DESCRIPTION><P>Methods used for generation of sequence of randomization are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:08:14 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Terpos-2003"><DESCRIPTION><P>Methods used for generation of sequence of randomization are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-22 20:23:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhang-2012"><DESCRIPTION><P>Methods used for generation of sequence of randomization are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-03-17 15:45:59 +0100" MODIFIED_BY="[Empty name]" NO="2"><NAME>Allocation concealment (selection bias)</NAME><DESCRIPTION><P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 14:58:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Attal-2006"><DESCRIPTION><P>Methods of allocation concealment are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 19:57:22 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aviles-2007"><DESCRIPTION><P>Methods used for concealment of allocation are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-22 20:17:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aviles-2013"><DESCRIPTION><P>Methods of allocation concealment are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 14:58:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belch-1991"><DESCRIPTION><P>Methods of allocation concealment are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 14:59:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berenson-1998a"><DESCRIPTION><P>Methods of allocation concealment are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:06:01 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Brincker-1998"><DESCRIPTION><P>Methods used for concealment of allocation are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:06:10 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Daragon-1993"><DESCRIPTION><P>Methods used for concealment of allocation are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:06:16 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Delmas-1982"><DESCRIPTION><P>Methods used for concealment of allocation are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-17 15:45:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Garcia_x002d_Sanz-2015"><DESCRIPTION><P>Methods used for concealment of allocation are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 14:59:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gimsing-2010"><DESCRIPTION><P>Methods of allocation concealment are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:06:23 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Heim-1995"><DESCRIPTION><P>Methods used for concealment of allocation are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:06:31 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kraj-2000"><DESCRIPTION><P>Methods used for concealment of allocation are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:06:39 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lahtinen-1992"><DESCRIPTION><P>Methods used for concealment of allocation are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:06:44 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Leng-2002"><DESCRIPTION><P>Methods used for concealment of allocation are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 15:00:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCloskey-2001"><DESCRIPTION><P>Methods of allocation concealment are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:07:03 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Menssen-2002"><DESCRIPTION><P>Methods used for concealment of allocation are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 15:01:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morgan-2010"><DESCRIPTION><P>Methods of allocation concealment are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:07:15 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Musto-2003"><DESCRIPTION><P>Methods used for concealment of allocation are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:07:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Musto-2008"><DESCRIPTION><P>Methods used for concealment of allocation are described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:07:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rosen-2003"><DESCRIPTION><P>Methods used for concealment of allocation are described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-22 20:20:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sezer-2010"><DESCRIPTION><P>Methods used for concealment of allocation are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:08:08 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Terpos-2000"><DESCRIPTION><P>Methods used for concealment of allocation are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-20 20:08:14 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Terpos-2003"><DESCRIPTION><P>Methods used for concealment of allocation are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-22 20:23:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhang-2012"><DESCRIPTION><P>Methods used for concealment of allocation are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]" NO="3"><NAME>Blinding (performance bias and detection bias)</NAME><DESCRIPTION><P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1" REF_IDS="CMP-002.03"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-12 15:45:45 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Attal-2006"><DESCRIPTION><P>Study does not involve any blinding.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-12 15:45:59 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aviles-2007"><DESCRIPTION><P>Study does not involve any blinding.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aviles-2013"><DESCRIPTION><P>Open-label study</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-20 14:58:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belch-1991"><DESCRIPTION><P>Study is double-blinded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-20 14:59:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berenson-1998a"><DESCRIPTION><P>Study is double-blinded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-20 14:59:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brincker-1998"><DESCRIPTION><P>Study is double-blinded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-20 14:59:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Daragon-1993"><DESCRIPTION><P>Study is double-blinded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-20 14:59:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Delmas-1982"><DESCRIPTION><P>Study is double-blinded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-03-17 15:46:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Garcia_x002d_Sanz-2015"><DESCRIPTION><P>Study does not involve any blinding.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-20 14:59:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gimsing-2010"><DESCRIPTION><P>Study is double-blind.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-10-20 20:13:31 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Heim-1995"><DESCRIPTION><P>Blinding methods are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-10-20 20:13:41 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kraj-2000"><DESCRIPTION><P>Blinding methods are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-20 15:00:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lahtinen-1992"><DESCRIPTION><P>Study is double-blind.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-10-20 20:13:51 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Leng-2002"><DESCRIPTION><P>Blinding methods are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-20 15:00:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCloskey-2001"><DESCRIPTION><P>Study is double-blind.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-20 15:01:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Menssen-2002"><DESCRIPTION><P>Study is double-blinded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-20 15:01:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Morgan-2010"><DESCRIPTION><P>Open-label study.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-10-20 20:11:29 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Musto-2003"><DESCRIPTION><P>Blinding methods are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-10-20 20:11:39 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Musto-2008"><DESCRIPTION><P>Blinding methods are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-10-20 20:11:45 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rosen-2003"><DESCRIPTION><P>Blinding methods are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-02-22 20:20:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sezer-2010"><DESCRIPTION><P>Study is not blinded</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-10-20 20:11:52 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Terpos-2000"><DESCRIPTION><P>Blinding methods are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-10-20 20:11:56 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Terpos-2003"><DESCRIPTION><P>Blinding methods are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-02-22 20:24:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhang-2012"><DESCRIPTION><P>Study is not blinded</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="GROUP" MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]" NO="10"><NAME>Blinding of participants and personnel (performance bias)</NAME><DESCRIPTION><P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-10.01" NO="1"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2011-10-20 20:12:33 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Attal-2006"><DESCRIPTION><P>Study does not involve any blinding.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2011-10-20 20:15:03 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aviles-2007"><DESCRIPTION><P>Study does not involve any blinding.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aviles-2013"><DESCRIPTION><P>Open-label study</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-03-20 14:58:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Belch-1991"><DESCRIPTION><P>Study is double-blinded but who was blinded is not mentioned.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2011-10-25 19:47:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berenson-1998a"><DESCRIPTION><P>Methods for blinding of participants and personnel are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-03-20 14:59:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brincker-1998"><DESCRIPTION><P>Study is double-blinded but who was blinded is not mentioned.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-03-20 14:59:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Daragon-1993"><DESCRIPTION><P>Study is double-blinded but who was blinded is not mentioned.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-03-20 14:59:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Delmas-1982"><DESCRIPTION><P>Study is double-blinded but who was blinded is not mentioned.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2016-03-17 15:46:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Garcia_x002d_Sanz-2015"><DESCRIPTION><P>Study does not involve any blinding.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2011-10-25 19:47:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gimsing-2010"><DESCRIPTION><P>Methods for blinding of participants and personnel are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-03-20 15:00:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Heim-1995"><DESCRIPTION><P>Who was blinded is not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-03-20 15:00:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kraj-2000"><DESCRIPTION><P>Who was blinded is not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2011-10-25 19:48:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lahtinen-1992"><DESCRIPTION><P>Methods for blinding of participants and personnel are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-03-20 15:00:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Leng-2002"><DESCRIPTION><P>Who was blinded is not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2011-10-25 19:48:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCloskey-2001"><DESCRIPTION><P>Methods for blinding of participants and personnel are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-03-20 15:01:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Menssen-2002"><DESCRIPTION><P>Study is double-blinded but who was blinded is not mentioned.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-03-20 15:01:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Morgan-2010"><DESCRIPTION><P>Who was blinded is not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-03-20 15:01:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Musto-2003"><DESCRIPTION><P>Who was blinded is not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-03-20 15:01:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Musto-2008"><DESCRIPTION><P>Who was blinded is not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-03-20 15:01:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rosen-2003"><DESCRIPTION><P>Who was blinded is not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2016-02-22 20:20:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sezer-2010"><DESCRIPTION><P>Who was blinded is not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-03-20 15:02:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Terpos-2000"><DESCRIPTION><P>Who was blinded is not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2012-03-20 15:02:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Terpos-2003"><DESCRIPTION><P>Who was blinded is not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2016-02-22 20:23:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhang-2012"><DESCRIPTION><P>Who was blinded is not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="GROUP" MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]" NO="11"><NAME>Blinding of outcome assessment (detection bias)</NAME><DESCRIPTION><P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-11.01" NO="1"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2011-10-20 20:12:34 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Attal-2006"><DESCRIPTION><P>Study does not involve any blinding.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2011-10-20 20:15:04 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aviles-2007"><DESCRIPTION><P>Study does not involve any blinding.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aviles-2013"><DESCRIPTION><P>Open-label study</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2012-03-20 14:58:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Belch-1991"><DESCRIPTION><P>Study is double-blinded but who was blinded is not mentioned.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2011-10-25 19:47:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berenson-1998a"><DESCRIPTION><P>Methods for blinding of participants and personnel are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2012-03-20 14:59:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brincker-1998"><DESCRIPTION><P>Study is double-blinded but who was blinded is not mentioned.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2012-03-20 14:59:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Daragon-1993"><DESCRIPTION><P>Study is double-blinded but who was blinded is not mentioned.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2012-03-20 14:59:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Delmas-1982"><DESCRIPTION><P>Study is double-blinded but who was blinded is not mentioned.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2016-03-17 15:46:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Garcia_x002d_Sanz-2015"><DESCRIPTION><P>Study does not involve any blinding.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2011-10-25 19:47:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gimsing-2010"><DESCRIPTION><P>Methods for blinding of participants and personnel are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2012-03-20 15:00:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Heim-1995"><DESCRIPTION><P>Who was blinded is not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2012-03-20 15:00:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kraj-2000"><DESCRIPTION><P>Who was blinded is not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2011-10-25 19:48:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lahtinen-1992"><DESCRIPTION><P>Methods for blinding of participants and personnel are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2012-03-20 15:00:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Leng-2002"><DESCRIPTION><P>Who was blinded is not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2011-10-25 19:48:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCloskey-2001"><DESCRIPTION><P>Methods for blinding of participants and personnel are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2012-03-20 15:01:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Menssen-2002"><DESCRIPTION><P>Study is double-blinded but who was blinded is not mentioned.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2012-03-20 15:01:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Morgan-2010"><DESCRIPTION><P>Who was blinded is not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2012-03-20 15:01:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Musto-2003"><DESCRIPTION><P>Who was blinded is not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2012-03-20 15:01:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Musto-2008"><DESCRIPTION><P>Who was blinded is not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2012-03-20 15:01:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rosen-2003"><DESCRIPTION><P>Who was blinded is not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2016-02-22 20:20:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sezer-2010"><DESCRIPTION><P>Who was blinded is not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2012-03-20 15:02:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Terpos-2000"><DESCRIPTION><P>Who was blinded is not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2012-03-20 15:02:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Terpos-2003"><DESCRIPTION><P>Who was blinded is not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-11.01" MODIFIED="2016-02-22 20:23:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhang-2012"><DESCRIPTION><P>Who was blinded is not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]" NO="4"><NAME>Incomplete outcome data (attrition bias)</NAME><DESCRIPTION><P>Attrition bias due to amount, nature or handling of incomplete outcome data</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1" REF_IDS="CMP-001.01 CMP-001.03 CMP-001.04 CMP-001.05 CMP-001.07 CMP-001.06 CMP-001.02 CMP-002.02 CMP-002.03"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-20 14:58:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Attal-2006"><DESCRIPTION><P>Dropouts are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-20 14:58:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aviles-2007"><DESCRIPTION><P>Dropouts are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-22 20:17:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aviles-2013"><DESCRIPTION><P>Dropouts are described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-20 14:58:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Belch-1991"><DESCRIPTION><P>Dropouts are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-20 14:59:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berenson-1998a"><DESCRIPTION><P>Dropouts are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-20 14:59:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brincker-1998"><DESCRIPTION><P>Dropouts are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-20 14:59:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Daragon-1993"><DESCRIPTION><P>Dropouts are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-20 14:59:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Delmas-1982"><DESCRIPTION><P>Dropouts are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garcia_x002d_Sanz-2015"><DESCRIPTION><P>The process for early stoppage is clearly described</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-20 14:59:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gimsing-2010"><DESCRIPTION><P>Dropouts are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-20 15:00:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Heim-1995"><DESCRIPTION><P>Dropouts are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-20 15:00:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kraj-2000"><DESCRIPTION><P>Dropouts are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-20 15:00:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lahtinen-1992"><DESCRIPTION><P>Dropouts are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-20 15:00:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Leng-2002"><DESCRIPTION><P>Dropouts are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-20 15:00:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCloskey-2001"><DESCRIPTION><P>Dropouts are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-20 15:01:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Menssen-2002"><DESCRIPTION><P>Dropouts are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-20 15:01:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morgan-2010"><DESCRIPTION><P>Dropouts are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-20 15:01:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Musto-2003"><DESCRIPTION><P>Dropouts are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-20 15:01:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Musto-2008"><DESCRIPTION><P>Dropouts are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-20 15:01:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rosen-2003"><DESCRIPTION><P>Dropouts are adequately described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-22 20:20:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sezer-2010"><DESCRIPTION><P>Dropouts are described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-20 15:02:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Terpos-2000"><DESCRIPTION><P>Dropouts are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-20 15:02:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Terpos-2003"><DESCRIPTION><P>Dropouts are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-22 20:25:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhang-2012"><DESCRIPTION><P>Dropouts are not described.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-04-12 15:58:19 +0200" MODIFIED_BY="[Empty name]" NO="5"><NAME>Selective reporting (reporting bias)</NAME><DESCRIPTION><P>Reporting bias due to selective outcome reporting</P></DESCRIPTION><QUALITY_ITEM_DATA/></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-03-17 15:47:51 +0100" MODIFIED_BY="[Empty name]" NO="6"><NAME>Other bias</NAME><DESCRIPTION><P>Bias due to problems not covered elsewhere in the table</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 14:58:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Attal-2006"><DESCRIPTION><P>Alpha and beta errors are not prespecified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 14:58:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aviles-2007"><DESCRIPTION><P>Alpha and beta errors are not prespecified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-22 20:17:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aviles-2013"><DESCRIPTION><P>Alpha and beta errors are prespecified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 14:58:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Belch-1991"><DESCRIPTION><P>Alpha and beta errors are prespecified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 14:59:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Berenson-1998a"><DESCRIPTION><P>Alpha and beta errors are not prespecified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 14:59:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brincker-1998"><DESCRIPTION><P>Alpha and beta errors are prespecified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 14:59:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Daragon-1993"><DESCRIPTION><P>Alpha and beta errors are not prespecified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 14:59:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Delmas-1982"><DESCRIPTION><P>Alpha and beta errors are not prespecified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-17 15:47:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Garcia_x002d_Sanz-2015"><DESCRIPTION><P>It is unclear if the interim analysis was pre-planned or post-hoc</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 14:59:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gimsing-2010"><DESCRIPTION><P>Alpha and beta errors are prespecified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 15:00:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Heim-1995"><DESCRIPTION><P>Alpha and beta errors are not prespecified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 15:00:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kraj-2000"><DESCRIPTION><P>Alpha and beta errors are not prespecified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 15:00:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lahtinen-1992"><DESCRIPTION><P>Alpha and beta errors are prespecified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 15:00:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Leng-2002"><DESCRIPTION><P>Alpha and beta errors are not prespecified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 15:00:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McCloskey-2001"><DESCRIPTION><P>Alpha and beta errors are not prespecified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 15:01:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Menssen-2002"><DESCRIPTION><P>Alpha and beta errors are not prespecified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 15:01:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morgan-2010"><DESCRIPTION><P>Alpha and beta errors are prespecified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 15:01:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Musto-2003"><DESCRIPTION><P>Alpha and beta errors are not prespecified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 15:01:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Musto-2008"><DESCRIPTION><P>Alpha and beta errors are prespecified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 15:01:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rosen-2003"><DESCRIPTION><P>Alpha and beta errors are not prespecified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-23 01:01:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sezer-2010"><DESCRIPTION><P>Alpha and beta errors are not prespecified. However, a total sample size of 220 patients was specified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 15:02:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Terpos-2000"><DESCRIPTION><P>Alpha and beta errors are not prespecified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-20 15:02:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Terpos-2003"><DESCRIPTION><P>Alpha and beta errors are not prespecified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-22 20:23:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhang-2012"><DESCRIPTION><P>Alpha and beta errors are not prespecified.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2017-11-16 18:52:09 +0100" MODIFIED_BY="[Empty name]" NO="7"><NAME>Intention to treat Analysis</NAME><DESCRIPTION><P>Wheter the data were analyzed using the intention to treat principle?</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Attal-2006"><DESCRIPTION><P>Benefits data are analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aviles-2007"><DESCRIPTION><P>Benefits data are analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aviles-2013"><DESCRIPTION><P>Benefits data are analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Belch-1991"><DESCRIPTION><P>Benefits data are not analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Berenson-1998a"><DESCRIPTION><P>Benefits data are not analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brincker-1998"><DESCRIPTION><P>Benefits data are analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Daragon-1993"><DESCRIPTION><P>Benefits data are not analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Delmas-1982"><DESCRIPTION><P>Benefits data are not analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garcia_x002d_Sanz-2015"><DESCRIPTION><P>Benefits data on accrued patients are analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gimsing-2010"><DESCRIPTION><P>Benefits data are analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Heim-1995"><DESCRIPTION><P>Benefits data are not analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kraj-2000"><DESCRIPTION><P>Benefits data are not analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lahtinen-1992"><DESCRIPTION><P>Benefits data are analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Leng-2002"><DESCRIPTION><P>Benefits data are not analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McCloskey-2001"><DESCRIPTION><P>Benefits data are not analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Menssen-2002"><DESCRIPTION><P>Benefits data are analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morgan-2010"><DESCRIPTION><P>Benefits data are analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Musto-2003"><DESCRIPTION><P>Benefits data are not analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Musto-2008"><DESCRIPTION><P>Benefits data are analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rosen-2003"><DESCRIPTION><P>Benefits data are analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sezer-2010"><DESCRIPTION><P>Benefits data are not analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Terpos-2000"><DESCRIPTION><P>Benefits data are not analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Terpos-2003"><DESCRIPTION><P>Benefits data are analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-11-16 18:52:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zhang-2012"><DESCRIPTION><P>Benefits data are analyzed according to ITT principle.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM></QUALITY_ITEMS><SOF_TABLES MODIFIED="2017-12-18 16:40:14 +0100" MODIFIED_BY="[Empty name]"><SOF_TABLE ID="SOF-01" MODIFIED="2017-12-18 16:40:14 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES"><TITLE MODIFIED="2016-02-26 16:12:47 +0100" MODIFIED_BY="[Empty name]">Summary of findings (direct comparisons)</TITLE><TABLE COLS="6" ROWS="21"><TR><TD COLSPAN="6"><P><B>Bisphosphonates in multiple myeloma</B></P></TD></TR><TR><TD COLSPAN="6"><P><B>Patient or population:</B> patients with multiple myeloma<BR/><B>Intervention:</B> bisphosphonates</P><P><B>Control:</B> no treatment/placebo<BR/></P></TD></TR><TR><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Outcomes</P></TH><TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP"><P>Illustrative comparative risks* (95% CI)</P></TH><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Relative effect<BR/>(95% CI)</P></TH><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>No of participants<BR/>(studies)</P></TH><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Quality of the evidence<BR/>(GRADE)</P></TH></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Assumed risk</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Corresponding risk</P></TH></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P><B>Control</B></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P><B>Bisphosphonates</B></P></TH></TR><TR><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>Overall survival##</B><BR/></P></TD><TD COLSPAN="2" ROWSPAN="1"><P><B>Medium-risk population#</B></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>HR 0.90</B><BR/>(0.76 to 1.07)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>2706<BR/>(14 studies)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>moderate</B><SUP>1,2,3</SUP></P></TD></TR><TR><TD ROWSPAN="1" VALIGN="TOP"><P><B>410 per 1000</B></P></TD><TD ROWSPAN="1" VALIGN="TOP"><P><B>378 per 1000</B><BR/>(330 to 431)</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>Progression-free survival###</B><BR/></P></TD><TD COLSPAN="2" ROWSPAN="1"><P><B>Medium-risk population#</B></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>HR 0.75</B><BR/>(0.57 to 1.00)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>908<BR/>(7 studies)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8853;&#8861;&#8861;<BR/><B>low</B><SUP>1,4,11</SUP></P></TD></TR><TR><TD ROWSPAN="1" VALIGN="TOP"><P><B>470 per 1000</B></P></TD><TD ROWSPAN="1" VALIGN="TOP"><P><B>379 per 1000</B><BR/>(304 to 470)</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>Vertebral fractures</B><BR/></P></TD><TD COLSPAN="2" ROWSPAN="1"><P><B>Medium-risk population#</B></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>RR 0.74 </B><BR/>(0.62 to 0.89)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>1116<BR/>(7 studies)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>moderate</B><SUP>1,5</SUP></P></TD></TR><TR><TD ROWSPAN="1" VALIGN="TOP"><P><B>360 per 1000</B></P></TD><TD ROWSPAN="1" VALIGN="TOP"><P><B>266 per 1000</B><BR/>(223 to 320)</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>Non-vertebral fractures</B><BR/></P></TD><TD COLSPAN="2" ROWSPAN="1"><P><B>Medium-risk population#</B></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>RR 1.03 </B><BR/>(0.68 to 1.56)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>1389<BR/>(6 studies)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>moderate</B><SUP>1,6</SUP></P></TD></TR><TR><TD ROWSPAN="1" VALIGN="TOP"><P><B>140 per 1000</B></P></TD><TD ROWSPAN="1" VALIGN="TOP"><P><B>144 per 1000</B><BR/>(95 to 218)</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>Skeletal-related events</B><BR/></P></TD><TD COLSPAN="2" ROWSPAN="1"><P><B>Medium-risk population#</B></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>RR 0.74 </B><BR/>(0.63 to 0.88)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>2141<BR/>(10 studies)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>moderate</B><SUP>1,7</SUP></P></TD></TR><TR><TD ROWSPAN="1" VALIGN="TOP"><P><B>400 per 1000</B></P></TD><TD ROWSPAN="1" VALIGN="TOP"><P><B>296 per 1000</B><BR/>(252 to 352)</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>Pain</B><BR/></P></TD><TD COLSPAN="2" ROWSPAN="1"><P><B>Medium-risk population</B></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>RR 0.75 </B><BR/>(0.60 to 0.95)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>1281<BR/>(8 studies)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8861;&#8861;&#8861;<BR/><B>very low</B><SUP>8,9</SUP></P></TD></TR><TR><TD ROWSPAN="1" VALIGN="TOP"><P><B>540 per 1000</B></P></TD><TD ROWSPAN="1" VALIGN="TOP"><P><B>410 per 1000</B><BR/>(329 to 508)</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>Osteonecrosis of jaw </B><BR/></P></TD><TD COLSPAN="2" ROWSPAN="1"><P><B>Medium-risk population#</B></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P><B>RR 4.61 </B></P><P>(0.99 to 21.35)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>1284<BR/>(6 studies)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8853;&#8861;&#8861;</P><P><B>low </B><SUP>10,11</SUP></P></TD></TR><TR><TD ROWSPAN="1" VALIGN="TOP"><P><B>NE</B></P></TD><TD ROWSPAN="1" VALIGN="TOP"><P><B>0 per 1000</B><BR/>(0 to 2)</P></TD></TR><TR><TD COLSPAN="6"><P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/><B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; <B>HR:</B> Hazard ratio; <B>NE</B>: not estimable due to rarity of events in the control arm</P></TD></TR><TR><TD COLSPAN="6"><P>GRADE Working Group grades of evidence<BR/><B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/><B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/><B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/><B>Very low quality:</B> We are very uncertain about the estimate.<BR/></P></TD></TR></TABLE><FOOTNOTES><P><SUP>1</SUP> A total of 20 RCTs were included in the direct meta-analysis. Only 35% (7/20) of trials had adequate allocation concealment. Only 20% (4/20) of trials reported methods of randomization. Similarly, 15% (3/20) of trials reported blinding procedures and personnel who were blinded to the intervention assignment. However, sensitivity analyses based on the methodological quality domains did not change the estimates. Hence, the assessment of studies&#8217; limitations may represent the poor quality of reporting rather than true biased estimates.<BR/><SUP>2</SUP> Downgraded the quality of evidence for the outcome of overall survival (OS) by one for the observed inconsistency (I<SUP>2</SUP> = 65%). However we noticed that this heterogeneity in the pooled estimate is driven by studies by Aviles and colleagues (<LINK REF="STD-Aviles-2007" TYPE="STUDY">Aviles 2007</LINK>; <LINK REF="STD-Aviles-2013" TYPE="STUDY">Aviles 2013</LINK>); when we removed these RCTs heterogeneity disappeared.<BR/><SUP>3</SUP> Note that overall mortality data denotes the mortality rates, i.e. the number of events refers to the number of deaths.<BR/><SUP>4</SUP> Downgraded the quality of evidence by one level due to the potential for publication bias.The progression-free survival data were extractable from only 35% (7/20) of studies eligible for direct meta-analysis.<BR/><SUP>5</SUP> Downgraded the quality of evidence by one level due to the potential for publication bias. Data related to patients with vertebral fractures were extractable from only 35% (7/20) of studies eligible for direct meta-analysis.<BR/><SUP>6</SUP> Downgraded the quality of evidence by one level due to the potential for publication bias. Data related to patients with non-vertebral fractures were extractable from only 30% (6/20) of studies eligible for direct meta-analysis.<BR/><SUP>7</SUP> Downgraded the quality of evidence by one level due to the potential for publication bias. Skeletal-related events data were extractable from 50% (10/20) of studies.<BR/><SUP>8</SUP> Downgraded the quality of evidence by one level due to variation in assessment instruments.There was significant variation in the assessment methods used to measure pain.</P><P><SUP>9</SUP> Downgraded the quality of evidence by one level due to variation in assessment of pain based on blinding of the assessors. Only 15% (3/20) of trials reported blinding procedures and personnel who were blinded to the intervention assignment. Moreover, we found that RCTs with double-blinding showed no significant benefit of bisphosphonates over placebo for amelioration of pain, while non-blinded RCTs favored bisphosphonates over placebo for pain relief. We also downgraded the quality of evidence by one level due to imprecision.</P><P><SUP>10 </SUP>Downgraded the quality of evidence by one level due to the potential for publication bias.The Osteonecrosis of jaw data were extractable from 30% (6/20) of studies eligible for direct meta-analysis.</P><P><SUP>11</SUP> Downgraded the quality of evidence by one level due to imprecision.All included RCTs and also the pooled estimate have wide confidence intervals.</P><P># The moderate control risk was calculated via GRADEpro software based on average risk in the control arm of the included studies. </P><P>## We have calculated and presented overall mortality instead of OS. The expected events represent a median timeline of 5 years.</P><P>### PFS events represent death or progress or relapse. The expected events represent a median timeline of 5 years.</P></FOOTNOTES></SOF_TABLE></SOF_TABLES><ADDITIONAL_TABLES MODIFIED="2017-12-18 16:20:03 +0100" MODIFIED_BY="[Empty name]"><ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-03-20 15:35:22 +0100" MODIFIED_BY="Rahul S Mhaskar" NO="1"><TITLE MODIFIED="2012-03-20 15:35:22 +0100" MODIFIED_BY="Rahul S Mhaskar">Bisphosphonate potency</TITLE><TABLE COLS="3" ROWS="9"><TR><TH><P>Type of bisphosphonates</P></TH><TH><P>Bisphosphontes</P></TH><TH><P>Relative potency</P></TH></TR><TR><TD ROWSPAN="3"><P>Nonaminobisphosphonates</P></TD><TD><P>Etidronate</P></TD><TD><P>1</P></TD></TR><TR><TD><P>Clodronate</P></TD><TD><P>10</P></TD></TR><TR><TD><P>Tiludronate</P></TD><TD><P>10</P></TD></TR><TR><TD ROWSPAN="5"><P>Aminobisphosphonates</P></TD><TD><P>Pamidronate</P></TD><TD><P>100</P></TD></TR><TR><TD><P>Alendronate</P></TD><TD><P>500</P></TD></TR><TR><TD><P>Ibandronate</P></TD><TD><P>1,000</P></TD></TR><TR><TD><P>Risendronate</P></TD><TD><P>2,000</P></TD></TR><TR><TD><P>Zoledronate</P></TD><TD><P>10,000</P></TD></TR></TABLE><FOOTNOTES><P>Based on information from (<LINK REF="REF-Drake-2008" TYPE="REFERENCE">Drake 2008</LINK>; <LINK REF="REF-Dunford-2001" TYPE="REFERENCE">Dunford 2001</LINK>).</P></FOOTNOTES></ADDITIONAL_TABLE><ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2017-12-18 16:20:03 +0100" MODIFIED_BY="[Empty name]" NO="2"><TITLE>Type and content of reporting in RCTs on bisphosphonates in myeloma</TITLE><TABLE COLS="5" ROWS="25"><TR><TH><P>Study ID</P></TH><TH><P>Adverse events</P><P>(gastrointestinal symptoms)</P></TH><TH><P>Adverse events</P><P>(hypocalcemia)</P></TH><TH><P>Adverse events</P><P>(serum creatinine)</P></TH><TH><P>Adverse events</P><P>(osteonecrosis of the jaw)</P></TH></TR><TR><TD><P><LINK REF="STD-Belch-1991" TYPE="STUDY">Belch 1991</LINK></P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD></TR><TR><TD><P><LINK REF="STD-Berenson-1998a" TYPE="STUDY">Berenson 1998a</LINK></P></TD><TD><P>Yes</P></TD><TD><P>Yes</P></TD><TD><P>No</P></TD><TD><P>No</P></TD></TR><TR><TD><P><LINK REF="STD-Brincker-1998" TYPE="STUDY">Brincker 1998</LINK></P></TD><TD><P>Yes</P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD></TR><TR><TD><P><LINK REF="STD-Delmas-1982" TYPE="STUDY">Delmas 1982</LINK></P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD></TR><TR><TD><P><LINK REF="STD-Daragon-1993" TYPE="STUDY">Daragon 1993</LINK></P></TD><TD><P>Yes</P></TD><TD><P>No</P></TD><TD><P>Yes</P></TD><TD><P>No</P></TD></TR><TR><TD><P><LINK REF="STD-Heim-1995" TYPE="STUDY">Heim 1995</LINK></P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD></TR><TR><TD><P><LINK REF="STD-Lahtinen-1992" TYPE="STUDY">Lahtinen 1992</LINK></P></TD><TD><P>Yes</P></TD><TD><P>No</P></TD><TD><P>Yes</P></TD><TD><P>No</P></TD></TR><TR><TD><P><LINK REF="STD-McCloskey-2001" TYPE="STUDY">McCloskey 2001</LINK></P></TD><TD><P>Yes</P></TD><TD><P>Yes</P></TD><TD><P>No</P></TD><TD><P>No</P></TD></TR><TR><TD><P><LINK REF="STD-Terpos-2000" TYPE="STUDY">Terpos 2000</LINK></P></TD><TD><P>Yes</P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD></TR><TR><TD><P><LINK REF="STD-Terpos-2003" TYPE="STUDY">Terpos 2003</LINK></P></TD><TD><P>No</P></TD><TD><P>Yes</P></TD><TD><P>No</P></TD><TD><P>No</P></TD></TR><TR><TD><P><LINK REF="STD-Kraj-2000" TYPE="STUDY">Kraj 2000</LINK></P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD></TR><TR><TD><P><LINK REF="STD-Attal-2006" TYPE="STUDY">Attal 2006</LINK></P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>Yes</P></TD></TR><TR><TD><P><LINK REF="STD-Musto-2003" TYPE="STUDY">Musto 2003</LINK></P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>Yes</P></TD></TR><TR><TD><P><LINK REF="STD-Musto-2008" TYPE="STUDY">Musto 2008</LINK></P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>Yes</P></TD></TR><TR><TD><P><LINK REF="STD-Aviles-2007" TYPE="STUDY">Aviles 2007</LINK></P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD></TR><TR><TD><P><LINK REF="STD-Menssen-2002" TYPE="STUDY">Menssen 2002</LINK></P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD></TR><TR><TD><P><LINK REF="STD-Leng-2002" TYPE="STUDY">Leng 2002</LINK></P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD></TR><TR><TD><P><LINK REF="STD-Morgan-2010" TYPE="STUDY">Morgan 2010</LINK></P></TD><TD><P>Yes</P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>Yes</P></TD></TR><TR><TD><P><LINK REF="STD-Rosen-2003" TYPE="STUDY">Rosen 2003</LINK></P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD></TR><TR><TD><P><LINK REF="STD-Gimsing-2010" TYPE="STUDY">Gimsing 2010</LINK></P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>Yes</P></TD></TR><TR><TD><P><LINK REF="STD-Aviles-2013" TYPE="STUDY">Aviles 2013</LINK></P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>Yes</P></TD></TR><TR><TD><P><LINK REF="STD-Sezer-2010" TYPE="STUDY">Sezer 2010</LINK></P></TD><TD><P>Yes</P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>Yes</P></TD></TR><TR><TD><P><LINK REF="STD-Zhang-2012" TYPE="STUDY">Zhang 2012</LINK></P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD></TR><TR><TD><P><LINK REF="STD-Garcia_x002d_Sanz-2015" TYPE="STUDY">Garcia-Sanz 2015</LINK></P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>No</P></TD><TD><P>Yes</P></TD></TR></TABLE><FOOTNOTES/></ADDITIONAL_TABLE><ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2017-11-16 19:43:57 +0100" MODIFIED_BY="[Empty name]" NO="3"><TITLE MODIFIED="2016-02-26 16:09:31 +0100" MODIFIED_BY="[Empty name]">Indirect comparisons</TITLE><TABLE COLS="9" ROWS="115"><TR><TD COLSPAN="3"><P/></TD><TD COLSPAN="5"><P><B>MTC method (REM)</B></P></TD><TD><P/></TD></TR><TR><TD><P>Outcome</P></TD><TD><P>Treatment1</P></TD><TD><P>Treatment2</P></TD><TD><P>NRCTs</P></TD><TD><P>Patients</P></TD><TD><P>HR/RR</P></TD><TD><P>95% LCRL</P></TD><TD><P>95% UCRL</P></TD><TD><P>Quality of the evidence (GRADE)</P></TD></TR><TR><TD><P>OS</P></TD><TD><P>PL</P></TD><TD><P>CLO</P></TD><TD><P>16</P></TD><TD><P>5260</P></TD><TD><P>1.19</P></TD><TD><P>0.88</P></TD><TD><P>1.63</P></TD><TD><P>&#8853;&#8853;&#8853;&#8861;</P><P>moderate</P></TD></TR><TR><TD><P>OS</P></TD><TD><P>ETI</P></TD><TD><P>CLO</P></TD><TD><P>16</P></TD><TD><P>5260</P></TD><TD><P>1.48</P></TD><TD><P>0.96</P></TD><TD><P>2.51</P></TD><TD><P>&#8853;&#8853;&#8853;&#8861;</P><P>moderate</P></TD></TR><TR><TD><P>OS</P></TD><TD><P>IBAN</P></TD><TD><P>CLO</P></TD><TD><P>16</P></TD><TD><P>5260</P></TD><TD><P>1.34</P></TD><TD><P>0.60</P></TD><TD><P>2.62</P></TD><TD><P>&#8853;&#8853;&#8853;&#8861;</P><P>moderate</P></TD></TR><TR><TD><P>OS</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>CLO</P></TD><TD><P>16</P></TD><TD><P>5260</P></TD><TD><P>1.04</P></TD><TD><P>0.64</P></TD><TD><P>1.64</P></TD><TD><P>&#8853;&#8853;&#8853;&#8861;</P><P>moderate</P></TD></TR><TR><TD><P>OS</P></TD><TD><P>ZOL</P></TD><TD><P>CLO</P></TD><TD><P>16</P></TD><TD><P>5260</P></TD><TD><P>0.78</P></TD><TD><P>0.52</P></TD><TD><P>1.14</P></TD><TD><P>&#8853;&#8853;&#8853;&#8861;</P><P>moderate</P></TD></TR><TR><TD><P>OS</P></TD><TD><P>PAM 30 mg</P></TD><TD><P>CLO</P></TD><TD><P>16</P></TD><TD><P>5260</P></TD><TD><P>1.04</P></TD><TD><P>0.48</P></TD><TD><P>2.09</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>OS</P></TD><TD><P>ETI</P></TD><TD><P>PL</P></TD><TD><P>16</P></TD><TD><P>5260</P></TD><TD><P>1.25</P></TD><TD><P>0.88</P></TD><TD><P>1.95</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>OS</P></TD><TD><P>IBAN</P></TD><TD><P>PL</P></TD><TD><P>16</P></TD><TD><P>5260</P></TD><TD><P>1.13</P></TD><TD><P>0.54</P></TD><TD><P>2.06</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>OS</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>PL</P></TD><TD><P>16</P></TD><TD><P>5260</P></TD><TD><P>0.87</P></TD><TD><P>0.60</P></TD><TD><P>1.23</P></TD><TD><P>&#8853;&#8853;&#8853;&#8861;</P><P>moderate</P></TD></TR><TR><TD><P>OS</P></TD><TD><P>ZOL</P></TD><TD><P>PL</P></TD><TD><P>16</P></TD><TD><P>5260</P></TD><TD><P>0.67</P></TD><TD><P>0.46</P></TD><TD><P>0.91</P></TD><TD><P>&#8853;&#8853;&#8853;&#8861;</P><P>moderate</P></TD></TR><TR><TD><P>OS</P></TD><TD><P>PAM 30 mg</P></TD><TD><P>PL</P></TD><TD><P>16</P></TD><TD><P>5260</P></TD><TD><P>0.87</P></TD><TD><P>0.44</P></TD><TD><P>1.64</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>OS</P></TD><TD><P>IBAN</P></TD><TD><P>ETI</P></TD><TD><P>16</P></TD><TD><P>5260</P></TD><TD><P>0.94</P></TD><TD><P>0.37</P></TD><TD><P>1.80</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>OS</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>ETI</P></TD><TD><P>16</P></TD><TD><P>5260</P></TD><TD><P>0.73</P></TD><TD><P>0.38</P></TD><TD><P>1.14</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>OS</P></TD><TD><P>ZOL</P></TD><TD><P>ETI</P></TD><TD><P>16</P></TD><TD><P>5260</P></TD><TD><P>0.56</P></TD><TD><P>0.29</P></TD><TD><P>0.87</P></TD><TD><P>&#8853;&#8853;&#8853;&#8861;</P><P>moderate</P></TD></TR><TR><TD><P>OS</P></TD><TD><P>PAM 30 mg</P></TD><TD><P>ETI</P></TD><TD><P>16</P></TD><TD><P>5260</P></TD><TD><P>0.72</P></TD><TD><P>0.30</P></TD><TD><P>1.40</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>OS</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>IBAN</P></TD><TD><P>16</P></TD><TD><P>5260</P></TD><TD><P>0.87</P></TD><TD><P>0.39</P></TD><TD><P>1.74</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>OS</P></TD><TD><P>ZOL</P></TD><TD><P>IBAN</P></TD><TD><P>16</P></TD><TD><P>5260</P></TD><TD><P>0.67</P></TD><TD><P>0.29</P></TD><TD><P>1.31</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>OS</P></TD><TD><P>PAM 30 mg</P></TD><TD><P>IBAN</P></TD><TD><P>16</P></TD><TD><P>5260</P></TD><TD><P>0.87</P></TD><TD><P>0.32</P></TD><TD><P>2.06</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>OS</P></TD><TD><P>ZOL</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>16</P></TD><TD><P>5260</P></TD><TD><P>0.79</P></TD><TD><P>0.46</P></TD><TD><P>1.26</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>OS</P></TD><TD><P>PAM 30 mg</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>16</P></TD><TD><P>5260</P></TD><TD><P>1.00</P></TD><TD><P>0.57</P></TD><TD><P>1.74</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>OS</P></TD><TD><P>PAM 30 mg</P></TD><TD><P>ZOL</P></TD><TD><P>16</P></TD><TD><P>5260</P></TD><TD><P>1.35</P></TD><TD><P>0.62</P></TD><TD><P>2.76</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>PFS</P></TD><TD><P>PL</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>9</P></TD><TD><P>3472</P></TD><TD><P>0.84</P></TD><TD><P>0.30</P></TD><TD><P>1.88</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>PFS</P></TD><TD><P>ZOL</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>9</P></TD><TD><P>3472</P></TD><TD><P>0.59</P></TD><TD><P>0.20</P></TD><TD><P>1.39</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>PFS</P></TD><TD><P>CLO</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>9</P></TD><TD><P>3472</P></TD><TD><P>0.66</P></TD><TD><P>0.16</P></TD><TD><P>1.71</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>PFS</P></TD><TD><P>PAM 30 mg</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>9</P></TD><TD><P>3472</P></TD><TD><P>1.04</P></TD><TD><P>0.38</P></TD><TD><P>2.16</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>PFS</P></TD><TD><P>ZOL</P></TD><TD><P>PL</P></TD><TD><P>9</P></TD><TD><P>3472</P></TD><TD><P>0.70</P></TD><TD><P>0.46</P></TD><TD><P>1.03</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>PFS</P></TD><TD><P>CLO</P></TD><TD><P>PL</P></TD><TD><P>9</P></TD><TD><P>3472</P></TD><TD><P>0.77</P></TD><TD><P>0.30</P></TD><TD><P>1.47</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>PFS</P></TD><TD><P>PAM 30 mg</P></TD><TD><P>PL</P></TD><TD><P>9</P></TD><TD><P>3472</P></TD><TD><P>1.55</P></TD><TD><P>0.34</P></TD><TD><P>4.29</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>PFS</P></TD><TD><P>CLO</P></TD><TD><P>ZOL</P></TD><TD><P>9</P></TD><TD><P>3472</P></TD><TD><P>1.10</P></TD><TD><P>0.45</P></TD><TD><P>1.95</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>PFS</P></TD><TD><P>PAM 30 mg</P></TD><TD><P>ZOL</P></TD><TD><P>9</P></TD><TD><P>3472</P></TD><TD><P>2.30</P></TD><TD><P>0.45</P></TD><TD><P>6.78</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>PFS</P></TD><TD><P>PAM 30 mg</P></TD><TD><P>CLO</P></TD><TD><P>9</P></TD><TD><P>3472</P></TD><TD><P>2.38</P></TD><TD><P>0.43</P></TD><TD><P>8.15</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>SREs</P></TD><TD><P>PL</P></TD><TD><P>CLO</P></TD><TD><P>13</P></TD><TD><P>5727</P></TD><TD><P>1.27</P></TD><TD><P>0.81</P></TD><TD><P>1.84</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>SREs</P></TD><TD><P>ETI</P></TD><TD><P>CLO</P></TD><TD><P>13</P></TD><TD><P>5727</P></TD><TD><P>1.01</P></TD><TD><P>0.37</P></TD><TD><P>2.20</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>SREs</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>CLO</P></TD><TD><P>13</P></TD><TD><P>5727</P></TD><TD><P>0.90</P></TD><TD><P>0.51</P></TD><TD><P>1.38</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>SREs</P></TD><TD><P>IBAN</P></TD><TD><P>CLO</P></TD><TD><P>13</P></TD><TD><P>5727</P></TD><TD><P>1.37</P></TD><TD><P>0.68</P></TD><TD><P>2.55</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>SREs</P></TD><TD><P>ZOL</P></TD><TD><P>CLO</P></TD><TD><P>13</P></TD><TD><P>5727</P></TD><TD><P>0.72</P></TD><TD><P>0.41</P></TD><TD><P>1.02</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>SREs</P></TD><TD><P>PAM 30 mg</P></TD><TD><P>CLO</P></TD><TD><P>13</P></TD><TD><P>5727</P></TD><TD><P>0.89</P></TD><TD><P>0.44</P></TD><TD><P>1.62</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>SREs</P></TD><TD><P>ETI</P></TD><TD><P>PL</P></TD><TD><P>13</P></TD><TD><P>5727</P></TD><TD><P>0.79</P></TD><TD><P>0.33</P></TD><TD><P>1.61</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>SREs</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>PL</P></TD><TD><P>13</P></TD><TD><P>5727</P></TD><TD><P>0.71</P></TD><TD><P>0.49</P></TD><TD><P>0.96</P></TD><TD><P>&#8853;&#8853;&#8853;&#8861;</P><P>moderate</P></TD></TR><TR><TD><P>SREs</P></TD><TD><P>IBAN</P></TD><TD><P>PL</P></TD><TD><P>13</P></TD><TD><P>5727</P></TD><TD><P>1.08</P></TD><TD><P>0.60</P></TD><TD><P>1.86</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>SREs</P></TD><TD><P>ZOL</P></TD><TD><P>PL</P></TD><TD><P>13</P></TD><TD><P>5727</P></TD><TD><P>0.57</P></TD><TD><P>0.37</P></TD><TD><P>0.76</P></TD><TD><P>&#8853;&#8853;&#8853;&#8861;</P><P>moderate</P></TD></TR><TR><TD><P>SREs</P></TD><TD><P>PAM 30 mg</P></TD><TD><P>PL</P></TD><TD><P>13</P></TD><TD><P>5727</P></TD><TD><P>0.71</P></TD><TD><P>0.38</P></TD><TD><P>1.23</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>SREs</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>ETI</P></TD><TD><P>13</P></TD><TD><P>5727</P></TD><TD><P>1.06</P></TD><TD><P>0.40</P></TD><TD><P>2.25</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>SREs</P></TD><TD><P>IBAN</P></TD><TD><P>ETI</P></TD><TD><P>13</P></TD><TD><P>5727</P></TD><TD><P>1.61</P></TD><TD><P>0.55</P></TD><TD><P>3.79</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>SREs</P></TD><TD><P>ZOL</P></TD><TD><P>ETI</P></TD><TD><P>13</P></TD><TD><P>5727</P></TD><TD><P>0.84</P></TD><TD><P>0.31</P></TD><TD><P>1.76</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>SREs</P></TD><TD><P>PAM30mg</P></TD><TD><P>ETI</P></TD><TD><P>13</P></TD><TD><P>5727</P></TD><TD><P>1.06</P></TD><TD><P>0.35</P></TD><TD><P>2.57</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>SREs</P></TD><TD><P>IBAN</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>13</P></TD><TD><P>5727</P></TD><TD><P>1.56</P></TD><TD><P>0.80</P></TD><TD><P>2.90</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>SREs</P></TD><TD><P>ZOL</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>13</P></TD><TD><P>5727</P></TD><TD><P>0.81</P></TD><TD><P>0.52</P></TD><TD><P>1.14</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>SREs</P></TD><TD><P>PAM 30 mg</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>13</P></TD><TD><P>5727</P></TD><TD><P>1.00</P></TD><TD><P>0.60</P></TD><TD><P>1.70</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>SREs</P></TD><TD><P>ZOL</P></TD><TD><P>IBAN</P></TD><TD><P>13</P></TD><TD><P>5727</P></TD><TD><P>0.56</P></TD><TD><P>0.26</P></TD><TD><P>0.98</P></TD><TD><P>&#8853;&#8853;&#8853;&#8861;</P><P>moderate</P></TD></TR><TR><TD><P>SREs</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>IBAN</P></TD><TD><P>13</P></TD><TD><P>5727</P></TD><TD><P>0.70</P></TD><TD><P>0.29</P></TD><TD><P>1.44</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>SREs</P></TD><TD><P>PAM 30 mg</P></TD><TD><P>ZOL</P></TD><TD><P>13</P></TD><TD><P>5727</P></TD><TD><P>1.28</P></TD><TD><P>0.68</P></TD><TD><P>2.51</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>Pain</P></TD><TD><P>ETI</P></TD><TD><P>CLO</P></TD><TD><P>8</P></TD><TD><P>1281</P></TD><TD><P>2.15</P></TD><TD><P>0.22</P></TD><TD><P>9.56</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>Pain</P></TD><TD><P>IBAN</P></TD><TD><P>CLO</P></TD><TD><P>8</P></TD><TD><P>1281</P></TD><TD><P>4.13</P></TD><TD><P>0.57</P></TD><TD><P>16.99</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>Pain</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>CLO</P></TD><TD><P>8</P></TD><TD><P>1281</P></TD><TD><P>1.76</P></TD><TD><P>0.57</P></TD><TD><P>16.99</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>Pain</P></TD><TD><P>IBAN</P></TD><TD><P>ETI</P></TD><TD><P>8</P></TD><TD><P>1281</P></TD><TD><P>4.07</P></TD><TD><P>0.23</P></TD><TD><P>19.62</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>Pain</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>ETI</P></TD><TD><P>8</P></TD><TD><P>1281</P></TD><TD><P>1.75</P></TD><TD><P>0.11</P></TD><TD><P>7.64</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>Pain</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>IBAN</P></TD><TD><P>8</P></TD><TD><P>1281</P></TD><TD><P>0.75</P></TD><TD><P>0.06</P></TD><TD><P>3</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>Vertebral fractures</P></TD><TD><P>PL</P></TD><TD><P>CLO</P></TD><TD><P>8</P></TD><TD><P>3076</P></TD><TD><P>1.50</P></TD><TD><P>0.87</P></TD><TD><P>2.62</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>Vertebral fractures</P></TD><TD><P>IBAN</P></TD><TD><P>CLO</P></TD><TD><P>8</P></TD><TD><P>3076</P></TD><TD><P>1.76</P></TD><TD><P>0.56</P></TD><TD><P>4.45</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>Vertebral fractures</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>CLO</P></TD><TD><P>8</P></TD><TD><P>3076</P></TD><TD><P>1.07</P></TD><TD><P>0.45</P></TD><TD><P>2.07</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>Vertebral fractures</P></TD><TD><P>ZOL</P></TD><TD><P>CLO</P></TD><TD><P>8</P></TD><TD><P>3076</P></TD><TD><P>0.59</P></TD><TD><P>0.22</P></TD><TD><P>1.17</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>Vertebral fractures</P></TD><TD><P>IBAN</P></TD><TD><P>PL</P></TD><TD><P>8</P></TD><TD><P>3076</P></TD><TD><P>1.16</P></TD><TD><P>0.41</P></TD><TD><P>2.56</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>Vertebral fractures</P></TD><TD><P>PAM90mg</P></TD><TD><P>PL</P></TD><TD><P>8</P></TD><TD><P>3076</P></TD><TD><P>0.72</P></TD><TD><P>0.35</P></TD><TD><P>1.18</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>Vertebral fractures</P></TD><TD><P>ZOL</P></TD><TD><P>PL</P></TD><TD><P>8</P></TD><TD><P>3076</P></TD><TD><P>0.42</P></TD><TD><P>0.12</P></TD><TD><P>0.94</P></TD><TD><P>&#8853;&#8853;&#8853;&#8861;</P><P>moderate</P></TD></TR><TR><TD><P>Vertebral fractures</P></TD><TD><P>PAM90mg</P></TD><TD><P>IBAN</P></TD><TD><P>8</P></TD><TD><P>3076</P></TD><TD><P>0.76</P></TD><TD><P>0.21</P></TD><TD><P>1.91</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>Vertebral fractures</P></TD><TD><P>ZOL</P></TD><TD><P>IBAN</P></TD><TD><P>8</P></TD><TD><P>3076</P></TD><TD><P>0.45</P></TD><TD><P>0.08</P></TD><TD><P>1.29</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>Vertebral fractures</P></TD><TD><P>ZOL</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>8</P></TD><TD><P>3076</P></TD><TD><P>0.64</P></TD><TD><P>0.17</P></TD><TD><P>1.68</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>Nonvertebral fractures</P></TD><TD><P>PL</P></TD><TD><P>CLO</P></TD><TD><P>7</P></TD><TD><P>3349</P></TD><TD><P>1.47</P></TD><TD><P>0.65</P></TD><TD><P>3.10</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>Nonvertebral fractures</P></TD><TD><P>IBAN</P></TD><TD><P>CLO</P></TD><TD><P>7</P></TD><TD><P>3349</P></TD><TD><P>2.13</P></TD><TD><P>0.44</P></TD><TD><P>7.20</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>Nonvertebral fractures</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>CLO</P></TD><TD><P>7</P></TD><TD><P>3349</P></TD><TD><P>3.17</P></TD><TD><P>0.52</P></TD><TD><P>10.88</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>Nonvertebral fractures</P></TD><TD><P>ZOL</P></TD><TD><P>CLO</P></TD><TD><P>7</P></TD><TD><P>3349</P></TD><TD><P>0.82</P></TD><TD><P>0.24</P></TD><TD><P>2.32</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>Nonvertebral fractures</P></TD><TD><P>IBAN</P></TD><TD><P>PL</P></TD><TD><P>7</P></TD><TD><P>3349</P></TD><TD><P>1.46</P></TD><TD><P>0.40</P></TD><TD><P>3.98</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>Non vertebral fractures</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>PL</P></TD><TD><P>7</P></TD><TD><P>3349</P></TD><TD><P>2.01</P></TD><TD><P>0.46</P></TD><TD><P>6.32</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>Non vertebral fractures</P></TD><TD><P>ZOL</P></TD><TD><P>PL</P></TD><TD><P>7</P></TD><TD><P>3349</P></TD><TD><P>0.66</P></TD><TD><P>0.13</P></TD><TD><P>2.30</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>Non-vertebral fractures</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>IBAN</P></TD><TD><P>7</P></TD><TD><P>3349</P></TD><TD><P>1.98</P></TD><TD><P>0.25</P></TD><TD><P>7.66</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>Non-vertebral fractures</P></TD><TD><P>ZOL</P></TD><TD><P>IBAN</P></TD><TD><P>7</P></TD><TD><P>3349</P></TD><TD><P>0.64</P></TD><TD><P>0.07</P></TD><TD><P>2.82</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>Non-vertebral fractures</P></TD><TD><P>ZOL</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>7</P></TD><TD><P>3349</P></TD><TD><P>0.49</P></TD><TD><P>0.04</P></TD><TD><P>2.14</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>*</SUP></P></TD></TR><TR><TD><P>Hypercalcemia</P></TD><TD><P>PL</P></TD><TD><P>CLO</P></TD><TD><P>11</P></TD><TD><P>4146</P></TD><TD><P>1.64</P></TD><TD><P>0.71</P></TD><TD><P>3.58</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*$</SUP></P></TD></TR><TR><TD><P>Hypercalcemia</P></TD><TD><P>ETI</P></TD><TD><P>CLO</P></TD><TD><P>11</P></TD><TD><P>4146</P></TD><TD><P>2.59</P></TD><TD><P>0.51</P></TD><TD><P>8.80</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*$</SUP></P></TD></TR><TR><TD><P>Hypercalcemia</P></TD><TD><P>IBAN</P></TD><TD><P>CLO</P></TD><TD><P>11</P></TD><TD><P>4146</P></TD><TD><P>1.27</P></TD><TD><P>0.20</P></TD><TD><P>4.53</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*$</SUP></P></TD></TR><TR><TD><P>Hypercalcemia</P></TD><TD><P>PAM90mg</P></TD><TD><P>CLO</P></TD><TD><P>11</P></TD><TD><P>4146</P></TD><TD><P>1.14</P></TD><TD><P>0.32</P></TD><TD><P>3.05</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*$</SUP></P></TD></TR><TR><TD><P>Hypercalcemia</P></TD><TD><P>ZOL</P></TD><TD><P>CLO</P></TD><TD><P>11</P></TD><TD><P>4146</P></TD><TD><P>1.04</P></TD><TD><P>0.32</P></TD><TD><P>2.47</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*$</SUP></P></TD></TR><TR><TD><P>Hypercalcemia</P></TD><TD><P>ETI</P></TD><TD><P>PL</P></TD><TD><P>11</P></TD><TD><P>4146</P></TD><TD><P>1.55</P></TD><TD><P>0.40</P></TD><TD><P>4.27</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*$</SUP></P></TD></TR><TR><TD><P>Hypercalcemia</P></TD><TD><P>IBAN</P></TD><TD><P>PL</P></TD><TD><P>11</P></TD><TD><P>4146</P></TD><TD><P>0.76</P></TD><TD><P>0.16</P></TD><TD><P>2.27</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*$</SUP></P></TD></TR><TR><TD><P>Hypercalcemia</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>PL</P></TD><TD><P>11</P></TD><TD><P>4146</P></TD><TD><P>0.70</P></TD><TD><P>0.26</P></TD><TD><P>1.40</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*$</SUP></P></TD></TR><TR><TD><P>Hypercalcemia</P></TD><TD><P>ZOL</P></TD><TD><P>PL</P></TD><TD><P>11</P></TD><TD><P>4146</P></TD><TD><P>0.73</P></TD><TD><P>0.16</P></TD><TD><P>1.92</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*$</SUP></P></TD></TR><TR><TD><P>Hypercalcemia</P></TD><TD><P>IBAN</P></TD><TD><P>ETI</P></TD><TD><P>11</P></TD><TD><P>4146</P></TD><TD><P>0.68</P></TD><TD><P>0.08</P></TD><TD><P>2.53</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*$</SUP></P></TD></TR><TR><TD><P>Hypercalcemia</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>ETI</P></TD><TD><P>11</P></TD><TD><P>4146</P></TD><TD><P>0.62</P></TD><TD><P>0.11</P></TD><TD><P>1.92</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*$</SUP></P></TD></TR><TR><TD><P>Hypercalcemia</P></TD><TD><P>ZOL</P></TD><TD><P>ETI</P></TD><TD><P>11</P></TD><TD><P>4146</P></TD><TD><P>0.65</P></TD><TD><P>0.08</P></TD><TD><P>2.28</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*$</SUP></P></TD></TR><TR><TD><P>Hypercalcemia</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>IBAN</P></TD><TD><P>11</P></TD><TD><P>4146</P></TD><TD><P>1.42</P></TD><TD><P>0.22</P></TD><TD><P>4.79</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*$</SUP></P></TD></TR><TR><TD><P>Hypercalcemia</P></TD><TD><P>ZOL</P></TD><TD><P>IBAN</P></TD><TD><P>11</P></TD><TD><P>4146</P></TD><TD><P>1.50</P></TD><TD><P>0.15</P></TD><TD><P>5.74</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*$</SUP></P></TD></TR><TR><TD><P>Hypercalcemia</P></TD><TD><P>ZOL</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>11</P></TD><TD><P>4146</P></TD><TD><P>1.23</P></TD><TD><P>0.21</P></TD><TD><P>4.05</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*$</SUP></P></TD></TR><TR><TD><P>GIToxicity</P></TD><TD><P>PL</P></TD><TD><P>CLO</P></TD><TD><P>8</P></TD><TD><P>3789</P></TD><TD><P>0.87</P></TD><TD><P>0.45</P></TD><TD><P>1.49</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>* $$</SUP></P></TD></TR><TR><TD><P>GIToxicity</P></TD><TD><P>ETI</P></TD><TD><P>CLO</P></TD><TD><P>8</P></TD><TD><P>3789</P></TD><TD><P>1.14</P></TD><TD><P>0.01</P></TD><TD><P>7.59</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>* $$</SUP></P></TD></TR><TR><TD><P>GIToxicity</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>CLO</P></TD><TD><P>8</P></TD><TD><P>3789</P></TD><TD><P>1.18</P></TD><TD><P>0.45</P></TD><TD><P>2.49</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>* $$</SUP></P></TD></TR><TR><TD><P>GIToxicity</P></TD><TD><P>ZOL</P></TD><TD><P>CLO</P></TD><TD><P>8</P></TD><TD><P>3789</P></TD><TD><P>0.86</P></TD><TD><P>0.35</P></TD><TD><P>1.74</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>* $$</SUP></P></TD></TR><TR><TD><P>GIToxicity</P></TD><TD><P>ETI</P></TD><TD><P>PL</P></TD><TD><P>8</P></TD><TD><P>3789</P></TD><TD><P>1.32</P></TD><TD><P>0.01</P></TD><TD><P>8.73</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>* $$</SUP></P></TD></TR><TR><TD><P>GIToxicity</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>PL</P></TD><TD><P>8</P></TD><TD><P>3789</P></TD><TD><P>1.36</P></TD><TD><P>0.69</P></TD><TD><P>2.39</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>* $$</SUP></P></TD></TR><TR><TD><P>GIToxicity</P></TD><TD><P>ZOL</P></TD><TD><P>PL</P></TD><TD><P>8</P></TD><TD><P>3789</P></TD><TD><P>1.07</P></TD><TD><P>0.38</P></TD><TD><P>2.39</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>* $$</SUP></P></TD></TR><TR><TD><P>GIToxicity</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>ETI</P></TD><TD><P>8</P></TD><TD><P>3789</P></TD><TD><P>15.96</P></TD><TD><P>0.14</P></TD><TD><P>102.19</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>* $$</SUP></P></TD></TR><TR><TD><P>GIToxicity</P></TD><TD><P>ZOL</P></TD><TD><P>ETI</P></TD><TD><P>8</P></TD><TD><P>3789</P></TD><TD><P>12.63</P></TD><TD><P>0.10</P></TD><TD><P>81.10</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>* $$</SUP></P></TD></TR><TR><TD><P>GIToxicity</P></TD><TD><P>ZOL</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>8</P></TD><TD><P>3789</P></TD><TD><P>0.86</P></TD><TD><P>0.24</P></TD><TD><P>2.27</P></TD><TD><P>&#8853;&#8853;&#8861;&#8861;</P><P>low<SUP>* $$</SUP></P></TD></TR><TR><TD><P>ONJ</P></TD><TD><P>PL</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>8</P></TD><TD><P>3746</P></TD><TD><P>1.10</P></TD><TD><P>0.04</P></TD><TD><P>5.99</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>ONJ</P></TD><TD><P>ZOL</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>8</P></TD><TD><P>3746</P></TD><TD><P>6.19</P></TD><TD><P>0.09</P></TD><TD><P>38.16</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>ONJ</P></TD><TD><P>CLO</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>8</P></TD><TD><P>3746</P></TD><TD><P>0.77</P></TD><TD><P>0.01</P></TD><TD><P>4.94</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>ONJ</P></TD><TD><P>PAM 30 mg</P></TD><TD><P>PAM 90 mg</P></TD><TD><P>8</P></TD><TD><P>3746</P></TD><TD><P>0.44</P></TD><TD><P>0.05</P></TD><TD><P>1.83</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>ONJ</P></TD><TD><P>ZOL</P></TD><TD><P>PL</P></TD><TD><P>8</P></TD><TD><P>3746</P></TD><TD><P>5.70</P></TD><TD><P>0.72</P></TD><TD><P>21.26</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>ONJ</P></TD><TD><P>CLO</P></TD><TD><P>PL</P></TD><TD><P>8</P></TD><TD><P>3746</P></TD><TD><P>0.71</P></TD><TD><P>0.04</P></TD><TD><P>3.43</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>ONJ</P></TD><TD><P>PAM 30 mg</P></TD><TD><P>PL</P></TD><TD><P>8</P></TD><TD><P>3746</P></TD><TD><P>2.19</P></TD><TD><P>0.03</P></TD><TD><P>13.55</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>ONJ</P></TD><TD><P>CLO</P></TD><TD><P>ZOL</P></TD><TD><P>8</P></TD><TD><P>3746</P></TD><TD><P>0.13</P></TD><TD><P>0.02</P></TD><TD><P>0.44</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low **</P></TD></TR><TR><TD><P>ONJ</P></TD><TD><P>PAM 30 mg</P></TD><TD><P>ZOL</P></TD><TD><P>8</P></TD><TD><P>3746</P></TD><TD><P>0.77</P></TD><TD><P>0.00</P></TD><TD><P>5.09</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR><TR><TD><P>ONJ</P></TD><TD><P>PAM 30 mg</P></TD><TD><P>CLO</P></TD><TD><P>8</P></TD><TD><P>3746</P></TD><TD><P>11.14</P></TD><TD><P>0.04</P></TD><TD><P>76.15</P></TD><TD><P>&#8853;&#8861;&#8861;&#8861;</P><P>very low <SUP>*^</SUP></P></TD></TR></TABLE><FOOTNOTES><P><B>REM</B>: Random effects model, for multiple treatment comparison method: sigma~Unif(0,1); <B>ONJ:</B> osteonecrosis of the jaw; <B>PL</B>: Placebo; #<B>RCTS:</B> Number of randomized controlled trials; <B>LCRL</B>: Lower credibility limit; <B>UCRL</B>: Upper credibility limit; <B>OS</B>: Overall survival; <B>PFS</B>: Progression-free survival; <B>SREs</B>: Skeletal-related events; <B>HR:</B> Hazard ratio; <B>RR</B>: Risk ratio; <B>ETI</B>: Etidronate; <B>CLO</B>: Clodronate; <B>PAM 90 mg</B>: Pamidronate 90 mg: <B>PAM 30 mg</B>: Pamidronate 30 mg; <B>IBAN</B>: Ibandronate: <B>ZOL</B>: Zoledronate; *Randomized controlled trial with direct (head-to-head) comparison of zoledronate versus clodronate (<LINK REF="STD-Morgan-2010" TYPE="STUDY">Morgan 2010</LINK>).* Imprecision; ^ Contributing direct evidence of low quality;$ For the contributing direct evidence, the pooled estimate along with individual studies have wide confidence intervals. Therefore, we downgraded the quality of evidence by two levels resulting in low quality evidence. $$ For the contributing direct evidence, individual studies have wide confidence intervals. Therefore, we downgraded the quality of evidence by one level resulting in moderate quality evidence.**The results from head to head RCT comparing zoledronate with clodronate showed no difference in risk of ONJ (<LINK REF="STD-Morgan-2010" TYPE="STUDY">Morgan 2010</LINK>). However, the results from network meta-analysis showed an increased risk of ONJ with zoledronate over clodronate which is indicative of incoherence.</P></FOOTNOTES></ADDITIONAL_TABLE><ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2017-11-09 18:52:20 +0100" MODIFIED_BY="[Empty name]" NO="4"><TITLE MODIFIED="2009-07-11 14:55:04 +0200" MODIFIED_BY="[Empty name]">Included ONJ studies</TITLE><TABLE COLS="8" ROWS="24"><TR><TH ALIGN="LEFT" VALIGN="MIDDLE"><P>Study</P></TH><TH ALIGN="LEFT" VALIGN="MIDDLE"><P>Study design</P></TH><TH ALIGN="LEFT" VALIGN="MIDDLE"><P>Type of bisphosphonate</P></TH><TH ALIGN="LEFT" VALIGN="BOTTOM"><P>Total number of patients</P></TH><TH ALIGN="LEFT" VALIGN="BOTTOM"><P>Number of patients with ONJ</P></TH><TH ALIGN="LEFT" VALIGN="BOTTOM"><P>Route, dose, frequency</P></TH><TH ALIGN="LEFT" VALIGN="BOTTOM"><P>Treatment duration</P></TH><TH ALIGN="LEFT" VALIGN="BOTTOM"><P>ONJ frequency</P></TH></TR><TR><TD ALIGN="LEFT" ROWSPAN="3" VALIGN="MIDDLE"><P><LINK REF="REF-Badros-2006" TYPE="REFERENCE">Badros 2006</LINK></P></TD><TD ALIGN="LEFT" ROWSPAN="3" VALIGN="MIDDLE"><P>Retrospective study</P></TD><TD ALIGN="LEFT" VALIGN="BOTTOM"><P>Pamidronate</P></TD><TD ALIGN="LEFT" VALIGN="BOTTOM"><P>17</P></TD><TD ALIGN="LEFT" VALIGN="BOTTOM"><P>3</P></TD><TD ALIGN="LEFT" ROWSPAN="3" VALIGN="MIDDLE"><P>Not reported</P></TD><TD ALIGN="LEFT" ROWSPAN="3" VALIGN="MIDDLE"><P>Not reported</P></TD><TD ALIGN="LEFT" VALIGN="BOTTOM"><P>17.65%</P></TD></TR><TR><TD ALIGN="LEFT"><P>Zoledronate</P></TD><TD ALIGN="LEFT"><P>34</P></TD><TD ALIGN="LEFT"><P>2</P></TD><TD ALIGN="LEFT"><P>5.88%</P></TD></TR><TR><TD ALIGN="LEFT"><P>Pamidronate + zoledronate</P></TD><TD ALIGN="LEFT"><P>33</P></TD><TD ALIGN="LEFT"><P>17</P></TD><TD ALIGN="LEFT"><P>51.51%</P></TD></TR><TR><TD ALIGN="LEFT"><P><LINK REF="REF-Berenson-2011" TYPE="REFERENCE">Berenson 2011</LINK></P></TD><TD ALIGN="LEFT"><P>Retrospective study</P></TD><TD ALIGN="LEFT"><P>Zoledronate</P></TD><TD ALIGN="LEFT"><P>300</P></TD><TD ALIGN="LEFT"><P>14</P></TD><TD ALIGN="LEFT"><P>Not clear</P></TD><TD ALIGN="LEFT"><P>Median: 18 months Range: 1-121 months</P></TD><TD ALIGN="LEFT"><P>5%</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="BOTTOM"><P><LINK REF="REF-Calvo_x002d_Villas-2006" TYPE="REFERENCE">Calvo-Villas 2006</LINK></P></TD><TD ALIGN="LEFT" VALIGN="BOTTOM"><P>Not clear</P></TD><TD ALIGN="LEFT" VALIGN="BOTTOM"><P>Zoledronate</P></TD><TD ALIGN="LEFT" VALIGN="BOTTOM"><P>64</P></TD><TD ALIGN="LEFT" VALIGN="BOTTOM"><P>7</P></TD><TD ALIGN="LEFT" VALIGN="BOTTOM"><P>Not reported</P></TD><TD ALIGN="LEFT" VALIGN="BOTTOM"><P>Not clear</P></TD><TD ALIGN="LEFT" VALIGN="BOTTOM"><P>9%</P></TD></TR><TR><TD ALIGN="LEFT"><P><LINK REF="REF-Cetiner-2009" TYPE="REFERENCE">Cetiner 2009</LINK></P></TD><TD ALIGN="LEFT"><P>Prospective study</P></TD><TD ALIGN="LEFT"><P>Zoledronate</P></TD><TD ALIGN="LEFT"><P>32</P></TD><TD ALIGN="LEFT"><P>5</P></TD><TD ALIGN="LEFT"><P>15 minute infusion of 4 mg IV zoledronate once a month</P></TD><TD ALIGN="LEFT"><P>Mean duration: 26.5 months, SD 18.7 months</P></TD><TD ALIGN="LEFT"><P>15%</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="3"><P><LINK REF="REF-Corso-2007" TYPE="REFERENCE">Corso 2007</LINK></P></TD><TD ALIGN="LEFT" ROWSPAN="3"><P>Retrospective study</P></TD><TD ALIGN="LEFT"><P>Pamidronate</P></TD><TD ALIGN="LEFT"><P>20</P></TD><TD ALIGN="LEFT"><P>0</P></TD><TD ALIGN="LEFT"><P>Not clear</P></TD><TD ALIGN="LEFT"><P>23 months</P></TD><TD ALIGN="LEFT"><P>0%</P></TD></TR><TR><TD ALIGN="LEFT"><P>Zoledronate</P></TD><TD ALIGN="LEFT"><P>37</P></TD><TD ALIGN="LEFT"><P>5</P></TD><TD ALIGN="LEFT"><P>Not clear</P></TD><TD ALIGN="LEFT"><P>28 months</P></TD><TD ALIGN="LEFT"><P>11.9%</P></TD></TR><TR><TD ALIGN="LEFT"><P>Pamidronate + zoledronate</P></TD><TD ALIGN="LEFT"><P>42</P></TD><TD ALIGN="LEFT"><P>2</P></TD><TD ALIGN="LEFT"><P>Not clear</P></TD><TD ALIGN="LEFT"><P>47 months</P></TD><TD ALIGN="LEFT"><P>4.55%</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="7"><P><LINK REF="REF-Dimopoulos-2006" TYPE="REFERENCE">Dimopoulos 2006</LINK></P></TD><TD ALIGN="LEFT" ROWSPAN="7"><P/></TD><TD ALIGN="LEFT"><P>Pamidronate</P></TD><TD ALIGN="LEFT"><P>93</P></TD><TD ALIGN="LEFT"><P>7</P></TD><TD ALIGN="LEFT" ROWSPAN="7"><P>Not reported</P></TD><TD ALIGN="LEFT" ROWSPAN="7"><P>39 months ONJ patients (11-76) vs 28 (4.5-123) months without ONJ</P></TD><TD ALIGN="LEFT"><P>7.5%</P></TD></TR><TR><TD ALIGN="LEFT"><P>Zoledronate</P></TD><TD ALIGN="LEFT"><P>33</P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD ALIGN="LEFT"><P>3%</P></TD></TR><TR><TD ALIGN="LEFT"><P>Pamidronate + zoledronate</P></TD><TD ALIGN="LEFT"><P>66</P></TD><TD ALIGN="LEFT"><P>6</P></TD><TD ALIGN="LEFT"><P>9.1%</P></TD></TR><TR><TD ALIGN="LEFT"><P>Ibandronate</P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD ALIGN="LEFT"><P>0</P></TD><TD ALIGN="LEFT"><P>0%</P></TD></TR><TR><TD ALIGN="LEFT"><P>Ibandronate + zoledronate</P></TD><TD ALIGN="LEFT"><P>4</P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD ALIGN="LEFT"><P>25%</P></TD></TR><TR><TD ALIGN="LEFT"><P>Clodronate + zoledronate</P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD ALIGN="LEFT"><P>0</P></TD><TD ALIGN="LEFT"><P>0%</P></TD></TR><TR><TD ALIGN="LEFT"><P>Alendronate + zoledronate</P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD ALIGN="LEFT"><P>0</P></TD><TD ALIGN="LEFT"><P>0%</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="3"><P><LINK REF="REF-Garcia_x002d_Garay-2006" TYPE="REFERENCE">Garcia-Garay 2006</LINK></P></TD><TD ALIGN="LEFT" ROWSPAN="3"><P>Retrospective study</P></TD><TD ALIGN="LEFT"><P>Pamidronate</P></TD><TD ALIGN="LEFT"><P>49</P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD ALIGN="LEFT"><P>90 mg monthly</P></TD><TD ALIGN="LEFT"><P>28 months</P></TD><TD ALIGN="LEFT"><P>2%</P></TD></TR><TR><TD ALIGN="LEFT"><P>Zoledronate</P></TD><TD ALIGN="LEFT"><P>64</P></TD><TD ALIGN="LEFT"><P>6</P></TD><TD ALIGN="LEFT"><P>4 mg monthly</P></TD><TD ALIGN="LEFT"><P>12 months (7-28)</P></TD><TD ALIGN="LEFT"><P>9.3%</P></TD></TR><TR><TD ALIGN="LEFT"><P>Pamidronate + zoledronate</P></TD><TD ALIGN="LEFT"><P>30</P></TD><TD ALIGN="LEFT"><P>7</P></TD><TD ALIGN="LEFT"><P/></TD><TD ALIGN="LEFT"><P>43.5 months (24-59)</P></TD><TD ALIGN="LEFT"><P>23.3%</P></TD></TR><TR><TD ALIGN="LEFT"><P><LINK REF="REF-Tosi-2006b" TYPE="REFERENCE">Tosi 2006b</LINK></P></TD><TD ALIGN="LEFT"><P>Retrospective study</P></TD><TD ALIGN="LEFT"><P>Zoledronate</P></TD><TD ALIGN="LEFT"><P>225</P></TD><TD ALIGN="LEFT"><P>6</P></TD><TD ALIGN="LEFT"><P>Not reported</P></TD><TD ALIGN="LEFT"><P>10 months (4-35)</P></TD><TD ALIGN="LEFT"><P>2.7%</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="3"><P><LINK REF="REF-Zervas-2006" TYPE="REFERENCE">Zervas 2006</LINK></P></TD><TD ALIGN="LEFT" ROWSPAN="3"><P>Retrospective study from 1991, prospective from 2001-2006</P></TD><TD ALIGN="LEFT"><P>Pamidronate</P></TD><TD ALIGN="LEFT"><P>78</P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD ALIGN="LEFT"><P>90 mg</P></TD><TD ALIGN="LEFT" ROWSPAN="3"><P>24 months (4-120)</P></TD><TD ALIGN="LEFT"><P>1.28%</P></TD></TR><TR><TD ALIGN="LEFT"><P>Pamidronate</P></TD><TD ALIGN="LEFT"><P>91</P></TD><TD ALIGN="LEFT"><P>6</P></TD><TD ALIGN="LEFT"><P>4 mg 4-6 weeks</P></TD><TD ALIGN="LEFT"><P>6.59%</P></TD></TR><TR><TD ALIGN="LEFT"><P>Pamidronate + zoledronate</P></TD><TD ALIGN="LEFT"><P>85</P></TD><TD ALIGN="LEFT"><P>21</P></TD><TD ALIGN="LEFT"><P/></TD><TD ALIGN="LEFT"><P>24.71%</P></TD></TR></TABLE><FOOTNOTES><P><B>ONJ:</B> Osteonecrosis of the jaw; <B>SD:</B> standard deviation; <B>IV: </B>intravenous.</P></FOOTNOTES></ADDITIONAL_TABLE><ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2017-10-31 15:32:25 +0100" MODIFIED_BY="Heather Maxwell" NO="5"><TITLE MODIFIED="2009-07-12 13:11:01 +0200" MODIFIED_BY="[Empty name]">Excluded ONJ studies</TITLE><TABLE COLS="2" ROWS="4"><TR><TH><P>Study_ID</P></TH><TH><P>Reason for exclusion</P></TH></TR><TR><TD><P><LINK REF="REF-Bujanda-2007" TYPE="REFERENCE">Bujanda 2007</LINK></P></TD><TD><P>No multiple myeloma patients with ONJ</P></TD></TR><TR><TD><P><LINK REF="REF-Hoff-2006" TYPE="REFERENCE">Hoff 2006</LINK></P></TD><TD><P>No extractable data for multiple myeloma patients (abstract)</P></TD></TR><TR><TD><P><LINK REF="REF-Kut-2004" TYPE="REFERENCE">Kut 2004</LINK></P></TD><TD><P>American Society of Hematology 2004 (abstract no 4933): Approximately 600 multiple myeloma patients. Teported frequency: 7 patients. Excluded due to imprecise reporting (e.g. approximately 600 multiple myeloma patients)</P></TD></TR></TABLE><FOOTNOTES><P><B>ONJ:</B> Osteonecrosis of the jaw.</P></FOOTNOTES></ADDITIONAL_TABLE><ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2017-10-31 15:33:16 +0100" MODIFIED_BY="Heather Maxwell" NO="6"><TITLE MODIFIED="2016-02-26 20:37:47 +0100" MODIFIED_BY="[Empty name]">ONJ case reports/case series: data stratified by bisphosphonate type</TITLE><TABLE COLS="8" ROWS="63"><TR><TH><P>Study</P></TH><TH ALIGN="LEFT"><P>Total number of patients</P></TH><TH><P>Clodronate</P></TH><TH><P>Pamidronate</P></TH><TH><P>Zoledronate</P></TH><TH><P>Pamidronate</P><P>/zoledronate</P></TH><TH><P>Not specified</P></TH><TH><P>Others</P></TH></TR><TR><TD><P><LINK REF="REF-Bagan-2006" TYPE="REFERENCE">Bagan 2006</LINK></P></TD><TD ALIGN="LEFT"><P>9</P></TD><TD><P/></TD><TD><P>2</P></TD><TD><P>7</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Battley-2006" TYPE="REFERENCE">Battley 2006</LINK></P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Braun-2006" TYPE="REFERENCE">Braun 2006</LINK></P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Broglia-2006" TYPE="REFERENCE">Broglia 2006</LINK></P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Capalbo-2006" TYPE="REFERENCE">Capalbo 2006</LINK></P></TD><TD ALIGN="LEFT"><P>9</P></TD><TD><P/></TD><TD><P>2</P></TD><TD><P>4</P></TD><TD><P>3</P></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Carneiro-2006" TYPE="REFERENCE">Carneiro 2006</LINK></P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Carter-2005" TYPE="REFERENCE">Carter 2005</LINK></P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD><P/></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Clarke-2007" TYPE="REFERENCE">Clarke 2007</LINK></P></TD><TD ALIGN="LEFT"><P>21</P></TD><TD><P/></TD><TD><P>12</P></TD><TD><P>1</P></TD><TD><P>8</P></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Curi-2007" TYPE="REFERENCE">Curi 2007</LINK></P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Dannemann-2007" TYPE="REFERENCE">Dannemann 2007</LINK></P></TD><TD ALIGN="LEFT"><P>7</P></TD><TD><P/></TD><TD><P/></TD><TD><P>2</P></TD><TD><P>5</P></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Diego-2007" TYPE="REFERENCE">Diego 2007</LINK></P></TD><TD ALIGN="LEFT"><P>3</P></TD><TD><P/></TD><TD><P/></TD><TD><P>3</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Dimitrakopoulos--2006" TYPE="REFERENCE">Dimitrakopoulos 2006</LINK></P></TD><TD ALIGN="LEFT"><P>5</P></TD><TD><P/></TD><TD><P/></TD><TD><P>2</P></TD><TD><P>3</P></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Elad-2006" TYPE="REFERENCE">Elad 2006</LINK></P></TD><TD ALIGN="LEFT"><P>22</P></TD><TD><P/></TD><TD><P/></TD><TD><P>17</P></TD><TD><P>4</P></TD><TD><P/></TD><TD><P>1(A)</P></TD></TR><TR><TD><P><LINK REF="REF-Ficarra-2005" TYPE="REFERENCE">Ficarra 2005</LINK></P></TD><TD ALIGN="LEFT"><P>2</P></TD><TD><P/></TD><TD><P/></TD><TD><P>1</P></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Fortuna-2012" TYPE="REFERENCE">Fortuna 2012</LINK></P></TD><TD><P>13</P></TD><TD><P/></TD><TD><P/></TD><TD><P>13</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Gabbert-2015" TYPE="REFERENCE">Gabbert 2015</LINK></P></TD><TD><P>101</P></TD><TD><P/></TD><TD><P>18</P></TD><TD><P>78</P></TD><TD><P/></TD><TD><P/></TD><TD><P>5</P></TD></TR><TR><TD><P><LINK REF="REF-Gander-2014" TYPE="REFERENCE">Gander 2014</LINK></P></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Hansen-2006" TYPE="REFERENCE">Hansen 2006</LINK></P></TD><TD ALIGN="LEFT"><P>5</P></TD><TD><P/></TD><TD><P/></TD><TD><P>1</P></TD><TD><P>4</P></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Hay-2006" TYPE="REFERENCE">Hay 2006</LINK></P></TD><TD ALIGN="LEFT"><P>2</P></TD><TD><P/></TD><TD><P/></TD><TD><P>2</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Herbozo-2007" TYPE="REFERENCE">Herbozo 2007</LINK></P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Junquera-2009" TYPE="REFERENCE">Junquera 2009</LINK></P></TD><TD><P>21</P></TD><TD><P/></TD><TD><P>1</P></TD><TD><P>19</P></TD><TD><P/></TD><TD><P/></TD><TD><P>1(A)</P></TD></TR><TR><TD><P><LINK REF="REF-Kademani-2006" TYPE="REFERENCE">Kademani 2006</LINK></P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Kamoh-2012" TYPE="REFERENCE">Kamoh 2012</LINK></P></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P>1</P></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Katz-2005" TYPE="REFERENCE">Katz 2005</LINK></P></TD><TD ALIGN="LEFT"><P>2</P></TD><TD><P/></TD><TD><P/></TD><TD><P>1</P></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Khamaisi-2006" TYPE="REFERENCE">Khamaisi 2006</LINK></P></TD><TD ALIGN="LEFT"><P>6</P></TD><TD><P/></TD><TD><P>6</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Kumar-2007" TYPE="REFERENCE">Kumar 2007</LINK></P></TD><TD ALIGN="LEFT"><P>2</P></TD><TD><P/></TD><TD><P>2</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Lazarovici-2009" TYPE="REFERENCE">Lazarovici 2009</LINK></P></TD><TD><P>101</P></TD><TD><P/></TD><TD><P>30</P></TD><TD><P>31</P></TD><TD><P>23</P></TD><TD><P/></TD><TD><P>17(16:A,1:U)</P></TD></TR><TR><TD><P><LINK REF="REF-Lenz-2005" TYPE="REFERENCE">Lenz 2005</LINK></P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Lugassy-2004" TYPE="REFERENCE">Lugassy 2004</LINK></P></TD><TD ALIGN="LEFT"><P>3</P></TD><TD><P/></TD><TD><P>1</P></TD><TD><P/></TD><TD><P>2</P></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Magopoulos-2007" TYPE="REFERENCE">Magopoulos 2007</LINK></P></TD><TD ALIGN="LEFT"><P>33</P></TD><TD><P/></TD><TD><P>6</P></TD><TD><P>19</P></TD><TD><P>7</P></TD><TD><P/></TD><TD><P>1(P,I,Z)</P></TD></TR><TR><TD><P><LINK REF="REF-Marunick-2005" TYPE="REFERENCE">Marunick 2005</LINK></P></TD><TD ALIGN="LEFT"><P>2</P></TD><TD><P/></TD><TD><P>1</P></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Melo-2005" TYPE="REFERENCE">Melo 2005</LINK></P></TD><TD ALIGN="LEFT"><P>7</P></TD><TD><P/></TD><TD><P>4</P></TD><TD><P>2</P></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Merigo-2006" TYPE="REFERENCE">Merigo 2006</LINK></P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Migliorati-2005" TYPE="REFERENCE">Migliorati 2005</LINK></P></TD><TD ALIGN="LEFT"><P>3</P></TD><TD><P/></TD><TD><P>1</P></TD><TD><P/></TD><TD><P>2</P></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Montazeri-2007" TYPE="REFERENCE">Montazeri 2007</LINK></P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Mortensen-2007" TYPE="REFERENCE">Mortensen 2007</LINK></P></TD><TD ALIGN="LEFT"><P>4</P></TD><TD><P/></TD><TD><P>2</P></TD><TD><P>2</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Murad-2007" TYPE="REFERENCE">Murad 2007</LINK></P></TD><TD ALIGN="LEFT"><P>2</P></TD><TD><P/></TD><TD><P/></TD><TD><P>2</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Pires-2005" TYPE="REFERENCE">Pires 2005</LINK></P></TD><TD ALIGN="LEFT"><P>4</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P>4</P></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Pozzi-2007" TYPE="REFERENCE">Pozzi 2007</LINK></P></TD><TD ALIGN="LEFT"><P>35</P></TD><TD><P/></TD><TD><P>3</P></TD><TD><P>14</P></TD><TD><P>18</P></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Purcell-2005" TYPE="REFERENCE">Purcell 2005</LINK></P></TD><TD ALIGN="LEFT"><P>3</P></TD><TD><P/></TD><TD><P>2</P></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Ruggiero-2004" TYPE="REFERENCE">Ruggiero 2004</LINK></P></TD><TD ALIGN="LEFT"><P>28</P></TD><TD><P/></TD><TD><P>14</P></TD><TD><P>4</P></TD><TD><P>10</P></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Pastor_x002d_Zuazaga-2006" TYPE="REFERENCE">Pastor-Zuazaga 2006</LINK></P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Phal-2007" TYPE="REFERENCE">Phal 2007</LINK></P></TD><TD ALIGN="LEFT"><P>3</P></TD><TD><P/></TD><TD><P/></TD><TD><P>1</P></TD><TD><P>1</P></TD><TD><P/></TD><TD><P>1(P/C)</P></TD></TR><TR><TD><P><LINK REF="REF-Polizzotto-2006" TYPE="REFERENCE">Polizzotto 2006</LINK></P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD><P/></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Saad-2012" TYPE="REFERENCE">Saad 2012</LINK></P></TD><TD><P>6</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P>6</P></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Salesi-2006" TYPE="REFERENCE">Salesi 2006</LINK></P></TD><TD ALIGN="LEFT"><P>2</P></TD><TD><P/></TD><TD><P/></TD><TD><P>2</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Saussez-2009" TYPE="REFERENCE">Saussez 2009</LINK></P></TD><TD><P>34</P></TD><TD><P/></TD><TD><P>3</P></TD><TD><P>20</P></TD><TD><P>5</P></TD><TD><P/></TD><TD><P>6 (:I/Z,3:A,1:U)</P></TD></TR><TR><TD><P><LINK REF="REF-Senel-2007" TYPE="REFERENCE">Senel 2007</LINK></P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Sitters-2005" TYPE="REFERENCE">Sitters 2005</LINK></P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Tennis-2012" TYPE="REFERENCE">Tennis 2012</LINK></P></TD><TD><P>11</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P>11</P></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Then-2012" TYPE="REFERENCE">Then 2012</LINK></P></TD><TD><P>23</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P>23</P></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Thumbigere_x002d_Math-2012" TYPE="REFERENCE">Thumbigere-Math 2012</LINK></P></TD><TD><P>6</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P>6</P></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Treister-2006" TYPE="REFERENCE">Treister 2006</LINK></P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD><P/></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Vannucchi-2005" TYPE="REFERENCE">Vannucchi 2005</LINK></P></TD><TD ALIGN="LEFT"><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Vescovi-2012" TYPE="REFERENCE">Vescovi 2012</LINK></P></TD><TD><P>56</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P>56</P></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Walter-2007" TYPE="REFERENCE">Walter 2007</LINK></P></TD><TD ALIGN="LEFT"><P>9</P></TD><TD><P/></TD><TD><P>1</P></TD><TD><P>1</P></TD><TD><P>7</P></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Watters-2013" TYPE="REFERENCE">Watters 2013</LINK></P></TD><TD><P>27</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P>27</P></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Wickham-2013" TYPE="REFERENCE">Wickham 2013</LINK></P></TD><TD><P>1</P></TD><TD><P>1</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Wutzl-2006" TYPE="REFERENCE">Wutzl 2006</LINK></P></TD><TD ALIGN="LEFT"><P>12</P></TD><TD><P/></TD><TD><P>2</P></TD><TD><P>8</P></TD><TD><P>2</P></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Yeo-2005" TYPE="REFERENCE">Yeo 2005</LINK></P></TD><TD ALIGN="LEFT"><P>2</P></TD><TD><P/></TD><TD><P>2</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><LINK REF="REF-Zarychanski-2006" TYPE="REFERENCE">Zarychanski 2006</LINK></P></TD><TD ALIGN="LEFT"><P>10</P></TD><TD><P/></TD><TD><P>10</P></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD><TD><P/></TD></TR><TR><TD><P><B>Total</B></P></TD><TD ALIGN="LEFT"><P>676</P></TD><TD><P>3</P></TD><TD><P>128</P></TD><TD><P>270</P></TD><TD><P>113</P></TD><TD><P>130</P></TD><TD><P>32</P></TD></TR></TABLE><FOOTNOTES><P><B>A:</B> Alendronate; <B>C:</B> Clodronate; <B>I:</B> Ibandronate; <B>P:</B> Pamidronate; <B>R:</B> Risedronate; <B>Z:</B> Zoledronate; <B>MM:</B> multiple myeloma; <B>U:</B> Unknown.</P></FOOTNOTES></ADDITIONAL_TABLE></ADDITIONAL_TABLES><ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2017-11-16 18:58:10 +0100" MODIFIED_BY="[Empty name]"><COMPARISON ID="CMP-001" MODIFIED="2017-11-16 18:58:10 +0100" MODIFIED_BY="[Empty name]" NO="1"><NAME>Bisphosphonates vs. control (efficacy)</NAME><IV_OUTCOME CHI2="36.981329230997446" CI_END="1.0701535469818777" CI_START="0.7597716743288202" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_SIZE="0.9017052468403114" ESTIMABLE="YES" I2="64.84712618414076" I2_Q="70.44048018837368" ID="CMP-001.01" LOG_CI_END="0.02944609527653466" LOG_CI_START="-0.11931690176840204" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.04493540324593371" MODIFIED="2016-03-14 21:46:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="4.171065961856568E-4" P_Q="0.008948658562988987" P_Z="0.23639138329604303" Q="13.532019550692173" RANDOM="YES" SCALE="156.94168656982916" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.04655076265184938" TOTALS="YES" TOTAL_1="1365" TOTAL_2="1341" WEIGHT="99.99999999999999" Z="1.184054821995963"><NAME>Mortality</NAME><GROUP_LABEL_1>Bisphosphonates</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Bisphosphonates</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE><IV_SUBGROUP CHI2="3.760851563410836" CI_END="1.7984621685072235" CI_START="0.8583666393780756" DF="1" EFFECT_SIZE="1.2424733106309171" ESTIMABLE="YES" I2="73.41027734971097" ID="CMP-001.01.01" LOG_CI_END="0.2549013066630869" LOG_CI_START="-0.06632716967159888" LOG_EFFECT_SIZE="0.094287068495744" MODIFIED="2016-02-24 00:21:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.05246589021915482" P_Z="0.24990578065349933" STUDIES="2" TAU2="0.055768777650825815" TOTAL_1="131" TOTAL_2="113" WEIGHT="24.899923635816887" Z="1.1505783084248007"><NAME>Etidronate</NAME><IV_DATA CI_END="2.3371097573504866" CI_START="1.0753579775124855" EFFECT_SIZE="1.5853168837456804" ESTIMABLE="YES" ESTIMATE="0.460784314" LOG_CI_END="0.3686791085806555" LOG_CI_START="0.03155306125489513" LOG_EFFECT_SIZE="0.2001160849177753" MODIFIED="2016-02-24 00:21:25 +0100" MODIFIED_BY="[Empty name]" ORDER="131" SE="0.198029509" STUDY_ID="STD-Belch-1991" TOTAL_1="92" TOTAL_2="74" WEIGHT="8.903230410673338"/><IV_DATA CI_END="1.148474110555346" CI_START="1.0035581663679853" EFFECT_SIZE="1.0735737387389959" ESTIMABLE="YES" ESTIMATE="0.070993026" LOG_CI_END="0.060121209570503674" LOG_CI_START="0.001542549320324584" LOG_EFFECT_SIZE="0.0308318794454141" MODIFIED="2009-07-17 20:26:41 +0200" MODIFIED_BY="[Empty name]" ORDER="130" SE="0.034409395" STUDY_ID="STD-Daragon-1993" TOTAL_1="39" TOTAL_2="39" WEIGHT="15.996693225143549"/></IV_SUBGROUP><IV_SUBGROUP CHI2="4.060621620314788" CI_END="1.2930615079536802" CI_START="0.6631148962625443" DF="2" EFFECT_SIZE="0.9259850688363143" ESTIMABLE="YES" I2="50.746457389818175" ID="CMP-001.01.02" LOG_CI_END="0.11161918375861435" LOG_CI_START="-0.17841121595473933" LOG_EFFECT_SIZE="-0.03339601609806251" MODIFIED="2011-10-20 19:45:34 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.13129495228192745" P_Z="0.6517254966542343" STUDIES="3" TAU2="0.04140590430325754" TOTAL_1="439" TOTAL_2="446" WEIGHT="24.23994749900037" Z="0.4513664005153502"><NAME>Clodronate</NAME><IV_DATA CI_END="20.92710233107858" CI_START="0.6281067887729261" EFFECT_SIZE="3.6255282433731204" ESTIMABLE="YES" ESTIMATE="1.288" LOG_CI_END="1.3207090979639171" LOG_CI_START="-0.20196651258114034" LOG_EFFECT_SIZE="0.5593712926913883" MODIFIED="2009-07-17 20:26:59 +0200" MODIFIED_BY="[Empty name]" ORDER="132" SE="0.894427191" STUDY_ID="STD-Delmas-1982" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.902011422600838"/><IV_DATA CI_END="1.0700233684914129" CI_START="0.5261827369393273" EFFECT_SIZE="0.7503518005721382" ESTIMABLE="YES" ESTIMATE="-0.287213115" LOG_CI_END="0.029393262447872374" LOG_CI_START="-0.2788634043973605" LOG_EFFECT_SIZE="-0.1247350709747441" MODIFIED="2009-07-17 20:26:59 +0200" MODIFIED_BY="[Empty name]" ORDER="134" SE="0.181071492" STUDY_ID="STD-Lahtinen-1992" TOTAL_1="168" TOTAL_2="168" WEIGHT="9.624667207226315"/><IV_DATA CI_END="1.1873037336605567" CI_START="0.8163453076830464" EFFECT_SIZE="0.9845048662999878" ESTIMABLE="YES" ESTIMATE="-0.015616438" LOG_CI_END="0.07456183351133268" LOG_CI_START="-0.08812609921210116" LOG_EFFECT_SIZE="-0.00678213285038426" MODIFIED="2009-07-17 20:26:59 +0200" MODIFIED_BY="[Empty name]" ORDER="133" SE="0.095563697" STUDY_ID="STD-McCloskey-2001" TOTAL_1="264" TOTAL_2="272" WEIGHT="13.713268869173216"/></IV_SUBGROUP><IV_SUBGROUP CHI2="3.4061992291149146" CI_END="1.0733523168059824" CI_START="0.6675788359708404" DF="4" EFFECT_SIZE="0.8464911637104917" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.030742298042484385" LOG_CI_START="-0.17549744006764645" LOG_EFFECT_SIZE="-0.07237757101258105" MODIFIED="2016-02-23 16:42:56 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.49228376718741707" P_Z="0.16892826278824832" STUDIES="5" TAU2="0.0" TOTAL_1="499" TOTAL_2="478" WEIGHT="23.857166270290605" Z="1.3756556692037503"><NAME>Pamidronate</NAME><IV_DATA CI_END="1.0373409547481836" CI_START="0.5397438171149026" EFFECT_SIZE="0.7482635675785652" ESTIMABLE="YES" ESTIMATE="-0.29" LOG_CI_END="0.015921524400933498" LOG_CI_START="-0.26781232390481957" LOG_EFFECT_SIZE="-0.12594539975194305" MODIFIED="2009-07-17 20:27:21 +0200" MODIFIED_BY="[Empty name]" ORDER="127" SE="0.166666667" STUDY_ID="STD-Berenson-1998a" TOTAL_1="203" TOTAL_2="189" WEIGHT="10.27328738285987"/><IV_DATA CI_END="5.725037102865297" CI_START="0.1409803522202579" EFFECT_SIZE="0.8983973214764136" ESTIMABLE="YES" ESTIMATE="-0.107142857" LOG_CI_END="0.7577783056001259" LOG_CI_START="-0.8508414087410243" LOG_EFFECT_SIZE="-0.04653155157044917" MODIFIED="2009-07-17 20:27:36 +0200" MODIFIED_BY="[Empty name]" ORDER="128" SE="0.944911183" STUDY_ID="STD-Brincker-1998" TOTAL_1="152" TOTAL_2="148" WEIGHT="0.8128507887925257"/><IV_DATA CI_END="2.461536119331162" CI_START="0.5131507620664901" EFFECT_SIZE="1.1238946282854885" ESTIMABLE="YES" ESTIMATE="0.1168" LOG_CI_END="0.39120621277224216" LOG_CI_START="-0.2897550217996425" LOG_EFFECT_SIZE="0.05072559548629978" MODIFIED="2009-07-17 20:27:49 +0200" MODIFIED_BY="[Empty name]" ORDER="126" SE="0.4" STUDY_ID="STD-Kraj-2000" TOTAL_1="23" TOTAL_2="23" WEIGHT="3.6969045667995637"/><IV_DATA CI_END="1.4591771615445128" CI_START="0.6584460506052224" EFFECT_SIZE="0.9801986733067553" ESTIMABLE="YES" ESTIMATE="-0.02" LOG_CI_END="0.16410802363455068" LOG_CI_START="-0.1814798029106808" LOG_EFFECT_SIZE="-0.008685889638065058" MODIFIED="2016-02-23 16:42:56 +0100" MODIFIED_BY="[Empty name]" ORDER="123" SE="0.203" STUDY_ID="STD-Musto-2003" TOTAL_1="89" TOTAL_2="88" WEIGHT="8.701008692933872"/><IV_DATA CI_END="1.9973227283629527" CI_START="0.007814239380720968" EFFECT_SIZE="0.12493021219858241" ESTIMABLE="YES" ESTIMATE="-2.08" LOG_CI_END="0.30044824405101456" LOG_CI_START="-2.107113288768542" LOG_EFFECT_SIZE="-0.9033325223587638" MODIFIED="2009-07-17 20:27:49 +0200" MODIFIED_BY="[Empty name]" ORDER="129" SE="1.414213562" STUDY_ID="STD-Terpos-2000" TOTAL_1="32" TOTAL_2="30" WEIGHT="0.37311483890477665"/></IV_SUBGROUP><IV_SUBGROUP CHI2="0.0" CI_END="1.6426294177702059" CI_START="0.6911012125008996" DF="0" EFFECT_SIZE="1.065468527132846" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.2155395963196573" LOG_CI_START="-0.16045834508342868" LOG_EFFECT_SIZE="0.02754062561811429" MODIFIED="2011-10-20 19:45:34 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.7740189328765187" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="8.00994904183923" Z="0.2871219673266129"><NAME>Ibandronate</NAME><IV_DATA CI_END="1.6426294177702059" CI_START="0.6911012125008996" EFFECT_SIZE="1.065468527132846" ESTIMABLE="YES" ESTIMATE="0.063414634" LOG_CI_END="0.2155395963196573" LOG_CI_START="-0.16045834508342868" LOG_EFFECT_SIZE="0.02754062561811429" MODIFIED="2009-07-17 20:28:01 +0200" MODIFIED_BY="[Empty name]" ORDER="135" SE="0.220863052" STUDY_ID="STD-Menssen-2002" TOTAL_1="99" TOTAL_2="99" WEIGHT="8.00994904183923"/></IV_SUBGROUP><IV_SUBGROUP CHI2="1.679854924080439" CI_END="0.748099301897674" CI_START="0.43044603847299423" DF="2" EFFECT_SIZE="0.5674648719403398" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.05" LOG_CI_END="-0.1260407505261689" LOG_CI_START="-0.3660812847731425" LOG_EFFECT_SIZE="-0.24606101764965574" MODIFIED="2016-03-14 21:46:47 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.4317421099982429" P_Z="5.863343492338151E-5" STUDIES="3" TAU2="0.0" TOTAL_1="197" TOTAL_2="205" WEIGHT="18.993013553052897" Z="4.018244119523578"><NAME>Zoledronate</NAME><IV_DATA CI_END="0.8141850851650212" CI_START="0.22042225825679854" EFFECT_SIZE="0.42363252367007637" ESTIMABLE="YES" ESTIMATE="-0.858888889" LOG_CI_END="-0.08927685760616311" LOG_CI_START="-0.6567445525152661" LOG_EFFECT_SIZE="-0.3730107050607146" MODIFIED="2016-02-24 00:21:28 +0100" MODIFIED_BY="[Empty name]" ORDER="125" SE="0.333333333" STUDY_ID="STD-Aviles-2007" TOTAL_1="46" TOTAL_2="48" WEIGHT="4.843266419298566"/><IV_DATA CI_END="0.7954508973374994" CI_START="0.40691382776227303" EFFECT_SIZE="0.5689287911791218" ESTIMABLE="YES" ESTIMATE="-0.564" LOG_CI_END="-0.09938662390369361" LOG_CI_START="-0.3904975516831744" LOG_EFFECT_SIZE="-0.24494208779343404" MODIFIED="2016-02-24 00:21:28 +0100" MODIFIED_BY="[Empty name]" ORDER="355" SE="0.171" STUDY_ID="STD-Aviles-2013" TOTAL_1="151" TOTAL_2="157" WEIGHT="10.074953148024225"/><IV_DATA CI_END="1.694030775889255" CI_START="0.38906425710321124" EFFECT_SIZE="0.8118416257690471" ESTIMABLE="YES" ESTIMATE="-0.20845" LOG_CI_END="0.22892129600500005" LOG_CI_START="-0.40997866551046575" LOG_EFFECT_SIZE="-0.09052868475273286" MODIFIED="2016-03-14 21:46:47 +0100" MODIFIED_BY="[Empty name]" ORDER="125" SE="0.375293" STUDY_ID="STD-Garcia_x002d_Sanz-2015" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.074793985730107"/></IV_SUBGROUP></IV_OUTCOME><IV_OUTCOME CHI2="10.094741475817159" CI_END="1.0014414372687703" CI_START="0.5686907103198965" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="0.7546591563773377" ESTIMABLE="YES" I2="40.56311383135935" I2_Q="24.48352955942794" ID="CMP-001.02" LOG_CI_END="6.255575091171846E-4" LOG_CI_START="-0.24512386597986915" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.12224915423537598" MODIFIED="2017-11-16 18:57:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1207186274102795" P_Q="0.26601201173971856" P_Z="0.05117781508830048" Q="2.648428863705841" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.05480859833719826" TOTALS="YES" TOTAL_1="452" TOTAL_2="456" WEIGHT="100.0" Z="1.9499857703841772"><NAME>Progression-free survival</NAME><GROUP_LABEL_1>Bisphosphonates</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Bisphosphonates</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2><EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE><IV_SUBGROUP CHI2="0.0" CI_END="2.3369925764299504" CI_START="0.1712860291085604" DF="0" EFFECT_SIZE="0.632688057792203" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.36865733283697266" LOG_CI_START="-0.7662780586836364" LOG_EFFECT_SIZE="-0.19881036292333185" MODIFIED="2016-02-23 02:09:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4922928116729436" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="4.173875576482618" Z="0.6866666666566668"><NAME>Clodronate</NAME><IV_DATA CI_END="2.3369925764299504" CI_START="0.1712860291085604" EFFECT_SIZE="0.632688057792203" ESTIMABLE="YES" ESTIMATE="-0.457777778" LOG_CI_END="0.36865733283697266" LOG_CI_START="-0.7662780586836364" LOG_EFFECT_SIZE="-0.19881036292333185" MODIFIED="2016-02-23 02:09:54 +0100" MODIFIED_BY="[Empty name]" ORDER="136" SE="0.666666667" STUDY_ID="STD-Heim-1995" TOTAL_1="14" TOTAL_2="12" WEIGHT="4.173875576482618"/></IV_SUBGROUP><IV_SUBGROUP CHI2="0.0" CI_END="2.3258861018374533" CI_START="0.6628009411289216" DF="0" EFFECT_SIZE="1.2416116531575172" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.36658844360196224" LOG_CI_START="-0.17861688358582212" LOG_EFFECT_SIZE="0.09398578000807006" MODIFIED="2016-02-23 23:37:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.49920522698122705" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="88" WEIGHT="13.241305946745445" Z="0.6757408069539101"><NAME>Pamidronate</NAME><IV_DATA CI_END="2.3258861018374533" CI_START="0.6628009411289216" EFFECT_SIZE="1.2416116531575172" ESTIMABLE="YES" ESTIMATE="0.216410256" LOG_CI_END="0.36658844360196224" LOG_CI_START="-0.17861688358582212" LOG_EFFECT_SIZE="0.09398578000807006" MODIFIED="2016-02-23 23:37:37 +0100" MODIFIED_BY="[Empty name]" ORDER="138" SE="0.320256308" STUDY_ID="STD-Musto-2003" TOTAL_1="89" TOTAL_2="88" WEIGHT="13.241305946745445"/></IV_SUBGROUP><IV_SUBGROUP CHI2="7.07604891397883" CI_END="0.9543443353802007" CI_START="0.5179445030113634" DF="4" EFFECT_SIZE="0.7030628723593702" ESTIMABLE="YES" I2="43.47127827087308" ID="CMP-001.02.03" LOG_CI_END="-0.02029489995614765" LOG_CI_START="-0.28571677177432253" LOG_EFFECT_SIZE="-0.15300583586523508" MODIFIED="2016-03-23 16:24:50 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.13192376756912072" P_Z="0.023840332196670092" STUDIES="5" TAU2="0.050727445012873976" TOTAL_1="349" TOTAL_2="356" WEIGHT="82.58481847677194" Z="2.259692659584152"><NAME>Zoledronate</NAME><IV_DATA CI_END="0.7776220094909679" CI_START="0.156951472754158" EFFECT_SIZE="0.34935500516760204" ESTIMABLE="YES" ESTIMATE="-1.051666667" LOG_CI_END="-0.10923145581685866" LOG_CI_START="-0.8042346047425107" LOG_EFFECT_SIZE="-0.4567330302796847" MODIFIED="2009-07-17 20:31:15 +0200" MODIFIED_BY="[Empty name]" ORDER="137" SE="0.40824829" STUDY_ID="STD-Aviles-2007" TOTAL_1="46" TOTAL_2="48" WEIGHT="9.408816316951423"/><IV_DATA CI_END="0.8053439429378619" CI_START="0.4267682447258077" EFFECT_SIZE="0.5862552523672196" ESTIMABLE="YES" ESTIMATE="-0.534" LOG_CI_END="-0.0940186033355298" LOG_CI_START="-0.36980790333714314" LOG_EFFECT_SIZE="-0.23191325333633647" MODIFIED="2016-02-23 23:41:36 +0100" MODIFIED_BY="[Empty name]" ORDER="356" SE="0.162" STUDY_ID="STD-Aviles-2013" TOTAL_1="151" TOTAL_2="157" WEIGHT="25.709479108082313"/><IV_DATA CI_END="1.399292924593321" CI_START="0.6049393613327534" EFFECT_SIZE="0.92004748144915" ESTIMABLE="YES" ESTIMATE="-0.08333" LOG_CI_END="0.1459086381644994" LOG_CI_START="-0.21828815651849526" LOG_EFFECT_SIZE="-0.036189759176997974" MODIFIED="2016-03-23 16:24:50 +0100" MODIFIED_BY="[Empty name]" ORDER="130" SE="0.213931" STUDY_ID="STD-Garcia_x002d_Sanz-2015" TOTAL_1="0" TOTAL_2="0" WEIGHT="20.719051558724836"/><IV_DATA CI_END="2.005805988237662" CI_START="0.52940593463936" EFFECT_SIZE="1.030478332575792" ESTIMABLE="YES" ESTIMATE="0.030023095" LOG_CI_END="0.30228892354351244" LOG_CI_START="-0.2762111945671982" LOG_EFFECT_SIZE="0.0130388644881571" MODIFIED="2011-10-20 19:50:59 +0200" MODIFIED_BY="[Empty name]" ORDER="122" SE="0.339813833" STUDY_ID="STD-Musto-2008" TOTAL_1="81" TOTAL_2="82" WEIGHT="12.23746256807745"/><IV_DATA CI_END="1.349952312014803" CI_START="0.41976121403613775" EFFECT_SIZE="0.7527666447061963" ESTIMABLE="YES" ESTIMATE="-0.284" LOG_CI_END="0.1303184270175036" LOG_CI_START="-0.3769976927385506" LOG_EFFECT_SIZE="-0.1233396328605235" MODIFIED="2016-02-22 21:45:12 +0100" MODIFIED_BY="[Empty name]" ORDER="357" SE="0.298" STUDY_ID="STD-Sezer-2010" TOTAL_1="71" TOTAL_2="69" WEIGHT="14.510008924935933"/></IV_SUBGROUP></IV_OUTCOME><DICH_OUTCOME CHI2="6.42002557360279" CI_END="0.8860790943136445" CI_START="0.6177912372778553" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7398728944907145" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="188" I2="6.542428356201703" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.05252750983889334" LOG_CI_START="-0.2091582560035921" LOG_EFFECT_SIZE="-0.13084288292124271" METHOD="MH" MODIFIED="2011-04-12 18:06:57 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.37781802886670335" P_Q="0.4033984282105758" P_Z="0.0010583168472006362" Q="1.8156613279131057" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.004096899327582902" TOTALS="YES" TOTAL_1="575" TOTAL_2="541" WEIGHT="99.99999999999999" Z="3.2745465936728646"><NAME>Vertebral fractures</NAME><GROUP_LABEL_1>Bisphosphonates</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Bisphosphonates</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.2941393496248176" CI_END="0.8878743710186534" CI_START="0.5585172927632571" DF="2" EFFECT_SIZE="0.7041968403899708" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="100" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.0516484799794406" LOG_CI_START="-0.2529633757526803" LOG_EFFECT_SIZE="-0.15230592786606048" MODIFIED="2009-06-23 20:33:47 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8632338420575285" P_Z="0.0030205012990988213" STUDIES="3" TAU2="0.0" TOTAL_1="223" TOTAL_2="210" WEIGHT="52.60290816144436" Z="2.9656437702024703"><NAME>Clodronate</NAME><DICH_DATA CI_END="3.6371418524301027" CI_START="0.05049939673511395" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5607602393352392" LOG_CI_START="-1.2967138099244282" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2009-06-23 20:33:47 +0200" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.0" SE="1.0910894511799618" STUDY_ID="STD-Delmas-1982" TOTAL_1="7" TOTAL_2="6" VAR="1.1904761904761905" WEIGHT="0.7086250662035453"/><DICH_DATA CI_END="1.084214993124351" CI_START="0.5060775293394323" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="38" LOG_CI_END="0.035115408650303284" LOG_CI_START="-0.29578294564031565" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2009-06-23 20:33:47 +0200" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.19437133128358017" STUDY_ID="STD-Lahtinen-1992" TOTAL_1="108" TOTAL_2="95" VAR="0.03778021442495127" WEIGHT="20.214010923710013"/><DICH_DATA CI_END="0.9261152967841564" CI_START="0.5135770874290777" EFFECT_SIZE="0.6896604938271605" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="60" LOG_CI_END="-0.033334942432422715" LOG_CI_START="-0.28939435998804564" LOG_EFFECT_SIZE="-0.16136465121023416" MODIFIED="2009-06-23 20:33:47 +0200" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.15041056938673203" STUDY_ID="STD-McCloskey-2001" TOTAL_1="108" TOTAL_2="109" VAR="0.02262333938324093" WEIGHT="31.680272171530806"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="5.001028542820277" CI_END="1.2020061984168293" CI_START="0.39739307349605685" DF="2" EFFECT_SIZE="0.691135976165454" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="68" I2="60.008226650269805" ID="CMP-001.03.02" LOG_CI_END="0.07990670721021881" LOG_CI_START="-0.4007797068504034" LOG_EFFECT_SIZE="-0.1604364998200923" MODIFIED="2009-06-23 20:35:36 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.08204286484250356" P_Z="0.19075924089271573" STUDIES="3" TAU2="0.12294116941571483" TOTAL_1="253" TOTAL_2="232" WEIGHT="37.01230891061082" Z="1.308336380039194"><NAME>Pamidronate</NAME><DICH_DATA CI_END="0.8547878611524382" CI_START="0.3826912768487408" EFFECT_SIZE="0.5719439290867863" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="49" LOG_CI_END="-0.06814165388272866" LOG_CI_START="-0.4171514370690292" LOG_EFFECT_SIZE="-0.2426465454758789" MODIFIED="2009-06-23 20:35:10 +0200" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="0.20501007426992252" STUDY_ID="STD-Berenson-1998a" TOTAL_1="198" TOTAL_2="179" VAR="0.04202913055215915" WEIGHT="18.351989907957506"/><DICH_DATA CI_END="1.402334278349937" CI_START="0.6267451802106477" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.14685154996338431" LOG_CI_START="-0.20290899716387142" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2009-06-23 20:35:36 +0200" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="0.20545107672518104" STUDY_ID="STD-Kraj-2000" TOTAL_1="23" TOTAL_2="23" VAR="0.04221014492753622" WEIGHT="18.280251924167967"/><DICH_DATA CI_END="2.4940882787181518" CI_START="0.007220838080780863" EFFECT_SIZE="0.1341991341991342" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3969118213484771" LOG_CI_START="-2.1414123934642206" LOG_EFFECT_SIZE="-0.8722502860578716" MODIFIED="2009-06-23 20:35:36 +0200" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="1.4910242086884862" STUDY_ID="STD-Terpos-2000" TOTAL_1="32" TOTAL_2="30" VAR="2.2231531908951263" WEIGHT="0.3800670784853479"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="0.0" CI_END="1.8114522782061577" CI_START="0.6086276813716462" DF="0" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.2580268972528472" LOG_CI_START="-0.21564829911297106" LOG_EFFECT_SIZE="0.021189299069938092" MODIFIED="2009-06-23 20:40:31 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.8608020046052721" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="10.384782927944801" Z="0.17535333643542947"><NAME>Ibandronate</NAME><DICH_DATA CI_END="1.8114522782061577" CI_START="0.6086276813716462" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="0.2580268972528472" LOG_CI_START="-0.21564829911297106" LOG_EFFECT_SIZE="0.021189299069938092" MODIFIED="2009-06-23 20:40:31 +0200" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="0.27823915507531904" STUDY_ID="STD-Menssen-2002" TOTAL_1="99" TOTAL_2="99" VAR="0.07741702741702743" WEIGHT="10.384782927944801"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="8.695203531378803" CI_END="1.5562053230742057" CI_START="0.6792162041790251" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0281049909720579" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="93" I2="53.99762655853879" I2_Q="50.19225840476354" ID="CMP-001.04" LOG_CI_END="0.19206689650673098" LOG_CI_START="-0.16799196160157778" LOG_EFFECT_SIZE="0.01203746745257656" METHOD="MH" MODIFIED="2010-02-12 17:06:33 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.06918625862828809" P_Q="0.13429473101472944" P_Z="0.8957351126706259" Q="4.015440041937732" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.11012095803740395" TOTALS="YES" TOTAL_1="708" TOTAL_2="681" WEIGHT="100.0" Z="0.1310508109483938"><NAME>Non-vertebral fractures</NAME><GROUP_LABEL_1>Bisphosphonates</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Bisphosphonates</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="3.288907572780651" CI_END="1.3091910402228488" CI_START="0.41933817007971025" DF="2" EFFECT_SIZE="0.740941141449037" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="52" I2="39.18953464815451" ID="CMP-001.04.01" LOG_CI_END="0.11700302444295499" LOG_CI_START="-0.37743560432548173" LOG_EFFECT_SIZE="-0.13021628994126333" MODIFIED="2009-06-24 16:31:25 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.19311819792236873" P_Z="0.301903693631848" STUDIES="3" TAU2="0.09694127200677129" TOTAL_1="379" TOTAL_2="373" WEIGHT="49.40261907422105" Z="1.0323596241701811"><NAME>Clodronate</NAME><DICH_DATA CI_END="6.070653789293791" CI_START="0.014013226152753591" EFFECT_SIZE="0.2916666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7832354656704027" LOG_CI_START="-1.853461869065101" LOG_EFFECT_SIZE="-0.5351132016973492" MODIFIED="2009-06-24 16:31:25 +0200" MODIFIED_BY="[Empty name]" ORDER="133" O_E="0.0" SE="1.5488090662859395" STUDY_ID="STD-Delmas-1982" TOTAL_1="7" TOTAL_2="6" VAR="2.3988095238095237" WEIGHT="1.7829270572112188"/><DICH_DATA CI_END="1.707689132702204" CI_START="0.6328375189516686" EFFECT_SIZE="1.0395622895622896" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="22" LOG_CI_END="0.2324088146903995" LOG_CI_START="-0.19870778078937995" LOG_EFFECT_SIZE="0.0168505169505098" MODIFIED="2009-06-24 16:31:25 +0200" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="0.25324002224638775" STUDY_ID="STD-Lahtinen-1992" TOTAL_1="108" TOTAL_2="95" VAR="0.06413050886735097" WEIGHT="25.671175802450612"/><DICH_DATA CI_END="0.9709439476991437" CI_START="0.2924976072321276" EFFECT_SIZE="0.5329153605015674" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="29" LOG_CI_END="-0.012805841057607164" LOG_CI_START="-0.5338776823002072" LOG_EFFECT_SIZE="-0.27334176167890717" MODIFIED="2009-06-24 16:31:25 +0200" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="0.30608017889311656" STUDY_ID="STD-McCloskey-2001" TOTAL_1="264" TOTAL_2="272" VAR="0.09368507591124224" WEIGHT="21.94851621455922"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="0.0" CI_END="2.874250964393511" CI_START="0.9455326731240219" DF="0" EFFECT_SIZE="1.648544266191325" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="17" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.45852468575116273" LOG_CI_START="-0.02432345940244114" LOG_EFFECT_SIZE="0.2171006131743608" MODIFIED="2009-06-24 16:31:37 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.07798523750792709" STUDIES="2" TAU2="0.0" TOTAL_1="230" TOTAL_2="209" WEIGHT="23.47350965023207" Z="1.7624977422578523"><NAME>Pamidronate</NAME><DICH_DATA CI_END="2.874250964393511" CI_START="0.9455326731240219" EFFECT_SIZE="1.648544266191325" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="17" LOG_CI_END="0.45852468575116273" LOG_CI_START="-0.02432345940244114" LOG_EFFECT_SIZE="0.2171006131743608" MODIFIED="2009-06-24 16:31:37 +0200" MODIFIED_BY="[Empty name]" ORDER="137" O_E="0.0" SE="0.283627390600093" STUDY_ID="STD-Berenson-1998a" TOTAL_1="198" TOTAL_2="179" VAR="0.08044449669861774" WEIGHT="23.47350965023207"/><DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-06-24 16:31:37 +0200" MODIFIED_BY="[Empty name]" ORDER="138" O_E="0.0" SE="0.0" STUDY_ID="STD-Terpos-2000" TOTAL_1="32" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="0.0" CI_END="1.9777323282729022" CI_START="0.7900462452188801" DF="0" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="24" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="0.2961675126300327" LOG_CI_START="-0.10234748661391985" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2009-06-24 16:31:47 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.34046870841055454" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="27.123871275546886" Z="0.9532395799277112"><NAME>Ibandronate</NAME><DICH_DATA CI_END="1.9777323282729022" CI_START="0.7900462452188801" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="24" LOG_CI_END="0.2961675126300327" LOG_CI_START="-0.10234748661391985" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2009-06-24 16:31:47 +0200" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="0.23408968323695897" STUDY_ID="STD-Menssen-2002" TOTAL_1="99" TOTAL_2="99" VAR="0.0547979797979798" WEIGHT="27.123871275546886"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="17.325262735960642" CI_END="0.8771102489372586" CI_START="0.6257569573312581" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7408494048179032" ESTIMABLE="YES" EVENTS_1="319" EVENTS_2="414" I2="48.05273583921224" I2_Q="46.20139442428146" ID="CMP-001.05" LOG_CI_END="-0.0569458142784571" LOG_CI_START="-0.20359431309204912" LOG_EFFECT_SIZE="-0.1302700636852531" METHOD="MH" MODIFIED="2017-11-16 18:58:10 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.04385947394974954" P_Q="0.11460381271702091" P_Z="4.974404999610919E-4" Q="7.435136946756405" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.028732074688969225" TOTALS="YES" TOTAL_1="1083" TOTAL_2="1058" WEIGHT="100.00000000000003" Z="3.482130879653719"><NAME>Total skeletal-related events</NAME><GROUP_LABEL_1>Bisphosphonates</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Bisphosphonates</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.0" CI_END="1.3893646481301705" CI_START="0.38706741135347567" DF="0" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.14281624421638636" LOG_CI_START="-0.41221339201129886" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2009-06-24 16:52:46 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3414438765458798" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="5.4955827212034" Z="0.9513162410650843"><NAME>Etidronate</NAME><DICH_DATA CI_END="1.3893646481301705" CI_START="0.38706741135347567" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.14281624421638636" LOG_CI_START="-0.41221339201129886" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2009-06-24 16:52:46 +0200" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="0.32602715576115177" STUDY_ID="STD-Daragon-1993" TOTAL_1="39" TOTAL_2="39" VAR="0.10629370629370632" WEIGHT="5.4955827212034"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="1.9089953990968884E-30" CI_END="0.8900721822769856" CI_START="0.6495764025224489" DF="0" EFFECT_SIZE="0.7603748326639893" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="83" I2="100.0" ID="CMP-001.05.02" LOG_CI_END="-0.050574771901805315" LOG_CI_START="-0.18736976030695454" LOG_EFFECT_SIZE="-0.1189722661043799" MODIFIED="2009-06-24 16:52:37 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="6.515153133907595E-4" STUDIES="1" TAU2="0.0" TOTAL_1="108" TOTAL_2="96" WEIGHT="21.08751433780783" Z="3.4092090571780447"><NAME>Clodronate</NAME><DICH_DATA CI_END="0.8900721822769856" CI_START="0.6495764025224489" EFFECT_SIZE="0.7603748326639893" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="83" LOG_CI_END="-0.050574771901805315" LOG_CI_START="-0.18736976030695454" LOG_EFFECT_SIZE="-0.1189722661043799" MODIFIED="2009-06-24 16:52:37 +0200" MODIFIED_BY="[Empty name]" ORDER="157" O_E="0.0" SE="0.0803540533352981" STUDY_ID="STD-Lahtinen-1992" TOTAL_1="108" TOTAL_2="96" VAR="0.006456773887411933" WEIGHT="21.08751433780783"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="2.7748407122394187" CI_END="0.9126102549455157" CI_START="0.5869422436397491" DF="2" EFFECT_SIZE="0.7318808035509365" ESTIMABLE="YES" EVENTS_1="139" EVENTS_2="179" I2="27.923790681811354" ID="CMP-001.05.03" LOG_CI_END="-0.03971465539545655" LOG_CI_START="-0.23140463214699317" LOG_EFFECT_SIZE="-0.1355596437712248" MODIFIED="2016-02-23 20:58:56 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.24971891873044283" P_Z="0.00556956964316549" STUDIES="3" TAU2="0.011249779225514196" TOTAL_1="483" TOTAL_2="467" WEIGHT="38.8765347913241" Z="2.7721013278963773"><NAME>Pamidronate</NAME><DICH_DATA CI_END="1.2584559492844014" CI_START="0.6036637108618317" EFFECT_SIZE="0.8715986394557823" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="48" LOG_CI_END="0.09983801820179684" LOG_CI_START="-0.21920493089849" LOG_EFFECT_SIZE="-0.059683456348346584" MODIFIED="2009-06-24 16:52:58 +0200" MODIFIED_BY="[Empty name]" ORDER="158" O_E="0.0" SE="0.18740740758957697" STUDY_ID="STD-Attal-2006" TOTAL_1="196" TOTAL_2="200" VAR="0.035121536419445834" WEIGHT="11.621039687567405"/><DICH_DATA CI_END="0.9481927811559031" CI_START="0.6012061807802578" EFFECT_SIZE="0.7550227550227551" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="91" LOG_CI_END="-0.023103355403996523" LOG_CI_START="-0.22097656323988374" LOG_EFFECT_SIZE="-0.12203995932194016" MODIFIED="2009-06-24 16:52:58 +0200" MODIFIED_BY="[Empty name]" ORDER="159" O_E="0.0" SE="0.11623170177097594" STUDY_ID="STD-Berenson-1998a" TOTAL_1="198" TOTAL_2="179" VAR="0.013509808496577094" WEIGHT="17.56657830868885"/><DICH_DATA CI_END="0.8349535028726331" CI_START="0.3541998875339133" EFFECT_SIZE="0.5438202247191011" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="40" LOG_CI_END="-0.07833770895723445" LOG_CI_START="-0.4507515810437662" LOG_EFFECT_SIZE="-0.26454464500050034" MODIFIED="2016-02-23 20:58:56 +0100" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="0.2187577519420268" STUDY_ID="STD-Musto-2003" TOTAL_1="89" TOTAL_2="88" VAR="0.04785495403472932" WEIGHT="9.688916795067845"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="0.0" CI_END="1.3463121482556817" CI_START="0.8010047062719539" DF="0" EFFECT_SIZE="1.0384615384615385" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="52" I2="0.0" ID="CMP-001.05.04" LOG_CI_END="0.12914576460429159" LOG_CI_START="-0.09636493222795281" LOG_EFFECT_SIZE="0.016390416188169384" MODIFIED="2009-06-26 17:18:41 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.7757164983233332" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="16.03405132893968" Z="0.2849055576670187"><NAME>Ibandronate</NAME><DICH_DATA CI_END="1.3463121482556817" CI_START="0.8010047062719539" EFFECT_SIZE="1.0384615384615385" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="52" LOG_CI_END="0.12914576460429159" LOG_CI_START="-0.09636493222795281" LOG_EFFECT_SIZE="0.016390416188169384" MODIFIED="2009-06-26 17:18:41 +0200" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.13246609961521302" STUDY_ID="STD-Menssen-2002" TOTAL_1="99" TOTAL_2="99" VAR="0.017547267547267542" WEIGHT="16.03405132893968"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="6.131480014908849" CI_END="0.8887562872021797" CI_START="0.2755116091261219" DF="3" EFFECT_SIZE="0.4948360079945984" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="85" I2="51.07217192740702" ID="CMP-001.05.05" LOG_CI_END="-0.05121731398363411" LOG_CI_START="-0.5598600967280175" LOG_EFFECT_SIZE="-0.3055387053558258" MODIFIED="2016-03-14 21:48:06 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.10538581222867893" P_Z="0.018538787280712527" STUDIES="4" TAU2="0.15523208088100612" TOTAL_1="354" TOTAL_2="357" WEIGHT="18.506316820725004" Z="2.3546775013668535"><NAME>Zoledronate</NAME><DICH_DATA CI_END="0.9681201619447446" CI_START="0.3742780118576887" EFFECT_SIZE="0.6019518996165911" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="38" LOG_CI_END="-0.014070735221780775" LOG_CI_START="-0.42680568613529846" LOG_EFFECT_SIZE="-0.22043821067853964" MODIFIED="2016-02-22 21:48:07 +0100" MODIFIED_BY="[Empty name]" ORDER="358" O_E="0.0" SE="0.24244255323755753" STUDY_ID="STD-Aviles-2013" TOTAL_1="151" TOTAL_2="157" VAR="0.05877839162034591" WEIGHT="8.479503997413834"/><DICH_DATA CI_END="0.5728450807015386" CI_START="0.03288656697408194" EFFECT_SIZE="0.13725490196078433" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="14" LOG_CI_END="-0.2419628120522785" LOG_CI_START="-1.4829814601150804" LOG_EFFECT_SIZE="-0.8624721360836795" MODIFIED="2016-03-14 21:48:06 +0100" MODIFIED_BY="[Empty name]" ORDER="126" O_E="0.0" SE="0.7289804970134731" STUDY_ID="STD-Garcia_x002d_Sanz-2015" TOTAL_1="51" TOTAL_2="49" VAR="0.5314125650260103" WEIGHT="1.3247388197144294"/><DICH_DATA CI_END="1.1281345570657226" CI_START="0.4320766128844631" EFFECT_SIZE="0.6981694338016177" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="29" LOG_CI_END="0.05236090275545878" LOG_CI_START="-0.3644392402152747" LOG_EFFECT_SIZE="-0.15603916872990797" MODIFIED="2009-09-08 15:54:22 +0200" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="0.24483046717499127" STUDY_ID="STD-Musto-2008" TOTAL_1="81" TOTAL_2="82" VAR="0.05994195765712447" WEIGHT="8.3682373435911"/><DICH_DATA CI_END="1.9694720443954963" CI_START="0.005925107683657547" EFFECT_SIZE="0.10802469135802469" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.29434982061053705" LOG_CI_START="-2.22730375232321" LOG_EFFECT_SIZE="-0.9664769658563366" MODIFIED="2016-02-22 21:53:30 +0100" MODIFIED_BY="[Empty name]" ORDER="359" O_E="0.0" SE="1.4812317911277826" STUDY_ID="STD-Sezer-2010" TOTAL_1="71" TOTAL_2="69" VAR="2.1940476190476192" WEIGHT="0.3338366600056419"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="18.934378322422717" CI_END="0.9464643332241196" CI_START="0.6013826804973507" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7544449997908785" ESTIMABLE="YES" EVENTS_1="276" EVENTS_2="318" I2="63.030209490900646" I2_Q="57.48104396327251" ID="CMP-001.06" LOG_CI_END="-0.023895747443249012" LOG_CI_START="-0.22084908350643626" LOG_EFFECT_SIZE="-0.12237241547484265" METHOD="MH" MODIFIED="2017-04-10 21:41:46 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.00839542481963429" P_Q="0.07014427835854053" P_Z="0.014868886412595076" Q="7.055676525568095" RANDOM="YES" SCALE="400.61263975888005" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.043448832077814956" TOTALS="YES" TOTAL_1="657" TOTAL_2="624" WEIGHT="100.0" Z="2.4355568869868294"><NAME>Pain</NAME><GROUP_LABEL_1>Favours Bisphosphonates</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Bisphosphonates</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.0" CI_END="1.3240572630021683" CI_START="0.25699626993943736" DF="0" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.12190676793455887" LOG_CI_START="-0.5900731800012948" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2009-06-24 16:46:19 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.19747273026356427" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="6.129629952974929" Z="1.2887853219495606"><NAME>Etidronate</NAME><DICH_DATA CI_END="1.3240572630021683" CI_START="0.25699626993943736" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.12190676793455887" LOG_CI_START="-0.5900731800012948" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2009-06-24 16:46:19 +0200" MODIFIED_BY="[Empty name]" ORDER="148" O_E="0.0" SE="0.41822054577510287" STUDY_ID="STD-Daragon-1993" TOTAL_1="39" TOTAL_2="39" VAR="0.1749084249084249" WEIGHT="6.129629952974929"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="8.6285272394416" CI_END="0.9069751379088784" CI_START="0.28958627122920916" DF="3" EFFECT_SIZE="0.5124915104512755" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="101" I2="65.2316100216177" ID="CMP-001.06.02" LOG_CI_END="-0.04240461769952103" LOG_CI_START="-0.5382220311169048" LOG_EFFECT_SIZE="-0.2903133244082129" MODIFIED="2009-06-24 16:46:30 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.03466018495194301" P_Z="0.021720834211860256" STUDIES="4" TAU2="0.19798441909665704" TOTAL_1="289" TOTAL_2="277" WEIGHT="38.99832633548251" Z="2.295214507091939"><NAME>Clodronate</NAME><DICH_DATA CI_END="0.9501314928581335" CI_START="0.04832843421367883" EFFECT_SIZE="0.21428571428571427" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="-0.022216286636523867" LOG_CI_START="-1.3157972752806275" LOG_EFFECT_SIZE="-0.6690067809585756" MODIFIED="2009-06-24 16:46:30 +0200" MODIFIED_BY="[Empty name]" ORDER="149" O_E="0.0" SE="0.7598558760587117" STUDY_ID="STD-Delmas-1982" TOTAL_1="7" TOTAL_2="3" VAR="0.5773809523809523" WEIGHT="2.155903625080014"/><DICH_DATA CI_END="0.7264212755214803" CI_START="0.11821324104734536" EFFECT_SIZE="0.29304029304029305" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.1388114446270204" LOG_CI_START="-0.9273338754706044" LOG_EFFECT_SIZE="-0.5330726600488125" MODIFIED="2009-06-24 16:46:30 +0200" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="0.4631819791265047" STUDY_ID="STD-Heim-1995" TOTAL_1="39" TOTAL_2="32" VAR="0.21453754578754583" WEIGHT="5.188061454821527"/><DICH_DATA CI_END="1.079530473268903" CI_START="0.6384561523250953" EFFECT_SIZE="0.8302005012531328" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="56" LOG_CI_END="0.03323490622164999" LOG_CI_START="-0.19486892370541792" LOG_EFFECT_SIZE="-0.08081700874188397" MODIFIED="2009-06-24 16:46:30 +0200" MODIFIED_BY="[Empty name]" ORDER="151" O_E="0.0" SE="0.13398931883132828" STUDY_ID="STD-Lahtinen-1992" TOTAL_1="114" TOTAL_2="100" VAR="0.01795313756088334" WEIGHT="21.798147368040595"/><DICH_DATA CI_END="0.9984805791847062" CI_START="0.30338748007282573" EFFECT_SIZE="0.5503875968992248" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="28" LOG_CI_END="-6.603778988782764E-4" LOG_CI_START="-0.5180023452614692" LOG_EFFECT_SIZE="-0.25933136158017367" MODIFIED="2009-06-24 16:46:30 +0200" MODIFIED_BY="[Empty name]" ORDER="152" O_E="0.0" SE="0.30388923251282574" STUDY_ID="STD-McCloskey-2001" TOTAL_1="129" TOTAL_2="142" VAR="0.09234866563723425" WEIGHT="9.856213887540372"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="1.0017838537920192" CI_END="1.008778765598168" CI_START="0.7162127958189801" DF="1" EFFECT_SIZE="0.8500001529834471" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="129" I2="0.17806773240223545" ID="CMP-001.06.03" LOG_CI_END="0.003795931930805248" LOG_CI_START="-0.14495792417313527" LOG_EFFECT_SIZE="-0.070580996121165" MODIFIED="2009-12-11 21:32:27 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3168795088927895" P_Z="0.0628948013145433" STUDIES="2" TAU2="0.002089792884754442" TOTAL_1="230" TOTAL_2="209" WEIGHT="27.866819077860754" Z="1.8599344449098973"><NAME>Pamidronate</NAME><DICH_DATA CI_END="0.9887671830191467" CI_START="0.7379665685046441" EFFECT_SIZE="0.8542114053925077" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="127" LOG_CI_END="-0.0049059561612151545" LOG_CI_START="-0.13196331221872487" LOG_EFFECT_SIZE="-0.06843463418996999" MODIFIED="2009-06-24 16:46:42 +0200" MODIFIED_BY="[Empty name]" ORDER="153" O_E="0.0" SE="0.07463411989223713" STUDY_ID="STD-Berenson-1998a" TOTAL_1="198" TOTAL_2="179" VAR="0.005570251852088826" WEIGHT="27.304655158106442"/><DICH_DATA CI_END="3.7605639664286143" CI_START="0.009386474808012716" EFFECT_SIZE="0.18787878787878787" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5752529803375793" LOG_CI_START="-2.0274974810968467" LOG_EFFECT_SIZE="-0.7261222503796336" MODIFIED="2009-12-11 21:32:27 +0100" MODIFIED_BY="[Empty name]" ORDER="154" O_E="0.0" SE="1.5288685048691535" STUDY_ID="STD-Terpos-2000" TOTAL_1="32" TOTAL_2="30" VAR="2.3374389051808406" WEIGHT="0.5621639197543119"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="0.0" CI_END="1.1656172227999382" CI_START="0.8579145713014538" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="76" I2="0.0" ID="CMP-001.06.04" LOG_CI_END="0.06655595581042073" LOG_CI_START="-0.06655595581042069" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-06-24 16:46:52 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="27.0052246336818" Z="0.0"><NAME>Ibandronate</NAME><DICH_DATA CI_END="1.1656172227999382" CI_START="0.8579145713014538" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="76" LOG_CI_END="0.06655595581042073" LOG_CI_START="-0.06655595581042069" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-06-24 16:46:52 +0200" MODIFIED_BY="[Empty name]" ORDER="155" O_E="0.0" SE="0.0781905958006716" STUDY_ID="STD-Menssen-2002" TOTAL_1="99" TOTAL_2="99" VAR="0.006113769271664004" WEIGHT="27.0052246336818"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="10.145043124903893" CI_END="1.086191503209183" CI_START="0.5567303139137907" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.777634706370633" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="108" I2="21.143755610444618" I2_Q="7.372004728788398" ID="CMP-001.07" LOG_CI_END="0.035906401178208106" LOG_CI_START="-0.2543551307551118" LOG_EFFECT_SIZE="-0.1092243647884518" METHOD="MH" MODIFIED="2017-04-10 21:41:46 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.25499316207304223" P_Q="0.36463315034668764" P_Z="0.14019783282684412" Q="4.318348883928813" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.05269384926025838" TOTALS="YES" TOTAL_1="1054" TOTAL_2="1120" WEIGHT="99.99999999999999" Z="1.4750547190580447"><NAME>Incidence of hypercalcemia</NAME><GROUP_LABEL_1>Bisphosphonates</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Bisphosphonates</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.0" CI_END="2.383121094453283" CI_START="0.7327254470836482" DF="0" EFFECT_SIZE="1.3214285714285714" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="14" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.37714611088051936" LOG_CI_START="-0.1350587254309679" LOG_EFFECT_SIZE="0.12104369272477576" MODIFIED="2009-06-24 16:36:23 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3542625008715794" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="74" WEIGHT="20.29821133541013" Z="0.9263531363925657"><NAME>Etidronate</NAME><DICH_DATA CI_END="2.383121094453283" CI_START="0.7327254470836482" EFFECT_SIZE="1.3214285714285714" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="14" LOG_CI_END="0.37714611088051936" LOG_CI_START="-0.1350587254309679" LOG_EFFECT_SIZE="0.12104369272477576" MODIFIED="2009-06-24 16:36:23 +0200" MODIFIED_BY="[Empty name]" ORDER="140" O_E="0.0" SE="0.30087165630419865" STUDY_ID="STD-Belch-1991" TOTAL_1="92" TOTAL_2="74" VAR="0.09052375356723183" WEIGHT="20.29821133541013"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="2.036297460302791" CI_END="1.3122420370778944" CI_START="0.45374471577368036" DF="2" EFFECT_SIZE="0.7716365013010884" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="38" I2="1.7825224953820589" ID="CMP-001.07.02" LOG_CI_END="0.11801394607068086" LOG_CI_START="-0.3431884196389049" LOG_EFFECT_SIZE="-0.11258723678411199" MODIFIED="2009-09-04 18:01:25 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3612632482272814" P_Z="0.3386075482690166" STUDIES="3" TAU2="0.005144643385601306" TOTAL_1="359" TOTAL_2="472" WEIGHT="30.118634347139373" Z="0.9569201965225581"><NAME>Clodronate</NAME><DICH_DATA CI_END="2.2008380373964553" CI_START="0.006311371344199827" EFFECT_SIZE="0.11785714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.34258808341971864" LOG_CI_START="-2.199876266348382" LOG_EFFECT_SIZE="-0.9286440914643318" MODIFIED="2009-09-04 17:39:21 +0200" MODIFIED_BY="[Empty name]" ORDER="141" O_E="0.0" SE="1.4934561444552885" STUDY_ID="STD-Heim-1995" TOTAL_1="39" TOTAL_2="32" VAR="2.2304112554112554" WEIGHT="1.2732927464421253"/><DICH_DATA CI_END="1.5891449192925855" CI_START="0.2796752134111788" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.20116350373932387" LOG_CI_START="-0.5533460218506865" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2009-09-04 18:01:25 +0200" MODIFIED_BY="[Empty name]" ORDER="142" O_E="0.0" SE="0.4432026302139591" STUDY_ID="STD-Lahtinen-1992" TOTAL_1="168" TOTAL_2="168" VAR="0.1964285714285714" WEIGHT="11.669207296176435"/><DICH_DATA CI_END="1.822979126031326" CI_START="0.47816276749847975" EFFECT_SIZE="0.9336384439359268" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="23" LOG_CI_END="0.26078169580730093" LOG_CI_START="-0.32042424356838467" LOG_EFFECT_SIZE="-0.02982127388054189" MODIFIED="2009-06-24 16:36:33 +0200" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="0.3414032458050776" STUDY_ID="STD-McCloskey-2001" TOTAL_1="152" TOTAL_2="272" VAR="0.11655617624624222" WEIGHT="17.176134304520815"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="3.6217110832207684" CI_END="1.3324163842240635" CI_START="0.3136821837787224" DF="2" EFFECT_SIZE="0.6464946102682941" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="41" I2="44.77748351418991" ID="CMP-001.07.03" LOG_CI_END="0.12463996440817557" LOG_CI_START="-0.5035101472452522" LOG_EFFECT_SIZE="-0.18943509141853834" MODIFIED="2009-06-24 16:36:48 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.1635142515670398" P_Z="0.23714351930543764" STUDIES="3" TAU2="0.17367602648307354" TOTAL_1="382" TOTAL_2="357" WEIGHT="35.977286251807996" Z="1.182156779726051"><NAME>Pamidronate</NAME><DICH_DATA CI_END="1.9333905247071577" CI_START="0.5350090648490395" EFFECT_SIZE="1.0170454545454546" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.2863195858419115" LOG_CI_START="-0.2716388595104247" LOG_EFFECT_SIZE="0.007340363165743365" MODIFIED="2009-06-24 16:36:48 +0200" MODIFIED_BY="[Empty name]" ORDER="144" O_E="0.0" SE="0.3277475527388108" STUDY_ID="STD-Berenson-1998a" TOTAL_1="198" TOTAL_2="179" VAR="0.10741845832627955" WEIGHT="18.156387931464987"/><DICH_DATA CI_END="0.9681662707631494" CI_START="0.24480839977025676" EFFECT_SIZE="0.4868421052631579" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="22" LOG_CI_END="-0.01405005149951136" LOG_CI_START="-0.6111736849280813" LOG_EFFECT_SIZE="-0.31261186821379633" MODIFIED="2009-06-24 16:36:48 +0200" MODIFIED_BY="[Empty name]" ORDER="145" O_E="0.0" SE="0.35075337808559814" STUDY_ID="STD-Brincker-1998" TOTAL_1="152" TOTAL_2="148" VAR="0.12302793223845855" WEIGHT="16.543544826083238"/><DICH_DATA CI_END="2.4940882787181518" CI_START="0.007220838080780863" EFFECT_SIZE="0.1341991341991342" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3969118213484771" LOG_CI_START="-2.1414123934642206" LOG_EFFECT_SIZE="-0.8722502860578716" MODIFIED="2009-06-24 16:36:48 +0200" MODIFIED_BY="[Empty name]" ORDER="146" O_E="0.0" SE="1.4910242086884862" STUDY_ID="STD-Terpos-2000" TOTAL_1="32" TOTAL_2="30" VAR="2.2231531908951263" WEIGHT="1.2773534942597664"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="0.0" CI_END="1.4190680972047587" CI_START="0.26686402548124394" DF="0" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" I2="0.0" ID="CMP-001.07.04" LOG_CI_END="0.15200323656434844" LOG_CI_START="-0.5737099671941347" LOG_EFFECT_SIZE="-0.21085336531489315" MODIFIED="2009-06-24 16:36:59 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.2547361269593853" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="12.401349466125442" Z="1.1389209949493821"><NAME>Ibandronate</NAME><DICH_DATA CI_END="1.4190680972047587" CI_START="0.26686402548124394" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.15200323656434844" LOG_CI_START="-0.5737099671941347" LOG_EFFECT_SIZE="-0.21085336531489315" MODIFIED="2009-06-24 16:36:59 +0200" MODIFIED_BY="[Empty name]" ORDER="147" O_E="0.0" SE="0.4262875282260281" STUDY_ID="STD-Menssen-2002" TOTAL_1="99" TOTAL_2="99" VAR="0.1817210567210567" WEIGHT="12.401349466125442"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="0.0" CI_END="3.907062616263255" CI_START="0.009465486518380953" DF="0" EFFECT_SIZE="0.1923076923076923" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.07.05" LOG_CI_END="0.5918503714704199" LOG_CI_START="-2.023857058740018" LOG_EFFECT_SIZE="-0.7160033436347992" MODIFIED="2016-03-14 21:51:10 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.28326642211751674" STUDIES="2" TAU2="0.0" TOTAL_1="122" TOTAL_2="118" WEIGHT="1.2045185995170506" Z="1.073010498136301"><NAME>Zoledronate</NAME><DICH_DATA CI_END="3.907062616263256" CI_START="0.009465486518380953" EFFECT_SIZE="0.19230769230769232" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5918503714704199" LOG_CI_START="-2.023857058740018" LOG_EFFECT_SIZE="-0.7160033436347991" MODIFIED="2016-03-14 21:51:10 +0100" MODIFIED_BY="[Empty name]" ORDER="128" O_E="0.0" SE="1.5364794924662128" STUDY_ID="STD-Garcia_x002d_Sanz-2015" TOTAL_1="51" TOTAL_2="49" VAR="2.3607692307692307" WEIGHT="1.2045185995170506"/><DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-22 21:55:48 +0100" MODIFIED_BY="[Empty name]" ORDER="360" O_E="0.0" SE="0.0" STUDY_ID="STD-Sezer-2010" TOTAL_1="71" TOTAL_2="69" VAR="0.0" WEIGHT="0.0"/></DICH_SUBGROUP></DICH_OUTCOME></COMPARISON><COMPARISON ID="CMP-002" MODIFIED="2017-11-16 18:53:54 +0100" MODIFIED_BY="[Empty name]" NO="2"><NAME>Bisphosphonates vs. control (adverse effects)</NAME><DICH_OUTCOME CHI2="0.3459246203387419" CI_END="21.34658900998151" CI_START="0.9940780472817381" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="4.606536173652414" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="1.3293284886120222" LOG_CI_START="-0.0025795168369464176" LOG_EFFECT_SIZE="0.6633744858875379" METHOD="MH" MODIFIED="2017-04-10 21:39:31 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.951172028158142" P_Q="0.7749738136015725" P_Z="0.05089402770812172" Q="0.08172455962739802" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="639" TOTAL_2="645" WEIGHT="100.00000000000001" Z="1.952372228837339"><NAME>Osteonecosis of jaw</NAME><GROUP_LABEL_1>Bisphosphonates</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours bisphosphonates</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.0" CI_END="74.68532738097647" CI_START="0.12544890732335423" DF="0" EFFECT_SIZE="3.0609137055837565" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="1.873235289052637" LOG_CI_START="-0.90153311709552" LOG_EFFECT_SIZE="0.4858510859785584" MODIFIED="2011-08-17 20:46:29 +0200" MODIFIED_BY="Rahul S Mhaskar" NO="1" P_CHI2="1.0" P_Z="0.4924835777582204" STUDIES="2" TAU2="0.0" TOTAL_1="285" TOTAL_2="288" WEIGHT="23.040663255727747" Z="0.6863640426766507"><NAME>Pamidronate</NAME><DICH_DATA CI_END="74.68532738097647" CI_START="0.12544890732335423" EFFECT_SIZE="3.0609137055837565" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.873235289052637" LOG_CI_START="-0.90153311709552" LOG_EFFECT_SIZE="0.4858510859785584" MODIFIED="2011-08-17 20:46:29 +0200" MODIFIED_BY="Rahul S Mhaskar" ORDER="214" O_E="0.0" SE="1.6299126970965583" STUDY_ID="STD-Attal-2006" TOTAL_1="196" TOTAL_2="200" VAR="2.656615400156577" WEIGHT="23.040663255727747"/><DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-17 20:46:13 +0200" MODIFIED_BY="Rahul S Mhaskar" ORDER="215" O_E="0.0" SE="0.0" STUDY_ID="STD-Musto-2003" TOTAL_1="89" TOTAL_2="88" VAR="0.0" WEIGHT="0.0"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="0.26143848030742134" CI_END="29.89842177800907" CI_START="0.906561519044244" DF="2" EFFECT_SIZE="5.2062230709121" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="1.4756482642043054" LOG_CI_START="-0.0426027194505364" LOG_EFFECT_SIZE="0.7165227723768846" MODIFIED="2016-03-14 21:52:13 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8774641026914587" P_Z="0.06431797958421026" STUDIES="4" TAU2="0.0" TOTAL_1="354" TOTAL_2="357" WEIGHT="76.95933674427226" Z="1.8499692647401582"><NAME>Zoledronate</NAME><DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-02-22 22:08:27 +0100" MODIFIED_BY="[Empty name]" ORDER="361" O_E="0.0" SE="0.0" STUDY_ID="STD-Aviles-2013" TOTAL_1="151" TOTAL_2="157" VAR="0.0" WEIGHT="0.0"/><DICH_DATA CI_END="69.15630250433965" CI_START="0.12032172941341984" EFFECT_SIZE="2.8846153846153846" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8398317653293415" LOG_CI_START="-0.9196559344875772" LOG_EFFECT_SIZE="0.46008791542088207" MODIFIED="2016-03-14 21:52:13 +0100" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="1.6209367345568726" STUDY_ID="STD-Garcia_x002d_Sanz-2015" TOTAL_1="51" TOTAL_2="49" VAR="2.6274358974358973" WEIGHT="23.29654584331547"/><DICH_DATA CI_END="103.80849068649607" CI_START="0.24673775673995063" EFFECT_SIZE="5.060975609756097" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0162328767059527" LOG_CI_START="-0.6077643880492007" LOG_EFFECT_SIZE="0.704234244328376" MODIFIED="2011-08-17 20:46:48 +0200" MODIFIED_BY="Rahul S Mhaskar" ORDER="213" O_E="0.0" SE="1.5413489823131217" STUDY_ID="STD-Musto-2008" TOTAL_1="81" TOTAL_2="82" VAR="2.375756685277696" WEIGHT="25.764499039106532"/><DICH_DATA CI_END="159.52723559603533" CI_START="0.4799337223762613" EFFECT_SIZE="8.75" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2028348394891872" LOG_CI_START="-0.31881873344456035" LOG_EFFECT_SIZE="0.9420080530223133" MODIFIED="2016-02-22 22:09:12 +0100" MODIFIED_BY="[Empty name]" ORDER="362" O_E="0.0" SE="1.4812317911277826" STUDY_ID="STD-Sezer-2010" TOTAL_1="71" TOTAL_2="69" VAR="2.1940476190476192" WEIGHT="27.89829186185025"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="1.0962490527682454" CI_END="1.5944037982376078" CI_START="0.9502201039176033" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2308673945019264" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="87" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.20259832028329247" LOG_CI_START="-0.02217578540058783" LOG_EFFECT_SIZE="0.0902112674413523" METHOD="MH" MODIFIED="2017-04-10 21:40:20 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9544351832084781" P_Q="0.8470573719050578" P_Z="0.11566525801133744" Q="0.8100684213409154" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="924" TOTAL_2="905" WEIGHT="100.0" Z="1.5732313528447628"><NAME>Gastrointestinal toxicity (grade III/IV)</NAME><GROUP_LABEL_1>Bisphosphonates</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Bisphosphonates</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.0" CI_END="7.939480235674019" CI_START="0.013994758827141083" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.8997920719274333" LOG_CI_START="-1.854034581366758" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2009-06-24 16:59:18 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4970383244017067" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="39" WEIGHT="0.6662225966281718" Z="0.679157109900482"><NAME>Etidronate</NAME><DICH_DATA CI_END="7.939480235674019" CI_START="0.013994758827141083" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8997920719274333" LOG_CI_START="-1.854034581366758" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2009-06-24 16:59:18 +0200" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="1.6176114078067905" STUDY_ID="STD-Daragon-1993" TOTAL_1="39" TOTAL_2="39" VAR="2.6166666666666667" WEIGHT="0.6662225966281718"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="0.14363036129225926" CI_END="1.719232899624568" CI_START="0.8200092591713741" DF="1" EFFECT_SIZE="1.1873444724949014" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="44" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.23533471331906358" LOG_CI_START="-0.08618124373295176" LOG_EFFECT_SIZE="0.07457673479305593" MODIFIED="2009-06-24 17:05:56 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7046984148991136" P_Z="0.3632230381319346" STUDIES="2" TAU2="0.0" TOTAL_1="432" TOTAL_2="440" WEIGHT="48.875081270291844" Z="0.9092408079474422"><NAME>Clodronate</NAME><DICH_DATA CI_END="1.7631322865465007" CI_START="0.7285014597289938" EFFECT_SIZE="1.1333333333333333" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="30" LOG_CI_END="0.24628489832419773" LOG_CI_START="-0.1375695736790124" LOG_EFFECT_SIZE="0.054357662322592676" MODIFIED="2009-06-24 16:57:31 +0200" MODIFIED_BY="[Empty name]" ORDER="163" O_E="0.0" SE="0.22547801696496664" STUDY_ID="STD-Lahtinen-1992" TOTAL_1="168" TOTAL_2="168" VAR="0.05084033613445378" WEIGHT="34.28935750083784"/><DICH_DATA CI_END="2.608457206573585" CI_START="0.6727212972409462" EFFECT_SIZE="1.3246753246753247" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.4163837162351612" LOG_CI_START="-0.1721648230562898" LOG_EFFECT_SIZE="0.12210944658943569" MODIFIED="2009-06-24 17:05:56 +0200" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="0.34571632534205393" STUDY_ID="STD-McCloskey-2001" TOTAL_1="264" TOTAL_2="272" VAR="0.1195197776080129" WEIGHT="14.585723769454003"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="0.1436489328485435" CI_END="1.8823486712976862" CI_START="0.9025264884770089" DF="1" EFFECT_SIZE="1.3034068959444953" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="41" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="0.2747000717985927" LOG_CI_START="-0.04454004301722593" LOG_EFFECT_SIZE="0.1150800143906834" MODIFIED="2009-06-24 16:57:40 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7046802208867097" P_Z="0.15763814714450808" STUDIES="3" TAU2="0.0" TOTAL_1="382" TOTAL_2="357" WEIGHT="49.5744198049265" Z="1.4130597821406012"><NAME>Pamidronate</NAME><DICH_DATA CI_END="1.9229781602300855" CI_START="0.8085843221381191" EFFECT_SIZE="1.24695228143504" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="29" LOG_CI_END="0.2839743518695662" LOG_CI_START="-0.09227468357482956" LOG_EFFECT_SIZE="0.09584983414736835" MODIFIED="2009-06-24 16:57:40 +0200" MODIFIED_BY="[Empty name]" ORDER="165" O_E="0.0" SE="0.22101054588280095" STUDY_ID="STD-Berenson-1998a" TOTAL_1="198" TOTAL_2="179" VAR="0.04884566139141366" WEIGHT="35.68960705041233"/><DICH_DATA CI_END="2.9249588209673405" CI_START="0.729287914695532" EFFECT_SIZE="1.4605263157894737" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="12" LOG_CI_END="0.4661197562463899" LOG_CI_START="-0.13710098323465772" LOG_EFFECT_SIZE="0.16450938650586608" MODIFIED="2009-06-24 16:57:40 +0200" MODIFIED_BY="[Empty name]" ORDER="166" O_E="0.0" SE="0.35433484836198526" STUDY_ID="STD-Brincker-1998" TOTAL_1="152" TOTAL_2="148" VAR="0.12555318476371108" WEIGHT="13.88481275451417"/><DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-06-24 16:57:40 +0200" MODIFIED_BY="[Empty name]" ORDER="167" O_E="0.0" SE="0.0" STUDY_ID="STD-Terpos-2000" TOTAL_1="32" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="0.0" CI_END="15.23141940682358" CI_START="0.06200705528221281" DF="0" EFFECT_SIZE="0.971830985915493" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-002.02.04" LOG_CI_END="1.182740376863771" LOG_CI_START="-1.207558892827411" LOG_EFFECT_SIZE="-0.012409257981819953" MODIFIED="2016-02-22 22:13:57 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.9837639003756424" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="69" WEIGHT="0.8842763281534859" Z="0.020350337740240858"><NAME>Zoledronate</NAME><DICH_DATA CI_END="15.23141940682358" CI_START="0.06200705528221281" EFFECT_SIZE="0.971830985915493" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.182740376863771" LOG_CI_START="-1.207558892827411" LOG_EFFECT_SIZE="-0.012409257981819953" MODIFIED="2016-02-22 22:13:50 +0100" MODIFIED_BY="[Empty name]" ORDER="363" O_E="0.0" SE="1.404073623188812" STUDY_ID="STD-Sezer-2010" TOTAL_1="71" TOTAL_2="69" VAR="1.971422739334558" WEIGHT="0.8842763281534859"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="0.02232797351100559" CI_END="9.739573196665983" CI_START="0.49168510366346974" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.188333397094845" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.9885399258319925" LOG_CI_START="-0.30831294911222756" LOG_EFFECT_SIZE="0.3401134883598825" METHOD="MH" MODIFIED="2017-04-10 21:40:38 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8812179213110323" P_Q="0.881306492201331" P_Z="0.30392966799991883" Q="0.02229443933967567" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="551" TOTAL_2="539" WEIGHT="100.00000000000001" Z="1.0280428886280948"><NAME>Hypocalcaemia</NAME><GROUP_LABEL_1>Bisphosphonates</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Bisphosphonates</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.0" CI_END="11.155259294656688" CI_START="0.38063636396513756" DF="0" EFFECT_SIZE="2.0606060606060606" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="1.047479669548571" LOG_CI_START="-0.41948972389187356" LOG_EFFECT_SIZE="0.3139949728283488" MODIFIED="2009-06-23 02:08:05 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4014500558597749" STUDIES="1" TAU2="0.0" TOTAL_1="264" TOTAL_2="272" WEIGHT="78.15185889670069" Z="0.8390343258994258"><NAME>Clodronate</NAME><DICH_DATA CI_END="11.155259294656688" CI_START="0.38063636396513756" EFFECT_SIZE="2.0606060606060606" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.047479669548571" LOG_CI_START="-0.41948972389187356" LOG_EFFECT_SIZE="0.3139949728283488" MODIFIED="2009-06-23 02:08:05 +0200" MODIFIED_BY="[Empty name]" ORDER="310" O_E="0.0" SE="0.8617050833225286" STUDY_ID="STD-McCloskey-2001" TOTAL_1="264" TOTAL_2="272" VAR="0.7425356506238859" WEIGHT="78.15185889670069"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="0.0" CI_END="66.18912494117423" CI_START="0.1112486443122345" DF="0" EFFECT_SIZE="2.71356783919598" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="1.8207866394998748" LOG_CI_START="-0.953705272673351" LOG_EFFECT_SIZE="0.4335406834132619" MODIFIED="2011-08-17 20:40:30 +0200" MODIFIED_BY="Rahul S Mhaskar" NO="2" P_CHI2="1.0" P_Z="0.540189848103952" STUDIES="2" TAU2="0.0" TOTAL_1="287" TOTAL_2="267" WEIGHT="21.848141103299323" Z="0.6125259342762304"><NAME>Pamidronate</NAME><DICH_DATA CI_END="66.18912494117423" CI_START="0.1112486443122345" EFFECT_SIZE="2.71356783919598" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8207866394998748" LOG_CI_START="-0.953705272673351" LOG_EFFECT_SIZE="0.4335406834132619" MODIFIED="2009-06-23 02:08:21 +0200" MODIFIED_BY="[Empty name]" ORDER="311" O_E="0.0" SE="1.6297502831670165" STUDY_ID="STD-Berenson-1998a" TOTAL_1="198" TOTAL_2="179" VAR="2.6560859854829704" WEIGHT="21.848141103299323"/><DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-17 20:40:30 +0200" MODIFIED_BY="Rahul S Mhaskar" ORDER="212" O_E="0.0" SE="0.0" STUDY_ID="STD-Musto-2003" TOTAL_1="89" TOTAL_2="88" VAR="0.0" WEIGHT="0.0"/></DICH_SUBGROUP></DICH_OUTCOME><CONT_OUTCOME CHI2="1.2161495429622777" CI_END="9.03446800675151" CI_START="-9.754219212416935" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.35987560283271214" ESTIMABLE="YES" I2="17.773270089448385" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2017-11-16 18:53:54 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.270117702538636" P_Q="1.0" P_Z="0.9401497137767197" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="9.065256409123139" TOTALS="YES" TOTAL_1="207" TOTAL_2="207" UNITS="" WEIGHT="100.0" Z="0.07508169274829983"><NAME>Renal dysfunction</NAME><GROUP_LABEL_1>Bisphosphonates</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Bisphosphonates</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><CONT_DATA CI_END="13.070706309017504" CI_START="-6.870706309017516" EFFECT_SIZE="3.0999999999999943" ESTIMABLE="YES" MEAN_1="89.3" MEAN_2="86.2" MODIFIED="2011-07-05 16:54:22 +0200" MODIFIED_BY="Rahul S Mhaskar" ORDER="124" SD_1="20.7" SD_2="24.1" SE="5.08718853390428" STUDY_ID="STD-Daragon-1993" TOTAL_1="39" TOTAL_2="39" WEIGHT="65.74380591254744"/><CONT_DATA CI_END="7.92664100221365" CI_START="-21.92664100221365" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="96.0" MEAN_2="103.0" MODIFIED="2011-07-05 16:52:37 +0200" MODIFIED_BY="Rahul S Mhaskar" ORDER="125" SD_1="38.88444419" SD_2="90.73036978" SE="7.615773106012707" STUDY_ID="STD-Lahtinen-1992" TOTAL_1="168" TOTAL_2="168" WEIGHT="34.256194087452556"/></CONT_OUTCOME></COMPARISON><COMPARISON ID="CMP-003" MODIFIED="2017-11-16 18:56:17 +0100" MODIFIED_BY="[Empty name]" NO="3"><NAME>Sensitivity analyses (assessment of bias: analysed outcome in brackets)</NAME><DICH_OUTCOME CHI2="6.420025573602793" CI_END="0.8860790943136445" CI_START="0.6177912372778553" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7398728944907145" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="188" I2="6.542428356201743" I2_Q="59.887496832011536" ID="CMP-003.01" LOG_CI_END="-0.05252750983889334" LOG_CI_START="-0.2091582560035921" LOG_EFFECT_SIZE="-0.13084288292124271" METHOD="MH" MODIFIED="2010-02-12 17:10:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.377818028866703" P_Q="0.11435468837769736" P_Z="0.0010583168472006411" Q="2.4929882730381276" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.004096899327582926" TOTALS="YES" TOTAL_1="575" TOTAL_2="541" WEIGHT="100.0" Z="3.2745465936728633"><NAME>Allocation concealment (vertebral fractures)</NAME><GROUP_LABEL_1>Bisphosphonate</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Bisphosphonates</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.5610159509791264" CI_END="0.819256745244592" CI_START="0.5092909759423802" DF="1" EFFECT_SIZE="0.6459412259122312" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="109" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="-0.08657997422334568" LOG_CI_START="-0.29303401896057707" LOG_EFFECT_SIZE="-0.1898069965919614" MODIFIED="2009-12-15 16:27:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4538512980869319" P_Z="3.135360282899962E-4" STUDIES="2" TAU2="0.0" TOTAL_1="306" TOTAL_2="288" WEIGHT="50.03226207948831" Z="3.6038516736976556"><NAME>Adeqaute concealment of allocation</NAME><DICH_DATA CI_END="0.8547878611524382" CI_START="0.3826912768487408" EFFECT_SIZE="0.5719439290867863" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="49" LOG_CI_END="-0.06814165388272866" LOG_CI_START="-0.4171514370690292" LOG_EFFECT_SIZE="-0.2426465454758789" MODIFIED="2009-06-24 16:14:45 +0200" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.20501007426992252" STUDY_ID="STD-Berenson-1998a" TOTAL_1="198" TOTAL_2="179" VAR="0.04202913055215915" WEIGHT="18.35198990795751"/><DICH_DATA CI_END="0.9261152967841564" CI_START="0.5135770874290777" EFFECT_SIZE="0.6896604938271605" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="60" LOG_CI_END="-0.033334942432422715" LOG_CI_START="-0.28939435998804564" LOG_EFFECT_SIZE="-0.16136465121023416" MODIFIED="2009-06-24 16:15:27 +0200" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.15041056938673203" STUDY_ID="STD-McCloskey-2001" TOTAL_1="108" TOTAL_2="109" VAR="0.02262333938324093" WEIGHT="31.680272171530802"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="3.318177820766045" CI_END="1.0852731144869059" CI_START="0.6658030008152735" DF="4" EFFECT_SIZE="0.8500459377760239" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="79" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.035539044349219895" LOG_CI_START="-0.17665425178286956" LOG_EFFECT_SIZE="-0.07055760371682483" MODIFIED="2010-02-12 17:10:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5060575048050222" P_Z="0.1924254010470463" STUDIES="5" TAU2="0.0" TOTAL_1="269" TOTAL_2="253" WEIGHT="49.967737920511695" Z="1.3034376169390478"><NAME>Inadequate concealment of allocation</NAME><DICH_DATA CI_END="3.6371418524301027" CI_START="0.05049939673511395" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5607602393352392" LOG_CI_START="-1.2967138099244282" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2009-06-24 16:15:05 +0200" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="1.0910894511799618" STUDY_ID="STD-Delmas-1982" TOTAL_1="7" TOTAL_2="6" VAR="1.1904761904761905" WEIGHT="0.7086250662035458"/><DICH_DATA CI_END="1.402334278349937" CI_START="0.6267451802106477" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.14685154996338431" LOG_CI_START="-0.20290899716387142" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2009-06-24 16:15:39 +0200" MODIFIED_BY="[Empty name]" ORDER="120" O_E="0.0" SE="0.20545107672518104" STUDY_ID="STD-Kraj-2000" TOTAL_1="23" TOTAL_2="23" VAR="0.04221014492753622" WEIGHT="18.280251924167974"/><DICH_DATA CI_END="1.084214993124351" CI_START="0.5060775293394323" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="38" LOG_CI_END="0.035115408650303284" LOG_CI_START="-0.29578294564031565" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2009-06-24 16:15:17 +0200" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.19437133128358017" STUDY_ID="STD-Lahtinen-1992" TOTAL_1="108" TOTAL_2="95" VAR="0.03778021442495127" WEIGHT="20.214010923710017"/><DICH_DATA CI_END="1.8114522782061577" CI_START="0.6086276813716462" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="0.2580268972528472" LOG_CI_START="-0.21564829911297106" LOG_EFFECT_SIZE="0.021189299069938092" MODIFIED="2009-06-24 16:16:16 +0200" MODIFIED_BY="[Empty name]" ORDER="122" O_E="0.0" SE="0.27823915507531904" STUDY_ID="STD-Menssen-2002" TOTAL_1="99" TOTAL_2="99" VAR="0.07741702741702743" WEIGHT="10.384782927944807"/><DICH_DATA CI_END="2.4940882787181518" CI_START="0.007220838080780863" EFFECT_SIZE="0.1341991341991342" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3969118213484771" LOG_CI_START="-2.1414123934642206" LOG_EFFECT_SIZE="-0.8722502860578716" MODIFIED="2009-06-24 16:15:54 +0200" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="1.4910242086884862" STUDY_ID="STD-Terpos-2000" TOTAL_1="32" TOTAL_2="30" VAR="2.2231531908951263" WEIGHT="0.3800670784853482"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="6.420025573602793" CI_END="0.8860790943136445" CI_START="0.6177912372778553" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7398728944907145" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="188" I2="6.542428356201743" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.05252750983889334" LOG_CI_START="-0.2091582560035921" LOG_EFFECT_SIZE="-0.13084288292124271" METHOD="MH" MODIFIED="2017-11-16 18:56:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.377818028866703" P_Q="0.8025981924833836" P_Z="0.0010583168472006411" Q="0.062492991154528804" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.004096899327582928" TOTALS="YES" TOTAL_1="575" TOTAL_2="541" WEIGHT="100.0" Z="3.2745465936728633"><NAME>Blinding (vertebral fractures)</NAME><GROUP_LABEL_1>Bisphosphonate</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Bisphosphonates</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="3.3848040138680706" CI_END="0.8518505663881061" CI_START="0.5844091745450524" DF="4" EFFECT_SIZE="0.7055701852676376" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="169" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="-0.06963658350210238" LOG_CI_START="-0.23328297476543694" LOG_EFFECT_SIZE="-0.15145977913376965" MODIFIED="2017-11-16 18:56:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4956090934988573" P_Z="2.85609602327853E-4" STUDIES="5" TAU2="0.0" TOTAL_1="520" TOTAL_2="488" WEIGHT="81.33968099734668" Z="3.6280141580499503"><NAME>Double-blind</NAME><DICH_DATA CI_END="0.8547878611524382" CI_START="0.3826912768487408" EFFECT_SIZE="0.5719439290867863" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="49" LOG_CI_END="-0.06814165388272866" LOG_CI_START="-0.4171514370690292" LOG_EFFECT_SIZE="-0.2426465454758789" MODIFIED="2009-06-24 16:21:58 +0200" MODIFIED_BY="[Empty name]" ORDER="126" O_E="0.0" SE="0.20501007426992252" STUDY_ID="STD-Berenson-1998a" TOTAL_1="198" TOTAL_2="179" VAR="0.04202913055215915" WEIGHT="18.35198990795751"/><DICH_DATA CI_END="3.6371418524301027" CI_START="0.05049939673511395" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5607602393352392" LOG_CI_START="-1.2967138099244282" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2009-06-24 16:21:27 +0200" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="1.0910894511799618" STUDY_ID="STD-Delmas-1982" TOTAL_1="7" TOTAL_2="6" VAR="1.1904761904761905" WEIGHT="0.7086250662035458"/><DICH_DATA CI_END="1.084214993124351" CI_START="0.5060775293394323" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="38" LOG_CI_END="0.035115408650303284" LOG_CI_START="-0.29578294564031565" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2009-06-24 16:21:38 +0200" MODIFIED_BY="[Empty name]" ORDER="128" O_E="0.0" SE="0.19437133128358017" STUDY_ID="STD-Lahtinen-1992" TOTAL_1="108" TOTAL_2="95" VAR="0.03778021442495127" WEIGHT="20.214010923710017"/><DICH_DATA CI_END="0.9261152967841564" CI_START="0.5135770874290777" EFFECT_SIZE="0.6896604938271605" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="60" LOG_CI_END="-0.033334942432422715" LOG_CI_START="-0.28939435998804564" LOG_EFFECT_SIZE="-0.16136465121023416" MODIFIED="2009-06-24 16:21:49 +0200" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.15041056938673203" STUDY_ID="STD-McCloskey-2001" TOTAL_1="108" TOTAL_2="109" VAR="0.02262333938324093" WEIGHT="31.680272171530802"/><DICH_DATA CI_END="1.8114522782061577" CI_START="0.6086276813716462" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="0.2580268972528472" LOG_CI_START="-0.21564829911297106" LOG_EFFECT_SIZE="0.021189299069938092" MODIFIED="2009-06-24 16:22:27 +0200" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.27823915507531904" STUDY_ID="STD-Menssen-2002" TOTAL_1="99" TOTAL_2="99" VAR="0.07741702741702743" WEIGHT="10.384782927944805"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="2.110731752245936" CI_END="3.7204824814454756" CI_START="0.08206973098872286" DF="1" EFFECT_SIZE="0.5525748785463254" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" I2="52.62306548731527" ID="CMP-003.02.02" LOG_CI_END="0.5705992639254543" LOG_CI_START="-1.0858169901213461" LOG_EFFECT_SIZE="-0.25760886309794595" MODIFIED="2009-06-24 16:22:17 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1462694166206302" P_Z="0.5421040787144421" STUDIES="2" TAU2="1.258105493736004" TOTAL_1="55" TOTAL_2="53" WEIGHT="18.66031900265332" Z="0.6096343144867714"><NAME>Not blinded</NAME><DICH_DATA CI_END="1.402334278349937" CI_START="0.6267451802106477" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.14685154996338431" LOG_CI_START="-0.20290899716387142" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2009-06-24 16:22:08 +0200" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.20545107672518104" STUDY_ID="STD-Kraj-2000" TOTAL_1="23" TOTAL_2="23" VAR="0.04221014492753622" WEIGHT="18.280251924167974"/><DICH_DATA CI_END="2.4940882787181518" CI_START="0.007220838080780863" EFFECT_SIZE="0.1341991341991342" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3969118213484771" LOG_CI_START="-2.1414123934642206" LOG_EFFECT_SIZE="-0.8722502860578716" MODIFIED="2009-06-24 16:22:17 +0200" MODIFIED_BY="[Empty name]" ORDER="132" O_E="0.0" SE="1.4910242086884862" STUDY_ID="STD-Terpos-2000" TOTAL_1="32" TOTAL_2="30" VAR="2.2231531908951263" WEIGHT="0.3800670784853482"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="6.420025573602793" CI_END="0.8860790943136445" CI_START="0.6177912372778552" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7398728944907145" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="188" I2="6.542428356201743" I2_Q="47.06430582462179" ID="CMP-003.03" LOG_CI_END="-0.05252750983889334" LOG_CI_START="-0.2091582560035922" LOG_EFFECT_SIZE="-0.13084288292124271" METHOD="MH" MODIFIED="2010-02-12 17:11:17 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.377818028866703" P_Q="0.16930543485997307" P_Z="0.00105831684720064" Q="1.8890845120250193" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.004096899327582926" TOTALS="YES" TOTAL_1="575" TOTAL_2="541" WEIGHT="100.00000000000001" Z="3.2745465936728637"><NAME>Randomization method (vertebral fractures)</NAME><GROUP_LABEL_1>Bisphosphonate</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Bisphosphonates</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.0" CI_END="0.8547878611524382" CI_START="0.3826912768487408" DF="0" EFFECT_SIZE="0.5719439290867863" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="49" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="-0.06814165388272866" LOG_CI_START="-0.4171514370690292" LOG_EFFECT_SIZE="-0.2426465454758789" MODIFIED="2009-06-24 17:21:01 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.006424274015777239" STUDIES="1" TAU2="0.0" TOTAL_1="198" TOTAL_2="179" WEIGHT="18.351989907957513" Z="2.725301770993167"><NAME>Randomization method is described</NAME><DICH_DATA CI_END="0.8547878611524382" CI_START="0.3826912768487408" EFFECT_SIZE="0.5719439290867863" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="49" LOG_CI_END="-0.06814165388272866" LOG_CI_START="-0.4171514370690292" LOG_EFFECT_SIZE="-0.2426465454758789" MODIFIED="2009-06-24 17:21:01 +0200" MODIFIED_BY="[Empty name]" ORDER="174" O_E="0.0" SE="0.20501007426992252" STUDY_ID="STD-Berenson-1998a" TOTAL_1="198" TOTAL_2="179" VAR="0.04202913055215915" WEIGHT="18.351989907957513"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="4.423100398330045" CI_END="0.9422447992496645" CI_START="0.6468143869205909" DF="5" EFFECT_SIZE="0.7806775852781909" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="139" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="-0.02583625097403884" LOG_CI_START="-0.18922032876140701" LOG_EFFECT_SIZE="-0.10752828986772295" MODIFIED="2009-06-24 17:21:43 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.49023804498313783" P_Z="0.009884895351624772" STUDIES="6" TAU2="0.0" TOTAL_1="377" TOTAL_2="362" WEIGHT="81.6480100920425" Z="2.579830033795548"><NAME>Randomization method is NOT described</NAME><DICH_DATA CI_END="3.6371418524301027" CI_START="0.05049939673511395" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5607602393352392" LOG_CI_START="-1.2967138099244282" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2009-06-24 17:20:25 +0200" MODIFIED_BY="[Empty name]" ORDER="168" O_E="0.0" SE="1.0910894511799618" STUDY_ID="STD-Delmas-1982" TOTAL_1="7" TOTAL_2="6" VAR="1.1904761904761905" WEIGHT="0.7086250662035458"/><DICH_DATA CI_END="1.402334278349937" CI_START="0.6267451802106477" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.14685154996338431" LOG_CI_START="-0.20290899716387142" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2009-06-24 17:21:12 +0200" MODIFIED_BY="[Empty name]" ORDER="169" O_E="0.0" SE="0.20545107672518104" STUDY_ID="STD-Kraj-2000" TOTAL_1="23" TOTAL_2="23" VAR="0.04221014492753622" WEIGHT="18.280251924167974"/><DICH_DATA CI_END="1.084214993124351" CI_START="0.5060775293394323" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="38" LOG_CI_END="0.035115408650303284" LOG_CI_START="-0.29578294564031565" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2009-06-24 17:20:37 +0200" MODIFIED_BY="[Empty name]" ORDER="170" O_E="0.0" SE="0.19437133128358017" STUDY_ID="STD-Lahtinen-1992" TOTAL_1="108" TOTAL_2="95" VAR="0.03778021442495127" WEIGHT="20.214010923710017"/><DICH_DATA CI_END="0.9261152967841564" CI_START="0.5135770874290777" EFFECT_SIZE="0.6896604938271605" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="60" LOG_CI_END="-0.033334942432422715" LOG_CI_START="-0.28939435998804564" LOG_EFFECT_SIZE="-0.16136465121023416" MODIFIED="2009-06-24 17:20:49 +0200" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.15041056938673203" STUDY_ID="STD-McCloskey-2001" TOTAL_1="108" TOTAL_2="109" VAR="0.02262333938324093" WEIGHT="31.680272171530806"/><DICH_DATA CI_END="1.8114522782061577" CI_START="0.6086276813716462" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="0.2580268972528472" LOG_CI_START="-0.21564829911297106" LOG_EFFECT_SIZE="0.021189299069938092" MODIFIED="2009-06-24 17:21:43 +0200" MODIFIED_BY="[Empty name]" ORDER="172" O_E="0.0" SE="0.27823915507531904" STUDY_ID="STD-Menssen-2002" TOTAL_1="99" TOTAL_2="99" VAR="0.07741702741702743" WEIGHT="10.384782927944809"/><DICH_DATA CI_END="2.4940882787181518" CI_START="0.007220838080780863" EFFECT_SIZE="0.1341991341991342" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3969118213484771" LOG_CI_START="-2.1414123934642206" LOG_EFFECT_SIZE="-0.8722502860578716" MODIFIED="2009-06-24 17:21:23 +0200" MODIFIED_BY="[Empty name]" ORDER="173" O_E="0.0" SE="1.4910242086884862" STUDY_ID="STD-Terpos-2000" TOTAL_1="32" TOTAL_2="30" VAR="2.2231531908951263" WEIGHT="0.38006707848534826"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="6.420025573602793" CI_END="0.8860790943136445" CI_START="0.6177912372778553" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7398728944907145" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="188" I2="6.542428356201743" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-0.05252750983889334" LOG_CI_START="-0.2091582560035921" LOG_EFFECT_SIZE="-0.13084288292124271" METHOD="MH" MODIFIED="2017-11-16 18:54:36 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.377818028866703" P_Q="0.5313877977911885" P_Z="0.0010583168472006411" Q="0.39173766601164994" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.004096899327582928" TOTALS="YES" TOTAL_1="575" TOTAL_2="541" WEIGHT="100.00000000000001" Z="3.2745465936728633"><NAME>Type of data analysis (vertebral fractures)</NAME><GROUP_LABEL_1>Bisphosphonate</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Bisphosphonates</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="2.5409749346259183" CI_END="1.218129576310826" CI_START="0.5519303608656712" DF="2" EFFECT_SIZE="0.8199528624466051" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="61" I2="21.290053957402" ID="CMP-003.04.01" LOG_CI_END="0.08569348803711453" LOG_CI_START="-0.2581157153861566" LOG_EFFECT_SIZE="-0.08621111367452099" MODIFIED="2017-11-16 18:54:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2806948682740109" P_Z="0.3256405079438228" STUDIES="3" TAU2="0.029962691466263174" TOTAL_1="239" TOTAL_2="224" WEIGHT="30.97886093014017" Z="0.9829328370894495"><NAME>Intention-to-treat analysis</NAME><DICH_DATA CI_END="1.084214993124351" CI_START="0.5060775293394323" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="38" LOG_CI_END="0.035115408650303284" LOG_CI_START="-0.29578294564031565" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2009-06-24 16:04:09 +0200" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.19437133128358017" STUDY_ID="STD-Lahtinen-1992" TOTAL_1="108" TOTAL_2="95" VAR="0.03778021442495127" WEIGHT="20.214010923710017"/><DICH_DATA CI_END="1.8114522782061577" CI_START="0.6086276813716462" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="0.2580268972528472" LOG_CI_START="-0.21564829911297106" LOG_EFFECT_SIZE="0.021189299069938092" MODIFIED="2009-06-24 16:05:14 +0200" MODIFIED_BY="[Empty name]" ORDER="113" O_E="0.0" SE="0.27823915507531904" STUDY_ID="STD-Menssen-2002" TOTAL_1="99" TOTAL_2="99" VAR="0.07741702741702743" WEIGHT="10.384782927944805"/><DICH_DATA CI_END="2.4940882787181518" CI_START="0.007220838080780863" EFFECT_SIZE="0.1341991341991342" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3969118213484771" LOG_CI_START="-2.1414123934642206" LOG_EFFECT_SIZE="-0.8722502860578716" MODIFIED="2009-06-24 16:05:00 +0200" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="1.4910242086884862" STUDY_ID="STD-Terpos-2000" TOTAL_1="32" TOTAL_2="30" VAR="2.2231531908951263" WEIGHT="0.3800670784853482"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="3.487498053877623" CI_END="0.8912246124815749" CI_START="0.5632308969816948" DF="3" EFFECT_SIZE="0.70849505142955" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="127" I2="13.978446621227254" ID="CMP-003.04.02" LOG_CI_END="-0.050012828322348754" LOG_CI_START="-0.2493135292554921" LOG_EFFECT_SIZE="-0.14966317878892046" MODIFIED="2011-08-17 17:16:10 +0200" MODIFIED_BY="Rahul S Mhaskar" NO="2" P_CHI2="0.3223873271737223" P_Z="0.0032438041291975184" STUDIES="4" TAU2="0.008232307723058664" TOTAL_1="336" TOTAL_2="317" WEIGHT="69.02113906985984" Z="2.9436368147692957"><NAME>Per protocol analysis</NAME><DICH_DATA CI_END="0.8547878611524382" CI_START="0.3826912768487408" EFFECT_SIZE="0.5719439290867863" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="49" LOG_CI_END="-0.06814165388272866" LOG_CI_START="-0.4171514370690292" LOG_EFFECT_SIZE="-0.2426465454758789" MODIFIED="2009-06-24 16:04:38 +0200" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.20501007426992252" STUDY_ID="STD-Berenson-1998a" TOTAL_1="198" TOTAL_2="179" VAR="0.04202913055215915" WEIGHT="18.35198990795751"/><DICH_DATA CI_END="3.6371418524301027" CI_START="0.05049939673511395" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5607602393352392" LOG_CI_START="-1.2967138099244282" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2009-06-24 16:03:56 +0200" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="1.0910894511799618" STUDY_ID="STD-Delmas-1982" TOTAL_1="7" TOTAL_2="6" VAR="1.1904761904761905" WEIGHT="0.7086250662035458"/><DICH_DATA CI_END="1.402334278349937" CI_START="0.6267451802106477" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.14685154996338431" LOG_CI_START="-0.20290899716387142" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2009-06-24 16:04:48 +0200" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="0.20545107672518104" STUDY_ID="STD-Kraj-2000" TOTAL_1="23" TOTAL_2="23" VAR="0.04221014492753622" WEIGHT="18.280251924167974"/><DICH_DATA CI_END="0.9261152967841564" CI_START="0.5135770874290777" EFFECT_SIZE="0.6896604938271605" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="60" LOG_CI_END="-0.033334942432422715" LOG_CI_START="-0.28939435998804564" LOG_EFFECT_SIZE="-0.16136465121023416" MODIFIED="2009-06-24 16:04:24 +0200" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="0.15041056938673203" STUDY_ID="STD-McCloskey-2001" TOTAL_1="108" TOTAL_2="109" VAR="0.02262333938324093" WEIGHT="31.680272171530802"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="6.420025573602793" CI_END="0.8860790943136445" CI_START="0.6177912372778552" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7398728944907145" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="188" I2="6.542428356201743" I2_Q="66.52568364769719" ID="CMP-003.05" LOG_CI_END="-0.05252750983889334" LOG_CI_START="-0.2091582560035922" LOG_EFFECT_SIZE="-0.13084288292124271" METHOD="MH" MODIFIED="2017-11-16 18:55:14 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.377818028866703" P_Q="0.08391680583244276" P_Z="0.00105831684720064" Q="2.9873649680412573" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.004096899327582928" TOTALS="YES" TOTAL_1="575" TOTAL_2="541" WEIGHT="100.0" Z="3.2745465936728637"><NAME>Description of withdrawals and drop outs (vertebral fractures)</NAME><GROUP_LABEL_1>Bisphosphonate</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Bisphosphonates</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.9122768211550425" CI_END="0.8211760374993831" CI_START="0.548628806581329" DF="2" EFFECT_SIZE="0.6712084843373712" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="147" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="-0.08556373213830364" LOG_CI_START="-0.26072139284730134" LOG_EFFECT_SIZE="-0.1731425624928025" MODIFIED="2017-11-16 18:54:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6337261476487026" P_Z="1.066986231976126E-4" STUDIES="3" TAU2="0.0" TOTAL_1="414" TOTAL_2="383" WEIGHT="70.24627300319833" Z="3.8748312269442873"><NAME>Withdrawals and dropouts well described</NAME><DICH_DATA CI_END="0.8547878611524382" CI_START="0.3826912768487408" EFFECT_SIZE="0.5719439290867863" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="49" LOG_CI_END="-0.06814165388272866" LOG_CI_START="-0.4171514370690292" LOG_EFFECT_SIZE="-0.2426465454758789" MODIFIED="2009-06-24 17:33:22 +0200" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="0.20501007426992252" STUDY_ID="STD-Berenson-1998a" TOTAL_1="198" TOTAL_2="179" VAR="0.04202913055215915" WEIGHT="18.35198990795751"/><DICH_DATA CI_END="1.084214993124351" CI_START="0.5060775293394323" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="38" LOG_CI_END="0.035115408650303284" LOG_CI_START="-0.29578294564031565" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2009-06-24 17:32:59 +0200" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="0.19437133128358017" STUDY_ID="STD-Lahtinen-1992" TOTAL_1="108" TOTAL_2="95" VAR="0.03778021442495127" WEIGHT="20.214010923710017"/><DICH_DATA CI_END="0.9261152967841564" CI_START="0.5135770874290777" EFFECT_SIZE="0.6896604938271605" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="60" LOG_CI_END="-0.033334942432422715" LOG_CI_START="-0.28939435998804564" LOG_EFFECT_SIZE="-0.16136465121023416" MODIFIED="2009-06-24 17:33:10 +0200" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.15041056938673203" STUDY_ID="STD-McCloskey-2001" TOTAL_1="108" TOTAL_2="109" VAR="0.02262333938324093" WEIGHT="31.680272171530802"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="2.4529114158322693" CI_END="1.2866510109424505" CI_START="0.680648029652908" DF="3" EFFECT_SIZE="0.9358186124719368" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="41" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="0.10946076557177949" LOG_CI_START="-0.1670774083444491" LOG_EFFECT_SIZE="-0.028808321386334858" MODIFIED="2017-11-16 18:55:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.483861415659969" P_Z="0.6830109465239698" STUDIES="4" TAU2="0.0" TOTAL_1="161" TOTAL_2="158" WEIGHT="29.75372699680167" Z="0.4083578883353418"><NAME>Withdrawals and dropouts NOT described</NAME><DICH_DATA CI_END="3.6371418524301027" CI_START="0.05049939673511395" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5607602393352392" LOG_CI_START="-1.2967138099244282" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2009-06-24 17:32:49 +0200" MODIFIED_BY="[Empty name]" ORDER="178" O_E="0.0" SE="1.0910894511799618" STUDY_ID="STD-Delmas-1982" TOTAL_1="7" TOTAL_2="6" VAR="1.1904761904761905" WEIGHT="0.7086250662035458"/><DICH_DATA CI_END="1.402334278349937" CI_START="0.6267451802106477" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.14685154996338431" LOG_CI_START="-0.20290899716387142" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2009-06-24 17:33:31 +0200" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="0.20545107672518104" STUDY_ID="STD-Kraj-2000" TOTAL_1="23" TOTAL_2="23" VAR="0.04221014492753622" WEIGHT="18.280251924167974"/><DICH_DATA CI_END="1.8114522782061577" CI_START="0.6086276813716462" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="0.2580268972528472" LOG_CI_START="-0.21564829911297106" LOG_EFFECT_SIZE="0.021189299069938092" MODIFIED="2009-06-24 17:33:53 +0200" MODIFIED_BY="[Empty name]" ORDER="180" O_E="0.0" SE="0.27823915507531904" STUDY_ID="STD-Menssen-2002" TOTAL_1="99" TOTAL_2="99" VAR="0.07741702741702743" WEIGHT="10.384782927944805"/><DICH_DATA CI_END="2.4940882787181518" CI_START="0.007220838080780863" EFFECT_SIZE="0.1341991341991342" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3969118213484771" LOG_CI_START="-2.1414123934642206" LOG_EFFECT_SIZE="-0.8722502860578716" MODIFIED="2009-06-24 17:33:42 +0200" MODIFIED_BY="[Empty name]" ORDER="181" O_E="0.0" SE="1.4910242086884862" STUDY_ID="STD-Terpos-2000" TOTAL_1="32" TOTAL_2="30" VAR="2.2231531908951263" WEIGHT="0.3800670784853482"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="6.420025573602793" CI_END="0.8860790943136445" CI_START="0.6177912372778553" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7398728944907145" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="188" I2="6.542428356201743" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-0.05252750983889334" LOG_CI_START="-0.2091582560035921" LOG_EFFECT_SIZE="-0.13084288292124271" METHOD="MH" MODIFIED="2009-08-27 17:50:00 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.377818028866703" P_Q="0.9844067521626139" P_Z="0.0010583168472006411" Q="3.8198679107529816E-4" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.004096899327582928" TOTALS="YES" TOTAL_1="575" TOTAL_2="541" WEIGHT="100.0" Z="3.2745465936728633"><NAME>Alpha error (vertebral fractures)</NAME><GROUP_LABEL_1>Bisphosphonate</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Bisphosphonates</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.0" CI_END="1.084214993124351" CI_START="0.5060775293394323" DF="0" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="38" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="0.035115408650303284" LOG_CI_START="-0.29578294564031565" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2009-06-24 17:36:24 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.12259424426695209" STUDIES="1" TAU2="0.0" TOTAL_1="108" TOTAL_2="95" WEIGHT="20.214010923710017" Z="1.5439755979882512"><NAME>Alpha error pre-specified</NAME><DICH_DATA CI_END="1.084214993124351" CI_START="0.5060775293394323" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="38" LOG_CI_END="0.035115408650303284" LOG_CI_START="-0.29578294564031565" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2009-06-24 17:36:24 +0200" MODIFIED_BY="[Empty name]" ORDER="182" O_E="0.0" SE="0.19437133128358017" STUDY_ID="STD-Lahtinen-1992" TOTAL_1="108" TOTAL_2="95" VAR="0.03778021442495127" WEIGHT="20.214010923710017"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="6.465062260179472" CI_END="0.9440122023724988" CI_START="0.5864696807370274" DF="5" EFFECT_SIZE="0.7440662167692184" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="150" I2="22.6612243041075" ID="CMP-003.06.02" LOG_CI_END="-0.025022391942617624" LOG_CI_START="-0.2317544350897382" LOG_EFFECT_SIZE="-0.12838841351617794" MODIFIED="2009-06-24 17:37:28 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2635580220686241" P_Z="0.014915534551448723" STUDIES="6" TAU2="0.019479232177167134" TOTAL_1="467" TOTAL_2="446" WEIGHT="79.78598907628998" Z="2.4344234468274215"><NAME>Alpha error NOT pre-specified</NAME><DICH_DATA CI_END="0.8547878611524382" CI_START="0.3826912768487408" EFFECT_SIZE="0.5719439290867863" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="49" LOG_CI_END="-0.06814165388272866" LOG_CI_START="-0.4171514370690292" LOG_EFFECT_SIZE="-0.2426465454758789" MODIFIED="2009-06-24 17:36:56 +0200" MODIFIED_BY="[Empty name]" ORDER="183" O_E="0.0" SE="0.20501007426992252" STUDY_ID="STD-Berenson-1998a" TOTAL_1="198" TOTAL_2="179" VAR="0.04202913055215915" WEIGHT="18.35198990795751"/><DICH_DATA CI_END="3.6371418524301027" CI_START="0.05049939673511395" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5607602393352392" LOG_CI_START="-1.2967138099244282" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2009-06-24 17:36:14 +0200" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="1.0910894511799618" STUDY_ID="STD-Delmas-1982" TOTAL_1="7" TOTAL_2="6" VAR="1.1904761904761905" WEIGHT="0.7086250662035458"/><DICH_DATA CI_END="1.402334278349937" CI_START="0.6267451802106477" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.14685154996338431" LOG_CI_START="-0.20290899716387142" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2009-06-24 17:37:07 +0200" MODIFIED_BY="[Empty name]" ORDER="185" O_E="0.0" SE="0.20545107672518104" STUDY_ID="STD-Kraj-2000" TOTAL_1="23" TOTAL_2="23" VAR="0.04221014492753622" WEIGHT="18.280251924167974"/><DICH_DATA CI_END="0.9261152967841564" CI_START="0.5135770874290777" EFFECT_SIZE="0.6896604938271605" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="60" LOG_CI_END="-0.033334942432422715" LOG_CI_START="-0.28939435998804564" LOG_EFFECT_SIZE="-0.16136465121023416" MODIFIED="2009-06-24 17:36:35 +0200" MODIFIED_BY="[Empty name]" ORDER="186" O_E="0.0" SE="0.15041056938673203" STUDY_ID="STD-McCloskey-2001" TOTAL_1="108" TOTAL_2="109" VAR="0.02262333938324093" WEIGHT="31.680272171530802"/><DICH_DATA CI_END="1.8114522782061577" CI_START="0.6086276813716462" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="0.2580268972528472" LOG_CI_START="-0.21564829911297106" LOG_EFFECT_SIZE="0.021189299069938092" MODIFIED="2009-06-24 17:37:28 +0200" MODIFIED_BY="[Empty name]" ORDER="187" O_E="0.0" SE="0.27823915507531904" STUDY_ID="STD-Menssen-2002" TOTAL_1="99" TOTAL_2="99" VAR="0.07741702741702743" WEIGHT="10.384782927944805"/><DICH_DATA CI_END="2.4940882787181518" CI_START="0.007220838080780863" EFFECT_SIZE="0.1341991341991342" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3969118213484771" LOG_CI_START="-2.1414123934642206" LOG_EFFECT_SIZE="-0.8722502860578716" MODIFIED="2009-06-24 17:37:16 +0200" MODIFIED_BY="[Empty name]" ORDER="188" O_E="0.0" SE="1.4910242086884862" STUDY_ID="STD-Terpos-2000" TOTAL_1="32" TOTAL_2="30" VAR="2.2231531908951263" WEIGHT="0.3800670784853482"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="6.420025573602793" CI_END="0.8860790943136445" CI_START="0.6177912372778552" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7398728944907145" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="188" I2="6.542428356201743" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="-0.05252750983889334" LOG_CI_START="-0.2091582560035922" LOG_EFFECT_SIZE="-0.13084288292124271" METHOD="MH" MODIFIED="2011-08-17 17:17:23 +0200" MODIFIED_BY="Rahul S Mhaskar" NO="7" P_CHI2="0.377818028866703" P_Q="0.9844067521626136" P_Z="0.00105831684720064" Q="3.8198679107530765E-4" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.004096899327582928" TOTALS="YES" TOTAL_1="575" TOTAL_2="541" WEIGHT="100.0" Z="3.2745465936728637"><NAME>Beta error (vertebral fractures)</NAME><GROUP_LABEL_1>Bisphosphonate</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Bisphosphonates</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.0" CI_END="1.084214993124351" CI_START="0.5060775293394323" DF="0" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="38" I2="0.0" ID="CMP-003.07.01" LOG_CI_END="0.035115408650303284" LOG_CI_START="-0.29578294564031565" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2009-06-24 17:40:25 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.12259424426695209" STUDIES="1" TAU2="0.0" TOTAL_1="108" TOTAL_2="95" WEIGHT="20.214010923710017" Z="1.5439755979882512"><NAME>Beta error pre-specified</NAME><DICH_DATA CI_END="1.084214993124351" CI_START="0.5060775293394323" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="38" LOG_CI_END="0.035115408650303284" LOG_CI_START="-0.29578294564031565" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2009-06-24 17:40:25 +0200" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="0.19437133128358017" STUDY_ID="STD-Lahtinen-1992" TOTAL_1="108" TOTAL_2="95" VAR="0.03778021442495127" WEIGHT="20.214010923710017"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="6.465062260179471" CI_END="0.9440122023724988" CI_START="0.5864696807370274" DF="5" EFFECT_SIZE="0.7440662167692185" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="150" I2="22.661224304107492" ID="CMP-003.07.02" LOG_CI_END="-0.025022391942617624" LOG_CI_START="-0.2317544350897382" LOG_EFFECT_SIZE="-0.12838841351617788" MODIFIED="2009-06-24 17:40:40 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.26355802206862455" P_Z="0.014915534551448723" STUDIES="6" TAU2="0.01947923217716712" TOTAL_1="467" TOTAL_2="446" WEIGHT="79.78598907628998" Z="2.4344234468274215"><NAME>Beta error NOT pre-specified</NAME><DICH_DATA CI_END="0.8547878611524382" CI_START="0.3826912768487408" EFFECT_SIZE="0.5719439290867863" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="49" LOG_CI_END="-0.06814165388272866" LOG_CI_START="-0.4171514370690292" LOG_EFFECT_SIZE="-0.2426465454758789" MODIFIED="2009-06-24 17:40:40 +0200" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="0.20501007426992252" STUDY_ID="STD-Berenson-1998a" TOTAL_1="198" TOTAL_2="179" VAR="0.04202913055215915" WEIGHT="18.35198990795751"/><DICH_DATA CI_END="3.6371418524301027" CI_START="0.05049939673511395" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5607602393352392" LOG_CI_START="-1.2967138099244282" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2009-06-24 17:40:40 +0200" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="1.0910894511799618" STUDY_ID="STD-Delmas-1982" TOTAL_1="7" TOTAL_2="6" VAR="1.1904761904761905" WEIGHT="0.7086250662035458"/><DICH_DATA CI_END="1.402334278349937" CI_START="0.6267451802106477" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.14685154996338431" LOG_CI_START="-0.20290899716387142" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2009-06-24 17:40:40 +0200" MODIFIED_BY="[Empty name]" ORDER="192" O_E="0.0" SE="0.20545107672518104" STUDY_ID="STD-Kraj-2000" TOTAL_1="23" TOTAL_2="23" VAR="0.04221014492753622" WEIGHT="18.280251924167974"/><DICH_DATA CI_END="0.9261152967841564" CI_START="0.5135770874290777" EFFECT_SIZE="0.6896604938271605" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="60" LOG_CI_END="-0.033334942432422715" LOG_CI_START="-0.28939435998804564" LOG_EFFECT_SIZE="-0.16136465121023416" MODIFIED="2009-06-24 17:40:40 +0200" MODIFIED_BY="[Empty name]" ORDER="193" O_E="0.0" SE="0.15041056938673203" STUDY_ID="STD-McCloskey-2001" TOTAL_1="108" TOTAL_2="109" VAR="0.02262333938324093" WEIGHT="31.680272171530802"/><DICH_DATA CI_END="1.8114522782061577" CI_START="0.6086276813716462" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="0.2580268972528472" LOG_CI_START="-0.21564829911297106" LOG_EFFECT_SIZE="0.021189299069938092" MODIFIED="2009-06-24 17:40:40 +0200" MODIFIED_BY="[Empty name]" ORDER="194" O_E="0.0" SE="0.27823915507531904" STUDY_ID="STD-Menssen-2002" TOTAL_1="99" TOTAL_2="99" VAR="0.07741702741702743" WEIGHT="10.384782927944805"/><DICH_DATA CI_END="2.4940882787181518" CI_START="0.007220838080780863" EFFECT_SIZE="0.1341991341991342" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3969118213484771" LOG_CI_START="-2.1414123934642206" LOG_EFFECT_SIZE="-0.8722502860578716" MODIFIED="2009-06-24 17:40:40 +0200" MODIFIED_BY="[Empty name]" ORDER="195" O_E="0.0" SE="1.4910242086884862" STUDY_ID="STD-Terpos-2000" TOTAL_1="32" TOTAL_2="30" VAR="2.2231531908951263" WEIGHT="0.3800670784853482"/></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="1.0962490527682451" CI_END="1.5944037982376078" CI_START="0.9502201039176033" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2308673945019264" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="87" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.20259832028329247" LOG_CI_START="-0.02217578540058783" LOG_EFFECT_SIZE="0.0902112674413523" METHOD="MH" MODIFIED="2016-12-29 17:14:11 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.9544351832084781" P_Q="0.9680866491115174" P_Z="0.11566525801133744" Q="0.0016006505683773013" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="924" TOTAL_2="905" WEIGHT="100.0" Z="1.5732313528447628"><NAME>Gastrointestinal toxicity (grade III/IV: oral vs IV bisphosphonates))</NAME><GROUP_LABEL_1>Bisphosphonates</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours Bisphosphonates</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="1.0639518426493115" CI_END="1.6966299377642653" CI_START="0.8858317661078613" DF="3" EFFECT_SIZE="1.2259399227536356" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="57" I2="0.0" ID="CMP-003.08.01" LOG_CI_END="0.2295871260459993" LOG_CI_START="-0.05264874988328555" LOG_EFFECT_SIZE="0.0884691880813569" MODIFIED="2016-12-29 17:14:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7857826176617477" P_Z="0.21917154013178775" STUDIES="4" TAU2="0.0" TOTAL_1="623" TOTAL_2="627" WEIGHT="63.42611662143419" Z="1.228734099164663"><NAME>Oral route</NAME><DICH_DATA CI_END="2.9249588209673405" CI_START="0.729287914695532" EFFECT_SIZE="1.4605263157894737" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="12" LOG_CI_END="0.4661197562463899" LOG_CI_START="-0.13710098323465772" LOG_EFFECT_SIZE="0.16450938650586608" MODIFIED="2016-11-14 22:02:38 +0100" MODIFIED_BY="[Empty name]" ORDER="166" O_E="0.0" SE="0.35433484836198526" STUDY_ID="STD-Brincker-1998" TOTAL_1="152" TOTAL_2="148" VAR="0.12555318476371108" WEIGHT="13.884812754514172"/><DICH_DATA CI_END="7.939480235674019" CI_START="0.013994758827141083" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8997920719274333" LOG_CI_START="-1.854034581366758" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2016-11-14 22:01:41 +0100" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="1.6176114078067905" STUDY_ID="STD-Daragon-1993" TOTAL_1="39" TOTAL_2="39" VAR="2.6166666666666667" WEIGHT="0.666222596628172"/><DICH_DATA CI_END="1.7631322865465007" CI_START="0.7285014597289938" EFFECT_SIZE="1.1333333333333333" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="30" LOG_CI_END="0.24628489832419773" LOG_CI_START="-0.1375695736790124" LOG_EFFECT_SIZE="0.054357662322592676" MODIFIED="2016-11-14 22:02:10 +0100" MODIFIED_BY="[Empty name]" ORDER="163" O_E="0.0" SE="0.22547801696496664" STUDY_ID="STD-Lahtinen-1992" TOTAL_1="168" TOTAL_2="168" VAR="0.05084033613445378" WEIGHT="34.289357500837845"/><DICH_DATA CI_END="2.608457206573585" CI_START="0.6727212972409462" EFFECT_SIZE="1.3246753246753247" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.4163837162351612" LOG_CI_START="-0.1721648230562898" LOG_EFFECT_SIZE="0.12210944658943569" MODIFIED="2016-11-14 22:02:26 +0100" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="0.34571632534205393" STUDY_ID="STD-McCloskey-2001" TOTAL_1="264" TOTAL_2="272" VAR="0.1195197776080129" WEIGHT="14.585723769454004"/></DICH_SUBGROUP><DICH_SUBGROUP CHI2="0.030783270675042128" CI_END="1.9013792494404806" CI_START="0.8079713908123674" DF="1" EFFECT_SIZE="1.2394595744243537" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="30" I2="0.0" ID="CMP-003.08.02" LOG_CI_END="0.27906874995962283" LOG_CI_START="-0.09260401674062547" LOG_EFFECT_SIZE="0.09323236660949863" MODIFIED="2016-12-29 17:14:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8607248217477984" P_Z="0.3254620336876105" STUDIES="3" TAU2="0.0" TOTAL_1="301" TOTAL_2="278" WEIGHT="36.57388337856581" Z="0.98329550679953"><NAME>Intervenous route</NAME><DICH_DATA CI_END="1.9229781602300855" CI_START="0.8085843221381191" EFFECT_SIZE="1.24695228143504" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="29" LOG_CI_END="0.2839743518695662" LOG_CI_START="-0.09227468357482956" LOG_EFFECT_SIZE="0.09584983414736835" MODIFIED="2016-11-14 22:02:42 +0100" MODIFIED_BY="[Empty name]" ORDER="165" O_E="0.0" SE="0.22101054588280095" STUDY_ID="STD-Berenson-1998a" TOTAL_1="198" TOTAL_2="179" VAR="0.04884566139141366" WEIGHT="35.68960705041233"/><DICH_DATA CI_END="15.23141940682358" CI_START="0.06200705528221281" EFFECT_SIZE="0.971830985915493" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.182740376863771" LOG_CI_START="-1.207558892827411" LOG_EFFECT_SIZE="-0.012409257981819953" MODIFIED="2016-11-14 22:03:03 +0100" MODIFIED_BY="[Empty name]" ORDER="363" O_E="0.0" SE="1.404073623188812" STUDY_ID="STD-Sezer-2010" TOTAL_1="71" TOTAL_2="69" VAR="1.971422739334558" WEIGHT="0.884276328153486"/><DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-11-14 22:03:42 +0100" MODIFIED_BY="[Empty name]" ORDER="167" O_E="0.0" SE="0.0" STUDY_ID="STD-Terpos-2000" TOTAL_1="32" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/></DICH_SUBGROUP></DICH_OUTCOME></COMPARISON></ANALYSES_AND_DATA><FIGURES MODIFIED="2017-11-16 18:52:10 +0100" MODIFIED_BY="[Empty name]"><FIGURE FILENAME="Figure 1.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2009-07-09 22:32:49 +0200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER"><CAPTION><P>Bisphosphonate chemical structures</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Flow chart 07122017.jpg" FILE_TYPE="JPG" ID="FIG-02" MODIFIED="2017-09-21 21:57:37 +0200" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER"><CAPTION><P>Study flowchart</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2017-11-16 18:52:10 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT"><CAPTION><P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="fig 4.jpg" FILE_TYPE="JPG" ID="FIG-04" MODIFIED="2017-04-14 19:50:48 +0200" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER"><CAPTION><P>Bisphosphonate potency metaregression for overall survival. HR: Hazard ratio.</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="fig 5.jpg" FILE_TYPE="JPG" ID="FIG-05" MODIFIED="2017-04-14 19:50:48 +0200" MODIFIED_BY="[Empty name]" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER"><CAPTION><P>Randomized controlled trial (RCT) network for overall survival (OS), progression free survival (PFS) and skeletal related events (SREs).</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Figure 6.jpg" FILE_TYPE="JPG" ID="FIG-06" MODIFIED="2017-04-14 19:50:48 +0200" MODIFIED_BY="[Empty name]" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER"><CAPTION><P>A: Ranking probabilities of competing bisphosphonates. The size of each bar corresponds to the probability of each treatment to be at a specific rank. OS: Overall survival; PFS: Progression-free survival; SRE: Skeletal-related events; Osteonecrosis; GI: Gastrointestinal toxicity; Hyper: Hypercalcemia.</P><P>B: Surface under the cumulative ranking curve (SUCRA) plots for each treatment. The outcomes are listed on the horizontal axis. SUCRA for each outcome are on the vertical axis.</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2017-04-14 19:50:48 +0200" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-001.06" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT"><CAPTION><P>Funnel plot of comparison: 1 Bisphosphonates vs. control (efficacy), outcome: 1.6 Pain.</P></CAPTION><FILE>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</FILE></FIGURE></FIGURES><FEEDBACK/><APPENDICES MODIFIED="2017-11-16 18:52:53 +0100" MODIFIED_BY="[Empty name]"><APPENDIX ID="APP-01" MODIFIED="2016-02-22 17:03:10 +0100" MODIFIED_BY="[Empty name]" NO="1"><TITLE MODIFIED="2012-03-20 15:27:26 +0100" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE><APPENDIX_BODY MODIFIED="2016-02-22 17:03:10 +0100" MODIFIED_BY="[Empty name]"><P>(((&#8220;Multiple Myeloma&#8221;[MeSH] OR &#8220;Plasmacytoma&#8221;[MeSH] OR multiple myeloma OR plasmacytoma OR plasmacytom* OR myelom*) AND (bisphosphonates OR pamidronate OR zoledronate OR etidronate OR ibandronate OR clodronate OR &#8220;Clodronic Acid&#8221;[MeSH] OR &#8220;pamidronate &#8221;[Substance Name] OR &#8220;Etidronic Acid&#8221;[MeSH] OR &#8220;zoledronic acid &#8221;[Substance Name] OR &#8220;ibandronic acid &#8221;[Substance Name]))) AND ((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading]) AND ((&#8220;2011/09/01&#8221;[EDat] : &#8220;3000&#8221;[EDat]) AND (Humans[MeSH]))<BR/>Limits:Publication Date from 2011/09/01<BR/>(((((((("pamidronate "[Substance Name] OR "Etidronic Acid"[MeSH]) OR "ibandronic acid "[Substance Name]) OR "Clodronic Acid"[MeSH]) OR "zoledronic acid "[Substance Name]) ) OR "Alendronate"[MeSH]) OR "risedronic acid "[Substance Name]) OR "tiludronic acid "[Substance Name]) AND "Multiple Myeloma"[MeSH]<BR/>Limits:Publication Date from 2011/09/01, Humans</P><P>2) Search strategy aimed at identifying observational studies and ONJ case reports.</P><P>(&#8220;MultipleMyeloma&#8221;[MeSH]AND(&#8220;pamidronate &#8221;[SubstanceName]OR&#8220;EtidronicAcid&#8221;[MeSH])OR&#8220;ibandronic acid &#8221;[Substance Name]) OR &#8220;Clodronic Acid&#8221;[MeSH]) OR &#8220;zoledronic acid &#8221;[Substance Name]) ) OR &#8220;Alendronate&#8221;[MeSH]) OR &#8220;risedronic acid &#8221;[Substance Name]) OR &#8220;tiludronic acid &#8221;[Substance Name]) AND (&#8220;Osteonecrosis &#8221;[MeSH] OR &#8220;Jaw Diseases&#8221;[MeSH])</P><P>Limits: Publication Date from 2011/09/01, Humans<BR/></P></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-02" MODIFIED="2016-02-22 17:02:44 +0100" MODIFIED_BY="[Empty name]" NO="2"><TITLE MODIFIED="2009-07-07 22:06:13 +0200" MODIFIED_BY="[Empty name]">Cochrane Library search strategy</TITLE><APPENDIX_BODY MODIFIED="2016-02-22 17:02:44 +0100" MODIFIED_BY="[Empty name]"><P>"bisphosphonate and myeloma"</P></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-03" MODIFIED="2012-03-20 15:27:32 +0100" MODIFIED_BY="[Empty name]" NO="3"><TITLE MODIFIED="2012-03-20 15:27:32 +0100" MODIFIED_BY="[Empty name]">www.clinicaltrials.gov search strategy</TITLE><APPENDIX_BODY MODIFIED="2009-07-07 22:06:58 +0200" MODIFIED_BY="[Empty name]"><P>"bisphosphonates and multiple myeloma"</P></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-04" MODIFIED="2017-11-16 18:52:53 +0100" MODIFIED_BY="[Empty name]" NO="4"><TITLE MODIFIED="2017-11-16 18:52:53 +0100" MODIFIED_BY="[Empty name]">Embase search strategy</TITLE><APPENDIX_BODY MODIFIED="2017-07-13 19:41:43 +0200" MODIFIED_BY="[Empty name]"><P>'bone'/exp OR bone AND ('neoplasms'/exp OR neoplasms) OR 'bone'/exp OR bone AND ('neoplasm'/exp OR neoplasm) OR multiple AND ('myeloma'/exp OR myeloma) OR 'neoplasm'/exp OR neoplasm AND ('metastasis'/exp OR metastasis) OR 'neoplasms'/exp OR neoplasms AND ('alendronate'/exp OR alendronate) OR 'clodronate'/exp OR clodronate OR 'etidronate'/exp OR etidronate OR 'risedronate'/exp OR risedronate OR 'ibandronate'/exp OR ibandronate OR 'pamidronate'/exp OR pamidronate OR 'tiludronate'/exp OR tiludronate OR 'zoledronate'/exp OR zoledronate OR diphosphonates. AND mp OR 'bisphosphonate'/exp OR bisphosphonate AND adj AND agent OR derivative.mp.tw. AND random.tw. OR clinical AND trial.mp. OR exp AND ('health'/exp OR health) AND care AND quality Date limits used: 09012011 onwards (till 07132017)</P></APPENDIX_BODY></APPENDIX></APPENDICES><EXTENSIONS MODIFIED="2009-06-23 01:23:41 +0200" MODIFIED_BY="[Empty name]"/></COCHRANE_REVIEW>